	
In	O
these	O
trials	O
,	O
636	O
patients	O
were	O
treated	O
with	O
TUDORZA	O
PRESSAIR	O
at	O
the	O
recommended	O
dose	O
of	O
400	O
mcg	O
twice	O
daily	O
.	O
	
Adverse	O
reactions	O
resulted	O
in	O
interruption	O
or	O
discontinuation	O
for	O
78	O
(	O
53	O
%	O
)	O
subjects	O
.	O
	
Renal	O
disorders	O
:	O
glycosuria	B
,	O
hemoglobinuria	B
.	O
	
In	O
patients	O
treated	O
for	O
these	O
two	O
indications	O
,	O
there	O
was	O
no	O
apparent	O
correlation	O
of	O
antibody	O
frequency	O
,	O
antibody	O
titers	O
,	O
or	O
neutralizing	O
status	O
to	O
clinical	O
response	O
or	O
adverse	O
reactions	O
.	O
	
Interrupt	O
and	O
then	O
reduce	O
or	O
discontinue	O
Zydelig	O
as	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
AdreView	O
safety	O
and	O
efficacy	O
have	O
not	O
been	O
established	O
in	O
these	O
patients	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
(	O
6.1	O
)	O
*	O
In	O
patients	O
with	O
severe	O
aplastic	O
anemia	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
20	O
%	O
)	O
were	O
:	O
nausea	B
,	O
fatigue	B
,	O
cough	B
,	O
diarrhea	B
,	O
and	O
headache	B
.	O
	
Of	O
the	O
372	O
patients	O
with	O
immunogenicity	O
assessment	O
at	O
baseline	O
(	O
prior	O
to	O
receiving	O
belatacept	O
treatment	O
)	O
,	O
29	O
patients	O
tested	O
positive	O
for	O
anti-belatacept	O
antibodies	O
;	O
13	O
of	O
these	O
patients	O
had	O
antibodies	O
to	O
the	O
modified	O
cytotoxic	O
T-lymphocyte-associated	O
antigen	O
4	O
(	O
CTLA-4	O
)	O
.	O
	
(	O
5.4	O
)	O
*	O
Monitor	O
for	O
dizziness	O
and	O
somnolence	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
>	O
=3	O
%	O
of	O
Patients	O
Treated	O
with	O
CIMZIA	O
Dosed	O
Every	O
Other	O
Week	O
during	O
Placebo-Controlled	O
Period	O
of	O
Rheumatoid	O
Arthritis	O
Studies	O
,	O
with	O
Concomitant	O
Methotrexate	O
.	O
	
Signs	O
and	O
symptoms	O
associated	O
with	O
more	O
severe	O
and/or	O
acute	O
cases	O
have	O
included	O
hallucination	B
,	O
syncope	B
,	O
seizure	B
,	O
coma	B
,	O
respiratory	B
arrest	I
,	O
and	O
death	B
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
*	O
In	O
male	O
and	O
female	O
rats	O
,	O
dulaglutide	O
causes	O
a	O
dose-related	O
and	O
treatment-duration-dependent	O
increase	O
in	O
the	O
incidence	O
of	O
thyroid	B
C-cell	I
tumors	I
)	O
after	O
lifetime	O
exposure	O
.	O
	
A	O
gradual	O
reduction	O
in	O
the	O
dose	O
rather	O
than	O
abrupt	O
cessation	O
is	O
recommended	O
whenever	O
possible	O
.	O
	
Changes	O
in	O
body	O
weight	O
(	O
kg	O
)	O
and	O
the	O
proportion	O
of	O
subjects	O
with	O
>	O
=7	O
%	O
gain	B
in	I
body	I
weight	I
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
in	O
adult	O
subjects	O
are	O
presented	O
in	O
Table	O
6	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
>	O
=4	O
%	O
of	O
patients	O
treated	O
with	O
NESINA	O
25	O
mg	O
and	O
more	O
frequently	O
than	O
in	O
patients	O
who	O
received	O
placebo	O
are	O
summarized	O
in	O
Table	O
1	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Picato	O
(	O
r	O
)	O
gel	O
in	O
499	O
subjects	O
with	O
actinic	O
keratosis	O
,	O
including	O
274	O
subjects	O
exposed	O
to	O
Picato	O
(	O
r	O
)	O
gel	O
field	O
treatment	O
(	O
skin	O
area	O
of	O
25	O
cm	O
2	O
in	O
the	O
face	O
or	O
scalp	O
regions	O
)	O
at	O
a	O
concentration	O
of	O
0.015	O
%	O
once	O
daily	O
for	O
3	O
consecutive	O
days	O
,	O
and	O
225	O
subjects	O
exposed	O
to	O
Picato	O
(	O
r	O
)	O
gel	O
field	O
treatment	O
(	O
skin	O
area	O
of	O
25	O
cm	O
2	O
in	O
the	O
trunk	O
or	O
extremities	O
regions	O
)	O
at	O
a	O
concentration	O
of	O
0.05	O
%	O
once	O
daily	O
for	O
2	O
consecutive	O
days	O
.	O
	
*	O
A	O
placebo-controlled	O
study	O
with	O
another	O
long-acting	O
beta2-adrenergic	O
agonist	O
(	O
salmeterol	O
)	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
patients	O
receiving	O
salmeterol	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Dyax	O
Corp.	O
at	O
1-888-452-5248	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
5.8	O
Embryo-fetal	O
Toxicity	O
TREANDA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
In	O
Study	O
3	O
,	O
22/230	O
(	O
9.6	O
%	O
)	O
patients	O
had	O
aspartate	B
aminotransferase	I
greater	I
than	I
or	I
equal	I
to	I
3	I
times	I
the	I
upper	I
limit	I
of	I
normal	I
during	O
the	O
overall	O
treatment	O
period	O
.	O
	
Consider	O
these	O
factors	O
prior	O
to	O
initiating	O
Qutenza	O
treatment	O
.	O
	
Acute	B
renal	I
failure	I
was	O
reported	O
more	O
frequently	O
in	O
patients	O
with	O
advanced	O
relapsed	O
and	O
refractory	O
multiple	O
myeloma	O
who	O
received	O
Kyprolis	O
monotherapy	O
.	O
	
What	O
is	O
the	O
most	O
important	O
information	O
I	O
should	O
know	O
about	O
DUAVEE	O
?	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
reactions	O
are	O
described	O
in	O
greater	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
:	O
*	O
Hypersensitivity	B
reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
in	O
either	O
indication	O
)	O
are	O
nausea	B
,	O
diarrhea	B
,	O
headache	B
and	O
pyrexia	B
.	O
	
Patients	O
received	O
ERWINAZE	O
25,000	O
International	O
Unit/m	O
2	O
/dose	O
,	O
administered	O
by	O
intravenous	O
infusion	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
and	O
Friday	O
schedule	O
(	O
6	O
doses	O
)	O
as	O
a	O
replacement	O
for	O
doses	O
remaining	O
on	O
their	O
original	O
treatment	O
plan	O
.	O
	
However	O
,	O
bronchitis	B
,	O
herpes	B
zoster	I
,	O
influenza	B
,	O
sinusitis	B
,	O
and	O
pneumonia	B
were	O
more	O
common	O
in	O
GILENYA-treated	O
patients	O
.	O
	
They	O
are	O
not	O
interchangeable	O
with	O
the	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
and	O
,	O
therefore	O
,	O
Units	O
of	O
biological	O
activity	O
of	O
XEOMIN	O
can	O
not	O
be	O
compared	O
to	O
or	O
converted	O
into	O
Units	O
of	O
any	O
other	O
botulinum	O
toxin	O
products	O
assessed	O
with	O
any	O
other	O
specific	O
assay	O
method	O
[	O
see	O
Description	O
(	O
11	O
)	O
]	O
.	O
	
When	O
switching	O
to	O
GILENYA	O
from	O
immune-modulating	O
or	O
immunosuppressive	O
medications	O
,	O
consider	O
the	O
duration	O
of	O
their	O
effects	O
and	O
their	O
mode	O
of	O
action	O
to	O
avoid	O
unintended	O
additive	O
immunosuppressive	O
effects	O
.	O
	
(	O
5.6	O
)	O
*	O
Hypothyroidism	B
requiring	O
thyroid	O
hormone	O
replacement	O
has	O
been	O
reported	O
.	O
	
Whether	O
antipsychotic	O
drug	O
products	O
differ	O
in	O
their	O
potential	O
to	O
cause	O
tardive	O
dyskinesia	O
is	O
unknown	O
.	O
	
Provide	O
patients	O
with	O
an	O
anti-diarrheal	O
agent	O
(	O
e.g.	O
,	O
loperamide	O
)	O
for	O
self-administration	O
at	O
the	O
onset	O
of	O
diarrhea	O
and	O
instruct	O
patients	O
to	O
continue	O
anti-diarrheal	O
therapy	O
until	O
loose	O
bowel	O
movements	O
cease	O
for	O
12	O
hours	O
.	O
	
BENLYSTA	O
should	O
be	O
administered	O
by	O
healthcare	O
providers	O
prepared	O
to	O
manage	O
anaphylaxis	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
SUPINE	B
HYPERTENSION	I
WARNING	O
:	O
SUPINE	B
HYPERTENSION	I
Monitor	O
supine	O
blood	O
pressure	O
prior	O
to	O
and	O
during	O
treatment	O
and	O
more	O
frequently	O
when	O
increasing	O
doses	O
.	O
	
*	O
While	O
the	O
effect	O
of	O
weak	O
CYP3A4	O
inhibitors	O
(	O
e.g	O
.	O
	
Table	O
2	O
summarizes	O
all	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
patients	O
(	O
2	O
or	O
more	O
patients	O
)	O
treated	O
with	O
alglucosidase	O
alfa	O
in	O
clinical	O
trials	O
described	O
above	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=10	O
%	O
of	O
Treatment-Naive	O
GD1	O
Patients	O
and	O
More	O
Frequently	O
than	O
Placebo	O
(	O
Trial	O
1	O
)	O
CERDELGA	O
(	O
N=20	O
)	O
Placebo	O
(	O
N=20	O
)	O
Adverse	O
Reaction	O
Patientsn	O
(	O
%	O
)	O
Patientsn	O
(	O
%	O
)	O
Arthralgia	B
9	O
(	O
45	O
)	O
2	O
(	O
10	O
)	O
Headache	B
8	O
(	O
40	O
)	O
6	O
(	O
30	O
)	O
Migraine	B
2	O
(	O
10	O
)	O
0	O
(	O
0	O
)	O
Flatulence	B
2	O
(	O
10	O
)	O
1	O
(	O
5	O
)	O
Nausea	B
2	O
(	O
10	O
)	O
1	O
(	O
5	O
)	O
Oropharyngeal	B
pain	I
2	O
(	O
10	O
)	O
1	O
(	O
5	O
)	O
Table	O
2	O
presents	O
the	O
profile	O
from	O
the	O
12-month	O
open-label	O
,	O
randomized	O
,	O
imiglucerase-controlled	O
trial	O
of	O
159	O
treated	O
patients	O
switching	O
from	O
enzyme	O
replacement	O
therapy	O
(	O
ERT	O
)	O
(	O
Trial	O
2	O
)	O
.	O
	
The	O
Grade	O
3	O
laboratory	O
abnormalities	O
were	O
elevated	B
total	I
bilirubin	I
reported	O
in	O
1	O
subject	O
each	O
.	O
	
ELIQUIS2.5	O
mg	O
po	O
bid35+/-3	O
days	O
Enoxaparin	O
40	O
mg	O
sc	O
qd	O
35+/-3	O
days	O
ELIQUIS	O
2.5	O
mg	O
po	O
bid	O
12+/-2	O
days	O
Enoxaparin	O
40	O
mg	O
sc	O
qd	O
12+/-2	O
days	O
ELIQUIS	O
2.5	O
mg	O
po	O
bid	O
12+/-2	O
days	O
Enoxaparin	O
30	O
mg	O
sc	O
q12h	O
12+/-2	O
days	O
First	O
dose	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
First	O
dose	O
9	O
to	O
15	O
hours	O
prior	O
to	O
surgery	O
First	O
dose	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
First	O
dose	O
9	O
to	O
15	O
hours	O
prior	O
to	O
surgery	O
First	O
dose	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
First	O
dose	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
All	O
treated	O
N=2673	O
N=2659	O
N=1501	O
N=1508	O
N=1596	O
N=1588	O
Major	O
(	O
including	O
surgical	O
site	O
)	O
22	O
(	O
0.82	O
%	O
)	O
18	O
(	O
0.68	O
%	O
)	O
9	O
(	O
0.60	O
%	O
)	O
?	O
	
Flush	O
immediately	O
with	O
water	O
if	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
comes	O
into	O
contact	O
with	O
eyes	O
.	O
	
1	O
Risks	O
of	O
Treatment	O
in	O
Patients	O
with	O
Infectious	O
Diarrhea	O
If	O
infectious	O
etiologies	O
are	O
not	O
considered	O
,	O
and	O
FULYZAQ	O
is	O
initiated	O
based	O
on	O
a	O
presumptive	O
diagnosis	O
of	O
non-infectious	O
diarrhea	O
,	O
then	O
there	O
is	O
a	O
risk	O
that	O
patients	O
with	O
infectious	O
etiologies	O
will	O
not	O
receive	O
the	O
appropriate	O
treatments	O
,	O
and	O
their	O
disease	O
may	O
worsen	O
.	O
	
*	O
Pulmonary	B
Toxicity	I
:	O
Monitor	O
patients	O
for	O
new	O
or	O
worsening	O
symptoms	O
(	O
5.10	O
)	O
.	O
	
(	O
5.1	O
,	O
13.1	O
)	O
*	O
TANZEUM	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
Multiple	O
Endocrine	O
Neoplasia	O
syndrome	O
type	O
2	O
(	O
MEN	O
2	O
)	O
.	O
	
An	O
increased	O
rate	O
of	O
stroke	B
was	O
observed	O
during	O
the	O
transition	O
from	O
ELIQUIS	O
to	O
warfarin	O
in	O
clinical	O
trials	O
in	O
atrial	O
fibrillation	O
patients	O
.	O
	
Other	O
GLP-1	O
receptor	O
agonists	O
have	O
caused	O
dose-related	O
and	O
treatment-duration-dependent	O
thyroid	B
C-cell	I
tumors	I
)	O
in	O
rodents	O
.	O
	
Activated	O
oral	O
charcoal	O
reduces	O
absorption	O
of	O
apixaban	O
,	O
thereby	O
lowering	O
apixaban	O
plasma	O
concentration	O
[	O
seeOverdosage	O
(	O
10	O
)	O
]	O
.	O
	
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
asthenia	B
,	O
chest	B
pain	I
,	O
edema	B
,	O
fatigue	B
,	O
feeling	B
abnormal	I
,	O
gait	B
disturbance	I
,	O
influenza-like	B
symptoms	I
,	O
mass	B
,	O
pain	B
,	O
thirst	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
See	O
the	O
peginterferon	O
alfa	O
and	O
ribavirin	O
prescribing	O
information	O
for	O
description	O
of	O
adverse	O
reactions	O
associated	O
with	O
their	O
use	O
.	O
	
Discontinuations	O
Adverse	O
reactions	O
led	O
to	O
treatment	O
discontinuation	O
in	O
21	O
%	O
of	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
Keep	O
DUAVEE	O
and	O
all	O
other	O
medicines	O
out	O
of	O
the	O
reach	O
of	O
children	O
.	O
	
(	O
6.1	O
,	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GE	O
Healthcare	O
at	O
1-800-654-0118	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
General	O
information	O
about	O
the	O
safe	O
and	O
effective	O
use	O
of	O
DUAVEE	O
Medicines	O
are	O
sometimes	O
prescribed	O
for	O
purposes	O
other	O
than	O
those	O
listed	O
in	O
a	O
Patient	O
Information	O
leaflet	O
.	O
	
STENDRA	O
was	O
administered	O
to	O
2215	O
men	O
during	O
clinical	O
trials	O
.	O
	
Respiratory	O
,	O
Thoracic	O
and	O
Mediastinal	O
Disorders	O
:	O
bronchitis	B
,	O
cough	B
,	O
dyspnea	B
,	O
epistaxis	B
,	O
nasal	B
dryness	I
,	O
paranasal	B
sinus	I
hypersecretion	I
,	O
pharyngeal	B
edema	I
,	O
respiratory	B
tract	I
congestion	I
,	O
sneezing	B
,	O
throat	B
irritation	I
,	O
upper	B
respiratory	I
tract	I
infection	I
.	O
	
Risk	O
may	O
be	O
increased	O
with	O
neutropenia	O
,	O
age	O
,	O
steroid	O
use	O
,	O
concomitant	O
use	O
of	O
NSAIDs	O
,	O
anti-platelet	O
therapy	O
or	O
anti-coagulants	O
,	O
and	O
patients	O
with	O
a	O
prior	O
history	O
of	O
pelvic	O
radiotherapy	O
,	O
adhesions	O
,	O
ulceration	O
and	O
GI	O
bleeding	O
.	O
	
The	O
treatment	O
discontinuation	O
rate	O
due	O
to	O
anemia	B
was	O
similar	O
in	O
subjects	O
randomized	O
to	O
receive	O
ribavirin	O
dose	O
reduction	O
compared	O
to	O
subjects	O
randomized	O
to	O
receive	O
ESA	O
(	O
2	O
%	O
in	O
each	O
group	O
)	O
.	O
	
PROMACTA	O
inhibits	O
UDP-glucuronosyltransferase	O
(	O
UGT	O
)	O
1A1	O
and	O
organic	O
anion-transporting	O
polypeptide	O
(	O
OATP	O
)	O
1B1	O
,	O
which	O
may	O
lead	O
to	O
indirect	B
hyperbilirubinemia	I
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
was	O
10.9	O
months	O
for	O
both	O
TAFINLAR	O
and	O
trametinib	O
(	O
2-mg	O
orally	O
once-daily	O
treatment	O
group	O
)	O
when	O
used	O
in	O
combination	O
,	O
10.6	O
months	O
for	O
both	O
TAFINLAR	O
and	O
trametinib	O
(	O
1-mg	O
orally	O
once-daily	O
treatment	O
group	O
)	O
when	O
used	O
in	O
combination	O
,	O
and	O
6.1	O
months	O
for	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
Gastrointestinal	O
Disorders	O
:	O
abdominal	B
distention	I
,	O
abdominal	B
pain	I
,	O
constipation	B
,	O
dry	B
mouth	I
,	O
dyspepsia	B
,	O
flatulence	B
,	O
frequent	B
stools	I
,	O
gastritis	B
,	O
gastroesophageal	B
reflux	I
disease	I
,	O
gastrointestinal	B
discomfort	I
,	O
gingival	B
pain	I
,	O
haematemesis	B
,	O
hyperchlorhydria	B
,	O
hematochezia	B
,	O
mouth	B
ulceration	I
,	O
pancreatitis	B
,	O
peptic	B
ulcer	I
,	O
vomiting	B
.	O
	
Report	O
any	O
diagnosis	O
of	O
NSF	O
following	O
Gadavist	O
administration	O
to	O
Bayer	O
Healthcare	O
(	O
1-888-842-2937	O
)	O
or	O
FDA	O
(	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
)	O
.	O
	
5.9	O
Renal	O
Impairment	O
and	O
Failure	O
Marked	O
increase	B
in	I
serum	I
creatinine	I
,	O
pre-renal	B
azotemia	I
and	O
acute	B
renal	I
failure	I
,	O
often	O
in	O
the	O
setting	O
of	O
heart	B
failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
or	O
hypovolemia	B
,	O
have	O
been	O
reported	O
in	O
patients	O
taking	O
MULTAQ	O
.	O
	
Tissue	O
culture	O
experiments	O
indicate	O
that	O
approximately	O
one-third	O
of	O
human	O
breast	O
cancers	O
are	O
prolactin-dependent	O
in	O
vitro	O
,	O
a	O
factor	O
of	O
potential	O
importance	O
if	O
the	O
prescription	O
of	O
these	O
drugs	O
is	O
considered	O
in	O
a	O
patient	O
with	O
previously-detected	O
breast	O
cancer	O
.	O
	
(	O
5.1	O
)	O
Local	B
skin	I
reactions	I
)	O
.	O
	
In	O
the	O
relapsed	O
classical	O
HL	O
and	O
sALCL	O
clinical	O
trials	O
,	O
54	O
%	O
of	O
patients	O
experienced	O
any	O
grade	O
of	O
neuropathy	B
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
exceeded	O
a	O
predetermined	O
threshold	O
value	O
is	O
shown	O
in	O
Table	O
4	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Salix	O
Pharmaceuticals	O
at	O
1-800-508-0024	O
or	O
www.Salix.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5	O
.	O
	
(	O
5.2	O
)	O
*	O
Contact	B
dermatitis	I
:	O
May	O
occur	O
with	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
.	O
	
Cardiomyopathy	B
was	O
identified	O
within	O
the	O
first	O
month	O
of	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
in	O
two	O
of	O
five	O
patients	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
bleeding	B
events	O
was	O
approximately	O
1	O
%	O
in	O
the	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
0.4	O
%	O
in	O
those	O
patients	O
in	O
the	O
placebo	O
group	O
in	O
the	O
AMPLIFY-EXT	O
study	O
.	O
	
These	O
reactions	O
occurred	O
within	O
the	O
first	O
hour	O
after	O
dosing	O
.	O
	
Opportunistic	B
infections	I
have	O
also	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
ILARIS	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Advise	O
patients	O
to	O
immediately	O
seek	O
medical	O
care	O
if	O
they	O
develop	O
symptoms	O
of	O
DVT	O
or	O
PE	O
,	O
such	O
as	O
shortness	O
of	O
breath	O
,	O
chest	O
pain	O
,	O
or	O
arm	O
or	O
leg	O
swelling	O
.	O
	
For	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
during	O
treatment	O
with	O
SIMPONI	O
ARIA	O
,	O
perform	O
a	O
prompt	O
and	O
complete	O
diagnostic	O
workup	O
appropriate	O
for	O
an	O
immunocompromised	O
patient	O
and	O
initiate	O
appropriate	O
antimicrobial	O
therapy	O
and	O
closely	O
monitor	O
them	O
.	O
	
Appropriate	O
laboratory	O
testing	O
prior	O
to	O
initiating	O
therapy	O
and	O
monitoring	O
for	O
hepatotoxicity	O
during	O
therapy	O
with	O
TIVICAY	O
are	O
recommended	O
in	O
patients	O
with	O
underlying	O
hepatic	O
disease	O
such	O
as	O
hepatitis	O
B	O
or	O
C.	O
5.3	O
Fat	O
Redistribution	O
buffalo	B
hump	I
,	O
facial	B
wasting	I
,	O
breast	B
enlargement	I
,	O
and	O
``	O
cushingoid	B
appearance	I
''	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
The	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
positive	O
for	O
antibodies	O
to	O
belimumab	O
in	O
specific	O
assays	O
.	O
	
Of	O
the	O
609	O
subjects	O
,	O
58	O
%	O
were	O
female	O
and	O
84	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
40	O
years	O
.	O
	
This	O
may	O
result	O
in	O
a	O
critical	O
loss	B
of	I
breathing	I
capacity	I
in	O
patients	O
with	O
respiratory	O
disorders	O
who	O
may	O
have	O
become	O
dependent	O
upon	O
these	O
accessory	O
muscles	O
.	O
	
5.2	O
Bullous	O
and	O
Exfoliative	O
Skin	O
Disorders	O
Grade	O
3	O
cutaneous	B
reactions	I
characterized	O
by	O
exfoliating	B
lesions	I
occurred	O
in	O
6	O
(	O
0.15	O
%	O
)	O
of	O
the	O
3865	O
patients	O
who	O
received	O
GILOTRIF	O
across	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Carfilzomib	O
caused	O
embryo-fetal	B
toxicity	I
in	O
pregnant	O
rabbits	O
at	O
doses	O
that	O
were	O
lower	O
than	O
in	O
patients	O
receiving	O
the	O
recommended	O
dose	O
.	O
	
Table	O
4	O
lists	O
treatment-emergent	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
patients	O
with	O
RLS	O
treated	O
with	O
HORIZANT	O
and	O
numerically	O
greater	O
than	O
placebo	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
depression	O
,	O
suicidal	O
thoughts	O
or	O
other	O
mood	O
changes	O
,	O
and	O
if	O
such	O
changes	O
occur	O
to	O
contact	O
their	O
healthcare	O
provider	O
.	O
	
Although	O
the	O
prevalence	O
of	O
the	O
syndrome	O
appears	O
to	O
be	O
highest	O
among	O
the	O
elderly	O
,	O
especially	O
elderly	O
women	O
,	O
it	O
is	O
impossible	O
to	O
rely	O
on	O
prevalence	O
estimates	O
to	O
predict	O
,	O
at	O
the	O
inception	O
of	O
antipsychotic	O
treatment	O
,	O
which	O
patients	O
are	O
likely	O
to	O
develop	O
the	O
syndrome	O
.	O
	
Prior	O
and	O
Concomitant	O
Treatment	O
with	O
Antineoplastic	O
,	O
Immunosuppressive	O
,	O
or	O
Immune-Modulating	O
Therapies	O
In	O
clinical	O
studies	O
,	O
patients	O
who	O
received	O
GILENYA	O
did	O
not	O
receive	O
concomitant	O
treatment	O
with	O
antineoplastic	O
,	O
non-corticosteroid	O
immunosuppressive	O
,	O
or	O
immune-modulating	O
therapies	O
used	O
for	O
treatment	O
of	O
MS.	O
Concomitant	O
use	O
of	O
GILENYA	O
with	O
any	O
of	O
these	O
therapies	O
,	O
and	O
also	O
with	O
corticosteroids	O
,	O
would	O
be	O
expected	O
to	O
increase	O
the	O
risk	O
of	O
immunosuppression	B
[	O
see	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
There	O
were	O
no	O
adverse	O
reactions	O
resulting	O
in	O
permanent	O
discontinuation	O
.	O
	
In	O
patients	O
>	O
=	O
75	O
years	O
of	O
age	O
,	O
the	O
risk	O
of	O
cardiac	O
failure	O
is	O
increased	O
.	O
	
5.5	O
Use	O
with	O
Abatacept	O
In	O
controlled	O
trials	O
,	O
the	O
concurrent	O
administration	O
of	O
another	O
TNF-blocker	O
and	O
abatacept	O
was	O
associated	O
with	O
a	O
greater	O
proportion	O
of	O
serious	O
infections	O
than	O
the	O
use	O
of	O
a	O
TNF-blocker	O
alone	O
;	O
and	O
the	O
combination	O
therapy	O
,	O
compared	O
to	O
the	O
use	O
of	O
a	O
TNF-blocker	O
alone	O
,	O
has	O
not	O
demonstrated	O
improved	O
clinical	O
benefit	O
in	O
the	O
treatment	O
of	O
RA	O
.	O
	
In	O
both	O
Studies	O
1	O
and	O
2	O
,	O
aminotransferase	B
elevations	I
of	O
at	O
least	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
developed	O
more	O
frequently	O
in	O
the	O
SIRTURO	O
treatment	O
group	O
(	O
11/102	O
[	O
10.8	O
%	O
]	O
vs	O
6/105	O
[	O
5.7	O
%	O
]	O
)	O
than	O
in	O
the	O
placebo	O
treatment	O
group	O
.	O
	
The	O
incidence	O
rates	O
of	O
adjudicated	O
bone	B
fractures	I
were	O
1.1	O
,	O
1.4	O
,	O
and	O
1.5	O
per	O
100	O
patient-years	O
of	O
exposure	O
in	O
the	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
groups	O
,	O
respectively	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
events	O
reported	O
in	O
patients	O
treated	O
with	O
XALKORI	O
were	O
dyspnea	B
(	O
4.1	O
%	O
)	O
and	O
pulmonary	B
embolism	I
(	O
2.9	O
%	O
)	O
.	O
	
No	O
study	O
adequate	O
to	O
determine	O
whether	O
the	O
rate	O
of	O
asthma-related	O
death	O
is	O
increased	O
in	O
patients	O
treated	O
with	O
ARCAPTA	O
NEOHALER	O
has	O
been	O
conducted	O
.	O
	
Hypersensitivity	B
reactions	I
including	O
anaphylaxis	B
,	O
angioedema	B
,	O
rash	B
,	O
urticaria	B
and	O
severe	O
cutaneous	B
adverse	I
reactions	I
,	O
including	O
Stevens-Johnson	B
syndrome	I
,	O
hepatic	B
enzyme	I
elevations	I
,	O
fulminant	B
hepatic	I
failure	I
,	O
severe	O
and	O
disabling	O
arthralgia	B
and	O
acute	B
pancreatitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1,5.2,5.3,5.5	O
)	O
]	O
.	O
	
Cases	O
of	O
SJS	B
and	O
TEN	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
when	O
TREANDA	O
was	O
administered	O
concomitantly	O
with	O
allopurinol	O
and	O
other	O
medications	O
known	O
to	O
cause	O
these	O
syndromes	O
.	O
	
(	O
2.2	O
)	O
Complications	O
of	O
myelosuppression	B
may	O
lead	O
to	O
death	B
.	O
	
Adverse	O
reactions	O
of	O
sinus	B
tachycardia	I
were	O
reported	O
more	O
frequently	O
in	O
patients	O
exposed	O
to	O
TRULICITY	O
.	O
	
Adverse	O
Reaction	O
(	O
Preferred	O
Term	O
)	O
Placebo+	O
MTX	O
(	O
%	O
)	O
N	O
=324	O
CIMZIA	O
200	O
mg	O
EOW	O
+	O
MTX	O
(	O
%	O
)	O
N	O
=640	O
Upper	B
respiratory	I
tract	I
infection	I
2	O
6	O
Headache	B
4	O
5	O
Hypertension	B
2	O
5	O
Nasopharyngitis	B
1	O
5	O
Back	B
pain	I
1	O
4	O
Pyrexia	B
2	O
3	O
Pharyngitis	B
1	O
3	O
Rash	B
1	O
3	O
Acute	B
bronchitis	I
1	O
3	O
Fatigue	B
2	O
3	O
Hypertensive	B
adverse	I
reactions	I
were	O
observed	O
more	O
frequently	O
in	O
patients	O
receiving	O
CIMZIA	O
than	O
in	O
controls	O
.	O
	
5.7	O
Topical	O
Ophthalmic	O
Use	O
Only	O
DUREZOL	O
is	O
not	O
indicated	O
for	O
intraocular	O
administration	O
.	O
	
1.5	O
8.4	O
6.9	O
Nasopharyngitis	B
6.2	O
6.6	O
6.3	O
Urinary	O
tract	O
infectionsUrinary	O
tract	B
infections	I
include	O
the	O
following	O
adverse	O
reactions	O
,	O
listed	O
in	O
order	O
of	O
frequency	O
reported	O
:	O
urinary	B
tract	I
infection	I
,	O
cystitis	B
,	O
Escherichia	B
urinary	I
tract	I
infection	I
,	O
genitourinary	B
tract	I
infection	I
,	O
pyelonephritis	B
,	O
trigonitis	B
,	O
urethritis	B
,	O
kidney	B
infection	I
,	O
and	O
prostatitis	B
.	O
	
TANZEUM	O
was	O
used	O
as	O
monotherapy	O
in	O
1	O
trial	O
and	O
as	O
add-on	O
therapy	O
in	O
3	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Ninety-two	O
percent	O
(	O
92	O
%	O
)	O
of	O
patients	O
on	O
the	O
COMETRIQ	O
arm	O
had	O
a	O
prior	O
thyroidectomy	O
,	O
and	O
89	O
%	O
were	O
taking	O
thyroid	O
hormone	O
replacement	O
prior	O
to	O
the	O
first	O
dose	O
.	O
	
*	O
Fatal	B
and	O
serious	O
intestinal	B
perforation	I
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
across	O
clinical	O
trials	O
.	O
	
The	O
adverse	O
reactions	O
described	O
in	O
this	O
section	O
reflect	O
EOVIST	O
exposure	O
in	O
1,989	O
subjects	O
with	O
the	O
majority	O
(	O
1,581	O
subjects	O
)	O
receiving	O
the	O
recommended	O
dose	O
.	O
	
Cases	O
were	O
consistent	O
with	O
hepatocellular	B
injury	I
,	O
including	O
elevations	B
of	I
transaminases	I
.	O
	
gfatal	O
:	O
Adjudicated	O
major	O
bleed	B
as	O
defined	O
above	O
and	O
adjudicated	O
death	B
with	O
primary	O
cause	O
from	O
bleeding	B
but	O
without	O
symptomatic	B
intracranial	I
bleed	I
based	O
on	O
investigator	O
's	O
clinical	O
assessment	O
.	O
	
Although	O
BREO	O
ELLIPTA	O
may	O
control	O
COPD	O
or	O
asthma	O
symptoms	O
during	O
these	O
episodes	O
,	O
in	O
recommended	O
doses	O
it	O
supplies	O
less	O
than	O
normal	O
physiological	O
amounts	O
of	O
glucocorticoid	O
systemically	O
and	O
does	O
NOT	O
provide	O
the	O
mineralocorticoid	O
activity	O
that	O
is	O
necessary	O
for	O
coping	O
with	O
these	O
emergencies	O
.	O
	
The	O
majority	O
of	O
the	O
patients	O
were	O
white	O
(	O
87.7	O
%	O
)	O
,	O
10.3	O
%	O
were	O
Asian	O
,	O
and	O
1.9	O
%	O
were	O
black	O
with	O
a	O
mean	O
CrCl	O
of	O
105.6	O
mL/min	O
.	O
	
Data	O
from	O
a	O
large	O
,	O
prospective	O
cohort	O
safety	O
study	O
of	O
various	O
COCs	O
suggest	O
that	O
this	O
increased	O
risk	O
,	O
as	O
compared	O
to	O
that	O
in	O
non-COC	O
users	O
,	O
is	O
greatest	O
during	O
the	O
first	O
6	O
months	O
of	O
COC	O
use	O
.	O
	
TRULICITY	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
MEN	O
2	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
FATAL	B
AND	O
SERIOUS	O
TOXICITIES	B
,	O
SEVERE	O
DIARRHEA	B
,	O
COLITIS	B
,	O
PNEUMONITIS	B
,	O
and	O
INTESTINAL	B
PERFORATION	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Increased	B
susceptibility	I
to	I
infection	I
and	O
the	O
possible	O
development	O
of	O
malignancies	B
may	O
result	O
from	O
immunosuppression	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
]	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
was	O
similar	O
after	O
each	O
injection	O
,	O
regardless	O
of	O
the	O
number	O
of	O
injections	O
administered	O
.	O
	
5.7	O
Hypertension	O
Assess	O
the	O
patient	O
's	O
pulse	O
and	O
blood	O
pressure	O
before	O
and	O
intermittently	O
for	O
30	O
minutes	O
after	O
AdreView	O
administration	O
.	O
	
(	O
5.2	O
)	O
item	O
{	O
Delayed	O
healing-	O
The	O
use	O
of	O
steroids	O
after	O
cataract	O
surgery	O
may	O
delay	B
healing	I
and	O
increase	B
the	I
incidence	I
of	I
bleb	I
formation	I
.	O
	
Anti-belatacept	O
antibody	O
titers	O
did	O
not	O
increase	O
during	O
treatment	O
in	O
these	O
29	O
patients	O
.	O
	
Percentage	O
(	O
%	O
)	O
of	O
Patients	O
YERVOY3	O
mg/kgn=131	O
YERVOY3	O
mg/kg+gp100n=380	O
Any	O
Immune-mediated	O
Adverse	O
Reaction	O
15	O
12	O
Enterocolitisa	O
,	O
b	O
7	O
7	O
Hepatotoxicitya	O
1	O
2	O
Dermatitisa	O
2	O
3	O
Neuropathya	O
1	O
<	O
1	O
Endocrinopathy	B
4	O
1	O
Hypopituitarism	B
4	O
1	O
Adrenal	B
insufficiency	I
0	O
1	O
Other	O
Pneumonitis	B
0	O
<	O
1	O
Meningitis	B
0	O
<	O
1	O
Nephritis	B
1	O
0	O
Eosinophiliac	O
1	O
0	O
Pericarditisa	O
,	O
c	O
0	O
<	O
1	O
Across	O
clinical	O
studies	O
that	O
utilized	O
YERVOY	O
doses	O
ranging	O
from	O
0.3	O
to	O
10	O
mg/kg	O
,	O
the	O
following	O
adverse	O
reactions	O
were	O
also	O
reported	O
(	O
incidence	O
less	O
than	O
1	O
%	O
unless	O
otherwise	O
noted	O
)	O
:	O
urticaria	B
(	O
2	O
%	O
)	O
,	O
large	B
intestinal	I
ulcer	I
,	O
esophagitis	B
,	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
renal	B
failure	I
,	O
and	O
infusion	B
reaction	I
.	O
	
Therefore	O
,	O
BREO	O
ELLIPTA	O
,	O
like	O
other	O
sympathomimetic	O
amines	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
cardiovascular	O
disorders	O
,	O
especially	O
coronary	O
insufficiency	O
,	O
cardiac	O
arrhythmias	O
,	O
and	O
hypertension	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
these	O
symptoms	O
when	O
discontinuing	O
treatment	O
with	O
PRISTIQ	O
.	O
	
In	O
other	O
XIAFLEX-treated	O
patients	O
(	O
9	O
of	O
1044	O
;	O
0.9	O
%	O
)	O
,	O
a	O
diagnosis	O
of	O
corporal	B
rupture	I
can	O
not	O
be	O
excluded	O
.	O
	
Patients	O
receiving	O
CIMZIA	O
400	O
mg	O
as	O
monotherapy	O
every	O
4	O
weeks	O
in	O
rheumatoid	O
arthritis	O
controlled	O
clinical	O
trials	O
had	O
similar	O
adverse	O
reactions	O
to	O
those	O
patients	O
receiving	O
CIMZIA	O
200	O
mg	O
every	O
other	O
week	O
.	O
	
(	O
5.1	O
)	O
*	O
Serious	O
Dermatologic	B
Reactions	I
,	O
Drug	B
Reaction	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
,	O
Anaphylactic	B
Reactions	I
and	O
Angioedema	B
:	O
Monitor	O
and	O
discontinue	O
if	O
another	O
cause	O
can	O
not	O
be	O
established	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
*	O
Long-acting	O
beta2-adrenergic	O
agonists	O
(	O
LABA	O
)	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
(	O
5.1	O
)	O
.	O
	
A	O
causal	O
relationship	O
between	O
study	O
drug	O
and	O
adverse	O
reactions	O
was	O
not	O
always	O
established	O
.	O
	
In	O
a	O
study	O
of	O
55	O
subjects	O
with	O
varying	O
degrees	O
of	O
renal	O
function	O
,	O
serum	O
calcium	O
levels	O
<	O
7.5	O
mg/dL	O
or	O
symptomatic	B
hypocalcemia	I
were	O
observed	O
in	O
5	O
subjects	O
.	O
	
Seven	O
(	O
8.9	O
%	O
)	O
SIRTURO-treated	O
patients	O
and	O
six	O
(	O
7.4	O
%	O
)	O
placebo-treated	O
patients	O
discontinued	O
Study	O
1	O
because	O
of	O
an	O
adverse	O
reaction	O
.	O
	
A	O
total	O
of	O
171	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
received	O
pemetrexed	O
500	O
mg/m	O
2	O
(	O
n=99	O
)	O
or	O
docetaxel	O
75	O
mg/m	O
2	O
(	O
n=72	O
)	O
by	O
intravenous	O
infusion	O
every	O
three	O
weeks	O
until	O
documented	O
disease	O
progression	O
,	O
intolerance	O
to	O
therapy	O
,	O
or	O
the	O
investigator	O
determined	O
that	O
the	O
patient	O
was	O
no	O
longer	O
experiencing	O
clinical	O
benefit	O
.	O
	
Adverse	O
Reactions	O
Associated	O
with	O
Discontinuation	O
of	O
Treatment	O
:	O
Approximately	O
10	O
%	O
(	O
38/379	O
)	O
of	O
SAPHRIS-treated	O
patients	O
in	O
short-term	O
,	O
placebo-controlled	O
trials	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
reaction	O
,	O
compared	O
with	O
about	O
6	O
%	O
(	O
12/203	O
)	O
on	O
placebo	O
.	O
	
Malignancies	O
in	O
Adult	O
Patients	O
The	O
risks	O
and	O
benefits	O
of	O
TNF-blocker	O
treatment	O
including	O
SIMPONI	O
ARIA	O
should	O
be	O
considered	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
a	O
known	O
malignancy	O
other	O
than	O
a	O
successfully	O
treated	O
non-melanoma	O
skin	O
cancer	O
(	O
NMSC	O
)	O
or	O
when	O
considering	O
continuing	O
a	O
TNF-blocker	O
in	O
patients	O
who	O
develop	O
a	O
malignancy	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
reaction	O
was	O
headache	B
(	O
1.5	O
%	O
)	O
.	O
	
This	O
may	O
result	O
in	O
critical	O
loss	B
of	I
breathing	I
capacity	I
in	O
patients	O
with	O
respiratory	O
disorders	O
who	O
may	O
have	O
become	O
dependent	O
upon	O
these	O
accessory	O
muscles	O
.	O
	
The	O
safety	O
data	O
described	O
below	O
are	O
based	O
on	O
two	O
12-week	O
efficacy	O
trials	O
,	O
one	O
24-week	O
efficacy	O
trial	O
,	O
and	O
two	O
long-term	O
trials	O
.	O
	
Because	O
postmarketing	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
The	O
incidence	O
of	O
macular	B
edema	I
is	O
also	O
increased	O
in	O
MS	O
patients	O
with	O
a	O
history	O
of	O
uveitis	O
.	O
	
Patients	O
should	O
be	O
instructed	O
to	O
contact	O
their	O
healthcare	O
provider	O
if	O
they	O
experience	O
new	O
or	O
worsening	O
depression	O
,	O
suicidal	O
thoughts	O
or	O
other	O
mood	O
changes	O
.	O
	
At	O
screening	O
,	O
the	O
mean	O
postbronchodilator	O
percent	O
predicted	O
FEV1was	O
45	O
%	O
(	O
range	O
:	O
12	O
%	O
to	O
91	O
%	O
)	O
,	O
and	O
the	O
mean	O
postbronchodilator	O
FEV1/FVC	O
ratio	O
was	O
46	O
%	O
(	O
range	O
:	O
17	O
%	O
to	O
81	O
%	O
)	O
,	O
indicating	O
that	O
the	O
subject	O
population	O
had	O
moderate	O
to	O
very	O
severely	O
impaired	O
airflow	O
obstruction	O
.	O
	
Patients	O
were	O
between	O
the	O
ages	O
of	O
16	O
and	O
63	O
on	O
the	O
date	O
of	O
the	O
first	O
dose	O
of	O
study	O
drug	O
,	O
and	O
included	O
20	O
males	O
and	O
20	O
females	O
.	O
	
Evaluate	O
for	O
tuberculosis	O
and	O
initiate	O
treatment	O
for	O
latent	O
infection	O
prior	O
to	O
NULOJIX	O
use	O
.	O
	
Immunogenicity	O
In	O
the	O
pool	O
of	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
116	O
(	O
5.5	O
%	O
)	O
of	O
2,098	O
patients	O
exposed	O
to	O
TANZEUM	O
tested	O
positive	O
for	O
anti-albiglutide	O
antibodies	O
at	O
any	O
time	O
during	O
the	O
trials	O
.	O
	
Psychiatric	O
disorders	O
-	O
Depersonalization	B
,	O
bruxism	B
.	O
	
Bleeding	B
into	I
an	I
operated	I
joint	I
requiring	O
re-operation	O
or	O
intervention	O
was	O
present	O
in	O
all	O
patients	O
with	O
this	O
category	O
of	O
bleeding	B
.	O
	
Severe	O
hypersensitivity	O
:	O
Severe	O
hypersensitivity	B
reactions	I
can	O
occur	O
and	O
may	O
include	O
generalized	B
rash/erythema	O
,	O
hypotension	B
and	O
bronchospasm	B
.	O
	
Among	O
these	O
were	O
vertigo	B
(	O
2	O
patients	O
)	O
,	O
infections	B
(	O
3	O
patients	O
)	O
,	O
including	O
intra-abdominal	B
abscess	I
following	O
appendectomy	O
(	O
1	O
patient	O
)	O
.	O
	
It	O
is	O
unknown	O
whether	O
TANZEUM	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Ophthalmic	O
Adverse	O
Reactions	O
Avoid	O
treatment	O
in	O
the	O
periocular	O
area	O
.	O
	
In	O
the	O
third	O
case	O
,	O
elevation	B
in	I
ALT	I
(	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
)	O
was	O
accompanied	O
by	O
an	O
increase	B
in	I
total	I
bilirubin	I
(	O
4	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
)	O
and	O
occurred	O
8	O
days	O
after	O
the	O
first	O
dose	O
of	O
TANZEUM	O
.	O
	
5.4	O
Genital	O
Mycotic	O
Infections	O
JARDIANCE	O
increases	O
the	O
risk	O
for	O
genital	B
mycotic	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Use	O
caution	O
in	O
patients	O
with	O
hemoglobin	O
<	O
10	O
g/dL	O
.	O
	
In	O
SAPHRIS	O
adult	O
clinical	O
trials	O
,	O
the	O
incidences	O
of	O
adverse	O
events	O
related	O
to	O
abnormal	B
prolactin	I
levels	I
were	O
0.4	O
%	O
versus	O
0	O
%	O
for	O
placebo	O
.	O
	
Concomitant	O
use	O
of	O
drugs	O
affecting	O
hemostasis	O
increases	O
the	O
risk	O
of	O
bleeding	B
.	O
	
5.6	O
Bone	O
Effects	O
of	O
Tenofovir	O
DF	O
Bone	O
Mineral	O
Density	O
:	O
In	O
clinical	O
trials	O
in	O
HIV-1	O
infected	O
adults	O
,	O
tenofovir	O
DF	O
(	O
a	O
component	O
of	O
STRIBILD	O
)	O
was	O
associated	O
with	O
slightly	O
greater	O
decreases	B
in	I
bone	I
mineral	I
density	I
)	O
and	O
increases	B
in	I
biochemical	I
markers	I
of	I
bone	I
metabolism	I
,	O
suggesting	O
increased	B
bone	I
turnover	I
relative	O
to	O
comparators	O
.	O
	
5.6	O
Embryofetal	O
Toxicity	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
XALKORI	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Nervous	O
System	O
Disorders	O
:	O
altered	B
taste	I
,	O
balance	B
disorder	I
,	O
cerebrovascular	B
accident	I
,	O
Guillain-Barre	B
syndrome	I
,	O
headache	B
,	O
hemiparesis	B
,	O
hypoesthesia	B
,	O
hyposmia	B
,	O
lacunar	B
infarction	I
,	O
lethargy	B
,	O
mental	B
impairment	I
,	O
migraine	B
,	O
paresthesia	B
,	O
somnolence	B
,	O
transient	B
ischemic	I
attack	I
,	O
tremor	B
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
cabazitaxel	O
or	O
to	O
other	O
drugs	O
formulated	O
with	O
polysorbate	O
80	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
*	O
Demyelinating	B
disease	I
,	O
may	O
occur	O
(	O
5.4	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
Worsening	B
of	I
narrow-angle	I
glaucoma	I
may	O
occur	O
.	O
	
In	O
an	O
open-label	O
,	O
long-term	O
extension	O
study	O
of	O
two	O
of	O
these	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
,	O
the	O
total	O
duration	O
of	O
treatment	O
was	O
up	O
to	O
52	O
weeks	O
.	O
	
Coartem	O
Tablets	O
may	O
reduce	O
the	O
effectiveness	O
of	O
hormonal	O
contraceptives	O
.	O
	
Treatment	O
delay	O
or	O
dosage	O
reduction	O
may	O
be	O
necessary	O
if	O
patients	O
experience	O
Grade	O
>	O
=	O
3	O
diarrhea	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Avoid	O
use	O
of	O
GBCAs	O
among	O
these	O
patients	O
unless	O
the	O
diagnostic	O
information	O
is	O
essential	O
and	O
not	O
available	O
with	O
non-contrast	O
enhanced	O
MRI	O
or	O
other	O
modalities	O
.	O
	
Vascular	O
Disorders	O
:	O
flushing	B
,	O
hot	B
flush	I
,	O
hypertension	B
,	O
hypotension	B
.	O
	
In	O
Study	O
3	O
,	O
serious	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
reported	O
in	O
25	O
%	O
of	O
ADCETRIS-treated	O
patients	O
.	O
	
Therefore	O
,	O
patients	O
using	O
oral	O
,	O
transdermal	O
patch	O
,	O
or	O
other	O
systemic	O
hormonal	O
contraceptives	O
should	O
be	O
advised	O
to	O
use	O
an	O
additional	O
non-hormonal	O
method	O
of	O
birth	O
control	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.5	O
)	O
]	O
.	O
	
Psychiatric	O
Disorders	O
:	O
agitation	B
,	O
anxiety	B
,	O
depression	B
,	O
insomnia	B
,	O
irritability	B
,	O
libido	B
decreased	I
,	O
nervousness	B
,	O
panic	B
attack	I
,	O
personality	B
change	I
.	O
	
*	O
Serious	O
infections	B
leading	O
to	O
hospitalization	O
or	O
death	B
including	O
tuberculosis	B
(	O
TB	B
)	O
,	O
bacterial	B
sepsis	I
,	O
histoplasmosis	B
have	O
occurred	O
in	O
patients	O
receiving	O
SIMPONI	O
ARIA	O
(	O
5.1	O
)	O
.	O
	
Adverse	O
reactions	O
led	O
to	O
dose	O
reductions	O
in	O
49	O
%	O
and	O
dose	O
interruptions	O
in	O
67	O
%	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
chronic	O
or	O
recurrent	O
genital	O
mycotic	O
infections	O
were	O
more	O
likely	O
to	O
develop	O
mycotic	B
genital	I
infections	I
.	O
	
5.4	O
Negative	O
Inotropy	O
Dihydropyridine	O
calcium	O
channel	O
blockers	O
can	O
produce	O
negative	B
inotropic	I
effects	I
and	O
exacerbate	B
heart	I
failure	I
.	O
	
b	O
Includes	O
all	O
preferred	O
terms	O
within	O
the	O
'infections	O
and	O
infestations	O
'	O
system	O
organ	O
class	O
,	O
the	O
most	O
common	O
being	O
nasopharyngitis	B
(	O
6	O
%	O
)	O
,	O
pneumonia	B
(	O
6	O
%	O
)	O
,	O
urinary	B
tract	I
infection	I
(	O
5	O
%	O
)	O
,	O
bronchitis	B
(	O
4	O
%	O
)	O
,	O
and	O
sinusitis	B
(	O
3	O
%	O
)	O
,	O
and	O
also	O
including	O
aspergillosis	B
(	O
<	O
1	O
%	O
)	O
,	O
candidiasis	B
(	O
<	O
1	O
%	O
)	O
,	O
and	O
sepsis	B
(	O
<	O
1	O
%	O
)	O
.	O
	
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
in	O
pregnant	O
women	O
using	O
Kyprolis	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
,	O
infections	B
,	O
asthenia	B
,	O
fatigue	B
,	O
cough	B
,	O
and	O
diarrhea	B
.	O
	
Long-Term	O
,	O
Open-Label	O
Trials	O
with	O
NORTHERA	O
In	O
the	O
long-term	O
,	O
open-label	O
extension	O
studies	O
,	O
a	O
total	O
of	O
422	O
patients	O
,	O
mean	O
age	O
65	O
years	O
,	O
were	O
treated	O
with	O
NORTHERA	O
for	O
a	O
mean	O
total	O
exposure	O
of	O
approximately	O
one	O
year	O
.	O
	
However	O
,	O
the	O
syndrome	O
can	O
develop	O
,	O
although	O
much	O
less	O
commonly	O
,	O
after	O
relatively	O
brief	O
treatment	O
periods	O
at	O
low	O
doses	O
.	O
	
The	O
safety	O
assessment	O
is	O
based	O
on	O
all	O
data	O
from	O
1203	O
subjects	O
in	O
the	O
Phase	O
3	O
placebo-controlled	O
trials	O
,	O
TMC125-C206	O
and	O
TMC125-C216	O
,	O
conducted	O
in	O
antiretroviral	O
treatment-experienced	O
HIV-1-infected	O
adult	O
subjects	O
,	O
599	O
of	O
whom	O
received	O
INTELENCE	O
(	O
r	O
)	O
(	O
200	O
mg	O
twice	O
daily	O
)	O
.	O
	
What	O
is	O
DUAVEE	O
used	O
for	O
?	O
	
Somnolence	B
includes	O
the	O
following	O
events	O
:	O
somnolence	B
,	O
sedation	B
,	O
and	O
hypersomnia	B
.	O
	
A	O
total	O
of	O
651	O
pediatric	O
patients	O
were	O
treated	O
with	O
SAPHRIS	O
.	O
	
Use	O
of	O
INVOKANA	O
has	O
been	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
renal-related	B
adverse	I
reactions	I
(	O
e.g.	O
,	O
increased	B
blood	I
creatinine	I
,	O
decreased	B
glomerular	I
filtration	I
rate	I
,	O
renal	B
impairment	I
,	O
and	O
acute	B
renal	I
failure	I
)	O
,	O
particularly	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
.	O
	
Table	O
3	O
and	O
Table	O
4	O
present	O
adverse	O
drug	O
reactions	O
and	O
laboratory	O
abnormalities	O
identified	O
from	O
analyses	O
of	O
Trial	O
1	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Inform	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
and	O
have	O
them	O
seek	O
immediate	O
medical	O
care	O
should	O
symptoms	O
occur	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
during	O
therapy	O
(	O
5.1	O
)	O
*	O
Impairment	B
in	I
Renal	I
Function	I
:	O
Monitor	O
renal	O
function	O
during	O
therapy	O
.	O
	
Permanent	O
discontinuation	O
due	O
to	O
an	O
adverse	O
reaction	O
occurred	O
in	O
34/359	O
patients	O
(	O
9	O
%	O
)	O
receiving	O
INLYTA	O
and	O
46/355	O
patients	O
(	O
13	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
a	O
>	O
=7	O
%	O
increase	B
in	I
body	I
weight	I
(	O
at	O
Endpoint	O
)	O
was	O
14.7	O
%	O
.Table	O
5provides	O
the	O
mean	O
weight	B
change	I
from	O
baseline	O
and	O
the	O
proportion	O
of	O
patients	O
with	O
a	O
weight	B
gain	I
of	O
>	O
=7	O
%	O
categorized	O
by	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
at	O
baseline	O
.	O
	
Hepatobiliary	O
disorders	O
:	O
Elevated	B
liver	I
enzymes	I
and	O
hepatitis	B
.	O
	
Do	O
not	O
administer	O
COMETRIQ	O
to	O
patients	O
with	O
severe	O
hemorrhage	O
.	O
	
5.2	O
Neurological	O
Toxicities	O
In	O
patients	O
receiving	O
BLINCYTO	O
in	O
clinical	O
trials	O
,	O
neurological	B
toxicities	I
have	O
occurred	O
in	O
approximately	O
50	O
%	O
of	O
patients	O
.	O
	
Concomitant	O
use	O
of	O
aspirin	O
,	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
warfarin	O
,	O
and	O
other	O
anticoagulants	O
may	O
add	O
to	O
this	O
risk	O
.	O
	
5.5	O
Neutropenia	O
and	O
Febrile	O
Neutropenia	O
Neutropenia	B
and	O
febrile	B
neutropenia	I
,	O
including	O
life-threatening	O
cases	O
,	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
Based	O
on	O
the	O
experience	O
in	O
the	O
entire	O
clinical	O
program	O
for	O
melanoma	O
,	O
the	O
incidence	O
and	O
severity	O
of	O
enterocolitis	B
and	O
hepatitis	B
appear	O
to	O
be	O
dose	O
dependent	O
.	O
	
Grade	O
3-4	O
lymphopenia	B
(	O
9	O
%	O
)	O
,	O
hyperglycemia	B
(	O
7	O
%	O
)	O
and	O
high	B
alanine	I
aminotransferase	I
(	O
6	O
%	O
)	O
occurred	O
at	O
a	O
greater	O
than	O
5	O
%	O
rate	O
in	O
the	O
ZYTIGA	O
arm	O
.	O
	
The	O
physician	O
responsible	O
for	O
maintenance	O
therapy	O
should	O
have	O
complete	O
information	O
requisite	O
for	O
the	O
follow-up	O
of	O
the	O
patient	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Discontinue	O
Zydelig	O
for	O
intestinal	O
perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
There	O
was	O
one	O
death	B
associated	O
with	O
arrhythmia	B
and	O
one	O
patient	O
with	O
sudden	B
death	I
in	O
the	O
ZYTIGA	O
arms	O
and	O
no	O
deaths	B
in	O
the	O
placebo	O
arms	O
.	O
	
One	O
HALAVEN-treated	O
patient	O
without	O
documented	O
liver	O
metastases	O
had	O
concomitant	O
Grade	O
2	O
elevations	B
in	I
bilirubin	I
;	O
these	O
abnormalities	O
resolved	O
and	O
did	O
not	O
recur	O
with	O
re-exposure	O
to	O
HALAVEN	O
.	O
	
In	O
addition	O
to	O
ADCETRIS	O
therapy	O
,	O
other	O
possible	O
contributory	O
factors	O
include	O
prior	O
therapies	O
and	O
underlying	O
disease	O
that	O
may	O
cause	O
immunosuppression	O
.	O
	
Bleeding	B
events	O
for	O
the	O
4	O
pivotal	O
studies	O
were	O
classified	O
as	O
major	O
bleeding	B
events	O
if	O
at	O
least	O
one	O
of	O
the	O
following	O
criteria	O
applied	O
:	O
fatal	B
bleeding	B
,	O
symptomatic	B
bleeding	I
in	I
a	I
critical	I
area	I
with	O
compartment	B
syndrome	I
,	O
retroperitoneal	B
bleeding	I
,	O
intra-articular	B
bleeding	I
,	O
or	O
pericardial	B
bleeding	I
)	O
,	O
bleeding	B
causing	O
a	O
fall	B
in	I
hemoglobin	I
level	I
of	O
2.0	O
g/dL	O
(	O
1.24	O
mmol/L	O
or	O
more	O
,	O
or	O
leading	O
to	O
transfusion	O
of	O
2	O
or	O
more	O
units	O
of	O
whole	O
blood	O
or	O
red	O
cells	O
)	O
.	O
	
5.11	O
Serious	O
Dermatologic	O
Reactions	O
Stevens-Johnson	B
syndrome	I
(	O
SJS	B
)	O
and	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
,	O
including	O
fatal	B
outcomes	O
,	O
have	O
been	O
reported	O
with	O
ADCETRIS	O
.	O
	
Overall	O
,	O
59	O
%	O
of	O
the	O
subjects	O
were	O
men	O
and	O
the	O
ethnic	O
distribution	O
was	O
64	O
%	O
Caucasian	O
,	O
22	O
%	O
Asian	O
,	O
3	O
%	O
Hispanic	O
,	O
2	O
%	O
Black	O
,	O
and	O
0.5	O
%	O
of	O
subjects	O
consisted	O
of	O
other	O
ethnic	O
groups	O
.	O
	
At	O
three	O
years	O
after	O
transplantation	O
,	O
the	O
total	O
cholesterol	O
,	O
HDL	O
,	O
LDL	O
,	O
and	O
triglycerides	O
were	O
176	O
mg/dL	O
,	O
49	O
mg/dL	O
,	O
100	O
mg/dL	O
,	O
and	O
141	O
mg/dL	O
,	O
respectively	O
,	O
in	O
NULOJIX-treated	O
patients	O
compared	O
to	O
193	O
mg/dL	O
,	O
48	O
mg/dL	O
,	O
106	O
mg/dL	O
,	O
and	O
180	O
mg/dL	O
in	O
cyclosporine-treated	O
patients	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
55	O
years	O
and	O
2	O
%	O
were	O
older	O
than	O
75	O
years	O
of	O
age	O
.	O
	
(	O
2.2	O
,	O
5.3	O
)	O
*	O
QT	B
Interval	I
Prolongation	I
:	O
ZYKADIA	O
can	O
cause	O
QTc	B
interval	I
prolongation	I
.	O
	
Most	O
patients	O
received	O
the	O
recommended	O
dose	O
of	O
CIMZIA	O
or	O
higher	O
.	O
	
The	O
clinical	O
significance	O
of	O
this	O
increase	O
in	O
early	B
proteinuria	I
is	O
unknown	O
.	O
	
Doses	O
of	O
the	O
related	O
beta2-adrenoceptor	O
agonist	O
albuterol	O
,	O
when	O
administered	O
intravenously	O
,	O
have	O
been	O
reported	O
to	O
aggravate	B
preexisting	I
diabetes	I
mellitus	I
.	O
	
Advise	O
patients	O
to	O
refrain	O
from	O
driving	O
and	O
engaging	O
in	O
hazardous	O
occupations	O
or	O
activities	O
such	O
as	O
operating	O
heavy	O
or	O
potentially	O
dangerous	O
machinery	O
while	O
BLINCYTO	O
is	O
being	O
administered	O
.	O
	
The	O
incidence	O
of	O
serious	O
GI	B
events	I
was	O
1	O
%	O
in	O
patients	O
treated	O
with	O
TECFIDERA	O
.	O
	
(	O
5.8	O
,	O
8.1	O
)	O
5.1	O
Myelosuppression	O
TREANDA	O
caused	O
severe	O
myelosuppression	B
(	O
Grade	O
3-4	O
)	O
in	O
98	O
%	O
of	O
patients	O
in	O
the	O
two	O
NHL	O
studies	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
dose	O
reduction	O
in	O
the	O
patients	O
treated	O
with	O
XALKORI	O
were	O
ALT	B
)	I
elevation	I
(	O
7.6	O
%	O
)	O
including	O
some	O
patients	O
with	O
concurrent	O
AST	B
)	I
elevation	I
,	O
QTc	B
prolongation	I
(	O
2.9	O
%	O
)	O
,	O
and	O
neutropenia	B
(	O
2.3	O
%	O
)	O
.	O
	
Additionally	O
,	O
placebo-adjusted	O
BMD	B
declines	I
were	I
0.1	I
%	I
at	I
the	I
femoral	I
neck	I
for	O
patients	O
randomized	O
to	O
INVOKANA	O
300	O
mg	O
.	O
	
(	O
5.2	O
)	O
*	O
If	O
irritation	O
of	O
eyes	O
or	O
airway	O
occurs	O
,	O
remove	O
the	O
affected	O
individual	O
from	O
the	O
vicinity	O
of	O
Qutenza	O
and	O
flush	O
the	O
mucous	O
membranes	O
or	O
eyes	O
with	O
water	O
.	O
	
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
	
One	O
death	B
was	O
due	O
to	O
disseminated	B
primary	I
herpes	I
zoster	I
and	O
the	O
other	O
to	O
herpes	B
simplex	I
encephalitis	I
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
Reaction	O
Rate	O
(	O
%	O
)	O
n=2813	O
Nausea	B
0.6	O
%	O
Headache	B
0.5	O
%	O
Injection	B
Site	I
Pain	I
0.4	O
%	O
Injection	B
Site	I
Coldness	I
0.2	O
%	O
Burning	B
Sensation	I
0.2	O
%	O
Adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
<	O
0.2	O
%	O
in	O
patients	O
who	O
received	O
DOTAREM	O
include	O
:	O
feeling	B
cold	I
,	O
rash	B
,	O
somnolence	B
,	O
fatigue	B
,	O
dizziness	B
,	O
vomiting	B
,	O
pruritus	B
,	O
paresthesia	B
,	O
dysgeusia	B
,	O
pain	B
in	I
extremity	I
,	O
anxiety	B
,	O
hypertension	B
,	O
palpitations	B
,	O
oropharyngeal	B
discomfort	I
,	O
serum	B
creatinine	I
increased	I
and	O
injection	B
site	I
reactions	I
.	O
	
Dysphagia	B
may	O
persist	O
for	O
several	O
months	O
,	O
and	O
require	O
use	O
of	O
a	O
feeding	O
tube	O
to	O
maintain	O
adequate	O
nutrition	O
and	O
hydration	O
.	O
	
5.4	O
Tardive	O
Dyskinesia	O
Tardive	B
dyskinesia	I
is	O
a	O
syndrome	O
consisting	O
of	O
potentially	O
irreversible	O
,	O
involuntary	B
,	I
dyskinetic	I
movements	I
,	O
which	O
may	O
develop	O
in	O
patients	O
treated	O
with	O
antipsychotic	O
drugs	O
.	O
	
None	O
of	O
the	O
subjects	O
tested	O
positive	O
.	O
	
*	O
Using	O
estrogens	O
may	O
increase	O
your	O
chance	O
of	O
getting	O
dementia	O
,	O
based	O
on	O
a	O
study	O
of	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
.	O
	
Withhold	O
Kyprolis	O
for	O
Grade	O
3	O
or	O
4	O
cardiac	O
adverse	O
events	O
until	O
recovery	O
,	O
and	O
consider	O
whether	O
to	O
restart	O
Kyprolis	O
at	O
1	O
dose	O
level	O
reduction	O
based	O
on	O
a	O
benefit/risk	O
assessment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
Approximately	O
1000	O
patients	O
received	O
at	O
least	O
2	O
years	O
of	O
treatment	O
with	O
GILENYA	O
0.5	O
mg	O
.	O
	
The	O
risk	O
of	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
occur	O
in	O
adults	O
treated	O
for	O
spasticity	O
and	O
other	O
conditions	O
,	O
and	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
The	O
EMTP	O
trial	O
enrolled	O
1368	O
patients	O
with	O
ALL	O
or	O
lymphoblastic	O
lymphoma	O
who	O
received	O
ERWINAZE	O
after	O
developing	O
systemic	O
hypersensitivity	O
to	O
an	O
E.	O
coli	O
-derived	O
asparaginase	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
of	O
moderate	O
to	O
severe	O
intensity	O
(	O
at	O
least	O
2	O
%	O
)	O
which	O
occurred	O
at	O
a	O
higher	O
rate	O
than	O
placebo	O
in	O
adults	O
are	O
rash	B
and	O
peripheral	B
neuropathy	I
.	O
	
Adverse	O
Reactions	O
with	O
BREO	O
ELLIPTA	O
100/25	O
with	O
>	O
=2	O
%	O
Incidence	O
and	O
More	O
Common	O
than	O
Placebo	O
in	O
Subjects	O
with	O
Asthma	O
(	O
Trial	O
1	O
)	O
Adverse	O
Reaction	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
201	O
)	O
%	O
Fluticasone	O
Furoate	O
100	O
mcg	O
(	O
n	O
=	O
205	O
)	O
%	O
Placebo	O
(	O
n	O
=	O
203	O
)	O
%	O
Infections	O
and	O
infestations	O
Nasopharyngitis	B
10	O
7	O
7	O
Oral	B
candidiasis	I
a	O
2	O
2	O
0	O
Nervous	O
system	O
disorders	O
Headache	B
5	O
4	O
4	O
Respiratory	O
,	O
thoracic	O
,	O
and	O
mediastinal	O
disorders	O
Oropharyngeal	B
pain	I
2	O
2	O
1	O
Dysphonia	B
2	O
1	O
0	O
a	O
Includes	O
oral	B
candidiasis	I
and	O
oropharyngeal	B
candidiasis	I
.	O
	
Renal	B
impairment	I
as	O
a	O
consequence	O
of	O
diarrhea	B
occurred	O
in	O
6.1	O
%	O
of	O
patients	O
treated	O
with	O
GILOTRIF	O
,	O
out	O
of	O
which	O
3	O
(	O
1.3	O
%	O
)	O
were	O
Grade	O
3	O
.	O
	
Bleeding	B
results	O
from	O
the	O
AMPLIFY	O
study	O
are	O
summarized	O
in	O
Table	O
5	O
.	O
	
Intracranial	B
hemorrhage	I
was	O
fatal	B
in	O
4	O
%	O
(	O
2/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Cases	O
of	O
active	O
tuberculosis	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
during	O
and	O
after	O
treatment	O
for	O
latent	O
tuberculosis	O
.	O
	
In	O
trials	O
of	O
STENDRA	O
for	O
use	O
as	O
needed	O
,	O
a	O
total	O
of	O
493	O
patients	O
were	O
exposed	O
for	O
greater	O
than	O
or	O
equal	O
to	O
6	O
months	O
,	O
and	O
153	O
patients	O
were	O
treated	O
for	O
greater	O
than	O
or	O
equal	O
to	O
12	O
months	O
.	O
	
The	O
median	O
duration	O
of	O
adverse	O
reactions	O
was	O
4.0	O
days	O
in	O
both	O
treatment	O
groups	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
are	O
discussed	O
in	O
more	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Hypertension	B
,	O
Hypokalemia	B
,	O
and	O
Fluid	B
Retention	I
due	O
to	O
Mineralocorticoid	B
Excess	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Treatment	O
for	O
latent	O
infection	O
should	O
be	O
initiated	O
prior	O
to	O
CIMZIA	O
use	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
may	O
occur	O
within	O
a	O
few	O
minutes	O
following	O
the	O
initiation	O
of	O
the	O
infusion	O
of	O
JEVTANA	O
,	O
thus	O
facilities	O
and	O
equipment	O
for	O
the	O
treatment	O
of	O
hypotension	O
and	O
bronchospasm	O
should	O
be	O
available	O
.	O
	
Monitoring	O
Closely	O
monitor	O
patients	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
SIMPONI	O
ARIA	O
.	O
	
Patients	O
who	O
remain	O
averse	O
to	O
food	O
during	O
treatment	O
should	O
be	O
closely	O
monitored	O
as	O
the	O
risk	O
of	O
recrudescence	O
may	O
be	O
greater	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
*	O
If	O
members	O
of	O
your	O
family	O
have	O
had	O
breast	O
cancer	O
or	O
if	O
you	O
have	O
ever	O
had	O
breast	O
lumps	O
or	O
an	O
abnormal	O
mammogram	O
,	O
you	O
may	O
need	O
to	O
have	O
breast	O
exams	O
more	O
often	O
.	O
	
Test	O
patients	O
for	O
latent	O
tuberculosis	O
before	O
SIMPONI	O
ARIA	O
use	O
and	O
during	O
therapy	O
.	O
	
Post-baseline	O
QT	B
prolongations	I
exceeding	O
500	O
msec	O
were	O
reported	O
at	O
comparable	O
rates	O
for	O
SAPHRIS	O
and	O
placebo	O
in	O
these	O
short-term	O
trials	O
.	O
	
Counsel	O
women	O
of	O
childbearing	O
potential	O
regarding	O
appropriate	O
contraceptive	O
choices	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
This	O
,	O
in	O
turn	O
,	O
may	O
inhibit	B
reproductive	I
function	I
by	O
impairing	B
gonadal	I
steroidogenesis	I
in	O
both	O
female	O
and	O
male	O
patients	O
.	O
	
*	O
Lymphoma	B
and	O
other	O
malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
children	O
and	O
adolescent	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
(	O
5.2	O
)	O
.	O
	
Patients	O
should	O
be	O
evaluated	O
for	O
tuberculosis	O
risk	O
factors	O
and	O
tested	O
for	O
latent	O
infection	O
prior	O
to	O
initiating	O
CIMZIA	O
and	O
periodically	O
during	O
therapy	O
.	O
	
Hyperprolactinemia	B
may	O
suppress	B
hypothalamic	I
GnRH	I
,	O
resulting	O
in	O
reduced	B
pituitary	I
gonadotropin	I
secretion	I
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Not	O
for	O
acute	O
use	O
:	O
Not	O
for	O
use	O
as	O
a	O
rescue	O
medication	O
.	O
	
Severe	O
hypersensitivity	B
reactions	I
can	O
occur	O
and	O
may	O
include	O
generalized	B
rash/erythema	O
,	O
hypotension	B
and	O
bronchospasm	B
.	O
	
Patients	O
should	O
be	O
tested	O
for	O
latent	O
tuberculosis	O
before	O
CIMZIA	O
use	O
and	O
during	O
therapy	O
.	O
	
Infections	O
and	O
Infestations	O
:	O
herpes	B
zoster	I
.	O
	
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
-	O
Rash	B
,	O
alopecia	B
,	O
photosensitivity	B
reaction	O
,	O
angioedema	B
.	O
	
(	O
5.6	O
)	O
*	O
Laboratory	O
test	O
alterations	O
:	O
Elevations	B
of	I
serum	I
creatinine	I
may	O
occur	O
.	O
	
Of	O
the	O
patients	O
who	O
reported	O
neuropathy	B
,	O
51	O
%	O
had	O
residual	B
neuropathy	I
at	O
the	O
time	O
of	O
their	O
last	O
evaluation	O
.	O
	
One	O
patient	O
experienced	O
related	O
Grade	O
3	O
flushing	B
.	O
	
Symptomatic	B
hypotension	I
may	O
occur	O
after	O
initiating	O
JARDIANCE	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
particularly	O
in	O
patients	O
with	O
renal	O
impairment	O
,	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
low	O
systolic	O
blood	O
pressure	O
,	O
and	O
in	O
patients	O
on	O
diuretics	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Takeda	O
Pharmaceuticals	O
at	O
1-877-TAKEDA-7	O
(	O
1-877-825-3327	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reaction	O
has	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
PRISTIQ	O
.	O
	
Adverse	O
Reactions	O
with	O
BREO	O
ELLIPTA	O
100/25	O
with	O
>	O
=3	O
%	O
Incidence	O
and	O
More	O
Common	O
than	O
Placebo	O
in	O
Subjects	O
with	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
Adverse	O
Reaction	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
410	O
)	O
%	O
Vilanterol	O
25	O
mcg	O
(	O
n	O
=	O
408	O
)	O
%	O
Fluticasone	O
Furoate	O
100	O
mcg	O
(	O
n	O
=	O
410	O
)	O
%	O
Placebo	O
(	O
n	O
=	O
412	O
)	O
%	O
Infections	O
and	O
infestations	O
Nasopharyngitis	B
9	O
10	O
8	O
8	O
Upper	B
respiratory	I
tract	I
infection	I
7	O
5	O
4	O
3	O
Oropharyngeal	B
candidiasis	I
a	O
5	O
2	O
3	O
2	O
Nervous	O
system	O
disorders	O
Headache	B
7	O
9	O
7	O
5	O
a	O
Includes	O
oral	B
candidiasis	I
,	O
oropharyngeal	B
candidiasis	I
,	O
candidiasis	B
,	O
and	O
fungal	B
oropharyngitis	I
.	O
	
Withhold	O
GILOTRIF	O
in	O
patients	O
who	O
develop	O
worsening	O
of	O
liver	O
function	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Discontinue	O
TIVICAY	O
and	O
other	O
suspect	O
agents	O
immediately	O
if	O
signs	O
or	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
develop	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
severe	O
rash	O
or	O
rash	O
accompanied	O
by	O
fever	O
,	O
general	O
malaise	O
,	O
fatigue	O
,	O
muscle	O
or	O
joint	O
aches	O
,	O
blisters	O
or	O
peeling	O
of	O
the	O
skin	O
,	O
oral	O
blisters	O
or	O
lesions	O
,	O
conjunctivitis	O
,	O
facial	O
edema	O
,	O
hepatitis	O
,	O
eosinophilia	O
,	O
angioedema	O
,	O
difficulty	O
breathing	O
)	O
.	O
	
(	O
5.1	O
)	O
*	O
QT	B
prolongation	I
:	O
Prolongs	B
QT	I
interval	I
and	O
may	O
be	O
associated	O
with	O
arrhythmia	B
and	O
sudden	B
death-consider	O
using	O
other	O
antipsychotics	O
first	O
.	O
	
(	O
6.1	O
)	O
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
in	O
at	O
least	O
2	O
%	O
of	O
pediatric	O
patients	O
are	O
rash	B
and	O
diarrhea	B
.	O
	
In	O
total	O
,	O
from	O
the	O
281	O
subjects	O
treated	O
in	O
the	O
long-term	O
studies	O
and	O
tested	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
,	O
3.6	O
%	O
developed	O
neutralizing	O
antibodies	O
after	O
treatment	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Sunovion	O
at	O
1-877-737-7226	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
A	O
total	O
of	O
1,224	O
patients	O
were	O
treated	O
with	O
DUAVEE	O
and	O
1,069	O
patients	O
received	O
placebo	O
.	O
	
In	O
patients	O
who	O
develop	O
HBV	O
reactivation	O
,	O
TNF-blockers	O
should	O
be	O
stopped	O
and	O
antiviral	O
therapy	O
with	O
appropriate	O
supportive	O
treatment	O
should	O
be	O
initiated	O
.	O
	
5.3	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
with	O
botulinum	O
toxin	O
products	O
(	O
anaphylaxis	B
,	O
serum	B
sickness	I
,	O
urticaria	B
,	O
soft	B
tissue	I
edema	I
,	O
and	O
dyspnea	B
)	O
.	O
	
Table	O
2	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
0.2	O
%	O
patients	O
who	O
received	O
DOTAREM	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
were	O
more	O
likely	O
to	O
develop	O
genital	B
mycotic	I
infections	I
on	O
INVOKANA	O
.	O
	
Monitor	O
ECGs	O
.	O
	
ARCAPTA	O
NEOHALER	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
asthma	O
.	O
	
*	O
119	O
patients	O
with	O
CP	O
CML	O
previously	O
treated	O
with	O
both	O
imatinib	O
and	O
at	O
least	O
1	O
additional	O
TKI	O
who	O
had	O
a	O
median	O
duration	O
of	O
BOSULIF	O
treatment	O
of	O
9	O
months	O
and	O
a	O
median	O
dose	O
intensity	O
of	O
475	O
mg/day	O
.	O
	
In	O
males	B
,	I
discontinuations	I
due	I
to	I
genital	I
mycotic	I
infections	I
occurred	O
in	O
0	O
%	O
and	O
0.5	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
and	O
INVOKANA	O
,	O
respectively	O
.	O
	
Skin	B
infections	I
,	O
including	O
erysipelas	B
and	O
cellulitis	B
,	O
leading	O
to	O
hospitalization	O
were	O
reported	O
more	O
frequently	O
in	O
patients	O
treated	O
with	O
Prolia	O
(	O
<	O
0.1	O
%	O
placebo	O
vs.	O
0.4	O
%	O
Prolia	O
)	O
.	O
	
Increased	O
Mortality	O
In	O
Study	O
1	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increased	B
mortality	I
risk	O
by	O
Week	O
120	O
in	O
the	O
SIRTURO	O
treatment	O
group	O
compared	O
to	O
the	O
placebo	O
treatment	O
group	O
(	O
9/79	O
(	O
11.4	O
%	O
)	O
versus	O
2/81	O
(	O
2.5	O
%	O
)	O
,	O
p-value=0.03	O
,	O
an	O
exact	O
95	O
%	O
confidence	O
interval	O
of	O
the	O
difference	O
[	O
1.1	O
%	O
,	O
18.2	O
%	O
]	O
)	O
.	O
	
(	O
5.6	O
)	O
*	O
Withdrawal	O
of	O
APTIOM	O
:	O
Withdraw	O
APTIOM	O
gradually	O
to	O
minimize	O
the	O
risk	O
of	O
increased	O
seizure	O
frequency	O
and	O
status	O
epilepticus	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Myelosuppression	B
:	O
Delay	O
or	O
reduce	O
dose	O
.	O
	
Overall	O
discontinuation	O
of	O
therapy	O
due	O
to	O
adverse	O
events	O
was	O
4.7	O
%	O
with	O
NESINA	O
25	O
mg	O
compared	O
to	O
4.5	O
%	O
with	O
placebo	O
or	O
6.2	O
%	O
with	O
active	O
comparator	O
.	O
	
Because	O
all	O
patients	O
developed	O
anti-drug	O
antibodies	O
,	O
associations	O
between	O
antibody	O
titers	O
and	O
reductions	O
in	O
treatment	O
effect	O
or	O
the	O
occurrence	O
of	O
anaphylaxis	O
or	O
other	O
hypersensitivity	O
reactions	O
could	O
not	O
be	O
determined	O
.	O
	
Life-threatening	O
anaphylactic	B
reactions	I
have	O
occurred	O
in	O
some	O
patients	O
during	O
Vimizim	O
infusions	O
.	O
	
5.7	O
Elevated	O
Liver	O
Enzymes	O
Treatment	O
with	O
BLINCYTO	O
was	O
associated	O
with	O
transient	O
elevations	B
in	I
liver	I
enzymes	I
.	O
	
During	O
marketing	O
of	O
SNRIs	O
(	O
Serotonin	O
and	O
Norepinephrine	O
Reuptake	O
Inhibitors	O
)	O
,	O
and	O
SSRIs	O
(	O
Selective	O
Serotonin	O
Reuptake	O
Inhibitors	O
)	O
,	O
there	O
have	O
been	O
spontaneous	O
reports	O
of	O
adverse	O
events	O
occurring	O
upon	O
discontinuation	O
of	O
these	O
drugs	O
,	O
particularly	O
when	O
abrupt	O
,	O
including	O
the	O
following	O
:	O
dysphoric	O
mood	O
,	O
irritability	O
,	O
agitation	O
,	O
dizziness	O
,	O
sensory	O
disturbances	O
(	O
e.g.	O
,	O
paresthesia	O
,	O
such	O
as	O
electric	O
shock	O
sensations	O
)	O
,	O
anxiety	O
,	O
confusion	O
,	O
headache	O
,	O
lethargy	O
,	O
emotional	O
lability	O
,	O
insomnia	O
,	O
hypomania	O
,	O
tinnitus	O
,	O
and	O
seizures	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Eli	O
Lilly	O
and	O
Company	O
at	O
1-800-LillyRx	O
(	O
1-800-545-5979	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
The	O
adverse	O
reaction	O
of	O
first	B
degree	I
AV	I
block	I
occurred	O
more	O
frequently	O
in	O
patients	O
treated	O
with	O
TRULICITY	O
than	O
placebo	O
(	O
0.9	O
%	O
,	O
1.7	O
%	O
and	O
2.3	O
%	O
for	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
)	O
.	O
	
Cases	O
with	O
serum	B
sodium	I
lower	I
than	I
110	I
mmol/L	I
have	O
been	O
reported	O
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
discontinuation	O
of	O
Zydelig	O
occurred	O
in	O
11	O
(	O
10	O
%	O
)	O
subjects	O
.	O
	
(	O
5.5	O
)	O
*	O
Osteonecrosis	B
of	I
the	I
jaw	I
:	O
Discontinue	O
COMETRIQ	O
.	O
	
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Dermatitis	B
,	O
erythema	B
nodosum	I
,	O
and	O
urticaria	B
.	O
	
Dose	O
modification	O
due	O
to	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
or	O
abdominal	B
pain	I
occurred	O
in	O
38	O
%	O
of	O
patients	O
.	O
	
The	O
use	O
of	O
COCs	O
increases	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
.	O
	
The	O
skin	B
discoloration	I
is	O
generally	O
described	O
as	O
blue	O
,	O
but	O
has	O
also	O
been	O
described	O
as	O
grey-blue	O
or	O
brown	O
.	O
	
If	O
pancreatitis	O
is	O
confirmed	O
,	O
TRULICITY	O
should	O
not	O
be	O
restarted	O
.	O
	
The	O
radiation	O
dose	O
to	O
patients	O
with	O
severe	O
renal	O
impairment	O
may	O
be	O
increased	O
due	O
to	O
the	O
delayed	O
elimination	O
of	O
the	O
drug	O
.	O
	
5.4	O
Serious	O
Infections	O
and	O
Opportunistic	O
Infections	O
Serious	O
infections	B
and	O
opportunistic	B
infections	I
such	O
as	O
pneumonia	B
,	O
bacteremia	B
,	O
and	O
sepsis	B
or	O
septic	B
shock	I
(	O
including	O
fatal	B
outcomes	O
)	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
ADCETRIS	O
.	O
	
5.7	O
Transferring	O
Patients	O
from	O
Systemic	O
Corticosteroid	O
Therapy	O
Particular	O
care	O
is	O
needed	O
for	O
patients	O
who	O
have	O
been	O
transferred	O
from	O
systemically	O
active	O
corticosteroids	O
to	O
inhaled	O
corticosteroids	O
because	O
deaths	O
due	O
to	O
adrenal	O
insufficiency	O
have	O
occurred	O
in	O
patients	O
with	O
asthma	O
during	O
and	O
after	O
transfer	O
from	O
systemic	O
corticosteroids	O
to	O
less	O
systemically	O
available	O
inhaled	O
corticosteroids	O
.	O
	
No	O
patients	O
developed	O
malignant	B
hypertension	I
.	O
	
In	O
placebo-controlled	O
studies	O
,	O
the	O
population	O
had	O
a	O
median	O
age	O
of	O
53	O
years	O
at	O
entry	O
;	O
approximately	O
80	O
%	O
were	O
females	O
,	O
93	O
%	O
were	O
Caucasian	O
and	O
all	O
patients	O
were	O
suffering	O
from	O
active	O
rheumatoid	O
arthritis	O
,	O
with	O
a	O
median	O
disease	O
duration	O
of	O
6.2	O
years	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
seizures	O
were	O
excluded	O
from	O
pre-marketing	O
clinical	O
studies	O
.	O
	
Immunogenicity	O
Across	O
four	O
Phase	O
2	O
and	O
five	O
Phase	O
3	O
clinical	O
studies	O
,	O
64	O
(	O
1.6	O
%	O
)	O
TRULICITY	O
treated	O
patients	O
developed	O
anti-drug	O
antibodies	O
(	O
ADAs	O
)	O
to	O
the	O
active	O
ingredient	O
in	O
TRULICITY	O
(	O
i.e.	O
,	O
dulaglutide	O
)	O
.	O
	
The	O
population	O
with	O
RLS	O
ranged	O
from	O
18	O
to	O
82	O
years	O
of	O
age	O
,	O
with	O
60	O
%	O
being	O
female	O
and	O
95	O
%	O
being	O
Caucasian	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
greater	O
than	O
20	O
%	O
)	O
are	O
diarrhea	B
,	O
nausea	B
,	O
thrombocytopenia	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
rash	B
,	O
anemia	B
,	O
pyrexia	B
,	O
and	O
fatigue	B
.	O
	
(	O
5.5	O
)	O
*	O
Neurological	B
Adverse	I
Reactions	I
:	O
Monitor	O
for	O
dizziness	O
,	O
disturbance	O
in	O
gait	O
and	O
coordination	O
,	O
somnolence	O
,	O
fatigue	O
,	O
cognitive	O
dysfunction	O
,	O
and	O
visual	O
changes	O
.	O
	
Schizophrenia	O
(	O
6-weeks	O
)	O
Bipolar	O
(	O
3-weeks	O
)	O
Placebo	O
SAPHRIS	O
Placebo	O
SAPHRIS5	O
or	O
10	O
mgtwice	O
daily	O
5	O
mgtwice	O
daily	O
10	O
mgtwice	O
daily	O
5	O
or	O
10	O
mgtwice	O
daily	O
S	O
Change	O
from	O
Baseline	O
(	O
kg	O
)	O
(	O
N*	O
)	O
0.0	O
(	O
348	O
)	O
1.0	O
(	O
251	O
)	O
0.9	O
(	O
200	O
)	O
1.1	O
(	O
532	O
)	O
0.2	O
(	O
171	O
)	O
1.3	O
(	O
336	O
)	O
Proportion	O
of	O
Patients	O
with	O
a	O
>	O
=7	O
%	O
Increase	B
in	I
Body	I
Weight	I
%	O
with	O
>	O
=7	O
%	O
increase	B
in	I
body	I
weight	I
1.6	O
%	O
4.4	O
%	O
4.8	O
%	O
4.9	O
%	O
0.5	O
%	O
5.8	O
%	O
Adult	O
Patients	O
:	O
In	O
a	O
52-week	O
,	O
double-blind	O
,	O
comparator-controlled	O
adult	O
trial	O
that	O
included	O
primarily	O
patients	O
with	O
schizophrenia	O
,	O
the	O
mean	O
weight	B
gain	I
from	O
baseline	O
was	O
0.9	O
kg	O
.	O
	
One	O
death	B
occurred	O
during	O
the	O
24-week	O
SIRTURO	O
treatment	O
period	O
.	O
	
These	O
subjects	O
did	O
not	O
receive	O
calcium	O
and	O
vitamin	O
D	O
supplementation	O
.	O
	
Males	O
represented	O
73	O
%	O
and	O
53	O
%	O
of	O
the	O
adult	O
and	O
pediatric	O
populations	O
,	O
respectively	O
.	O
	
(	O
5.6	O
,	O
5.7	O
)	O
5.1	O
Asthma-Related	O
Death	O
[	O
See	O
Boxed	O
Warning	O
]	O
*	O
Data	O
from	O
a	O
large	O
placebo-controlled	O
study	O
in	O
asthma	O
patients	O
showed	O
that	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonists	O
may	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
Median	O
duration	O
of	O
treatment	O
was	O
5.2	O
months	O
for	O
patients	O
who	O
received	O
XALKORI	O
after	O
cross	O
over	O
from	O
chemotherapy	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
Among	O
SAPHRIS-Treated	O
(	O
Monotherapy	O
)	O
patients	O
with	O
Bipolar	O
I	O
Disorder	O
:	O
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
SAPHRIS	O
(	O
incidence	O
of	O
2	O
%	O
or	O
greater	O
,	O
rounded	O
to	O
the	O
nearest	O
percent	O
,	O
and	O
SAPHRIS	O
incidence	O
greater	O
than	O
placebo	O
)	O
that	O
occurred	O
during	O
acute	O
monotherapy	O
(	O
up	O
to	O
3-weeks	O
in	O
patients	O
with	O
bipolar	O
mania	O
)	O
are	O
shown	O
in	O
Table	O
9	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
:	O
*	O
Severe	O
hypersensitivity	B
reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Adult	O
Patients	O
with	O
Schizophrenia	O
:	O
The	O
following	O
findings	O
are	O
based	O
on	O
the	O
short-term	O
placebo-controlled	O
pre-marketing	O
trials	O
for	O
schizophrenia	O
(	O
a	O
pool	O
of	O
three	O
6-week	O
fixed-dose	O
trials	O
and	O
one	O
6-week	O
flexible-dose	O
trial	O
)	O
in	O
which	O
sublingual	O
SAPHRIS	O
was	O
administered	O
in	O
doses	O
ranging	O
from	O
5	O
to	O
10	O
mg	O
twice	O
daily	O
.	O
	
(	O
5.5	O
)	O
*	O
Weight	B
Gain	I
:	O
Weight	O
gain	O
has	O
been	O
reported	O
.	O
	
Advise	O
patients	O
to	O
contact	O
their	O
healthcare	O
provider	O
if	O
they	O
become	O
pregnant	O
,	O
or	O
if	O
pregnancy	O
is	O
suspected	O
,	O
while	O
taking	O
GILOTRIF	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1and8.6	O
)	O
]	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
of	O
CERDELGA	O
is	O
based	O
on	O
two	O
controlled	O
studies	O
,	O
Trials	O
1	O
and	O
2	O
.	O
	
1	O
Neonatal	O
Toxicity	O
Intravenous	O
administration	O
of	O
products	O
containing	O
benzyl	O
alcohol	O
has	O
been	O
associated	O
with	O
neonatal	B
gasping	I
syndrome	I
consisting	O
of	O
severe	O
metabolic	B
acidosis	I
,	O
gasping	B
respirations	I
,	O
progressive	B
hypotension	I
,	O
seizures	B
,	O
central	B
nervous	I
system	I
depression	I
,	O
intraventricular	B
hemorrhage	I
,	O
and	O
death	B
in	O
preterm	O
,	O
low	O
birth	O
weight	O
infants	O
.	O
	
*	O
Serious	O
infections	B
and	O
opportunistic	B
infections	I
:	O
Closely	O
monitor	O
patients	O
for	O
the	O
emergence	O
of	O
bacterial	O
,	O
fungal	O
or	O
viral	O
infections	O
(	O
5.4	O
)	O
.	O
	
More	O
patients	O
experienced	O
these	O
events	O
during	O
PRISTIQ	O
treatment	O
as	O
compared	O
to	O
placebo	O
.	O
	
Concomitant	O
use	O
of	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
renal	O
impairment	O
is	O
expected	O
to	O
produce	O
increased	O
exposure	O
of	O
dabigatran	O
compared	O
to	O
that	O
seen	O
with	O
either	O
factor	O
alone	O
.	O
	
One	O
patient	O
discontinued	O
treatment	O
due	O
to	O
potential	O
infection	B
.	O
	
Common	O
adverse	O
reactions	O
(	O
>	O
=1	O
%	O
)	O
were	O
gingival	B
bleeding	I
,	O
epistaxis	B
,	O
contusion	B
,	O
hematuria	B
,	O
rectal	B
hemorrhage	I
,	O
hematoma	B
,	O
menorrhagia	B
,	O
and	O
hemoptysis	B
.	O
	
5.1	O
Hypersensitivity	O
Reactions	O
,	O
Including	O
Anaphylaxis	O
Potentially	O
serious	O
hypersensitivity	B
reactions	O
,	O
including	O
anaphylaxis	B
,	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
KALBITOR	O
.	O
	
Assess	O
LVEF	O
by	O
echocardiogram	O
or	O
multigated	O
acquisition	O
(	O
MUGA	O
)	O
scan	O
before	O
initiation	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
,	O
one	O
month	O
after	O
initiation	O
,	O
and	O
then	O
at	O
2-	O
to	O
3-month	O
intervals	O
while	O
on	O
treatment	O
with	O
the	O
combination	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
VICTRELIS	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
*	O
Have	O
a	O
pelvic	O
exam	O
,	O
breast	O
exam	O
and	O
mammogram	O
(	O
breast	O
X-ray	O
)	O
every	O
year	O
unless	O
your	O
healthcare	O
provider	O
tells	O
you	O
something	O
else	O
.	O
	
*	O
Invasive	B
fungal	I
infections	I
,	O
including	O
histoplasmosis	B
,	O
coccidioidomycosis	B
,	O
candidiasis	B
,	O
aspergillosis	B
,	O
blastomycosis	B
,	O
and	O
pneumocystosis	B
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
treatment	O
discontinuation	O
in	O
2	O
or	O
more	O
patients	O
were	O
peripheral	B
sensory	I
neuropathy	I
(	O
14	O
%	O
)	O
,	O
peripheral	B
motor	I
neuropathy	I
(	O
7	O
%	O
)	O
,	O
acute	B
respiratory	I
distress	I
syndrome	I
(	O
1	O
%	O
)	O
,	O
paraesthesia	B
(	O
1	O
%	O
)	O
and	O
vomiting	B
(	O
1	O
%	O
)	O
.	O
	
In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
PROMACTA	O
in	O
combination	O
with	O
interferon	O
and	O
ribavirin	O
may	O
increase	O
the	O
risk	O
of	O
hepatic	B
decompensation	I
.	O
	
In	O
the	O
wet	O
AMD	O
,	O
RVO	O
,	O
and	O
DME	O
studies	O
,	O
the	O
pre-treatment	O
incidence	O
of	O
immunoreactivity	O
to	O
EYLEA	O
was	O
approximately	O
1	O
%	O
to	O
3	O
%	O
across	O
treatment	O
groups	O
.	O
	
A	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
.	O
	
(	O
5.2	O
)	O
*	O
There	O
is	O
a	O
potential	O
risk	O
of	O
arterial	B
thromboembolic	I
events	I
following	O
intravitreal	O
use	O
of	O
VEGF	O
inhibitors	O
.	O
	
Long-standing	O
hyperprolactinemia	B
when	O
associated	O
with	O
hypogonadism	B
may	O
lead	O
to	O
decreased	B
bone	I
density	I
in	O
both	O
female	O
and	O
male	O
subjects	O
.	O
	
These	O
include	O
aspirin	O
and	O
other	O
antiplatelet	O
agents	O
,	O
other	O
anticoagulants	O
,	O
heparin	O
,	O
thrombolytic	O
agents	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
,	O
serotonin	O
norepinephrine	O
reuptake	O
inhibitors	O
,	O
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
[	O
seeDrug	O
Interactions	O
(	O
7.3	O
)	O
]	O
.	O
	
Pheochromocytoma	O
and	O
Neuroblastoma	O
Serious	O
adverse	O
reactions	O
were	O
not	O
observed	O
in	O
the	O
AdreView	O
clinical	O
study	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
severe	O
hypersensitivity	O
to	O
milk	O
proteins	O
.	O
	
After	O
dosing	O
with	O
EYLEA	O
for	O
24-100	O
weeks	O
,	O
antibodies	O
to	O
EYLEA	O
were	O
detected	O
in	O
a	O
similar	O
percentage	O
range	O
of	O
patients	O
.	O
	
83.9	O
%	O
of	O
patients	O
were	O
White	O
,	O
13.8	O
%	O
were	O
Black	O
,	O
1.4	O
%	O
Asian	O
,	O
and	O
<	O
1	O
%	O
Hispanic	O
.	O
	
Instruct	O
patients	O
to	O
consult	O
a	O
physician	O
immediately	O
should	O
any	O
of	O
these	O
signs	O
or	O
symptoms	O
develop	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
were	O
:	O
injection	B
site	I
reaction	I
(	O
3.9	O
%	O
)	O
.	O
	
Adverse	O
drug	O
reactions	O
listed	O
in	O
Table	O
2	O
showed	O
higher	O
rates	O
than	O
placebo	O
from	O
both	O
trials	O
.	O
	
The	O
reactions	O
either	O
resolved	O
spontaneously	O
or	O
following	O
the	O
administration	O
of	O
corticosteroids	O
and	O
antihistamines	O
.	O
	
More	O
frequent	O
monitoring	O
is	O
recommended	O
in	O
patients	O
with	O
eGFR	O
below	O
60	O
mL/min/1.73	O
m	O
2	O
(	O
5.2	O
)	O
*	O
Hypoglycemia	B
:	O
Consider	O
lowering	O
the	O
dose	O
of	O
insulin	O
secretagogue	O
or	O
insulin	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	O
when	O
initiating	O
JARDIANCE	O
(	O
5.3	O
)	O
*	O
Genital	B
mycotic	I
infections	I
:	O
Monitor	O
and	O
treat	O
as	O
appropriate	O
(	O
5.4	O
)	O
*	O
Urinary	B
tract	I
infections	I
:	O
Monitor	O
and	O
treat	O
as	O
appropriate	O
(	O
5.5	O
)	O
*	O
Increased	B
LDL-C	I
:	O
Monitor	O
and	O
treat	O
as	O
appropriate	O
(	O
5.6	O
)	O
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
JARDIANCE	O
(	O
5.7	O
)	O
5.1	O
Hypotension	O
JARDIANCE	O
causes	O
intravascular	B
volume	I
contraction	I
.	O
	
The	O
median	O
age	O
of	O
the	O
study	O
population	O
was	O
37	O
years	O
(	O
range	O
:	O
18	O
to	O
79	O
years	O
)	O
,	O
63	O
%	O
were	O
male	O
,	O
79	O
%	O
were	O
White	O
,	O
3	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
)	O
Renal	O
angiomyolipoma	O
with	O
TSC	O
:	O
Most	O
common	O
adverse	O
reaction	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
is	O
stomatitis	B
.	O
	
Decreases	B
in	I
hemoglobin	I
may	O
also	O
occur	O
.	O
	
This	O
trial	O
did	O
not	O
have	O
a	O
placebo	O
arm	O
.	O
	
Monitor	O
CrCl	O
at	O
least	O
daily	O
in	O
patients	O
with	O
changing	O
renal	O
function	O
and	O
adjust	O
the	O
dose	O
of	O
ZERBAXA	O
accordingly	O
.	O
	
Dysphagia	B
may	O
persist	O
for	O
several	O
weeks	O
,	O
and	O
require	O
use	O
of	O
a	O
feeding	O
tube	O
to	O
maintain	O
adequate	O
nutrition	O
and	O
hydration	O
.	O
	
(	O
5.5	O
)	O
*	O
Dyslipidemia	B
:	O
Undesirable	O
alterations	O
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
to	O
CERDELGA	O
(	O
occurring	O
in	O
>	O
=10	O
%	O
of	O
the	O
126	O
GD1	O
patients	O
treated	O
with	O
CERDELGA	O
across	O
Trials	O
1	O
and	O
2	O
)	O
were	O
fatigue	B
,	O
headache	B
,	O
nausea	B
,	O
diarrhea	B
,	O
back	B
pain	I
,	O
pain	B
in	I
extremities	I
,	O
and	O
upper	B
abdominal	I
pain	I
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
highly	O
effective	O
contraception	O
during	O
treatment	O
,	O
and	O
for	O
at	O
least	O
2	O
weeks	O
after	O
the	O
last	O
dose	O
of	O
GILOTRIF	O
.	O
	
Adverse	O
Reactions	O
Associated	O
with	O
Discontinuation	O
of	O
Treatment	O
:	O
A	O
total	O
of	O
9	O
%	O
of	O
SAPHRIS-treated	O
patients	O
and	O
10	O
%	O
of	O
placebo-treated	O
patients	O
discontinued	O
due	O
to	O
adverse	O
reactions	O
.	O
	
If	O
a	O
patient	O
requires	O
antipsychotic	O
drug	O
treatment	O
after	O
recovery	O
from	O
NMS	O
,	O
the	O
potential	O
reintroduction	O
of	O
drug	O
therapy	O
should	O
be	O
carefully	O
considered	O
.	O
	
Herpes	O
Viral	O
Infections	O
In	O
placebo-controlled	O
trials	O
,	O
the	O
rate	O
of	O
herpetic	B
infections	I
was	O
9	O
%	O
in	O
patients	O
receiving	O
GILENYA	O
0.5	O
mg	O
and	O
7	O
%	O
on	O
placebo	O
.	O
	
(	O
5.7	O
)	O
*	O
Venous	B
Thrombosis	I
:	O
Thromboprophylaxis	O
is	O
recommended	O
.	O
	
The	O
diagnostic	O
evaluation	O
of	O
patients	O
with	O
this	O
syndrome	O
is	O
complicated	O
.	O
	
5.5	O
Use	O
in	O
Elderly	O
Patients	O
In	O
the	O
randomized	O
clinical	O
trial	O
,	O
3	O
of	O
131	O
(	O
2	O
%	O
)	O
patients	O
<	O
65	O
years	O
of	O
age	O
and	O
15	O
of	O
240	O
(	O
6	O
%	O
)	O
>	O
=	O
65	O
years	O
of	O
age	O
died	B
of	O
causes	O
other	O
than	O
disease	O
progression	O
within	O
30	O
days	O
of	O
the	O
last	O
cabazitaxel	O
dose	O
.	O
	
Patients	O
treated	O
with	O
KALBITOR	O
were	O
between	O
the	O
ages	O
of	O
10	O
and	O
78	O
years	O
.	O
	
Adverse	O
reactions	O
of	O
any	O
toxicity	O
grade	O
reported	O
for	O
greater	O
than	O
20	O
%	O
of	O
patients	O
in	O
the	O
Phase	O
1/2	O
safety	O
population	O
(	O
n=546	O
)	O
were	O
diarrhea	B
(	O
82	O
%	O
)	O
,	O
nausea	B
(	O
46	O
%	O
)	O
,	O
thrombocytopenia	B
(	O
41	O
%	O
)	O
,	O
vomiting	B
(	O
39	O
%	O
)	O
,	O
abdominal	B
pain	I
(	O
37	O
%	O
)	O
,	O
rash	B
(	O
35	O
%	O
)	O
,	O
anemia	B
(	O
27	O
%	O
)	O
,	O
pyrexia	B
(	O
26	O
%	O
)	O
,	O
and	O
fatigue	B
(	O
24	O
%	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Patients	O
should	O
not	O
wear	O
contact	O
lenses	O
if	O
they	O
have	O
signs	O
or	O
symptoms	O
of	O
bacterial	O
conjunctivitis	O
or	O
during	O
the	O
course	O
of	O
therapy	O
with	O
Besivance	O
(	O
5.3	O
)	O
5.1	O
Topical	O
Ophthalmic	O
Use	O
Only	O
NOT	O
FOR	O
INJECTION	O
INTO	O
THE	O
EYE	O
.	O
	
TEN	O
has	O
been	O
reported	O
for	O
rituximab	O
(	O
see	O
rituximab	O
package	O
insert	O
)	O
.	O
	
These	O
included	O
no	O
subjects	O
in	O
the	O
normal	O
renal	O
function	O
group	O
,	O
10	O
%	O
of	O
subjects	O
in	O
the	O
creatinine	O
clearance	O
50	O
to	O
80	O
mL/min	O
group	O
,	O
29	O
%	O
of	O
subjects	O
in	O
the	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
group	O
,	O
and	O
29	O
%	O
of	O
subjects	O
in	O
the	O
hemodialysis	O
group	O
.	O
	
Among	O
ENTEREG-treated	O
patients	O
undergoing	O
surgeries	O
that	O
included	O
a	O
bowel	O
resection	O
,	O
the	O
most	O
common	O
adverse	O
reaction	O
(	O
incidence	O
>	O
=1.5	O
%	O
)	O
occurring	O
with	O
a	O
higher	O
frequency	O
than	O
placebo	O
was	O
dyspepsia	B
(	O
ENTEREG	O
,	O
1.5	O
%	O
;	O
placebo	O
,	O
0.8	O
%	O
)	O
.	O
	
The	O
median	O
time	O
to	O
death	B
for	O
the	O
remaining	O
eight	O
subjects	O
in	O
the	O
SIRTURO	O
treatment	O
group	O
was	O
329	O
days	O
after	O
last	O
intake	O
of	O
SIRTURO	O
.	O
	
To	O
manage	O
gastrointestinal	O
toxicity	O
,	O
withhold	O
,	O
dose	O
reduce	O
,	O
or	O
discontinue	O
BOSULIF	O
as	O
necessary	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
TREANDA	O
.	O
	
Symptomatic	B
hypotension	I
can	O
occur	O
after	O
initiating	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
particularly	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
(	O
eGFR	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
elderly	O
patients	O
,	O
patients	O
on	O
either	O
diuretics	O
or	O
medications	O
that	O
interfere	O
with	O
the	O
renin-angiotensin-aldosterone	O
system	O
(	O
e.g.	O
,	O
angiotensin-converting-enzyme	O
[	O
ACE	O
]	O
inhibitors	O
,	O
angiotensin	O
receptor	O
blockers	O
[	O
ARBs	O
]	O
)	O
,	O
or	O
patients	O
with	O
low	O
systolic	O
blood	O
pressure	O
.	O
	
(	O
5.3	O
)	O
*	O
Hypoglycemia	B
:	O
When	O
an	O
insulin	O
secretagogue	O
(	O
e.g.	O
,	O
sulfonylurea	O
)	O
or	O
insulin	O
is	O
used	O
in	O
combination	O
with	O
NESINA	O
,	O
a	O
lower	O
dose	O
of	O
the	O
insulin	O
secretagogue	O
or	O
insulin	O
may	O
be	O
required	O
to	O
minimize	O
the	O
risk	O
of	O
hypoglycemia	O
.	O
	
Hyperglycemia	O
and	O
Diabetes	O
Mellitus	O
Hyperglycemia	B
,	O
in	O
some	O
cases	O
extreme	O
and	O
associated	O
with	O
ketoacidosis	B
or	O
hyperosmolar	B
coma	I
or	O
death	B
,	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
including	O
FANAPT	O
.	O
	
Other	O
serious	O
or	O
significant	O
adverse	O
reactions	O
reported	O
in	O
controlled	O
and	O
uncontrolled	O
studies	O
in	O
Crohn	O
's	O
disease	O
and	O
other	O
diseases	O
,	O
occurring	O
in	O
patients	O
receiving	O
CIMZIA	O
at	O
doses	O
of	O
400	O
mg	O
or	O
other	O
doses	O
include	O
:	O
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
Anemia	B
,	O
leukopenia	B
,	O
lymphadenopathy	B
,	O
pancytopenia	B
,	O
and	O
thrombophilia	B
.	O
	
(	O
5.3	O
)	O
item	O
{	O
Bacterial	O
infections-	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
suppress	B
the	I
host	I
response	I
and	O
thus	O
increase	O
the	O
hazard	O
of	O
secondary	B
ocular	I
infections	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
in	O
patients	O
who	O
received	O
YERVOY	O
at	O
3	O
mg/kg	O
were	O
fatigue	B
,	O
diarrhea	B
,	O
pruritus	B
,	O
rash	B
,	O
and	O
colitis	B
.	O
	
Funduscopic	B
abnormalities	I
have	O
most	O
commonly	O
been	O
described	O
as	O
perivascular	B
pigmentation	I
(	I
bone	I
spicule	I
pattern	I
)	I
in	I
the	I
retinal	I
periphery	I
and/or	O
as	O
areas	O
of	O
focal	B
retinal	I
pigment	I
epithelium	I
clumping	I
.	O
	
If	O
infectious	O
etiologies	O
are	O
not	O
considered	O
,	O
there	O
is	O
a	O
risk	O
that	O
patients	O
with	O
infectious	O
etiologies	O
will	O
not	O
receive	O
the	O
appropriate	O
therapy	O
and	O
their	O
disease	O
may	O
worsen	O
.	O
	
PRISTIQ	O
has	O
not	O
been	O
systematically	O
evaluated	O
in	O
patients	O
with	O
a	O
seizure	O
disorder	O
.	O
	
The	O
risk	O
of	O
major	O
bleeds	B
was	O
similar	O
with	O
PRADAXA	O
150	O
mg	O
and	O
warfarin	O
across	O
major	O
subgroups	O
defined	O
by	O
baseline	O
characteristics	O
(	O
see	O
Figure	O
1	O
)	O
,	O
with	O
the	O
exception	O
of	O
age	O
,	O
where	O
there	O
was	O
a	O
trend	O
towards	O
a	O
higher	O
incidence	O
of	O
major	O
bleeding	B
on	O
PRADAXA	O
(	O
hazard	O
ratio	O
1.2	O
,	O
95	O
%	O
CI	O
:	O
1.0	O
to	O
1.5	O
)	O
for	O
patients	O
>	O
=75	O
years	O
of	O
age	O
.	O
	
(	O
2.2	O
,	O
5.7	O
)	O
*	O
Embryofetal	B
Toxicity	I
:	O
ZYKADIA	O
may	O
cause	O
fetal	B
harm	I
.	O
	
(	O
5.7	O
)	O
*	O
Uterine	B
bleeding	I
:	O
Evaluate	O
irregular	O
bleeding	O
or	O
amenorrhea	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
:	O
*	O
Paradoxical	B
bronchospasm	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Worsening	B
of	I
narrow-angle	I
glaucoma	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Worsening	B
of	I
urinary	I
retention	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Immediate	B
Hypersensitivity	I
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=3	O
%	O
incidence	O
and	O
greater	O
than	O
placebo	O
)	O
are	O
headache	B
,	O
nasopharyngitis	B
and	O
cough	B
.	O
	
The	O
risk	O
of	O
postpartum	O
thromboembolism	O
decreases	O
after	O
the	O
third	O
postpartum	O
week	O
,	O
whereas	O
the	O
risk	O
of	O
ovulation	O
increases	O
after	O
the	O
third	O
postpartum	O
week	O
.	O
	
Interrupt	O
or	O
adjust	O
dosage	O
until	O
recovery	O
,	O
or	O
permanently	O
discontinue	O
Beleodaq	O
based	O
on	O
the	O
severity	O
of	O
the	O
hepatic	O
toxicity	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
If	O
the	O
AdreView	O
imaging	O
information	O
is	O
essential	O
for	O
clinical	O
care	O
,	O
consider	O
the	O
withdrawal	O
of	O
the	O
following	O
categories	O
of	O
medications	O
if	O
the	O
withdrawal	O
can	O
be	O
accomplished	O
safely	O
:	O
antihypertensives	O
that	O
deplete	O
norepinephrine	O
stores	O
or	O
inhibit	O
reuptake	O
(	O
e.g.	O
,	O
reserpine	O
,	O
labetalol	O
)	O
,	O
antidepressants	O
that	O
inhibit	O
norepinephrine	O
transporter	O
function	O
(	O
e.g.	O
,	O
amitriptyline	O
and	O
derivatives	O
,	O
imipramine	O
and	O
derivatives	O
,	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
)	O
,	O
and	O
sympathomimetic	O
amines	O
(	O
e.g.	O
,	O
phenylephrine	O
,	O
phenylpropanolamine	O
,	O
pseudoephedrine	O
and	O
ephedrine	O
)	O
.	O
	
Out	O
of	O
715	O
patients	O
who	O
received	O
two	O
concurrent	O
injections	O
of	O
XIAFLEX	O
0.58	O
mg	O
in	O
the	O
same	O
hand	O
(	O
1450	O
XIAFLEX	O
injections	O
)	O
in	O
Study	O
3	O
,	O
one	O
(	O
0.1	O
%	O
)	O
patient	O
experienced	O
a	O
tendon	B
rupture	I
of	I
the	I
treated	I
finger	I
within	O
3	O
days	O
of	O
the	O
injection	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatotoxicity	B
:	O
Increases	B
in	I
liver	I
enzymes	I
have	O
led	O
to	O
drug	O
interruption	O
,	O
dose	O
modification	O
and/or	O
discontinuation	O
.	O
	
(	O
2.2	O
,	O
5.1	O
)	O
*	O
Infection	B
:	O
Serious	O
and	O
fatal	B
infections	B
(	O
e.g.	O
,	O
pneumonia	B
and	O
sepsis	B
)	O
.	O
	
Both	O
the	O
loading	O
dose	O
of	O
400	O
mg	O
every	O
other	O
week	O
at	O
Weeks	O
0	O
,	O
2	O
and	O
4	O
and	O
concomitant	O
use	O
of	O
MTX	O
were	O
associated	O
with	O
reduced	O
immunogenicity	O
.	O
	
Use	O
ZYTIGA	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiovascular	O
disease	O
.	O
	
In	O
clinical	O
trials	O
,	O
patients	O
were	O
not	O
eligible	O
for	O
AdreView	O
imaging	O
if	O
they	O
were	O
receiving	O
medications	O
in	O
the	O
above	O
categories	O
and	O
the	O
risks	O
for	O
medication	O
withdrawal	O
were	O
unacceptable	O
or	O
if	O
they	O
were	O
not	O
clinically	O
stable	O
(	O
e.g.	O
,	O
experiencing	O
continuing	O
chest	O
pain	O
,	O
hemodynamic	O
instability	O
,	O
or	O
clinically	O
significant	O
arrhythmia	O
)	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
other	O
trials	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
and	O
initiate	O
systemic	O
high-dose	O
corticosteroid	O
therapy	O
for	O
severe	O
immune-mediated	O
reactions	O
.	O
	
These	O
immune-mediated	O
reactions	O
may	O
involve	O
any	O
organ	O
system	O
;	O
however	O
,	O
the	O
most	O
common	O
severe	O
immune-mediated	B
adverse	I
reactions	I
are	O
enterocolitis	B
,	O
hepatitis	B
,	O
dermatitis	B
(	O
including	O
toxic	B
epidermal	I
necrolysis	I
)	O
,	O
neuropathy	B
,	O
and	O
endocrinopathy	B
.	O
	
Therefore	O
,	O
the	O
efficacy	O
and	O
safety	O
of	O
XIAFLEX	O
in	O
patients	O
receiving	O
anticoagulant	O
medications	O
(	O
other	O
than	O
low-dose	O
aspirin	O
,	O
e.g.	O
,	O
up	O
to	O
150	O
mg	O
per	O
day	O
)	O
within	O
7	O
days	O
prior	O
to	O
XIAFLEX	O
administration	O
is	O
not	O
known	O
.	O
	
(	O
5.6	O
,	O
8.1	O
,	O
8.3	O
)	O
5.1	O
Hepatotoxicity	O
Drug-induced	O
hepatotoxicity	B
with	O
fatal	B
outcome	O
occurred	O
in	O
2	O
(	O
0.1	O
%	O
)	O
of	O
the	O
1669	O
patients	O
treated	O
with	O
XALKORI	O
across	O
clinical	O
trials	O
in	O
patients	O
with	O
NSCLC	O
.	O
	
pneumonia	O
,	O
systemic	O
infection	O
)	O
and	O
untreated	O
or	O
inadequately	O
treated	O
extrapyramidal	O
signs	O
and	O
symptoms	O
(	O
EPS	O
)	O
.	O
	
The	O
acute	O
reactions	O
requiring	O
intervention	O
were	O
managed	O
by	O
either	O
temporarily	O
interrupting	O
or	O
discontinuing	O
infusion	O
,	O
and	O
administering	O
additional	O
antihistamine	O
,	O
antipyretics	O
,	O
or	O
corticosteroids	O
.	O
	
*	O
Serious	O
asthma-related	O
events	O
,	O
including	O
death	B
,	O
were	O
reported	O
in	O
clinical	O
studies	O
with	O
ARCAPTA	O
NEOHALER	O
.	O
	
Doses	O
of	O
the	O
related	O
beta2-agonist	O
albuterol	O
,	O
when	O
administered	O
intravenously	O
,	O
have	O
been	O
reported	O
to	O
aggravate	B
pre-existing	I
diabetes	I
mellitus	I
.	O
	
The	O
onset	O
of	O
vision	B
disorder	I
generally	O
was	O
within	O
the	O
first	O
week	O
of	O
drug	O
administration	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
the	O
discontinuation	O
of	O
CIMZIA	O
(	O
for	O
at	O
least	O
2	O
patients	O
and	O
with	O
a	O
higher	O
incidence	O
than	O
placebo	O
)	O
were	O
abdominal	B
pain	I
(	O
0.4	O
%	O
CIMZIA	O
,	O
0.2	O
%	O
placebo	O
)	O
,	O
diarrhea	B
(	O
0.4	O
%	O
CIMZIA	O
,	O
0	O
%	O
placebo	O
)	O
,	O
and	O
intestinal	B
obstruction	I
(	O
0.4	O
%	O
CIMZIA	O
,	O
0	O
%	O
placebo	O
)	O
.	O
	
5.6	O
Gastrointestinal	O
Perforation	O
and	O
Fistula	O
Formation	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
gastrointestinal	B
perforation	I
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
.	O
	
In	O
placebo-controlled	O
monotherapy	O
trials	O
,	O
diarrhea	B
was	O
reported	O
up	O
to	O
2	O
%	O
in	O
patients	O
treated	O
with	O
Edarbi	O
80	O
mg	O
daily	O
compared	O
with	O
0.5	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
Discontinue	O
for	O
life-threatening	O
cutaneous	O
reactions	O
.	O
	
Other	O
Adverse	O
Reactions	O
Observed	O
During	O
the	O
Premarketing	O
Evaluation	O
of	O
SAPHRIS	O
:	O
Following	O
is	O
a	O
list	O
of	O
MedDRA	O
terms	O
that	O
reflect	O
adverse	O
reactions	O
reported	O
by	O
patients	O
treated	O
with	O
sublingual	O
SAPHRIS	O
at	O
multiple	O
doses	O
of	O
>	O
=5	O
mg	O
twice	O
daily	O
during	O
any	O
phase	O
of	O
a	O
trial	O
within	O
the	O
database	O
of	O
adult	O
patients	O
.	O
	
5.3	O
Malignancy	O
The	O
impact	O
of	O
treatment	O
with	O
BENLYSTA	O
on	O
the	O
development	O
of	O
malignancies	B
is	O
not	O
known	O
.	O
	
If	O
involvement	O
of	O
the	O
tongue	O
,	O
hypopharynx	O
,	O
or	O
larynx	O
occurs	O
,	O
fesoterodine	O
should	O
be	O
promptly	O
discontinued	O
and	O
appropriate	O
therapy	O
and/or	O
measures	O
to	O
ensure	O
a	O
patent	O
airway	O
should	O
be	O
promptly	O
provided	O
.	O
	
The	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
AEDs	O
was	O
observed	O
as	O
early	O
as	O
1	O
week	O
after	O
starting	O
drug	O
treatment	O
with	O
AEDs	O
and	O
persisted	O
for	O
the	O
duration	O
of	O
treatment	O
assessed	O
.	O
	
*	O
DUAVEE	O
should	O
be	O
swallowed	O
whole	O
.	O
	
Closely	O
observe	O
patients	O
during	O
and	O
after	O
alglucosidase	O
alfa	O
administration	O
and	O
be	O
prepared	O
to	O
manage	O
anaphylaxis	O
and	O
hypersensitivity	O
reactions	O
.	O
	
Because	O
of	O
the	O
potential	O
risk	O
of	O
myocardial	O
infarction	O
with	O
long-term	O
use	O
,	O
ENTEREG	O
is	O
available	O
only	O
through	O
a	O
restricted	O
program	O
for	O
short-term	O
use	O
(	O
15	O
doses	O
)	O
under	O
a	O
Risk	O
Evaluation	O
and	O
Mitigation	O
Strategy	O
(	O
REMS	O
)	O
called	O
the	O
ENTEREG	O
Access	O
Support	O
and	O
Education	O
(	O
E.A.S.E	O
.	O
	
Severe	O
acute	O
exacerbations	O
of	O
hepatitis	O
B	O
have	O
been	O
reported	O
in	O
patients	O
who	O
are	O
coinfected	O
with	O
HBV	O
and	O
HIV-1	O
and	O
have	O
discontinued	O
emtricitabine	O
or	O
tenofovir	O
DF	O
,	O
two	O
of	O
the	O
components	O
of	O
STRIBILD	O
.	O
	
A	O
majority	O
of	O
these	O
cases	O
have	O
been	O
in	O
women	O
.	O
	
Safety	O
results	O
are	O
based	O
on	O
a	O
median	O
follow-up	O
of	O
approximately	O
13	O
months	O
.	O
	
The	O
median	O
time	O
between	O
diagnosis	O
of	O
the	O
first	O
cuSCC	B
and	O
the	O
second	O
cuSCC	B
was	O
6	O
weeks	O
.	O
	
5.10	O
Glucose-6-Phosphate	O
Dehydrogenase	O
Deficiency	O
TAFINLAR	O
,	O
which	O
contains	O
a	O
sulfonamide	O
moiety	O
,	O
confers	O
a	O
potential	O
risk	O
of	O
hemolytic	B
anemia	I
in	O
patients	O
with	O
glucose-6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
deficiency	O
.	O
	
The	O
test	O
results	O
for	O
the	O
ecallantide	O
program	O
were	O
determined	O
using	O
one	O
of	O
two	O
assay	O
formats	O
:	O
ELISA	O
and	O
bridging	O
electrochemiluminescence	O
(	O
ECL	O
)	O
.	O
	
5.2	O
Tumor	O
Promotion	O
in	O
BRAF	O
Wild-Type	O
Melanoma	O
In	O
vitro	O
experiments	O
have	O
demonstrated	O
paradoxical	O
activation	O
of	O
MAP-kinase	O
signaling	O
and	O
increased	B
cell	I
proliferation	I
in	O
BRAF	O
wild-type	O
cells	O
which	O
are	O
exposed	O
to	O
BRAF	O
inhibitors	O
.	O
	
The	O
incidence	O
of	O
the	O
following	O
grade	O
3-4	O
adverse	O
reactions	O
were	O
higher	O
in	O
patients	O
>	O
=	O
65	O
years	O
of	O
age	O
compared	O
to	O
younger	O
patients	O
;	O
neutropenia	B
(	O
87	O
%	O
vs.	O
74	O
%	O
)	O
,	O
and	O
febrile	B
neutropenia	I
(	O
8	O
%	O
vs.	O
6	O
%	O
)	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Evaluate	O
patients	O
who	O
develop	O
fever	O
and	O
lung	O
infiltrates	O
or	O
respiratory	O
distress	O
after	O
receiving	O
GRANIX	O
,	O
for	O
ARDS	O
.	O
	
*	O
PRISTIQ	O
is	O
not	O
approved	O
for	O
use	O
in	O
pediatric	O
patients	O
(	O
8.4	O
)	O
.	O
	
The	O
possibility	O
that	O
GRANIX	O
acts	O
as	O
a	O
growth	B
factor	I
for	I
any	I
tumor	I
type	O
,	O
including	O
myeloid	B
malignancies	I
and	O
myelodysplasia	B
,	O
diseases	O
for	O
which	O
GRANIX	O
is	O
not	O
approved	O
,	O
can	O
not	O
be	O
excluded	O
.	O
	
Monitor	O
blood	O
pressure	O
regularly	O
during	O
treatment	O
(	O
5.3	O
)	O
.	O
	
Patients	O
with	O
Crohn	O
's	O
disease	O
that	O
require	O
chronic	O
exposure	O
to	O
immunosuppressant	O
therapies	O
may	O
be	O
at	O
higher	O
risk	O
than	O
the	O
general	O
population	O
for	O
the	O
development	O
of	O
lymphoma	B
,	O
even	O
in	O
the	O
absence	O
of	O
TNF	O
blocker	O
therapy	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
There	O
were	O
no	O
reports	O
of	O
seizures	B
in	O
pediatric	O
patients	O
treated	O
with	O
SAPHRIS	O
in	O
a	O
3-week-term	O
,	O
bipolar	O
mania	O
trial	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
drug	O
reactions	O
to	O
STRIBILD	O
(	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
,	O
all	O
grades	O
)	O
are	O
nausea	B
and	O
diarrhea	B
.	O
	
It	O
is	O
generally	O
believed	O
(	O
though	O
not	O
established	O
in	O
controlled	O
studies	O
)	O
that	O
treating	O
such	O
an	O
episode	O
with	O
an	O
antidepressant	O
alone	O
may	O
increase	O
the	O
likelihood	O
of	O
precipitation	B
of	I
a	I
mixed/manic	I
episode	I
in	O
patients	O
at	O
risk	O
for	O
bipolar	O
disorder	O
.	O
	
Only	O
anemia	B
and	O
fatigue	B
were	O
reported	O
as	O
events	O
that	O
led	O
to	O
discontinuation	O
in	O
more	O
than	O
1	O
%	O
of	O
subjects	O
in	O
any	O
arm	O
.	O
	
The	O
usefulness	O
of	O
hemodialysis	O
in	O
the	O
prevention	O
of	O
NSF	O
is	O
unknown	O
.	O
	
In	O
a	O
large	O
,	O
randomized	O
,	O
placebo-controlled	O
clinical	O
study	O
,	O
a	O
generalized	O
effect	B
of	I
estrogens	I
on	I
blood	I
pressure	I
was	O
not	O
seen	O
.	O
	
Of	O
the	O
patients	O
who	O
reported	O
neuropathy	B
,	O
59	O
%	O
had	O
complete	O
resolution	O
and	O
41	O
%	O
had	O
residual	B
neuropathy	I
(	O
26	O
%	O
partial	O
improvement	O
,	O
15	O
%	O
no	O
improvement	O
)	O
at	O
the	O
time	O
of	O
their	O
last	O
evaluation	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Gilead	O
Sciences	O
,	O
Inc.	O
at	O
1-800-GILEAD-5	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
The	O
following	O
symptoms	O
that	O
could	O
be	O
compatible	O
with	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
rarely	O
following	O
CIMZIA	O
administration	O
to	O
patients	O
:	O
angioedema	B
,	O
dyspnea	B
,	O
hypotension	B
,	O
rash	B
,	O
serum	B
sickness	I
,	O
and	O
urticaria	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
prescribing	O
information	O
.	O
	
As	O
with	O
other	O
antipsychotic	O
drugs	O
,	O
SAPHRIS	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
potentially	O
lower	O
the	O
seizure	O
threshold	O
.	O
	
Appropriate	O
care	O
is	O
advised	O
when	O
prescribing	O
SAPHRIS	O
for	O
patients	O
who	O
will	O
be	O
experiencing	O
conditions	O
that	O
may	O
contribute	O
to	O
an	O
elevation	O
in	O
core	O
body	O
temperature	O
,	O
e.g.	O
,	O
exercising	O
strenuously	O
,	O
exposure	O
to	O
extreme	O
heat	O
,	O
receiving	O
concomitant	O
medication	O
with	O
anticholinergic	O
activity	O
,	O
or	O
being	O
subject	O
to	O
dehydration	O
.	O
	
DAMPA	O
interferes	O
with	O
the	O
measurement	O
of	O
methotrexate	O
concentration	O
using	O
immunoassays	O
resulting	O
in	O
an	O
erroneous	O
measurement	O
which	O
overestimates	O
the	O
methotrexate	O
concentration	O
.	O
	
Laboratory	O
Tests	O
Increase	B
in	I
Low-Density	I
Lipoprotein	I
Cholesterol	I
(	O
LDL-C	O
)	O
Dose-related	O
increases	B
in	I
low-density	I
lipoprotein	I
cholesterol	I
(	O
LDL-C	O
)	O
were	O
observed	O
in	O
patients	O
treated	O
with	O
JARDIANCE	O
.	O
	
TAFINLAR	O
and	O
trametinib	O
may	O
be	O
resumed	O
at	O
lower	O
dose	O
levels	O
in	O
patients	O
with	O
improvement	O
or	O
recovery	O
from	O
skin	O
toxicity	O
within	O
3	O
weeks	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
following	O
symptoms	O
,	O
anxiety	B
,	O
agitation	B
,	O
panic	B
attacks	I
,	O
insomnia	B
,	O
irritability	B
,	O
hostility	B
,	O
aggressiveness	B
,	O
impulsivity	B
,	O
akathisia	B
(	O
psychomotor	B
restlessness	I
)	O
,	O
hypomania	B
,	O
and	O
mania	B
,	O
have	O
been	O
reported	O
in	O
adult	O
and	O
pediatric	O
patients	O
being	O
treated	O
with	O
antidepressants	O
for	O
major	O
depressive	O
disorder	O
as	O
well	O
as	O
for	O
other	O
indications	O
,	O
both	O
psychiatric	O
and	O
nonpsychiatric	O
.	O
	
GILENYA	O
has	O
not	O
been	O
tested	O
in	O
MS	O
patients	O
with	O
compromised	O
respiratory	O
function	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
Similar	O
adverse	O
reactions	O
have	O
been	O
observed	O
postmarketing	O
as	O
described	O
for	O
clinical	O
trial	O
experience	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
(	O
r	O
)	O
)	O
Program	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
(	O
5.2	O
)	O
]	O
.	O
	
Side	O
effects	O
are	O
grouped	O
by	O
how	O
serious	O
they	O
are	O
and	O
how	O
often	O
they	O
happen	O
when	O
you	O
are	O
treated	O
.	O
	
Etiologies	O
included	O
infection	B
,	O
cardiovascular	B
disease	I
,	O
and	O
suicide	B
.	O
	
*	O
Gastrointestinal	B
Adverse	I
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Immune-mediated	B
hepatitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Discontinuations	O
due	O
to	O
adverse	O
events	O
were	O
reported	O
for	O
16	O
%	O
of	O
XTANDI-treated	O
patients	O
and	O
18	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Consider	O
follow-up	O
renal	O
function	O
assessments	O
for	O
patients	O
with	O
a	O
history	O
of	O
renal	O
dysfunction	O
.	O
	
4Includes	O
the	O
preferred	O
terms	O
fatigue	B
and	O
lethargy	B
.	O
	
In	O
clinical	O
trials	O
with	O
INLYTA	O
,	O
venous	B
thromboembolic	I
events	I
were	O
reported	O
in	O
22/715	O
patients	O
(	O
3	O
%	O
)	O
,	O
with	O
two	O
deaths	B
secondary	O
to	O
pulmonary	B
embolism	I
.	O
	
There	O
has	O
been	O
no	O
long-term	O
use	O
of	O
Edarbi	O
in	O
patients	O
with	O
unilateral	O
or	O
bilateral	O
renal	O
artery	O
stenosis	O
,	O
but	O
similar	O
results	O
may	O
be	O
expected	O
.	O
	
The	O
most	O
common	O
(	O
per	O
patient	O
incidence	O
>	O
=	O
10	O
%	O
)	O
adverse	O
reactions	O
reported	O
with	O
Prolia	O
in	O
patients	O
with	O
bone	O
loss	O
receiving	O
androgen	O
deprivation	O
therapy	O
for	O
prostate	O
cancer	O
or	O
adjuvant	O
aromatase	O
inhibitor	O
therapy	O
for	O
breast	O
cancer	O
are	O
arthralgia	B
and	O
back	B
pain	I
.	O
	
This	O
was	O
not	O
clinically	O
significant	O
among	O
patients	O
in	O
the	O
development	O
program	O
but	O
could	O
be	O
a	O
factor	O
in	O
patients	O
whose	O
diabetes	O
is	O
difficult	O
to	O
control	O
.	O
	
Free	O
T4	O
and	O
free	O
T3	O
concentrations	O
are	O
unaltered	O
.	O
	
Based	O
on	O
the	O
Visual	O
Symptom	O
Assessment	O
Questionnaire	O
(	O
VSAQ-ALK	O
)	O
,	O
patients	O
treated	O
with	O
XALKORI	O
in	O
Studies	O
1	O
and	O
2	O
reported	O
a	O
higher	O
incidence	O
of	O
visual	B
disturbances	I
compared	O
to	O
patients	O
treated	O
with	O
chemotherapy	O
.	O
	
Other	O
important	O
considerations	O
in	O
the	O
differential	O
diagnosis	O
include	O
central	O
anticholinergic	O
toxicity	O
,	O
heat	O
stroke	O
,	O
drug	O
fever	O
,	O
and	O
primary	O
central	O
nervous	O
system	O
pathology	O
.	O
	
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
5.9	O
Abnormal	O
Thyroid	O
Function	O
Tests	O
Dose-dependent	O
decreases	B
in	I
serum	I
T3	I
and	I
T4	I
(	I
free	I
)	O
values	O
have	O
been	O
observed	O
in	O
patients	O
taking	O
APTIOM	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
(	O
>	O
=	O
2	O
%	O
)	O
included	O
febrile	B
neutropenia	I
,	O
pyrexia	B
,	O
pneumonia	B
,	O
sepsis	B
,	O
neutropenia	B
,	O
device-related	B
infection	I
,	O
tremor	B
,	O
encephalopathy	B
,	O
infection	B
,	O
overdose	B
,	O
confusion	B
,	O
Staphylococcal	B
bacteremia	I
,	O
and	O
headache	B
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
during	O
therapy	O
.	O
	
Among	O
those	O
,	O
2110	O
patients	O
were	O
treated	O
with	O
the	O
recommended	O
dose	O
of	O
2	O
mg.	O
Serious	O
adverse	O
reactions	O
related	O
to	O
the	O
injection	O
procedure	O
have	O
occurred	O
in	O
<	O
0.1	O
%	O
of	O
intravitreal	O
injections	O
with	O
EYLEA	O
including	O
endophthalmitis	B
and	O
retinal	B
detachment	I
.	O
	
Immune	O
System	O
Disorders	O
:	O
sarcoidosis	B
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
SERIOUS	O
INFECTIONS	B
AND	O
MALIGNANCY	B
WARNING	O
:	O
SERIOUS	O
INFECTIONS	B
AND	O
MALIGNANCY	B
SERIOUS	O
INFECTIONS	O
Patients	O
treated	O
with	O
CIMZIA	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
NNRTI-related	O
rash	B
did	O
not	O
appear	O
to	O
be	O
at	O
increased	O
risk	O
for	O
the	O
development	O
of	O
INTELENCE	O
(	O
r	O
)	O
-related	O
rash	B
compared	O
to	O
patients	O
without	O
a	O
history	O
of	O
NNRTI-related	O
rash	B
.	O
	
5.3	O
Interstitial	O
Lung	O
Disease	O
(	O
ILD	O
)	O
/Pneumonitis	O
Severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
ILD/pneumonitis	O
can	O
occur	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
Table	O
5	O
shows	O
the	O
number	O
of	O
patients	O
experiencing	O
bleeding	B
events	O
in	O
the	O
study	O
.	O
	
The	O
mechanism	O
of	O
Ferriprox-associated	O
agranulocytosis	B
is	O
unknown	O
.	O
	
Monitor	O
with	O
liver	O
laboratory	O
tests	O
including	O
ALT	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
and	O
total	O
bilirubin	O
once	O
a	O
month	O
and	O
as	O
clinically	O
indicated	O
,	O
with	O
more	O
frequent	O
testing	O
in	O
patients	O
who	O
develop	O
transaminase	O
elevations	O
.	O
	
5.8	O
Embryofetal	O
Toxicity	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
ZYKADIA	O
may	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
(	O
2.2	O
)	O
Assess	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
enterocolitis	O
,	O
dermatitis	O
,	O
neuropathy	O
,	O
and	O
endocrinopathy	O
and	O
evaluate	O
clinical	O
chemistries	O
including	O
liver	O
function	O
tests	O
and	O
thyroid	O
function	O
tests	O
at	O
baseline	O
and	O
before	O
each	O
dose	O
.	O
	
Mean	O
percent	O
changes	B
from	I
baseline	I
at	I
Week	I
24	I
,	I
were	I
0.0	I
%	I
versus	I
2.5	I
%	I
for	I
total	I
cholesterol	I
,	O
in	O
the	O
placebo	O
and	O
FARXIGA	O
10	O
mg	O
groups	O
,	O
respectively	O
.	O
	
5.11	O
Hepatic	O
Impairment	O
COMETRIQ	O
is	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
hepatic	O
impairment	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Based	O
on	O
patient	O
diaries	O
,	O
amenorrhea	O
occurs	O
in	O
approximately	O
16	O
%	O
of	O
cycles	O
in	O
women	O
using	O
Natazia	O
.	O
	
In	O
addition	O
to	O
the	O
reactions	O
in	O
Table	O
1	O
,	O
the	O
following	O
adverse	O
reactions	O
were	O
reported	O
more	O
frequently	O
in	O
TRULICITY-treated	O
patients	O
than	O
placebo	O
(	O
frequencies	O
listed	O
,	O
respectively	O
,	O
as	O
:	O
placebo	O
;	O
0.75	O
mg	O
;	O
1.5	O
mg	O
)	O
:	O
constipation	B
(	O
0.7	O
%	O
,	O
3.9	O
%	O
,	O
3.7	O
%	O
)	O
,	O
flatulence	B
(	O
1.4	O
%	O
,	O
1.4	O
%	O
,	O
3.4	O
%	O
)	O
,	O
abdominal	B
distension	I
(	O
0.7	O
%	O
,	O
2.9	O
%	O
,	O
2.3	O
%	O
)	O
,	O
gastroesophageal	B
reflux	I
disease	I
(	O
0.5	O
%	O
,	O
1.7	O
%	O
,	O
2.0	O
%	O
)	O
,	O
and	O
eructation	B
(	O
0.2	O
%	O
,	O
0.6	O
%	O
,	O
1.6	O
%	O
)	O
.	O
	
The	O
liver	O
transplant	O
recipient	O
was	O
treated	O
with	O
6	O
months	O
of	O
a	O
NULOJIX	O
dosage	O
regimen	O
that	O
was	O
more	O
intensive	O
than	O
that	O
studied	O
in	O
kidney	O
transplant	O
recipients	O
,	O
MMF	O
at	O
doses	O
higher	O
than	O
the	O
recommended	O
dose	O
,	O
and	O
corticosteroids	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
The	O
safety	O
profile	O
for	O
patients	O
with	O
PsA	O
treated	O
with	O
CIMZIA	O
was	O
similar	O
to	O
the	O
safety	O
profile	O
seen	O
in	O
patients	O
with	O
RA	O
and	O
previous	O
experience	O
with	O
CIMZIA	O
.	O
	
Galactorrhea	B
,	O
amenorrhea	B
,	O
gynecomastia	B
,	O
and	O
impotence	B
have	O
been	O
reported	O
with	O
prolactin-elevating	O
compounds	O
.	O
	
high	O
tumor	O
burden	O
)	O
.	O
	
The	O
sizes	O
of	O
these	O
studies	O
were	O
not	O
adequate	O
to	O
precisely	O
quantify	O
the	O
differences	O
in	O
serious	O
asthma	O
exacerbation	O
rates	O
between	O
treatment	O
groups	O
.	O
	
Hazardous	O
Activities	O
Prescribers	O
should	O
advise	O
patients	O
against	O
engaging	O
in	O
hazardous	O
activities	O
requiring	O
mental	O
alertness	O
,	O
such	O
as	O
operating	O
motor	O
vehicles	O
or	O
dangerous	O
machinery	O
,	O
until	O
the	O
effect	O
of	O
APTIOM	O
is	O
known	O
.	O
	
Patients	O
with	O
moderate	O
renal	O
impairment	O
at	O
baseline	O
had	O
larger	O
mean	O
changes	O
.	O
	
Closely	O
supervise	O
high-risk	O
patients	O
.	O
	
Concurrent	O
elevations	B
in	I
alanine	I
aminotransferase	I
)	O
greater	O
than	O
or	O
equal	O
to	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
and	O
total	B
bilirubin	I
greater	I
than	I
or	I
equal	I
to	I
two	I
times	I
the	I
ULN	I
,	O
with	O
normal	O
alkaline	O
phosphatase	O
,	O
occurred	O
in	O
10	O
patients	O
(	O
0.6	O
%	O
)	O
treated	O
with	O
XALKORI	O
.	O
	
Table	O
2	O
:	O
Shift	O
from	O
Baseline	O
to	O
Lowest	O
Observed	O
eGFR	O
Group	O
During	O
Treatment	O
Safety	O
Population	O
in	O
Clinical	O
Studies	O
(	O
n=818	O
)	O
Among	O
the	O
818	O
patients	O
,	O
eGFR	O
was	O
missing	O
in	O
5	O
patients	O
at	O
baseline	O
or	O
on-therapy	O
.	O
	
Serious	O
Infections	O
S	O
erious	O
infection	B
was	O
reported	O
in	O
1	O
patient	O
(	O
0.8	O
%	O
)	O
in	O
the	O
placebo	O
group	O
and	O
no	O
patients	O
in	O
the	O
Prolia	O
group	O
.	O
	
*	O
currently	O
have	O
or	O
have	O
had	O
liver	O
problems	O
*	O
have	O
been	O
diagnosed	O
with	O
a	O
bleeding	O
disorder	O
*	O
think	O
you	O
may	O
be	O
pregnant	O
.	O
	
*	O
Possible	O
clinically	O
significant	O
adverse	O
reactions	O
from	O
greater	O
exposures	O
of	O
concomitant	O
drugs	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
below	O
and	O
also	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Hypocalcemia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Serious	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Dermatologic	B
Adverse	I
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
*	O
Osteonecrosis	B
of	I
the	I
Jaw	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Atypical	B
Subtrochanteric	I
and	I
Diaphyseal	I
Femoral	I
Fractures	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
with	O
Prolia	O
in	O
patients	O
with	O
postmenopausal	O
osteoporosis	O
are	O
back	B
pain	I
,	O
pain	B
in	I
extremity	I
,	O
musculoskeletal	B
pain	I
,	O
hypercholesterolemia	B
,	O
and	O
cystitis	B
.	O
	
Do	O
not	O
use	O
to	O
treat	O
acute	O
symptoms	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
hypertension	O
and	O
treated	O
as	O
needed	O
with	O
standard	O
anti-hypertensive	O
therapy	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Seattle	O
Genetics	O
,	O
Inc.	O
at	O
1-855-473-2436	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Galactorrhea	B
or	O
dysmenorrhea	B
were	O
reported	O
in	O
0	O
%	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
2	O
%	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
1	O
%	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
compared	O
to	O
1	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
The	O
mean	O
exposure	O
to	O
NESINA	O
was	O
40	O
weeks	O
with	O
more	O
than	O
2400	O
subjects	O
treated	O
for	O
more	O
than	O
one	O
year	O
.	O
	
*	O
Pancreatitis	B
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Diarrhea	O
:	O
Diarrhea	B
may	O
result	O
in	O
dehydration	B
and	O
renal	B
failure	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
another	O
section	O
of	O
the	O
label	O
:	O
*	O
Bone	B
Marrow	I
Suppression	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
increased	B
aspartate	I
transaminase	I
)	O
,	O
anemia	B
,	O
leukopenia	B
,	O
thrombocytopenia	B
,	O
lymphopenia	B
,	O
increased	B
alanine	I
transaminase	I
)	O
,	O
and	O
hypertriglyceridemia	B
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
in	O
the	O
221	O
patients	O
treated	O
with	O
KALYDECO	O
were	O
headache	B
(	O
17	O
%	O
)	O
,	O
upper	B
respiratory	I
tract	I
infection	I
(	O
16	O
%	O
)	O
,	O
nasal	B
congestion	I
(	O
16	O
%	O
)	O
,	O
nausea	B
(	O
10	O
%	O
)	O
,	O
rash	B
(	O
10	O
%	O
)	O
,	O
rhinitis	B
(	O
6	O
%	O
)	O
,	O
dizziness	B
(	O
5	O
%	O
)	O
,	O
arthralgia	B
(	O
5	O
%	O
)	O
,	O
and	O
bacteria	B
in	I
sputum	I
(	O
5	O
%	O
)	O
.	O
	
Confirm	O
evidence	O
of	O
BRAF	O
V600E	O
or	O
V600K	O
mutation	O
status	O
prior	O
to	O
initiation	O
of	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
or	O
combination	O
therapy	O
[	O
see	O
Indications	O
and	O
Usage	O
(	O
1	O
)	O
,	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
immunogenicity	O
with	O
the	O
use	O
of	O
KALBITOR	O
.	O
	
In	O
Trial	O
1	O
,	O
the	O
incidence	O
of	O
new	O
primary	B
malignant	I
melanomas	I
was	O
2	O
%	O
(	O
3/187	O
)	O
for	O
patients	O
receiving	O
TAFINLAR	O
while	O
no	O
dacarbazine-treated	O
patient	O
was	O
diagnosed	O
with	O
new	O
primary	O
malignant	O
melanoma	O
.	O
	
Tuberculosis	O
Tuberculosis	B
was	O
more	O
frequently	O
observed	O
in	O
patients	O
receiving	O
NULOJIX	O
than	O
cyclosporine	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
*	O
Abnormal	B
Bleeding	I
:	O
PRISTIQ	O
may	O
increase	O
risk	O
of	O
bleeding	B
events	O
.	O
	
5.11	O
Vaccinations	O
During	O
AFINITOR	O
treatment	O
,	O
avoid	O
the	O
use	O
of	O
live	O
vaccines	O
and	O
avoid	O
close	O
contact	O
with	O
individuals	O
who	O
have	O
received	O
live	O
vaccines	O
(	O
e.g.	O
,	O
intranasal	O
influenza	O
,	O
measles	O
,	O
mumps	O
,	O
rubella	O
,	O
oral	O
polio	O
,	O
BCG	O
,	O
yellow	O
fever	O
,	O
varicella	O
,	O
and	O
TY21a	O
typhoid	O
vaccines	O
)	O
.	O
	
5.5	O
Overestimation	O
of	O
Extent	O
of	O
Malignant	O
Disease	O
in	O
MRI	O
of	O
the	O
Breast	O
Gadavist	O
MRI	O
of	O
the	O
breast	O
overestimated	O
the	O
histologically	O
confirmed	O
extent	O
of	O
malignancy	O
in	O
the	O
diseased	O
breast	O
in	O
up	O
to	O
50	O
%	O
of	O
the	O
patients	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
(	O
4	O
,	O
5.2	O
,	O
14.4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Determine	O
cardiac	O
rhythm	O
at	O
least	O
once	O
every	O
3	O
months	O
.	O
	
5.2	O
Clostridium	O
difficile-Associated	O
Diarrhea	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
for	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
Teflaro	O
,	O
and	O
may	O
range	O
in	O
severity	O
from	O
mild	O
diarrhea	B
to	O
fatal	B
colitis	B
.	O
	
Median	O
duration	O
of	O
treatment	O
was	O
7	O
cycles	O
(	O
range	O
,	O
1-16	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Have	O
resuscitation	O
equipment	O
and	O
trained	O
personnel	O
available	O
at	O
time	O
of	O
Vizamyl	O
administration	O
(	O
5.1	O
)	O
*	O
Image	O
interpretation	O
errors	O
(	O
especially	O
false	O
positives	O
)	O
have	O
been	O
observed	O
(	O
5.2	O
)	O
*	O
Radiation	B
risk	I
:	O
Vizamyl	O
,	O
similar	O
to	O
all	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
When	O
Coartem	O
Tablets	O
are	O
coadministered	O
with	O
an	O
inhibitor	O
of	O
CYP3A4	O
,	O
including	O
grapefruit	O
juice	O
it	O
may	O
result	O
in	O
increased	O
concentrations	O
of	O
artemether	O
and/or	O
lumefantrine	O
and	O
potentiate	O
QT	B
prolongation	I
.	O
	
These	O
reactions	O
occurred	O
several	O
weeks	O
to	O
3	O
years	O
after	O
initiation	O
of	O
alglucosidase	O
alfa	O
infusions	O
.	O
	
Serotonin	B
syndrome	I
symptoms	O
may	O
include	O
mental	B
status	I
changes	I
(	O
e.g.	O
,	O
agitation	B
,	O
hallucinations	B
,	O
delirium	B
,	O
and	O
coma	B
)	O
,	O
autonomic	B
instability	I
(	O
e.g.	O
,	O
tachycardia	B
,	O
labile	B
blood	I
pressure	I
,	O
dizziness	B
,	O
diaphoresis	B
,	O
flushing	B
,	O
hyperthermia	B
)	O
,	O
neuromuscular	B
symptoms	I
(	O
e.g.	O
,	O
tremor	B
,	O
rigidity	B
,	O
myoclonus	B
,	O
hyperreflexia	B
,	O
incoordination	B
)	O
,	O
seizures	B
,	O
and/or	O
gastrointestinal	B
symptoms	I
(	O
e.g.	O
,	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
)	O
.	O
	
*	O
Before	O
EOVIST	O
administration	O
,	O
assess	O
all	O
patients	O
for	O
any	O
history	O
of	O
a	O
reaction	O
to	O
contrast	O
media	O
,	O
bronchial	O
asthma	O
and	O
allergic	O
disorders	O
.	O
	
Severe	O
Aplastic	O
Anemia	O
:	O
In	O
the	O
single-arm	O
,	O
open-label	O
trial	O
,	O
43	O
patients	O
with	O
severe	O
aplastic	O
anemia	O
received	O
PROMACTA	O
.	O
	
The	O
use	O
of	O
estrogen-alone	O
has	O
been	O
reported	O
to	O
result	O
in	O
an	O
increase	O
in	O
abnormal	O
mammograms	O
requiring	O
further	O
evaluation	O
.	O
	
Prescriptions	O
for	O
PRISTIQ	O
should	O
be	O
written	O
for	O
the	O
smallest	O
quantity	O
of	O
tablets	O
consistent	O
with	O
good	O
patient	O
management	O
,	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
overdose	O
.	O
	
Safety	O
of	O
combined	O
use	O
of	O
PDE5	O
inhibitors	O
and	O
alpha-blockers	O
may	O
be	O
affected	O
by	O
other	O
variables	O
,	O
including	O
intravascular	O
volume	O
depletion	O
and	O
other	O
anti-hypertensive	O
drugs	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Six	O
of	O
these	O
patients	O
again	O
experienced	O
liver	B
test	I
abnormalities	I
(	O
predominantly	O
Grade	O
1	O
)	O
resulting	O
in	O
discontinuation	O
of	O
PROMACTA	O
in	O
one	O
patient	O
.	O
	
5.3	O
Drug	O
Interactions	O
with	O
CYP3A4	O
When	O
Coartem	O
Tablets	O
are	O
coadministered	O
with	O
substrates	O
of	O
CYP3A4	O
it	O
may	O
result	O
in	O
decreased	O
concentrations	O
of	O
the	O
substrate	O
and	O
potential	O
loss	O
of	O
substrate	O
efficacy	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
ribavirin	O
for	O
additional	O
information	O
.	O
	
5.14	O
Suicide	O
The	O
possibility	O
of	O
a	O
suicide	O
attempt	O
is	O
inherent	O
in	O
psychotic	O
illnesses	O
and	O
bipolar	O
disorder	O
,	O
and	O
close	O
supervision	O
of	O
high-risk	O
patients	O
should	O
accompany	O
drug	O
therapy	O
.	O
	
If	O
an	O
allergic	O
reaction	O
to	O
Teflaro	O
occurs	O
,	O
discontinue	O
Teflaro	O
and	O
institute	O
appropriate	O
treatment	O
and	O
supportive	O
measures	O
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
Conditions	O
that	O
lower	O
the	O
seizure	O
threshold	O
may	O
be	O
more	O
prevalent	O
in	O
patients	O
65	O
years	O
or	O
older	O
.	O
	
ALT	O
=	O
Alanine	O
aminotransferase	O
;	O
AST	O
=	O
Aspartate	O
aminotransferase	O
;	O
GGT	O
=	O
Gamma	O
glutamyltransferase	O
.	O
	
Other	O
adverse	O
reactions	O
which	O
occurred	O
in	O
2-5	O
%	O
of	O
subjects	O
were	O
eye	B
irritation	I
,	O
headache	B
,	O
and	O
nasopharyngitis	B
.	O
	
One	O
additional	O
patient	O
's	O
death	B
was	O
attributed	O
to	O
neutropenia	B
without	O
a	O
documented	O
infection	B
.	O
	
Spirometric	O
evaluation	O
of	O
respiratory	O
function	O
and	O
evaluation	O
of	O
DLCO	O
should	O
be	O
performed	O
during	O
therapy	O
with	O
GILENYA	O
if	O
clinically	O
indicated	O
.	O
	
Because	O
of	O
the	O
risk	O
of	O
anaphylaxis	O
,	O
KALBITOR	O
should	O
only	O
be	O
administered	O
by	O
a	O
healthcare	O
professional	O
with	O
appropriate	O
medical	O
support	O
to	O
manage	O
anaphylaxis	O
and	O
hereditary	O
angioedema	O
.	O
	
EXCERPT	O
:	O
Exclusive	O
of	O
an	O
uncommon	O
,	O
mild	O
injection	B
site	I
reaction	I
,	O
no	O
other	O
adverse	O
reactions	O
have	O
been	O
reported	O
(	O
6	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Serious	O
allergic	B
reactions	I
,	O
including	O
anaphylactic	B
reactions	I
,	O
may	O
occur	O
.	O
	
Patients	O
who	O
are	O
coinfected	O
with	O
HIV-1	O
and	O
HBV	O
should	O
be	O
closely	O
monitored	O
with	O
both	O
clinical	O
and	O
laboratory	O
follow-up	O
for	O
at	O
least	O
several	O
months	O
after	O
stopping	O
treatment	O
with	O
STRIBILD	O
.	O
	
In	O
all	O
open-label	O
trials	O
combined	O
,	O
857	O
,	O
701	O
,	O
529	O
,	O
and	O
105	O
patients	O
received	O
Toviaz	O
for	O
at	O
least	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
,	O
respectively	O
.	O
	
Although	O
the	O
causes	O
of	O
death	B
were	O
varied	O
,	O
most	O
of	O
the	O
deaths	B
appeared	O
to	O
be	O
either	O
cardiovascular	O
(	O
e.g.	O
,	O
heart	B
failure	I
,	O
sudden	B
death	I
)	O
or	O
infectious	O
(	O
e.g.	O
,	O
pneumonia	B
)	O
in	O
nature	O
.	O
	
Serious	O
adverse	O
reactions	O
,	O
whether	O
considered	O
drug-related	O
or	O
not	O
by	O
the	O
investigators	O
,	O
that	O
occurred	O
more	O
frequently	O
in	O
KALYDECO-treated	O
patients	O
included	O
abdominal	B
pain	I
,	O
increased	B
hepatic	I
enzymes	I
,	O
and	O
hypoglycemia	B
.	O
	
There	O
were	O
no	O
reports	O
of	O
gynecomastia	B
in	O
this	O
trial	O
.	O
	
Symptoms	O
of	O
taking	O
too	O
much	O
DUAVEE	O
include	O
:	O
nauseavomitingbreast	O
tendernessdizzinessabdominal	O
painfeeling	O
tiredvaginal	O
bleeding	O
What	O
are	O
the	O
possible	O
side	O
effects	O
of	O
DUAVEE	O
?	O
	
Approximately	O
8500	O
patients	O
with	O
type	O
2	O
diabetes	O
have	O
been	O
treated	O
with	O
NESINA	O
in	O
14	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
clinical	O
trials	O
with	O
approximately	O
2900	O
subjects	O
randomized	O
to	O
placebo	O
and	O
approximately	O
2200	O
to	O
an	O
active	O
comparator	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
was	O
8.3	O
months	O
with	O
XTANDI	O
and	O
3.0	O
months	O
with	O
placebo	O
.	O
	
In	O
clinical	O
studies	O
of	O
gabapentin	O
as	O
adjunctive	O
therapy	O
in	O
epilepsy	O
comprising	O
2,085	O
patient-years	O
of	O
exposure	O
in	O
patients	O
>	O
12	O
years	O
of	O
age	O
,	O
new	O
tumors	B
,	O
1	O
non-Hodgkin	B
's	I
lymphoma	I
,	O
1	O
endometrial	B
carcinoma	I
in	I
situ	I
)	O
,	O
and	O
preexisting	O
tumors	B
worsened	I
in	I
11	I
patients	I
(	I
9	I
brain	I
)	O
during	O
or	O
up	O
to	O
2	O
years	O
following	O
discontinuation	O
of	O
gabapentin	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
drug	O
reactions	O
(	O
adverse	O
events	O
assessed	O
as	O
causally	O
related	O
by	O
the	O
investigator	O
or	O
ADRs	O
)	O
are	O
discussed	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Hypersensitivity	B
reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Patients	O
who	O
experienced	O
bradycardia	B
were	O
generally	O
asymptomatic	O
,	O
but	O
some	O
patients	O
experienced	O
hypotension	B
,	O
dizziness	B
,	O
fatigue	B
,	O
palpitations	B
,	O
and/or	O
chest	B
pain	I
that	O
usually	O
resolved	O
within	O
the	O
first	O
24	O
hours	O
on	O
treatment	O
.	O
	
Healthcare	O
providers	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
hypersensitivity	O
reactions	O
,	O
which	O
may	O
present	O
as	O
infusion	O
reactions	O
,	O
and	O
monitor	O
patients	O
closely	O
.	O
	
The	O
incidence	O
of	O
eyelid	B
ptosis	I
did	O
not	O
increase	O
in	O
the	O
long-term	O
safety	O
studies	O
with	O
multiple	O
re-treatments	O
at	O
intervals	O
>	O
=	O
three	O
months	O
.	O
	
Perform	O
hepatic	O
enzyme	O
tests	O
monthly	O
for	O
the	O
first	O
three	O
months	O
of	O
BOSULIF	O
treatment	O
and	O
as	O
clinically	O
indicated	O
.	O
	
There	O
were	O
no	O
patients	O
with	O
kidney	O
failure	O
at	O
baseline	O
.	O
	
Use	O
caution	O
in	O
a	O
patient	O
with	O
a	O
history	O
of	O
angioedema	O
with	O
another	O
DPP-4	O
inhibitor	O
because	O
it	O
is	O
unknown	O
whether	O
such	O
patients	O
will	O
be	O
predisposed	O
to	O
angioedema	O
with	O
NESINA	O
.	O
	
5.1	O
Anaphylaxis	O
and	O
Hypersensitivity	O
Reactions	O
Anaphylaxis	B
and	O
hypersensitivity	B
reactions	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
Vimizim	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Anyone	O
considering	O
prescribing	O
APTIOM	O
or	O
any	O
other	O
AED	O
must	O
balance	O
this	O
risk	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
Eosinophilia	B
is	O
often	O
present	O
.	O
	
(	O
5.11	O
,	O
8.1	O
)	O
5.1	O
Perforations	O
and	O
Fistulas	O
GI	B
)	I
perforations	I
were	O
reported	O
in	O
3	O
%	O
and	O
1	O
%	O
of	O
COMETRIQ-treated	O
patients	O
,	O
respectively	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RETINAL	B
ABNORMALITIES	I
AND	O
POTENTIAL	O
VISION	B
LOSS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
5.3	O
Spinal/Epidural	O
Anesthesia	O
or	O
Puncture	O
When	O
neuraxial	O
anesthesia	O
(	O
spinal/epidural	O
anesthesia	O
)	O
or	O
spinal	O
puncture	O
is	O
employed	O
,	O
patients	O
treated	O
with	O
anticoagulant	O
agents	O
are	O
at	O
risk	O
of	O
developing	O
an	O
spinal	B
hematoma	I
which	O
can	O
result	O
in	O
long-term	O
or	O
paralysis	B
[	O
see	O
Boxed	O
Warning	O
]	O
.	O
	
Assess	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
enterocolitis	O
,	O
dermatitis	O
,	O
neuropathy	O
,	O
and	O
endocrinopathy	O
and	O
evaluate	O
clinical	O
chemistries	O
including	O
liver	O
function	O
tests	O
and	O
thyroid	O
function	O
tests	O
at	O
baseline	O
and	O
before	O
each	O
dose	O
.	O
	
Monitor	O
patients	O
for	O
hypertension	O
,	O
hypokalemia	O
,	O
and	O
fluid	O
retention	O
at	O
least	O
once	O
a	O
month	O
.	O
	
In	O
this	O
situation	O
,	O
the	O
patient	O
requires	O
immediate	O
reevaluation	O
with	O
reassessment	O
of	O
the	O
treatment	O
regimen	O
,	O
giving	O
special	O
consideration	O
to	O
the	O
possible	O
need	O
for	O
replacing	O
the	O
current	O
strength	O
of	O
BREO	O
ELLIPTA	O
with	O
a	O
higher	O
strength	O
,	O
adding	O
additional	O
inhaled	O
corticosteroid	O
,	O
or	O
initiating	O
systemic	O
corticosteroids	O
.	O
	
In	O
patients	O
with	O
hepatotoxicity	O
,	O
rule	O
out	O
infectious	O
or	O
malignant	O
causes	O
and	O
increase	O
frequency	O
of	O
liver	O
function	O
test	O
monitoring	O
until	O
resolution	O
.	O
	
Bradycardia	B
was	O
reported	O
as	O
an	O
adverse	O
drug	O
reaction	O
in	O
3	O
%	O
of	O
patients	O
in	O
Study	O
1	O
.	O
	
(	O
5.4	O
)	O
*	O
Failure	O
to	O
block	O
thyroid	O
iodine	O
uptake	O
may	O
result	O
in	O
iodine	O
123	O
accumulation	O
in	O
the	O
thyroid	O
.	O
	
(	O
5.4	O
)	O
*	O
Embryo-fetal	B
toxicity	I
:	O
Beleodaq	O
may	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
At	O
the	O
time	O
of	O
perforation	O
,	O
some	O
patients	O
had	O
moderate	O
to	O
severe	O
diarrhea	B
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
taking	O
Zydelig	O
.	O
	
Patients	O
treated	O
with	O
concomitant	O
immunosuppressant	O
therapy	O
(	O
MTX	O
)	O
in	O
RA-I	O
,	O
RA-II	O
,	O
RA-III	O
had	O
a	O
lower	O
rate	O
of	O
neutralizing	O
antibody	O
formation	O
overall	O
than	O
patients	O
treated	O
with	O
CIMZIA	O
monotherapy	O
in	O
RA-IV	O
(	O
2	O
%	O
vs.	O
8	O
%	O
)	O
.	O
	
Adverse	O
Reaction	O
Placebo	O
(	O
N=568	O
)	O
%	O
Trulicity	O
0.75	O
mg	O
(	O
N=836	O
)	O
%	O
Trulicity	O
1.5	O
mg	O
(	O
N=834	O
)	O
%	O
Nausea	B
5.3	O
12.4	O
21.1	O
Diarrhea	B
a	O
6.7	O
8.9	O
12.6	O
Vomiting	B
b	O
2.3	O
6.0	O
12.7	O
Abdominal	B
Pain	I
c	O
4.9	O
6.5	O
9.4	O
Decreased	B
Appetite	I
1.6	O
4.9	O
8.6	O
Dyspepsia	B
2.3	O
4.1	O
5.8	O
Fatigue	B
d	O
2.6	O
4.2	O
5.6	O
Gastrointestinal	O
Adverse	O
Reactions	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
gastrointestinal	B
adverse	I
reactions	I
occurred	O
more	O
frequently	O
among	O
patients	O
receiving	O
TRULICITY	O
than	O
placebo	O
(	O
placebo	O
21.3	O
%	O
,	O
0.75	O
mg	O
31.6	O
%	O
,	O
1.5	O
mg	O
41.0	O
%	O
)	O
.	O
	
The	O
adverse	O
reactions	O
with	O
>	O
=	O
10	O
%	O
incidence	O
for	O
any	O
grade	O
or	O
>	O
=	O
5	O
%	O
incidence	O
for	O
Grade	O
3	O
or	O
higher	O
are	O
summarized	O
in	O
Table	O
2	O
.	O
	
These	O
immune-mediated	B
reactions	I
may	O
involve	O
any	O
organ	O
system	O
;	O
however	O
,	O
the	O
most	O
common	O
severe	O
immune-mediated	B
adverse	I
reactions	I
are	O
enterocolitis	B
,	O
hepatitis	B
,	O
dermatitis	B
(	O
including	O
toxic	B
epidermal	I
necrolysis	I
)	O
,	O
neuropathy	B
,	O
and	O
endocrinopathy	B
.	O
	
Adequately	O
supplement	O
patients	O
with	O
calcium	O
and	O
vitamin	O
D	O
(	O
5.3	O
)	O
*	O
Osteonecrosis	B
of	I
the	I
jaw	I
:	O
Has	O
been	O
reported	O
with	O
Prolia	O
.	O
	
Therefore	O
,	O
a	O
lower	O
dose	O
of	O
insulin	O
or	O
insulin	O
secretagogue	O
may	O
be	O
required	O
to	O
minimize	O
the	O
risk	O
of	O
hypoglycemia	O
when	O
used	O
in	O
combination	O
with	O
NESINA	O
.	O
	
Table	O
4	O
:	O
Incidence	O
of	O
Hematology	O
Laboratory	O
Abnormalities	O
in	O
Patients	O
Who	O
Received	O
TREANDA	O
in	O
the	O
NHL	O
Studies	O
Percent	O
of	O
patients	O
Hematology	O
variable	O
All	O
Grades	O
Grades	O
3/4	O
Lymphocytes	B
Decreased	I
99	O
94	O
Leukocytes	B
Decreased	I
94	O
56	O
Hemoglobin	B
Decreased	I
88	O
11	O
Neutrophils	B
Decreased	I
86	O
60	O
Platelets	B
Decreased	I
86	O
25	O
In	O
both	O
studies	O
,	O
serious	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
reported	O
in	O
37	O
%	O
of	O
patients	O
receiving	O
TREANDA	O
.	O
	
5.6	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
NESINA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
of	O
PRADAXA	O
were	O
bleeding	B
and	O
gastrointestinal	B
events	I
(	O
i.e.	O
,	O
dyspepsia	B
,	O
nausea	B
,	O
upper	B
abdominal	I
pain	I
,	O
gastrointestinal	B
hemorrhage	I
,	O
and	O
diarrhea	B
)	O
.	O
	
The	O
incidence	O
of	O
nonfatal	O
serious	O
adverse	O
events	O
was	O
7.5	O
%	O
in	O
the	O
placebo	O
group	O
and	O
8.3	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
An	O
increased	O
incidence	O
was	O
observed	O
in	O
patients	O
on	O
the	O
300	O
mg	O
dose	O
.	O
	
Increasing	O
inhaled	O
beta2-agonist	O
use	O
is	O
a	O
signal	O
of	O
deteriorating	O
disease	O
for	O
which	O
prompt	O
medical	O
attention	O
is	O
indicated	O
.	O
	
Five	O
patients	O
experienced	O
serious	O
adverse	O
reactions	O
of	O
hypersensitivity	B
with	O
INVOKANA	O
,	O
which	O
included	O
4	O
patients	O
with	O
urticaria	B
and	O
1	O
patient	O
with	O
a	O
diffuse	B
rash	I
and	O
urticaria	B
occurring	O
within	O
hours	O
of	O
exposure	O
to	O
INVOKANA	O
.	O
	
*	O
Radiation	B
risk	I
:	O
Amyvid	O
,	O
similar	O
to	O
all	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
None	O
of	O
these	O
abnormalities	O
were	O
reported	O
in	O
the	O
placebo	O
group	O
.	O
	
5.4	O
Extravasation	O
and	O
Injection	O
Site	O
Reactions	O
Ensure	O
catheter	O
and	O
venous	O
patency	O
before	O
the	O
injection	O
of	O
DOTAREM	O
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
who	O
had	O
an	O
arterial	O
thromboembolic	O
event	O
within	O
the	O
previous	O
12	O
months	O
.	O
	
Use	O
of	O
live	O
vaccines	O
could	O
result	O
in	O
clinical	O
infections	O
,	O
including	O
disseminated	O
infections	O
.	O
	
Two	O
suicides	B
(	O
0.1	O
%	O
)	O
were	O
reported	O
in	O
patients	O
receiving	O
BENLYSTA	O
.	O
	
Discontinue	O
if	O
significant	O
liver	O
injury	O
occurs	O
.	O
	
In	O
premarketing	O
controlled	O
trials	O
of	O
all	O
patient	O
populations	O
combined	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
8	O
%	O
)	O
were	O
upper	B
respiratory	I
infections	I
(	O
18	O
%	O
)	O
,	O
rash	B
(	O
9	O
%	O
)	O
and	O
urinary	B
tract	I
infections	I
(	O
8	O
%	O
)	O
.	O
	
Other	O
Reactions	O
During	O
the	O
Premarketing	O
Evaluation	O
of	O
FANAPT	O
The	O
following	O
is	O
a	O
list	O
of	O
MedDRA	O
terms	O
that	O
reflect	O
treatment-emergent	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
FANAPT	O
at	O
multiple	O
doses	O
>	O
=4	O
mg/day	O
during	O
any	O
phase	O
of	O
a	O
trial	O
with	O
the	O
database	O
of	O
3210	O
FANAPT-treated	O
patients	O
.	O
	
Do	O
not	O
take	O
2	O
doses	O
at	O
the	O
same	O
time	O
unless	O
your	O
healthcare	O
provider	O
tells	O
you	O
to	O
.	O
	
More	O
GILOTRIF-treated	O
patients	O
(	O
2.2	O
%	O
;	O
n=5	O
)	O
experienced	O
ventricular	B
dysfunction	I
(	O
defined	O
as	O
diastolic	B
dysfunction	I
,	O
left	B
ventricular	I
dysfunction	I
,	O
or	O
ventricular	B
dilation	I
;	O
all	O
<	O
Grade	O
3	O
)	O
compared	O
to	O
chemotherapy-treated	O
patients	O
(	O
0.9	O
%	O
;	O
n=1	O
)	O
.	O
	
Dose	O
reductions	O
were	O
reported	O
in	O
12	O
%	O
of	O
JEVTANA-treated	O
patients	O
and	O
4	O
%	O
of	O
mitoxantrone-treated	O
patients	O
.	O
	
Appropriate	O
screening	O
tests	O
should	O
be	O
performed	O
in	O
all	O
patients	O
.	O
	
5.3	O
Allergic	O
Reactions	O
Serious	O
allergic	B
reactions	I
including	O
anaphylaxis	B
can	O
occur	O
in	O
patients	O
receiving	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
ECG	B
Changes	I
and	O
Potential	O
for	O
Cardiac	B
Arrhythmias	I
:	O
Not	O
recommended	O
in	O
patients	O
with	O
pre-existing	O
cardiac	O
disease	O
,	O
long	O
QT	O
syndrome	O
,	O
and	O
concomitant	O
use	O
of	O
Class	O
IA	O
and	O
Class	O
III	O
antiarrhythmics	O
(	O
5.2	O
)	O
5.1	O
Drug-Drug	O
Interactions	O
Eliglustat	O
is	O
a	O
CYP2D6	O
and	O
CYP3A	O
substrate	O
.	O
	
Data	O
from	O
a	O
large	O
placebo-controlled	O
US	O
trial	O
that	O
compared	O
the	O
safety	O
of	O
another	O
LABA	O
(	O
salmeterol	O
)	O
or	O
placebo	O
added	O
to	O
usual	O
asthma	O
therapy	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
subjects	O
receiving	O
salmeterol	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Maintain	O
aseptic	O
technique	O
.	O
	
Volume	O
Depletion	O
JARDIANCE	O
causes	O
an	O
osmotic	B
diuresis	I
,	O
which	O
may	O
lead	O
to	O
intravascular	B
volume	I
contraction	I
and	O
adverse	O
reactions	O
related	O
to	O
volume	B
depletion	I
.	O
	
(	O
5.5	O
)	O
*	O
Patients	O
who	O
receive	O
prolonged	O
Cleviprex	O
infusions	O
and	O
are	O
not	O
transitioned	O
to	O
other	O
antihypertensive	O
therapies	O
should	O
be	O
monitored	O
for	O
the	O
possibility	O
of	O
rebound	O
hypertension	O
for	O
at	O
least	O
8	O
hours	O
after	O
the	O
infusion	O
is	O
stopped	O
.	O
	
There	O
is	O
insufficient	O
information	O
to	O
determine	O
the	O
reversibility	O
of	O
the	O
decrease	B
of	I
DLCO	I
after	O
drug	O
discontinuation	O
.	O
	
PRISTIQ	O
should	O
also	O
not	O
be	O
started	O
in	O
a	O
patient	O
who	O
is	O
being	O
treated	O
with	O
MAOIs	O
such	O
as	O
linezolid	O
or	O
intravenous	O
methylene	O
blue	O
.	O
	
Antimalarials	O
should	O
not	O
be	O
given	O
concomitantly	O
with	O
Coartem	O
Tablets	O
,	O
unless	O
there	O
is	O
no	O
other	O
treatment	O
option	O
,	O
due	O
to	O
limited	O
safety	O
data	O
.	O
	
Adverse	O
Reactions	O
(	O
>	O
=10	O
%	O
and	O
Greater	O
than	O
Placebo	O
)	O
from	O
Two	O
Placebo-controlled	O
Trials	O
in	O
Adults	O
with	O
Chronic	O
Hepatitis	O
C	O
Adverse	O
Reaction	O
PROMACTA	O
+	O
Peginterferon/Ribavirin	O
n	O
=	O
955	O
(	O
%	O
)	O
Placebo	O
+	O
Peginterferon/Ribavirin	O
n	O
=	O
484	O
(	O
%	O
)	O
Anemia	B
40	O
35	O
Pyrexia	B
30	O
24	O
Fatigue	B
28	O
23	O
Headache	B
21	O
20	O
Nausea	B
19	O
14	O
Diarrhea	B
19	O
11	O
Decreased	B
appetite	I
18	O
14	O
Influenza-like	B
illness	I
18	O
16	O
Asthenia	B
16	O
13	O
Insomnia	B
16	O
15	O
Cough	B
15	O
12	O
Pruritus	B
15	O
13	O
Chills	B
14	O
9	O
Myalgia	B
12	O
10	O
Alopecia	B
10	O
6	O
Peripheral	B
edema	I
10	O
5	O
In	O
the	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
hyperbilirubinemia	B
was	O
reported	O
in	O
8	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
compared	O
with	O
3	O
%	O
for	O
placebo	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
re-administering	O
alglucosidase	O
alfa	O
following	O
an	O
immune-mediated	O
reaction	O
should	O
be	O
considered	O
.	O
	
In	O
a	O
placebo	O
controlled	O
study	O
in	O
patients	O
with	O
permanent	O
AF	O
increased	O
rates	O
of	O
heart	B
failure	I
were	O
observed	O
in	O
patients	O
with	O
normal	O
left	O
ventricular	O
function	O
and	O
no	O
history	O
of	O
symptomatic	O
heart	O
failure	O
,	O
as	O
well	O
as	O
those	O
with	O
a	O
history	O
of	O
heart	O
failure	O
or	O
left	O
ventricular	O
dysfunction	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
hypersensitivity	B
reactions	I
with	O
cardiovascular	O
,	O
respiratory	O
or	O
cutaneous	O
manifestations	O
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
death	B
,	O
have	O
uncommonly	O
occurred	O
following	O
Gadavist	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Based	O
on	O
published	O
literature	O
,	O
the	O
annual	O
incidence	O
of	O
NAION	O
is	O
2.5-11.8	O
cases	O
per	O
100,000	O
in	O
males	O
aged	O
>	O
=	O
50	O
.	O
	
The	O
most	O
common	O
infusion	O
reaction	O
in	O
SIMPONI	O
ARIA	O
treated	O
patients	O
was	O
rash	B
.	O
	
Advise	O
patients	O
to	O
consult	O
a	O
physician	O
if	O
they	O
develop	O
signs	O
or	O
symptoms	O
of	O
heart	O
failure	O
,	O
such	O
as	O
weight	O
gain	O
,	O
dependent	O
edema	O
,	O
or	O
increasing	O
shortness	O
of	O
breath	O
.	O
	
The	O
ELISA	O
assay	O
is	O
subject	O
to	O
interference	O
by	O
co-present	O
golimumab	O
and	O
thus	O
the	O
results	O
are	O
an	O
underestimate	O
of	O
the	O
rate	O
of	O
product	O
immunogenicity	O
and	O
are	O
in	O
addition	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
drug	O
reactions	O
are	O
discussed	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Lactic	B
Acidosis/Severe	O
Hepatomegaly	B
with	O
Steatosis	B
[	O
see	O
Boxed	O
Warning	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Strictly	O
avoid	O
intramuscular	O
administration	O
of	O
EOVIST	O
because	O
it	O
may	O
cause	O
myocyte	O
necrosis	O
and	O
inflammation	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.2	O
)	O
]	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
.	O
	
All	O
reports	O
with	O
methylene	O
blue	O
that	O
provided	O
information	O
on	O
the	O
route	O
of	O
administration	O
involved	O
intravenous	O
administration	O
in	O
the	O
dose	O
range	O
of	O
1	O
mg/kg	O
to	O
8	O
mg/kg	O
.	O
	
The	O
absolute	O
risk	O
of	O
probable	O
dementia	B
for	O
CE-alone	O
versus	O
placebo	O
was	O
37	O
versus	O
25	O
cases	O
per	O
10,000	O
women-years	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
and	O
Clinical	O
Studies	O
(	O
14.6	O
)	O
]	O
.	O
	
Pulmonary	O
Toxicity	O
In	O
a	O
trial	O
in	O
patients	O
with	O
classical	O
HL	O
that	O
studied	O
ADCETRIS	O
with	O
bleomycin	O
as	O
part	O
of	O
a	O
combination	O
regimen	O
,	O
the	O
rate	O
of	O
non-infectious	B
pulmonary	I
toxicity	I
was	O
higher	O
than	O
the	O
historical	O
incidence	O
reported	O
with	O
ABVD	O
(	O
adriamycin	O
,	O
bleomycin	O
,	O
vinblastine	O
,	O
dacarbazine	O
)	O
.	O
	
In	O
MS	O
placebo-controlled	O
trials	O
,	O
dyspnea	B
was	O
reported	O
in	O
9	O
%	O
of	O
patients	O
receiving	O
GILENYA	O
0.5	O
mg	O
and	O
7	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
The	O
95	O
%	O
confidence	O
limits	O
that	O
are	O
shown	O
do	O
not	O
take	O
into	O
account	O
how	O
many	O
comparisons	O
were	O
made	O
,	O
nor	O
do	O
they	O
reflect	O
the	O
effect	O
of	O
a	O
particular	O
factor	O
after	O
adjustment	O
for	O
all	O
other	O
factors	O
.	O
	
As	O
in	O
controlled	O
clinical	O
trials	O
,	O
a	O
dose-dependent	O
increase	O
in	O
the	O
incidence	O
of	O
seizures	B
has	O
been	O
observed	O
in	O
open-label	O
clinical	O
trials	O
with	O
AMPYRA	O
in	O
patients	O
with	O
MS	O
as	O
follows	O
:	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
0.41	O
per	O
100	O
person-years	O
(	O
95	O
%	O
confidence	O
interval	O
0.13-0.96	O
)	O
;	O
dalfampridine	O
15	O
mg	O
twice	O
daily	O
1.7	O
per	O
100	O
person-years	O
(	O
95	O
%	O
confidence	O
interval	O
0.21-6.28	O
)	O
.	O
	
In	O
some	O
postmarketing	O
cases	O
,	O
hypocalcemia	B
persisted	O
for	O
weeks	O
or	O
months	O
and	O
required	O
frequent	O
monitoring	O
and	O
intravenous	O
and/or	O
oral	O
calcium	O
replacement	O
,	O
with	O
or	O
without	O
vitamin	O
D.	O
Hypocalcemia	B
following	O
Prolia	O
administration	O
is	O
a	O
significant	O
risk	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
[	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
]	O
or	O
receiving	O
dialysis	O
.	O
	
Urinary	B
Tract	I
Infections	I
In	O
the	O
pool	O
of	O
five	O
placebo-controlled	O
clinical	O
trials	O
,	O
the	O
incidence	O
of	O
urinary	B
tract	I
infections	I
(	O
e.g.	O
,	O
urinary	B
tract	I
infection	I
,	O
asymptomatic	B
bacteriuria	I
,	O
and	O
cystitis	B
)	O
was	O
increased	O
in	O
patients	O
treated	O
with	O
JARDIANCE	O
compared	O
to	O
placebo	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
Caution	O
patients	O
about	O
risk	O
of	O
activation	O
of	O
mania/hypomania	O
(	O
5.6	O
)	O
.	O
	
*	O
Use	O
in	O
Elderly	O
Patients	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
5.4	O
Controlled	O
Narrow-Angle	O
Glaucoma	O
Toviaz	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
being	O
treated	O
for	O
narrow-angle	O
glaucoma	O
,	O
and	O
only	O
where	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
The	O
most	O
frequent	O
serious	O
infections	B
included	O
pneumonia	B
,	O
urinary	B
tract	I
infection	I
,	O
cellulitis	B
,	O
and	O
bronchitis	B
.	O
	
*	O
Take	O
DUAVEE	O
with	O
or	O
without	O
food	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
prolactin	B
elevations	I
>	O
=4	O
times	O
ULN	O
(	O
at	O
Endpoint	O
)	O
were	O
2.3	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
0.7	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
The	O
extended	O
normal	O
range	O
for	O
lowered	O
hematocrit	O
was	O
defined	O
in	O
each	O
of	O
these	O
trials	O
as	O
the	O
value	O
15	O
%	O
below	O
the	O
normal	O
range	O
for	O
the	O
centralized	O
laboratory	O
that	O
was	O
used	O
in	O
the	O
trial	O
.	O
	
Respiratory	O
,	O
Thoracic	O
and	O
Mediastinal	O
Disorders	O
:	O
Infrequent	O
-	O
epistaxis	B
,	O
asthma	B
,	O
rhinorrhea	B
,	O
sinus	B
congestion	I
,	O
nasal	B
dryness	I
;	O
Rare	O
-	O
dry	B
throat	I
,	O
sleep	B
apnea	I
syndrome	I
,	O
dyspnea	B
exertional	I
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
FANAPT	O
:	O
retrograde	B
ejaculation	I
.	O
	
Permanently	O
discontinue	O
YERVOY	O
for	O
immune-mediated	O
ocular	O
disease	O
that	O
is	O
unresponsive	O
to	O
local	O
immunosuppressive	O
therapy	O
.	O
	
In	O
clinical	O
trials	O
,	O
premature	O
discontinuation	O
because	O
of	O
adverse	O
reactions	O
occurred	O
in	O
11.8	O
%	O
of	O
the	O
dronedarone-treated	O
patients	O
and	O
in	O
7.7	O
%	O
of	O
the	O
placebo-treated	O
group	O
.	O
	
Extrapyramidal	B
symptoms	I
included	O
:	O
dystonia	B
,	O
parkinsonism	B
,	O
oculogyration	B
,	O
and	O
tremor	B
(	O
excluding	O
akathisia	B
)	O
.	O
	
Do	O
not	O
use	O
BREO	O
ELLIPTA	O
for	O
patients	O
whose	O
asthma	O
is	O
adequately	O
controlled	O
on	O
low-	O
or	O
medium-dose	O
ICS	O
.	O
	
Common	O
Adverse	O
Events	O
(	O
>	O
=	O
10	O
%	O
)	O
The	O
adverse	O
events	O
in	O
the	O
first	O
12	O
cycles	O
of	O
therapy	O
that	O
occurred	O
at	O
a	O
rate	O
of	O
10	O
%	O
or	O
greater	O
in	O
the	O
KRd	O
arm	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
Persistent	O
or	O
worsening	O
bone	O
pain	O
,	O
pain	O
in	O
extremities	O
,	O
fractures	O
and/or	O
muscular	O
pain	O
or	O
weakness	O
may	O
be	O
manifestations	O
of	O
proximal	O
renal	O
tubulopathy	O
and	O
should	O
prompt	O
an	O
evaluation	O
of	O
renal	O
function	O
in	O
at-risk	O
patients	O
.	O
	
5.5	O
Cardiac	O
Failure	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
cardiac	B
failure	I
was	O
reported	O
in	O
6/359	O
patients	O
(	O
2	O
%	O
)	O
receiving	O
INLYTA	O
and	O
3/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Because	O
this	O
disorder	O
is	O
variable	O
in	O
its	O
expression	O
,	O
other	O
organ	O
systems	O
not	O
noted	O
here	O
may	O
be	O
involved	O
.	O
	
abnormal	B
platelet	I
and	I
WBC	I
counts	I
were	O
observed	O
in	O
<	O
0.1	O
%	O
of	O
subjects	O
.	O
	
Consider	O
dose	O
adjustment	O
in	O
patients	O
with	O
baseline	O
and	O
treatment	O
emergent	O
renal	O
impairment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.7	O
)	O
]	O
.	O
	
Perform	O
an	O
ophthalmological	O
evaluation	O
.	O
	
Although	O
the	O
causes	O
of	O
death	B
were	O
varied	O
,	O
most	O
of	O
the	O
deaths	B
appeared	O
to	O
be	O
either	O
cardiovascular	O
(	O
e.g.	O
,	O
heart	B
failure	I
,	O
sudden	B
death	I
)	O
or	O
infectious	O
(	O
e.g.	O
,	O
pneumonia	B
)	O
in	O
nature	O
.	O
	
Behaviors	O
of	O
concern	O
should	O
be	O
reported	O
immediately	O
to	O
healthcare	O
providers	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypoglycemia	B
:	O
In	O
patients	O
taking	O
insulin	O
or	O
an	O
insulin	O
secretagogue	O
with	O
FARXIGA	O
,	O
consider	O
a	O
lower	O
dose	O
of	O
insulin	O
or	O
the	O
insulin	O
secretagogue	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	O
.	O
	
5.13	O
Priapism	O
Three	O
cases	O
of	O
priapism	B
were	O
reported	O
in	O
the	O
premarketing	O
FANAPT	O
program	O
.	O
	
Other	O
Adverse	O
Reactions	O
Hypoglycemia	O
Table	O
2	O
summarizes	O
the	O
incidence	O
of	O
documented	O
hypoglycemia	B
in	O
the	O
placebo-controlled	O
clinical	O
studies	O
.	O
	
Rates	O
of	O
serious	O
infections	B
in	O
the	O
200	O
mg	O
every	O
other	O
week	O
dose	O
group	O
were	O
0.06	O
per	O
patient-year	O
and	O
in	O
the	O
400	O
mg	O
every	O
4	O
weeks	O
dose	O
group	O
were	O
0.04	O
per	O
patient-year	O
.	O
	
Appropriate	O
care	O
is	O
advised	O
when	O
prescribing	O
FANAPT	O
for	O
patients	O
who	O
will	O
be	O
experiencing	O
conditions	O
which	O
may	O
contribute	O
to	O
an	O
elevation	O
in	O
core	O
body	O
temperature	O
,	O
e.g.	O
,	O
exercising	O
strenuously	O
,	O
exposure	O
to	O
extreme	O
heat	O
,	O
receiving	O
concomitant	O
medication	O
with	O
anticholinergic	O
activity	O
,	O
or	O
being	O
subject	O
to	O
dehydration	O
.	O
	
(	O
5.4	O
)	O
*	O
Psychological	B
Dependence	I
:	O
Monitor	O
patients	O
with	O
a	O
history	O
of	O
substance	O
abuse	O
for	O
signs	O
of	O
habituation	O
and	O
dependence	O
(	O
5.5	O
,	O
9	O
)	O
*	O
Suicidal	B
Behavior	I
:	O
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behaviors	O
(	O
5.6	O
)	O
5.1	O
Somnolence	O
or	O
Sedation	O
ONFI	O
causes	O
somnolence	B
and	O
sedation	B
.	O
	
c	O
Confidence	O
interval	O
Patients	O
Major	O
bleeding	B
event	O
a	O
Bleeding	B
sites	O
for	O
MBE	B
b	O
Clinically	O
relevant	O
non-major	O
bleeding	B
Any	O
bleeding	B
The	O
rate	O
of	O
any	O
gastrointestinal	B
bleeds	I
in	O
patients	O
receiving	O
PRADAXA	O
150	O
mg	O
in	O
the	O
full	O
treatment	O
period	O
was	O
3.1	O
%	O
(	O
2.4	O
%	O
on	O
warfarin	O
)	O
.	O
	
When	O
such	O
an	O
infection	O
develops	O
,	O
it	O
should	O
be	O
treated	O
with	O
appropriate	O
local	O
or	O
systemic	O
(	O
i.e.	O
,	O
oral	O
)	O
antifungal	O
therapy	O
while	O
treatment	O
with	O
BREO	O
ELLIPTA	O
continues	O
,	O
but	O
at	O
times	O
therapy	O
with	O
BREO	O
ELLIPTA	O
may	O
need	O
to	O
be	O
interrupted	O
.	O
	
Rash	B
generally	O
resolved	O
within	O
1	O
to	O
2	O
weeks	O
on	O
continued	O
therapy	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
If	O
infection	O
occurs	O
while	O
on	O
Ferriprox	O
,	O
interrupt	O
therapy	O
and	O
monitor	O
the	O
ANC	O
more	O
frequently	O
.	O
	
There	O
were	O
63	O
(	O
12	O
%	O
)	O
patients	O
with	O
moderate	O
(	O
Grade	O
2	O
)	O
dermatitis	B
.	O
	
Across	O
the	O
development	O
program	O
of	O
ZYKADIA	O
,	O
one	O
of	O
304	O
patients	O
(	O
less	O
than	O
1	O
%	O
)	O
treated	O
with	O
ZYKADIA	O
doses	O
ranging	O
from	O
50	O
to	O
750	O
mg	O
was	O
found	O
to	O
have	O
a	O
QTc	B
greater	I
than	I
500	I
msec	I
and	O
3	O
%	O
of	O
patients	O
had	O
an	O
increase	B
from	I
baseline	I
QTc	I
greater	O
than	O
60	O
msec	O
.	O
	
[	O
See	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
.	O
]	O
	
(	O
5.3	O
)	O
*	O
Patients	O
with	O
severe	O
renal	O
impairment	O
may	O
have	O
increased	O
radiation	O
exposure	O
and	O
decreased	O
quality	O
of	O
AdreView	O
images	O
.	O
	
Vascular	O
disorder	O
:	O
systemic	B
vasculitis	I
has	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
TNF	O
blockers	O
.	O
	
Symptoms	O
and	O
signs	O
of	O
adrenocortical	B
insufficiency	I
may	O
be	O
masked	O
by	O
adverse	O
reactions	O
associated	O
with	O
mineralocorticoid	B
excess	I
seen	O
in	O
patients	O
treated	O
with	O
ZYTIGA	O
.	O
	
In	O
this	O
setting	O
a	O
reevaluation	O
of	O
the	O
patient	O
and	O
the	O
COPD	O
treatment	O
regimen	O
should	O
be	O
undertaken	O
at	O
once	O
.	O
	
Exposure	O
to	O
excessive	O
amounts	O
of	O
benzyl	O
alcohol	O
has	O
been	O
associated	O
with	O
toxicity	O
(	O
hypotension	O
,	O
metabolic	O
acidosis	O
)	O
,	O
particularly	O
in	O
neonates	O
,	O
and	O
an	O
increased	O
incidence	O
of	O
kernicterus	O
,	O
particularly	O
in	O
small	O
preterm	O
infants	O
.	O
	
Discontinue	O
ONFI	O
gradually	O
.	O
	
Beleodaq	O
may	O
cause	O
teratogenicity	B
and/or	O
embryo-fetal	B
lethality	I
because	O
it	O
is	O
genotoxic	B
and	O
targets	O
actively	O
dividing	O
cells	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
BREO	O
ELLIPTA	O
has	O
not	O
been	O
studied	O
in	O
the	O
relief	O
of	O
acute	O
symptoms	O
and	O
extra	O
doses	O
should	O
not	O
be	O
used	O
for	O
that	O
purpose	O
.	O
	
However	O
,	O
there	O
is	O
controversy	O
about	O
the	O
extent	O
to	O
which	O
these	O
findings	O
may	O
be	O
due	O
to	O
differences	O
in	O
sexual	O
behavior	O
and	O
other	O
factors	O
.	O
	
Seven	O
(	O
54	O
%	O
)	O
YERVOY-treated	O
patients	O
with	O
severe	O
dermatitis	B
received	O
high-dose	O
corticosteroids	O
(	O
median	O
dose	O
60	O
mg	O
prednisone/day	O
or	O
equivalent	O
)	O
for	O
up	O
to	O
14.9	O
weeks	O
followed	O
by	O
corticosteroid	O
taper	O
.	O
	
Re-treatment	O
with	O
ZYTIGA	O
at	O
a	O
reduced	O
dose	O
level	O
may	O
take	O
place	O
only	O
after	O
return	O
of	O
liver	O
function	O
tests	O
to	O
the	O
patient	O
's	O
baseline	O
or	O
to	O
AST	O
and	O
ALT	O
less	O
than	O
or	O
equal	O
to	O
2.5*	O
ULN	O
and	O
total	O
bilirubin	O
less	O
than	O
or	O
equal	O
to	O
1.5*	O
ULN	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
A	O
total	O
of	O
2.2	O
%	O
of	O
HIV-1-infected	O
subjects	O
in	O
Phase	O
3	O
trials	O
receiving	O
INTELENCE	O
(	O
r	O
)	O
discontinued	O
due	O
to	O
rash	B
.	O
	
In	O
the	O
placebo	O
group	O
,	O
no	O
serious	O
infection	B
occurred	O
in	O
more	O
than	O
one	O
subject	O
.	O
	
In	O
clinical	O
studies	O
,	O
less	O
than	O
1	O
%	O
of	O
patients	O
treated	O
with	O
BLINCYTO	O
tested	O
positive	O
for	O
binding	O
anti-blinatumomab	O
antibodies	O
.	O
	
In	O
Study	O
1	O
,	O
35	O
%	O
were	O
Black	O
,	O
17.5	O
%	O
were	O
Hispanic	O
,	O
12.5	O
%	O
were	O
White	O
,	O
9.4	O
%	O
were	O
Asian	O
,	O
and	O
25.6	O
%	O
were	O
of	O
another	O
race	O
.	O
	
5.4	O
Wound	O
Complications	O
Wound	B
complications	I
have	O
been	O
reported	O
with	O
COMETRIQ	O
.	O
	
Of	O
the	O
28	O
patients	O
with	O
moderate	O
enterocolitis	B
,	O
46	O
%	O
were	O
not	O
treated	O
with	O
systemic	O
corticosteroids	O
,	O
29	O
%	O
were	O
treated	O
with	O
<	O
40	O
mg	O
prednisone	O
or	O
equivalent	O
per	O
day	O
for	O
a	O
median	O
duration	O
of	O
5.1	O
weeks	O
,	O
and	O
25	O
%	O
were	O
treated	O
with	O
high-dose	O
corticosteroids	O
for	O
a	O
median	O
duration	O
of	O
10	O
days	O
prior	O
to	O
corticosteroid	O
taper	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
to	O
XEOMIN	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Hypersensitivity	B
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Dysphagia	B
and	O
Breathing	B
Difficulties	I
in	O
Treatment	O
of	O
cervical	O
dystonia	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Spread	B
of	I
Effects	I
from	I
Toxin	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
Cervical	O
Dystonia	O
:	O
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
of	O
patients	O
and	O
>	O
placebo	O
)	O
are	O
dysphagia	B
,	O
neck	B
pain	I
,	O
muscle	B
weakness	I
,	O
injection	B
site	I
pain	I
,	O
and	O
musculoskeletal	B
pain	I
(	O
6.1	O
)	O
.	O
	
Fatal	B
adverse	O
events	O
occurred	O
in	O
15	O
%	O
of	O
patients	O
.	O
	
[	O
See	O
Boxed	O
Warning	O
.	O
]	O
	
Discontinue	O
use	O
if	O
severe	O
symptoms	O
develop	O
(	O
5.8	O
)	O
*	O
Suppression	B
of	I
bone	I
turnover	I
:	O
Significant	O
suppression	O
has	O
been	O
demonstrated	O
.	O
	
Observe	O
patients	O
closely	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
Vimizim	O
,	O
taking	O
into	O
account	O
the	O
time	O
to	O
onset	O
of	O
anaphylaxis	O
seen	O
in	O
premarketing	O
clinical	O
trials	O
.	O
	
The	O
mechanism	O
for	O
the	O
bleeding	O
events	O
is	O
not	O
well	O
understood	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=5	O
%	O
of	O
patients	O
were	O
febrile	B
neutropenia	I
and	O
pneumonia	B
.	O
	
Should	O
suicidal	O
thoughts	O
and	O
behavior	O
emerge	O
during	O
treatment	O
,	O
the	O
prescriber	O
needs	O
to	O
consider	O
whether	O
the	O
emergence	O
of	O
these	O
symptoms	O
in	O
any	O
given	O
patient	O
may	O
be	O
related	O
to	O
the	O
illness	O
being	O
treated	O
.	O
	
Other	O
increased	B
(	I
angiotensinogen	I
)	O
.	O
	
The	O
extent	O
to	O
which	O
the	O
findings	O
of	O
increased	B
mortality	I
in	O
observational	O
studies	O
may	O
be	O
attributed	O
to	O
the	O
antipsychotic	O
drug	O
as	O
opposed	O
to	O
some	O
characteristic	O
(	O
s	O
)	O
of	O
the	O
patients	O
is	O
not	O
clear	O
.	O
	
(	O
5.2	O
)	O
*	O
QT	B
Interval	I
Prolongation	I
:	O
Occurred	O
in	O
2.1	O
%	O
of	O
patients	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Bradycardia	B
and/or	O
atrioventricular	B
conduction	I
after	O
first	O
dose	O
:	O
Monitor	O
patients	O
.	O
	
The	O
following	O
coagulation	B
proteins	I
were	I
decreased	I
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
of	O
moderate	O
to	O
severe	O
intensity	O
and	O
incidence	O
at	O
least	O
2	O
%	O
(	O
in	O
those	O
receiving	O
TIVICAY	O
in	O
any	O
one	O
adult	O
trial	O
)	O
are	O
insomnia	B
,	O
fatigue	B
,	O
and	O
headache	B
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
and	O
adults	O
,	O
and	O
in	O
approved	O
indications	O
,	O
cases	O
of	O
spread	B
of	I
effect	I
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
those	O
used	O
to	O
treat	O
cervical	O
dystonia	O
and	O
at	O
lower	O
doses	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Potential	O
neonatal	B
adverse	I
effects	I
.	O
	
Laboratory	O
Test	O
Abnormalities	O
in	O
Clinical	O
Trials	O
There	O
were	O
no	O
differences	O
between	O
FANAPT	O
and	O
placebo	O
in	O
the	O
incidence	O
of	O
discontinuation	O
due	O
to	O
changes	O
in	O
hematology	O
,	O
urinalysis	O
,	O
or	O
serum	O
chemistry	O
.	O
	
For	O
patients	O
who	O
develop	O
moderate	O
to	O
severe	O
proteinuria	O
,	O
reduce	O
the	O
dose	O
or	O
temporarily	O
interrupt	O
INLYTA	O
treatment	O
.	O
	
Psoriatic	O
Arthritis	O
Clinical	O
Trials	O
OTEZLA	O
was	O
evaluated	O
in	O
3	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
[	O
Studies	O
PsA-1	O
,	O
PsA-2	O
,	O
and	O
PsA-3	O
]	O
of	O
similar	O
design	O
in	O
adult	O
patients	O
with	O
active	O
psoriatic	O
arthritis	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Reactions	O
are	O
further	O
categorized	O
by	O
MedDRA	O
system	O
organ	O
class	O
and	O
listed	O
in	O
order	O
of	O
decreasing	O
frequency	O
according	O
to	O
the	O
following	O
definitions	O
:	O
frequent	O
adverse	O
events	O
are	O
those	O
occurring	O
in	O
at	O
least	O
1/100	O
patients	O
(	O
only	O
those	O
not	O
listed	O
in	O
Table	O
7	O
appear	O
in	O
this	O
listing	O
)	O
;	O
infrequent	O
adverse	O
reactions	O
are	O
those	O
occurring	O
in	O
1/100	O
to	O
1/1000	O
patients	O
;	O
rare	O
events	O
are	O
those	O
occurring	O
in	O
fewer	O
than	O
1/1000	O
patients	O
.	O
	
Patients	O
who	O
tested	O
positive	O
for	O
uptake	O
inhibition	O
tended	O
to	O
have	O
higher	O
IgG	O
titers	O
than	O
patients	O
who	O
tested	O
negative	O
for	O
uptake	O
inhibition	O
.	O
	
Table	O
2	O
shows	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=8	O
%	O
of	O
KALYDECO-treated	O
patients	O
with	O
CF	O
who	O
have	O
a	O
G551D	O
mutation	O
in	O
the	O
CFTR	O
gene	O
that	O
also	O
occurred	O
at	O
a	O
higher	O
rate	O
than	O
in	O
the	O
placebo-treated	O
patients	O
in	O
the	O
two	O
double-blind	O
,	O
placebo-controlled	O
trials	O
.	O
	
There	O
were	O
no	O
asthma-related	O
deaths	B
or	O
asthma-related	O
intubations	O
observed	O
in	O
this	O
trial	O
.	O
	
If	O
you	O
are	O
not	O
sure	O
about	O
your	O
dosing	O
,	O
call	O
your	O
healthcare	O
provider	O
.	O
	
EXCERPT	O
:	O
*	O
COPD	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
)	O
are	O
nasopharyngitis	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
headache	B
,	O
and	O
oral	B
candidiasis	I
.	O
	
Any	O
type	O
of	O
hemorrhagic	B
stroke	I
was	O
adjudicated	O
and	O
counted	O
as	O
an	O
intracranial	B
major	I
bleed	I
.	O
	
More	O
frequent	O
monitoring	O
is	O
recommended	O
when	O
AFINITOR	O
is	O
co-administered	O
with	O
other	O
drugs	O
that	O
may	O
induce	O
hyperglycemia	O
.	O
	
*	O
Radiation	B
risk	I
:	O
Choline	O
C	O
11	O
Injection	O
contributes	O
to	O
a	O
patient	O
's	O
long-term	O
cumulative	O
radiation	O
exposure	O
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
Cleviprex	O
:	O
increased	B
blood	I
triglycerides	I
,	O
ileus	B
,	O
hypersensitivity	B
,	O
hypotension	B
,	O
nausea	B
,	O
decreased	B
oxygen	I
saturation	I
(	O
possible	O
pulmonary	B
shunting	I
)	O
and	O
reflex	B
tachycardia	I
.	O
	
Non-cutaneous	O
Malignancies	O
:	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
TAFINLAR	O
may	O
promote	O
the	O
growth	O
and	O
development	O
of	O
malignancies	B
with	O
activation	O
of	O
RAS	O
through	O
mutation	O
or	O
other	O
mechanisms	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Instruct	O
all	O
patients	O
with	O
severe	O
renal	O
impairment	O
,	O
including	O
those	O
receiving	O
dialysis	O
,	O
about	O
the	O
symptoms	O
of	O
hypocalcemia	O
and	O
the	O
importance	O
of	O
maintaining	O
calcium	O
levels	O
with	O
adequate	O
calcium	O
and	O
vitamin	O
D	O
supplementation	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Gout	O
Flare	O
After	O
initiation	O
of	O
ULORIC	O
,	O
an	O
increase	O
in	O
gout	B
flares	I
is	O
frequently	O
observed	O
.	O
	
Such	O
monitoring	O
should	O
include	O
daily	O
observation	O
by	O
families	O
and	O
caregivers	O
.	O
	
Of	O
the	O
patients	O
who	O
reported	O
neuropathy	B
,	O
51	O
%	O
had	O
residual	B
neuropathy	I
at	O
the	O
time	O
of	O
their	O
last	O
evaluation	O
.	O
	
Among	O
the	O
factors	O
that	O
may	O
increase	O
the	O
risk	O
for	O
NSF	B
are	O
repeated	O
or	O
higher	O
than	O
recommended	O
doses	O
of	O
a	O
GBCA	O
and	O
degree	O
of	O
renal	O
impairment	O
at	O
the	O
time	O
of	O
exposure	O
.	O
	
Most	O
of	O
the	O
patients	O
were	O
receiving	O
concomitant	O
immunosuppressants	O
.	O
	
Of	O
these	O
patients	O
,	O
one	O
SIMPONI	O
ARIA-treated	O
patient	O
and	O
no	O
control-treated	O
patients	O
had	O
newly	B
positive	I
anti-dsDNA	I
antibodies	I
.	O
	
Patients	O
should	O
be	O
cautioned	O
about	O
performing	O
activities	O
requiring	O
mental	O
alertness	O
,	O
such	O
as	O
operating	O
hazardous	O
machinery	O
or	O
operating	O
a	O
motor	O
vehicle	O
,	O
until	O
they	O
are	O
reasonably	O
certain	O
that	O
SAPHRIS	O
therapy	O
does	O
not	O
affect	O
them	O
adversely	O
.	O
	
Image	O
interpretation	O
is	O
performed	O
independently	O
of	O
the	O
patient	O
's	O
clinical	O
information	O
.	O
	
No	O
data	O
are	O
available	O
on	O
the	O
effectiveness	O
of	O
vaccinations	O
with	O
inactivated	O
(	O
killed	O
)	O
antigens	O
in	O
patients	O
receiving	O
ILARIS	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
It	O
was	O
usually	O
transient	O
with	O
the	O
highest	O
incidence	O
reported	O
during	O
the	O
first	O
week	O
of	O
treatment	O
.	O
	
If	O
heart	O
failure	O
develops	O
or	O
worsens	O
and	O
requires	O
hospitalization	O
,	O
discontinue	O
MULTAQ	O
.	O
	
For	O
patients	O
receiving	O
hemodialysis	O
,	O
consider	O
the	O
prompt	O
initiation	O
of	O
hemodialysis	O
following	O
the	O
administration	O
of	O
a	O
GBCA	O
in	O
order	O
to	O
enhance	O
the	O
contrast	O
agent	O
's	O
elimination	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Adverse	O
events	O
(	O
regardless	O
of	O
investigator	O
's	O
causality	O
assessment	O
)	O
reported	O
in	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
reported	O
at	O
a	O
rate	O
of	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
than	O
PegIntron/REBETOL	O
alone	O
in	O
SPRINT-1	O
,	O
SPRINT-2	O
,	O
and	O
RESPOND-2	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
*	O
Severe	O
Acute	B
Exacerbations	I
of	I
Hepatitis	I
B	I
[	O
see	O
Boxed	O
Warning	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Liver	O
Enzyme	O
Elevations	O
There	O
have	O
been	O
reports	O
of	O
severe	O
hepatic	B
reactions	I
including	O
acute	B
liver	I
failure	I
in	O
patients	O
receiving	O
TNF-blockers	O
.	O
	
5.4	O
Probable	O
Dementia	O
In	O
the	O
WHIMS	O
estrogen-alone	O
ancillary	O
study	O
of	O
WHI	O
,	O
a	O
population	O
of	O
2,947	O
hysterectomized	O
women	O
65	O
to	O
79	O
years	O
of	O
age	O
was	O
randomized	O
to	O
daily	O
CE	O
(	O
0.625	O
mg	O
)	O
-alone	O
or	O
placebo	O
.	O
	
Of	O
these	O
patients	O
,	O
49	O
%	O
had	O
complete	O
resolution	O
,	O
31	O
%	O
had	O
partial	O
improvement	O
,	O
and	O
20	O
%	O
had	O
no	O
improvement	O
.	O
	
5.8	O
Laboratory	O
Tests	O
and	O
Monitoring	O
Renal	O
Function	O
Elevations	B
of	I
serum	I
creatinine	I
and	O
proteinuria	B
have	O
been	O
reported	O
in	O
patients	O
taking	O
AFINITOR	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
For	O
DLCO	B
,	I
the	I
reduction	I
from	O
baseline	O
in	O
percent	O
of	O
predicted	O
values	O
at	O
the	O
time	O
of	O
last	O
assessment	O
on	O
drug	O
was	O
3.3	O
%	O
for	O
GILENYA	O
0.5	O
mg	O
and	O
0.5	O
%	O
for	O
placebo	O
.	O
	
Do	O
not	O
administer	O
KALBITOR	O
to	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
KALBITOR	O
.	O
	
*	O
a	O
Data	O
presented	O
are	O
to	O
the	O
primary	O
endpoint	O
and	O
include	O
only	O
events	O
occurring	O
on-therapy	O
with	O
randomized	O
medications	O
and	O
excludes	O
events	O
occurring	O
after	O
use	O
of	O
glycemic	O
rescue	O
medications	O
(	O
i.e.	O
,	O
primarily	O
metformin	O
or	O
insulin	O
)	O
.	O
	
Cutaneous	B
squamous	I
cell	I
carcinoma	I
(	O
SCC	B
)	O
,	O
including	O
keratoacanthoma	B
,	O
occurred	O
in	O
7	O
%	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
19	O
%	O
of	O
patients	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
*	O
Allergic	B
reactions	I
:	O
have	O
emergency	O
resuscitation	O
equipment	O
and	O
personnel	O
readily	O
available	O
(	O
5.2	O
)	O
.	O
	
Patients	O
testing	O
positive	O
in	O
tuberculosis	O
screening	O
should	O
be	O
treated	O
according	O
to	O
standard	O
medical	O
practice	O
prior	O
to	O
therapy	O
with	O
ILARIS	O
.	O
	
5.10	O
Hepatic	O
Impairment	O
Exposure	O
to	O
everolimus	O
was	O
increased	O
in	O
patients	O
with	O
hepatic	B
impairment	I
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
allergic	B
reactions	I
,	O
including	O
anaphylactic	B
reactions	I
,	O
may	O
occur	O
.	O
	
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
the	O
overall	O
incidence	O
of	O
infections	B
was	O
71	O
%	O
in	O
patients	O
treated	O
with	O
BENLYSTA	O
compared	O
with	O
67	O
%	O
in	O
patients	O
who	O
received	O
placebo	O
.	O
	
*	O
If	O
you	O
take	O
a	O
calcium	O
or	O
vitamin	O
D	O
supplement	O
,	O
you	O
may	O
take	O
it	O
at	O
the	O
same	O
time	O
you	O
take	O
DUAVEE	O
.	O
	
See	O
the	O
list	O
of	O
ingredients	O
in	O
DUAVEE	O
at	O
the	O
end	O
of	O
this	O
leaflet	O
.	O
	
5.4	O
Hemorrhage	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
hemorrhagic	B
events	I
were	O
reported	O
in	O
58/359	O
patients	O
(	O
16	O
%	O
)	O
receiving	O
INLYTA	O
and	O
64/355	O
patients	O
(	O
18	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
ViiV	O
Healthcare	O
at	O
1-877-844-8872	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
in	O
Adult	O
Subjects	O
Treatment	O
-	O
emergent	O
Adverse	O
Drug	O
Reactions	O
(	O
ADRs	O
)	O
Treatment-naive	O
Subjects	O
:	O
The	O
safety	O
assessment	O
of	O
TIVICAY	O
in	O
HIV-1-infected	O
treatment-naive	O
subjects	O
is	O
based	O
on	O
the	O
analyses	O
of	O
96-week	O
data	O
from	O
2	O
international	O
,	O
multicenter	O
,	O
double-blind	O
trials	O
,	O
SPRING-2	O
(	O
ING113086	O
)	O
and	O
SINGLE	O
(	O
ING114467	O
)	O
and	O
48-week	O
data	O
from	O
the	O
international	O
,	O
multicenter	O
,	O
open-label	O
FLAMINGO	O
(	O
ING114915	O
)	O
trial	O
.	O
	
5.1	O
Risk	O
for	O
Image	O
Misinterpretation	O
and	O
other	O
Errors	O
Errors	O
may	O
occur	O
in	O
the	O
Amyvid	O
estimation	O
of	O
brain	O
neuritic	O
plaque	O
density	O
during	O
image	O
interpretation	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Clinical	O
manifestations	O
of	O
NMS	B
are	O
hyperpyrexia	B
,	O
muscle	B
rigidity	I
,	O
altered	B
mental	I
status	I
,	O
and	O
evidence	O
of	O
autonomic	B
instability	I
(	O
irregular	B
pulse	I
,	O
tachycardia	B
,	O
diaphoresis	B
,	O
and	O
cardiac	B
dysrhythmia	I
)	O
.	O
	
Prolonged	O
exposure	O
to	O
elevated	O
plasma	O
ammonia	O
levels	O
can	O
rapidly	O
result	O
in	O
injury	O
to	O
the	O
brain	O
or	O
death	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
>	O
=	O
5	O
%	O
of	O
men	O
with	O
osteoporosis	O
and	O
more	O
frequently	O
with	O
Prolia	O
than	O
in	O
the	O
placebo-treated	O
patients	O
were	O
:	O
back	B
pain	I
(	O
6.7	O
%	O
placebo	O
vs.	O
8.3	O
%	O
Prolia	O
)	O
,	O
arthralgia	B
(	O
5.8	O
%	O
placebo	O
vs.	O
6.7	O
%	O
Prolia	O
)	O
,	O
and	O
nasopharyngitis	B
(	O
5.8	O
%	O
placebo	O
vs.	O
6.7	O
%	O
Prolia	O
)	O
.	O
	
5.13	O
Pregnancy	O
INLYTA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
based	O
on	O
its	O
mechanism	O
of	O
action	O
.	O
	
5.3	O
Topical	O
Ophthalmic	O
Use	O
Only	O
BEPREVE	O
is	O
for	O
topical	O
ophthalmic	O
use	O
only	O
.	O
	
Discontinue	O
permanently	O
if	O
a	O
clinically	O
significant	O
reaction	O
occurs	O
(	O
5.2	O
)	O
*	O
Hypocalcemia	B
:	O
Must	O
be	O
corrected	O
before	O
initiating	O
Prolia	O
.	O
	
Periodically	O
monitor	O
patients	O
clinically	O
for	O
atrial	O
fibrillation	O
.	O
	
An	O
earlier	O
onset	O
can	O
not	O
be	O
ruled	O
out	O
,	O
and	O
it	O
is	O
possible	O
that	O
retinal	B
abnormalities	I
were	O
present	O
earlier	O
in	O
the	O
course	O
of	O
exposure	O
to	O
POTIGA	O
.	O
	
Stop	O
treatment	O
with	O
COMETRIQ	O
at	O
least	O
28	O
days	O
prior	O
to	O
scheduled	O
surgery	O
.	O
	
Table	O
2	O
:	O
Incidence	O
(	O
%	O
)	O
of	O
Documented	O
Hypoglycemia	B
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
Trials	O
Placebo	O
TRULICITY	O
0.75	O
mg	O
TRULICITY	O
1.5	O
mg	O
Add-on	O
to	O
Metformin	O
(	O
26	O
weeks	O
)	O
N=177	O
N=302	O
N=304	O
Documented	O
symptomatic	O
1.1	O
%	O
2.6	O
%	O
5.6	O
%	O
Severe	O
0	O
0	O
0	O
Add-on	O
to	O
Metformin	O
+	O
Pioglitazone	O
(	O
26	O
weeks	O
)	O
N=141	O
N=280	O
N=279	O
Documented	O
symptomatic	O
1.4	O
%	O
4.6	O
%	O
5.0	O
%	O
Severe	O
0	O
0	O
0	O
Hypoglycemia	B
was	O
more	O
frequent	O
when	O
TRULICITY	O
was	O
used	O
in	O
combination	O
with	O
a	O
sulfonylurea	O
or	O
insulin	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Patients	O
in	O
the	O
treatment	O
studies	O
who	O
rolled	O
over	O
into	O
the	O
RE-MEDY	O
study	O
had	O
a	O
combined	O
treatment	O
duration	O
of	O
up	O
to	O
more	O
than	O
3	O
years	O
,	O
with	O
mean	O
exposure	O
of	O
473	O
days	O
.	O
	
Stevens-Johnson	B
syndrome	I
,	O
drug	O
hypersensitivity	B
reaction	O
and	O
erythema	B
multiforme	I
were	O
reported	O
in	O
less	O
than	O
0.1	O
%	O
of	O
subjects	O
during	O
clinical	O
development	O
with	O
INTELENCE	O
(	O
r	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
5.6	O
Embryo-fetal	O
Toxicity	O
Beleodaq	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
5.2	O
Adrenocortical	O
Insufficiency	O
Adrenal	B
insufficiency	I
occurred	O
in	O
the	O
two	O
randomized	O
clinical	O
studies	O
in	O
0.5	O
%	O
of	O
patients	O
taking	O
ZYTIGA	O
and	O
in	O
0.2	O
%	O
of	O
patients	O
taking	O
placebo	O
.	O
	
In	O
Study	O
RA-IV	O
(	O
monotherapy	O
)	O
,	O
the	O
ACR20	O
response	O
was	O
33	O
%	O
versus	O
56	O
%	O
,	O
antibody-positive	O
versus	O
antibody-negative	O
status	O
,	O
respectively	O
.	O
	
5.4	O
Serious	O
Dermatological	O
Reactions	O
Serious	O
skin	B
reactions	I
,	O
including	O
Stevens-Johnson	B
syndrome	I
(	O
SJS	B
)	O
and	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
,	O
have	O
been	O
reported	O
with	O
ONFI	O
in	O
both	O
children	O
and	O
adults	O
during	O
the	O
post-marketing	O
period	O
.	O
	
Hypersensitivity	O
Reactions	O
The	O
following	O
symptoms	O
that	O
could	O
be	O
compatible	O
with	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
rarely	O
following	O
CIMZIA	O
administration	O
to	O
patients	O
:	O
angioedema	B
,	O
dermatitis	B
allergic	I
,	O
dizziness	B
(	I
postural	I
)	O
,	O
dyspnea	B
,	O
hot	B
flush	I
,	O
hypotension	B
,	O
injection	B
site	I
reactions	I
,	O
malaise	B
,	O
pyrexia	B
,	O
rash	B
,	O
serum	B
sickness	I
,	O
and	O
(	O
vasovagal	B
)	I
syncope	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
If	O
BREO	O
ELLIPTA	O
100/25	O
no	O
longer	O
controls	O
symptoms	O
of	O
bronchoconstriction	O
;	O
the	O
patient	O
's	O
inhaled	O
,	O
short-acting	O
,	O
beta2-agonist	O
becomes	O
less	O
effective	O
;	O
or	O
the	O
patient	O
needs	O
more	O
short-acting	O
beta2-agonist	O
than	O
usual	O
,	O
these	O
may	O
be	O
markers	O
of	O
deterioration	O
of	O
disease	O
.	O
	
A	O
subset	O
of	O
patients	O
who	O
had	O
recurrence	O
of	O
contracture	O
in	O
a	O
joint	O
that	O
was	O
previously	O
successfully	O
treated	O
with	O
XIAFLEX	O
in	O
Study	O
4	O
were	O
retreated	O
(	O
Study	O
5	O
)	O
.	O
	
However	O
,	O
the	O
attributable	O
risk	O
of	O
liver	B
cancers	I
in	O
COC	O
users	O
is	O
less	O
than	O
one	O
case	O
per	O
million	O
users	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
certolizumab	O
pegol	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
5.2	O
Peripheral	O
Neuropathy	O
Grade	O
3	O
peripheral	B
neuropathy	I
occurred	O
in	O
8	O
%	O
(	O
40/503	O
)	O
of	O
patients	O
,	O
and	O
Grade	O
4	O
in	O
0.4	O
%	O
(	O
2/503	O
)	O
of	O
patients	O
in	O
Study	O
1	O
.	O
	
The	O
clinical	O
significance	O
of	O
CMV	O
serology	O
as	O
a	O
risk	O
factor	O
for	O
PTLD	B
remains	O
to	O
be	O
determined	O
;	O
however	O
,	O
these	O
findings	O
should	O
be	O
considered	O
when	O
prescribing	O
NULOJIX	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.5	O
)	O
5.1	O
Immune-mediated	O
Enterocolitis	O
In	O
Study	O
1	O
,	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
(	O
diarrhea	B
of	O
7	O
or	O
more	O
stools	O
above	O
baseline	O
,	O
fever	B
,	O
ileus	B
,	O
peritoneal	B
signs	I
;	O
Grade	O
3-5	O
)	O
immune-mediated	B
enterocolitis	I
occurred	O
in	O
34	O
(	O
7	O
%	O
)	O
YERVOY-treated	O
patients	O
,	O
and	O
moderate	O
(	O
diarrhea	B
with	O
up	O
to	O
6	O
stools	O
above	O
baseline	O
,	O
abdominal	B
pain	I
,	O
blood	B
in	I
stool	I
;	O
Grade	O
2	O
)	O
enterocolitis	B
occurred	O
in	O
28	O
(	O
5	O
%	O
)	O
YERVOY-treated	O
patients	O
.	O
	
By	O
Week	O
24	O
,	O
hematocrit	B
values	I
>	I
55	I
%	I
were	O
reported	O
in	O
0.4	O
%	O
of	O
placebo-treated	O
patients	O
and	O
1.3	O
%	O
of	O
FARXIGA	O
10	O
mg-treated	O
patients	O
.	O
	
Note	O
:	O
Percentages	O
reflect	O
the	O
number	O
of	O
patients	O
that	O
reported	O
at	O
least	O
1	O
treatment-	O
emergent	O
occurrence	O
of	O
the	O
adverse	O
reaction	O
.	O
	
(	O
5.1	O
,	O
5.2	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
*	O
?	O
	
Monitor	O
urine	O
protein	O
regularly	O
during	O
COMETRIQ	O
treatment	O
.	O
	
Advise	O
patients	O
to	O
seek	O
prompt	O
medical	O
attention	O
if	O
they	O
develop	O
signs	O
or	O
symptoms	O
of	O
infection	O
,	O
including	O
cellulitis	O
(	O
5.6	O
)	O
*	O
Dermatologic	B
reactions	I
:	O
Dermatitis	B
,	O
rashes	B
,	O
and	O
eczema	B
have	O
been	O
reported	O
.	O
	
If	O
neurological	O
compromise	O
is	O
noted	O
,	O
urgent	O
diagnosis	O
and	O
treatment	O
is	O
necessary	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
was	O
2	O
cycles	O
(	O
range	O
1	O
-	O
33	O
cycles	O
)	O
.	O
	
Monitor	O
heart	O
rate	O
and	O
blood	O
pressure	O
regularly	O
.	O
	
Photosensitivity-related	B
adverse	I
reactions	I
(	O
including	O
photosensitivity	B
reaction	I
,	O
polymorphic	B
light	I
eruption	I
,	O
and	O
sunburn	B
)	O
occurred	O
in	O
0.1	O
%	O
,	O
0.2	O
%	O
,	O
and	O
0.2	O
%	O
of	O
patients	O
receiving	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
*	O
are	O
breastfeeding	O
or	O
plan	O
to	O
breastfeed	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
events	O
were	O
:	O
pneumonia	B
(	O
8	O
%	O
)	O
,	O
acute	B
renal	I
failure	I
(	O
5	O
%	O
)	O
,	O
disease	B
progression	I
(	O
4	O
%	O
)	O
,	O
pyrexia	B
(	O
3	O
%	O
)	O
,	O
hypercalcemia	B
(	O
3	O
%	O
)	O
,	O
congestive	B
heart	I
failure	I
(	O
3	O
%	O
)	O
,	O
multiple	B
myeloma	I
(	O
3	O
%	O
)	O
,	O
anemia	B
(	O
2	O
%	O
)	O
,	O
and	O
dyspnea	B
(	O
2	O
%	O
)	O
.	O
	
In	O
some	O
cases	O
glucose	B
intolerance	I
may	O
be	O
irreversible	O
.	O
	
estimated	O
creatinine	O
clearance	O
less	O
than	O
70	O
mL	O
per	O
minute	O
)	O
at	O
baseline	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
29	O
%	O
of	O
patients	O
treated	O
with	O
GILOTRIF	O
.	O
	
These	O
events	O
generally	O
occurred	O
within	O
hours	O
of	O
the	O
infusion	O
;	O
however	O
,	O
they	O
may	O
occur	O
later	O
.	O
	
Inform	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
,	O
hypersensitivity	O
reactions	O
,	O
and	O
immune-mediated	O
reactions	O
and	O
have	O
them	O
seek	O
immediate	O
medical	O
care	O
should	O
signs	O
and	O
symptoms	O
occur	O
(	O
5.1	O
,	O
5.2	O
)	O
.	O
	
After	O
cross-over	O
to	O
open-label	O
AFINITOR	O
,	O
there	O
were	O
three	O
additional	O
deaths	B
,	O
one	O
due	O
to	O
hypoglycemia	B
and	O
cardiac	B
arrest	I
in	O
a	O
patient	O
with	O
insulinoma	O
,	O
one	O
due	O
to	O
myocardial	B
infarction	I
with	O
congestive	B
heart	I
failure	I
,	O
and	O
the	O
other	O
due	O
to	O
sudden	B
death	I
.	O
	
Fever	B
was	O
complicated	O
with	O
chills/rigors	O
in	O
51	O
%	O
(	O
28/55	O
)	O
,	O
dehydration	B
in	O
9	O
%	O
(	O
5/55	O
)	O
,	O
renal	B
failure	I
in	O
4	O
%	O
(	O
2/55	O
)	O
,	O
and	O
syncope	B
in	O
4	O
%	O
(	O
2/55	O
)	O
of	O
patients	O
in	O
Trial	O
2	O
.	O
	
Out	O
of	O
1082	O
patients	O
who	O
received	O
0.58	O
mg	O
of	O
XIAFLEX	O
in	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
of	O
the	O
XIAFLEX	O
studies	O
(	O
2630	O
XIAFLEX	O
injections	O
)	O
,	O
3	O
(	O
0.3	O
%	O
)	O
patients	O
had	O
a	O
flexor	B
tendon	I
rupture	I
of	I
the	I
treated	I
finger	I
within	O
7	O
days	O
of	O
the	O
injection	O
.	O
	
Patient	O
presenting	O
with	O
an	O
atypical	O
femur	O
fracture	O
should	O
also	O
be	O
assessed	O
for	O
symptoms	O
and	O
signs	O
of	O
fracture	O
in	O
the	O
contralateral	O
limb	O
.	O
	
On	O
average	O
,	O
women	O
with	O
hepatic	O
impairment	O
treated	O
with	O
bazedoxifene	O
alone	O
showed	O
a	O
4.3-fold	O
increase	O
in	O
overall	O
exposures	O
compared	O
with	O
controls	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Mild	O
(	O
less	O
than	O
LLN	O
and	O
greater	O
than	O
75x10	O
9	O
/L	O
)	O
and	O
transient	O
decreases	B
in	I
platelet	I
counts	I
were	O
observed	O
in	O
3	O
(	O
6.3	O
%	O
)	O
ILARIS	O
treated	O
patients	O
versus	O
1	O
(	O
2.0	O
%	O
)	O
placebo-treated	O
patient	O
.	O
	
In	O
2-year	O
placebo-controlled	O
trials	O
,	O
the	O
reduction	B
from	I
baseline	I
in	I
the	I
percent	I
of	I
predicted	I
values	I
for	I
FEV1	I
at	O
the	O
time	O
of	O
last	O
assessment	O
on	O
drug	O
was	O
2.8	O
%	O
for	O
GILENYA	O
0.5	O
mg	O
and	O
1.0	O
%	O
for	O
placebo	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Splenic	B
Rupture	I
:	O
Discontinue	O
GRANIX	O
if	O
suspected	O
(	O
5.1	O
)	O
*	O
Acute	B
Respiratory	I
Distress	I
Syndrome	I
(	O
ARDS	B
)	O
:	O
Monitor	O
for	O
and	O
manage	O
immediately	O
.	O
	
Exercise	O
caution	O
in	O
considering	O
the	O
use	O
of	O
CIMZIA	O
in	O
patients	O
with	O
pre-existing	O
or	O
recent-onset	O
central	O
or	O
peripheral	O
nervous	O
system	O
demyelinating	O
disorders	O
.	O
	
Table	O
2	O
:	O
Bleeding	B
Events	O
in	O
Patients	O
with	O
Nonvalvular	O
Atrial	O
Fibrillation	O
in	O
AVERROES	O
ELIQUISN=2798n	O
(	O
%	O
/year	O
)	O
AspirinN=2780n	O
(	O
%	O
/year	O
)	O
Hazard	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
P-value	O
Events	O
associated	O
with	O
each	O
endpoint	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
11	O
C-choline	O
uptake	O
is	O
not	O
specific	O
for	O
prostate	O
cancer	O
and	O
may	O
occur	O
with	O
other	O
types	O
of	O
cancer	O
(	O
such	O
as	O
lung	O
carcinoma	O
and	O
brain	O
tumors	O
)	O
.	O
	
The	O
efficacy	O
and	O
safety	O
of	O
DUAVEE	O
in	O
premenopausal	O
women	O
have	O
not	O
been	O
established	O
,	O
and	O
its	O
use	O
is	O
not	O
recommended	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
MULTAQ	O
.	O
	
*	O
receiving	O
other	O
medications	O
that	O
prolong	O
the	O
QT	O
interval	O
,	O
such	O
as	O
class	O
IA	O
(	O
quinidine	O
,	O
procainamide	O
,	O
disopyramide	O
)	O
,	O
or	O
class	O
III	O
(	O
amiodarone	O
,	O
sotalol	O
)	O
antiarrhythmic	O
agents	O
;	O
antipsychotics	O
(	O
pimozide	O
,	O
ziprasidone	O
)	O
;	O
antidepressants	O
;	O
certain	O
antibiotics	O
(	O
macrolide	O
antibiotics	O
,	O
fluoroquinolone	O
antibiotics	O
,	O
imidazole	O
,	O
and	O
triazole	O
antifungal	O
agents	O
)	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.6	O
)	O
]	O
.	O
	
5.3	O
Direct	O
Coombs	O
'	O
Test	O
Seroconversion	O
Seroconversion	B
from	I
a	I
negative	I
to	I
a	I
positive	I
direct	I
Coombs	I
'	I
test	I
result	I
occurred	O
in	O
120/1114	O
(	O
10.8	O
%	O
)	O
of	O
patients	O
receiving	O
Teflaro	O
and	O
49/1116	O
(	O
4.4	O
%	O
)	O
of	O
patients	O
receiving	O
comparator	O
drugs	O
in	O
the	O
four	O
pooled	O
Phase	O
3	O
trials	O
.	O
	
ILARIS	O
should	O
not	O
be	O
administered	O
to	O
any	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
ILARIS	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
(	O
See	O
current	O
recommended	O
immunization	O
schedules	O
at	O
the	O
website	O
of	O
the	O
Centers	O
for	O
Disease	O
Control	O
,	O
http	O
:	O
//www.cdc.gov/vaccines/schedules/index.html	O
)	O
.	O
	
All	O
patients	O
who	O
were	O
positive	O
for	O
antibodies	O
to	O
golimumab	O
had	O
neutralizing	O
antibodies	O
based	O
on	O
an	O
in	O
vitro	O
cell-based	O
assay	O
.	O
	
Decreases	O
in	O
neutrophils	O
or	O
platelets	O
may	O
require	O
a	O
decrease	O
in	O
dosage	O
or	O
interruption	O
of	O
peginterferon	O
alfa	O
,	O
or	O
discontinuation	O
of	O
therapy	O
[	O
see	O
prescribing	O
information	O
for	O
peginterferon	O
alfa	O
and	O
ribavirin	O
]	O
.	O
	
Table	O
2	O
:	O
Laboratory	O
data/ECG	O
parameters	O
not	O
necessarily	O
reported	O
as	O
adverse	O
events	O
Placebo	O
MULTAQ	O
400	O
mg	O
twice	O
daily	O
(	O
N=2875	O
)	O
(	O
N=3282	O
)	O
Early	O
increases	B
in	I
creatinine	I
>	O
=10	O
%	O
21	O
%	O
51	O
%	O
(	O
N=2237	O
)	O
(	O
N=2701	O
)	O
QTc	B
prolonged	I
19	O
%	O
28	O
%	O
Assessment	O
of	O
demographic	O
factors	O
such	O
as	O
gender	O
or	O
age	O
on	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
events	O
did	O
not	O
suggest	O
an	O
excess	O
of	O
adverse	O
events	O
in	O
any	O
particular	O
sub-group	O
.	O
	
During	O
adult	O
pre-marketing	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
dysphagia	B
was	O
reported	O
in	O
0.1	O
%	O
(	O
2/1953	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
of	O
Trial	O
1	O
,	O
958	O
total	O
patient-years	O
of	O
follow-up	O
with	O
a	O
median	O
follow-up	O
of	O
approximately	O
92	O
weeks	O
,	O
the	O
incidence	O
per	O
100	O
patient-years	O
of	O
all	O
serious	O
infections	B
was	O
4.07	O
(	O
CI	O
:	O
2.90	O
,	O
5.57	O
)	O
in	O
patients	O
receiving	O
SIMPONI	O
ARIA	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Apparent	O
homogeneity	O
or	O
heterogeneity	O
among	O
groups	O
should	O
not	O
be	O
over-interpreted	O
.	O
	
Do	O
not	O
administer	O
KALBITOR	O
to	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
KALBITOR	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
No	O
dose	O
modifications	O
of	O
TAFINLAR	O
or	O
trametinib	O
are	O
required	O
in	O
patients	O
who	O
develop	O
new	O
primary	O
cutaneous	O
malignancies	O
.	O
	
5.15	O
Premenopausal	O
Women	O
There	O
is	O
no	O
indication	O
for	O
premenopausal	O
use	O
of	O
DUAVEE	O
.	O
	
Injection	O
Site	O
Reactions	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
injection	B
site	I
reactions	I
occurred	O
more	O
frequently	O
on	O
TANZEUM	O
(	O
18	O
%	O
)	O
than	O
on	O
placebo	O
(	O
8	O
%	O
)	O
.	O
	
Therapy	O
with	O
leucovorin	O
should	O
be	O
continued	O
until	O
the	O
methotrexate	O
concentration	O
has	O
been	O
maintained	O
below	O
the	O
leucovorin	O
treatment	O
threshold	O
for	O
a	O
minimum	O
of	O
3	O
days	O
.	O
	
(	O
5.1	O
)	O
*	O
Hypotension	B
and	O
reflex	B
tachycardia	I
are	O
potential	O
consequences	O
of	O
rapid	O
upward	O
titration	O
of	O
Cleviprex	O
.	O
	
Deaths	B
due	O
to	O
causes	O
other	O
than	O
disease	O
progression	O
within	O
30	O
days	O
of	O
last	O
study	O
drug	O
dose	O
were	O
reported	O
in	O
18	O
(	O
5	O
%	O
)	O
JEVTANA-treated	O
patients	O
and	O
3	O
(	O
<	O
1	O
%	O
)	O
mitoxantrone-treated	O
patients	O
.	O
	
Exercise	O
caution	O
with	O
the	O
use	O
of	O
AFINITOR	O
in	O
the	O
peri-surgical	O
period	O
.	O
	
Any	O
patient	O
who	O
presents	O
with	O
thigh	O
or	O
groin	O
pain	O
should	O
be	O
suspected	O
of	O
having	O
an	O
atypical	O
fracture	O
and	O
should	O
be	O
evaluated	O
to	O
rule	O
out	O
an	O
incomplete	O
femur	O
fracture	O
.	O
	
All	O
patients	O
continued	O
androgen	O
deprivation	O
therapy	O
.	O
	
Figures	O
rounded	O
to	O
the	O
nearest	O
integer	O
.	O
	
This	O
imbalance	O
has	O
not	O
been	O
observed	O
in	O
other	O
studies	O
of	O
ENTEREG	O
in	O
patients	O
treated	O
with	O
opioids	O
for	O
chronic	O
pain	O
,	O
nor	O
in	O
patients	O
treated	O
within	O
the	O
surgical	O
setting	O
,	O
including	O
patients	O
undergoing	O
surgeries	O
that	O
included	O
bowel	O
resection	O
who	O
received	O
ENTEREG	O
12	O
mg	O
twice	O
daily	O
for	O
up	O
to	O
7	O
days	O
(	O
the	O
indicated	O
dose	O
and	O
patient	O
population	O
;	O
ENTEREG	O
12	O
mg	O
,	O
n	O
=	O
1,142	O
;	O
placebo	O
,	O
n	O
=	O
1,120	O
)	O
.	O
	
Notable	O
requirements	O
of	O
the	O
E.A.S.E	O
.	O
	
None	O
of	O
the	O
59	O
evaluable	O
patients	O
tested	O
positive	O
for	O
inhibition	O
of	O
enzyme	O
activity	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
Long-acting	O
beta2-adrenergic	O
agonists	O
(	O
LABA	O
)	O
,	O
such	O
as	O
vilanterol	O
,	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
BREO	O
ELLIPTA	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
Laboratory	O
Abnormalities	O
In	O
the	O
two	O
randomized	O
clinical	O
trials	O
,	O
Grade	O
1-4	O
neutropenia	B
occurred	O
in	O
15	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
(	O
1	O
%	O
Grade	O
3-4	O
)	O
and	O
in	O
6	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
(	O
0.5	O
%	O
Grade	O
3-4	O
)	O
.	O
	
*	O
Before	O
DOTAREM	O
administration	O
,	O
assess	O
all	O
patients	O
for	O
any	O
history	O
of	O
a	O
reaction	O
to	O
contrast	O
media	O
,	O
bronchial	O
asthma	O
and/or	O
allergic	O
disorders	O
.	O
	
5.9	O
Vaccinations/Therapeutic	O
Infectious	O
Agents	O
Live	O
Vaccines	O
Patients	O
treated	O
with	O
SIMPONI	O
ARIA	O
may	O
receive	O
vaccinations	O
,	O
except	O
for	O
live	O
vaccines	O
.	O
	
HORIZANT	O
should	O
be	O
discontinued	O
if	O
an	O
alternative	O
etiology	O
for	O
the	O
signs	O
or	O
symptoms	O
can	O
not	O
be	O
established	O
.	O
	
Among	O
these	O
subjects	O
,	O
42	O
%	O
were	O
women	O
and	O
99	O
%	O
Caucasian	O
.	O
	
In	O
Study	O
3	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
in	O
the	O
ADCETRIS-treatment	O
arm	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
neutropenia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
thrombocytopenia	B
,	O
anemia	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
fatigue	B
,	O
peripheral	B
motor	I
neuropathy	I
,	O
nausea	B
,	O
cough	B
,	O
and	O
diarrhea	B
.	O
	
ARCAPTA	O
NEOHALER	O
has	O
not	O
been	O
studied	O
in	O
the	O
relief	O
of	O
acute	O
symptoms	O
and	O
extra	O
doses	O
should	O
not	O
be	O
used	O
for	O
that	O
purpose	O
.	O
	
Pool	O
of	O
Placebo-	O
and	O
Active-Controlled	O
Trials	O
The	O
occurrence	O
of	O
adverse	O
reactions	O
for	O
canagliflozin	O
was	O
evaluated	O
in	O
a	O
larger	O
pool	O
of	O
patients	O
participating	O
in	O
placebo-	O
and	O
active-controlled	O
trials	O
.	O
	
In	O
these	O
patients	O
,	O
the	O
majority	O
of	O
lymphocyte	B
counts	I
remained	I
<	I
0.5x10	I
9	I
/L	I
with	O
continued	O
therapy	O
.	O
	
5.2	O
Interstitial	O
Lung	O
Disease	O
(	O
Pneumonitis	O
)	O
Severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
interstitial	B
lung	I
disease	I
(	O
ILD	B
)	O
/pneumonitis	O
can	O
occur	O
in	O
patients	O
treated	O
with	O
XALKORI	O
.	O
	
Worsening	B
hypertension	I
was	O
reported	O
in	O
4	O
patients	O
treated	O
with	O
TREANDA	O
in	O
the	O
CLL	O
trial	O
and	O
in	O
none	O
treated	O
with	O
chlorambucil	O
.	O
	
5.10	O
Body	O
Temperature	O
Regulation	O
Disruption	B
of	I
the	I
body	I
's	I
ability	I
to	I
reduce	I
core	I
body	I
temperature	I
has	O
been	O
attributed	O
to	O
antipsychotic	O
agents	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
greater	O
than	O
1	O
%	O
of	O
patients	O
and	O
at	O
a	O
higher	O
rate	O
with	O
FIRAZYR	O
versus	O
placebo	O
)	O
are	O
shown	O
in	O
Table	O
1	O
.	O
	
All	O
cases	O
of	O
PTLD	B
reported	O
up	O
to	O
36	O
months	O
post	O
transplant	O
in	O
NULOJIX-	O
or	O
cyclosporine-treated	O
patients	O
presented	O
within	O
18	O
months	O
of	O
transplantation	O
.	O
	
Among	O
the	O
404	O
EBV	O
seropositive	O
recipients	O
treated	O
with	O
the	O
recommended	O
dosage	O
regimen	O
of	O
NULOJIX	O
,	O
three	O
PTLD	B
cases	O
were	O
detected	O
among	O
99	O
CMV	O
seronegative	O
patients	O
(	O
3	O
%	O
)	O
and	O
there	O
was	O
no	O
case	O
detected	O
among	O
303	O
CMV	O
seropositive	O
patients	O
.	O
	
Patients	O
with	O
neutropenia	O
should	O
be	O
carefully	O
monitored	O
for	O
fever	O
or	O
other	O
symptoms	O
or	O
signs	O
of	O
infection	O
and	O
treated	O
promptly	O
if	O
such	O
symptoms	O
or	O
signs	O
occur	O
.	O
	
and	O
MinorMinor	O
episodes	O
of	O
hypoglycemia	B
were	O
defined	O
as	O
either	O
a	O
symptomatic	O
episode	O
with	O
a	O
plasma	B
glucose	I
measurement	I
<	I
63	I
mg/dL	I
regardless	O
of	O
need	O
for	O
external	O
assistance	O
,	O
or	O
an	O
asymptomatic	O
plasma	B
glucose	I
measurement	I
<	I
63	I
mg/dL	I
that	O
does	O
not	O
qualify	O
as	O
a	O
major	O
episode	O
.	O
	
Clinical	O
studies	O
of	O
HALAVEN	O
did	O
not	O
include	O
patients	O
with	O
baseline	O
neutrophil	O
counts	O
below	O
1,500/mm	O
3	O
.	O
	
Avoid	O
HALAVEN	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
.	O
	
If	O
clinically	O
indicated	O
,	O
perform	O
appropriate	O
tests	O
to	O
confirm	O
the	O
diagnosis	O
of	O
adrenocortical	O
insufficiency	O
.	O
	
Therefore	O
,	O
a	O
lower	O
dose	O
of	O
insulin	O
or	O
insulin	O
secretagogue	O
may	O
be	O
required	O
to	O
minimize	O
the	O
risk	O
of	O
hypoglycemia	O
when	O
these	O
agents	O
are	O
used	O
in	O
combination	O
with	O
FARXIGA	O
.	O
	
ONFI	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
sign	O
of	O
rash	O
,	O
unless	O
the	O
rash	O
is	O
clearly	O
not	O
drug-related	O
.	O
	
5.2	O
Severe	O
Diarrhea	O
or	O
Colitis	O
Severe	O
diarrhea	B
or	O
colitis	B
(	O
Grade	O
3	O
or	O
higher	O
)	O
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
across	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Jazz	O
Pharmaceuticals	O
,	O
Inc.	O
at	O
1-800-520-5568	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Studies	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
controlled	O
,	O
but	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
ERWINAZE	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
other	O
drugs	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Pool	O
of	O
Placebo-controlled	O
Trials	O
The	O
data	O
in	O
Table	O
1	O
are	O
derived	O
from	O
the	O
placebo-controlled	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
At	O
Week	O
24	O
,	O
the	O
mean	O
changes	B
from	I
baseline	I
in	I
hematocrit	I
were	O
-0.33	O
%	O
in	O
the	O
placebo	O
group	O
and	O
2.30	O
%	O
in	O
the	O
FARXIGA	O
10	O
mg	O
group	O
.	O
	
5.8	O
Proteinuria	O
Proteinuria	B
was	O
observed	O
in	O
4	O
(	O
2	O
%	O
)	O
of	O
patients	O
receiving	O
COMETRIQ	O
,	O
including	O
one	O
with	O
nephrotic	B
syndrome	I
,	O
as	O
compared	O
to	O
none	O
of	O
the	O
patients	O
receiving	O
placebo	O
.	O
	
(	O
5.1	O
)	O
*	O
If	O
retinal	O
pigmentary	O
abnormalities	O
or	O
vision	O
changes	O
are	O
detected	O
,	O
POTIGA	O
should	O
be	O
discontinued	O
unless	O
no	O
other	O
suitable	O
treatment	O
options	O
are	O
available	O
and	O
the	O
benefits	O
of	O
treatment	O
outweigh	O
the	O
potential	O
risk	O
of	O
vision	O
loss	O
.	O
	
b	O
Includes	O
retching	B
,	O
vomiting	B
,	O
vomiting	B
projectile	I
.	O
	
Contraception	O
and	O
Heavy	O
Menstrual	O
Bleeding	O
Studies	O
A	O
total	O
of	O
2,131	O
women	O
,	O
18	O
to	O
54	O
years	O
of	O
age	O
,	O
who	O
took	O
at	O
least	O
one	O
dose	O
of	O
Natazia	O
were	O
enrolled	O
in	O
four	O
clinical	O
phase	O
3	O
trials	O
.	O
	
5.2	O
Infections	O
Fatal	B
and	O
non-fatal	O
infections	B
have	O
occurred	O
with	O
IMBRUVICA	O
therapy	O
.	O
	
Adverse	O
reactions	O
occurring	O
less	O
frequently	O
but	O
possibly	O
related	O
to	O
TREANDA	O
treatment	O
were	O
hemolysis	B
,	O
dysgeusia/taste	O
disorder	B
,	O
atypical	B
pneumonia	I
,	O
sepsis	B
,	O
herpes	B
zoster	I
,	O
erythema	B
,	O
dermatitis	B
,	O
and	O
skin	B
necrosis	I
.	O
	
To	O
manage	O
myelosuppression	O
,	O
withhold	O
,	O
dose	O
reduce	O
,	O
or	O
discontinue	O
BOSULIF	O
as	O
necessary	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.2	O
QT	O
Prolongation	O
SIRTURO	O
prolongs	B
the	I
QT	I
interval	I
.	O
	
Ocular	O
adverse	O
reactions	O
occurring	O
in	O
<	O
1	O
%	O
of	O
subjects	O
included	O
application	B
site	I
discomfort	I
,	O
corneal	B
pigmentation	I
,	O
episcleritis	B
,	O
eye	B
pruritis	I
,	O
eyelid	B
irritation	I
,	O
foreign	B
body	I
sensation	I
,	O
increased	B
lacrimation	I
,	O
macular	B
edema	I
,	O
sclera	B
hyperemia	I
,	O
and	O
uveitis	B
.	O
	
All	O
men	O
were	O
instructed	O
to	O
take	O
at	O
least	O
1000	O
mg	O
of	O
calcium	O
and	O
400	O
IU	O
of	O
vitamin	O
D	O
supplementation	O
per	O
day	O
.	O
	
Serious	O
adverse	O
events	O
were	O
reported	O
,	O
regardless	O
of	O
causality	O
,	O
in	O
50	O
%	O
of	O
patients	O
in	O
the	O
pooled	O
Kyprolis	O
monotherapy	O
studies	O
(	O
n	O
=	O
598	O
)	O
.	O
	
(	O
2.2,5.12	O
)	O
*	O
INLYTA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
based	O
on	O
its	O
mechanism	O
of	O
action	O
.	O
	
Some	O
patients	O
experienced	O
circulatory	B
collapse	I
and	O
died	B
.	O
	
Patients	O
with	O
diabetes	O
mellitus	O
or	O
a	O
history	O
of	O
uveitis	O
are	O
at	O
increased	O
risk	O
.	O
	
These	O
symptoms	O
have	O
been	O
reported	O
hours	O
to	O
weeks	O
after	O
injection	O
.	O
	
Cases	O
of	O
acute	O
renal	O
failure	O
after	O
initiation	O
of	O
high	O
dose	O
or	O
multiple	O
NSAIDs	O
have	O
been	O
reported	O
in	O
HIV-infected	O
patients	O
with	O
risk	O
factors	O
for	O
renal	O
dysfunction	O
who	O
appeared	O
stable	O
on	O
tenofovir	O
DF	O
.	O
	
In	O
clinical	O
studies	O
,	O
cases	O
of	O
pancytopenia	B
,	O
leukopenia	B
,	O
neutropenia	B
,	O
and	O
thrombocytopenia	B
have	O
also	O
occurred	O
in	O
SIMPONI	O
ARIA-treated	O
patients	O
.	O
	
(	O
5.1	O
,	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
A	O
higher	O
number	O
of	O
myocardial	B
infarctions	I
was	O
reported	O
in	O
patients	O
treated	O
with	O
alvimopan	O
0.5	O
mg	O
twice	O
daily	O
compared	O
with	O
placebo	O
in	O
a	O
12-month	O
study	O
in	O
patients	O
treated	O
with	O
opioids	O
for	O
chronic	O
non-cancer	O
pain	O
,	O
although	O
a	O
causal	O
relationship	O
with	O
long-term	O
use	O
has	O
not	O
been	O
established	O
.	O
	
All	O
other	O
patients	O
tested	O
negative	O
for	O
inhibition	O
of	O
cellular	O
uptake	O
.	O
	
Table	O
1	O
displays	O
adverse	O
reactions	O
more	O
common	O
with	O
dronedarone	O
400	O
mg	O
twice	O
daily	O
than	O
with	O
placebo	O
in	O
AF	O
or	O
AFL	O
patients	O
,	O
presented	O
by	O
system	O
organ	O
class	O
and	O
by	O
decreasing	O
order	O
of	O
frequency	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Potential	O
Risk	O
of	O
Myocardial	O
Infarction	O
with	O
Long-term	O
Use	O
There	O
were	O
more	O
reports	O
of	O
myocardial	B
infarctions	I
in	O
patients	O
treated	O
with	O
alvimopan	O
0.5	O
mg	O
twice	O
daily	O
compared	O
with	O
placebo-treated	O
patients	O
in	O
a	O
12-month	O
study	O
of	O
patients	O
treated	O
with	O
opioids	O
for	O
chronic	O
non-cancer	O
pain	O
(	O
alvimopan	O
0.5	O
mg	O
,	O
n	O
=	O
538	O
;	O
placebo	O
,	O
n	O
=	O
267	O
)	O
.	O
	
If	O
it	O
is	O
almost	O
time	O
for	O
your	O
next	O
dose	O
,	O
skip	O
the	O
missed	O
dose	O
.	O
	
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
in	O
an	O
LGS	O
Placebo	O
Controlled	O
Clinical	O
Trial	O
(	O
Study	O
1	O
)	O
The	O
adverse	O
reactions	O
associated	O
with	O
ONFI	O
treatment	O
discontinuation	O
in	O
>	O
=1	O
%	O
of	O
patients	O
in	O
decreasing	O
order	O
of	O
frequency	O
included	O
lethargy	B
,	O
somnolence	B
,	O
ataxia	B
,	O
aggression	B
,	O
fatigue	B
,	O
and	O
insomnia	B
.	O
	
In	O
Trial	O
2	O
,	O
the	O
incidence	O
of	O
any	O
skin	B
toxicity	I
was	O
similar	O
for	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
(	O
65	O
%	O
[	O
36/55	O
]	O
)	O
compared	O
with	O
patients	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
(	O
68	O
%	O
[	O
36/53	O
]	O
)	O
.	O
	
Because	O
of	O
the	O
continuing	O
pharmacodynamic	O
effects	O
of	O
fingolimod	O
,	O
initiating	O
other	O
drugs	O
during	O
this	O
period	O
warrants	O
the	O
same	O
considerations	O
needed	O
for	O
concomitant	O
administration	O
(	O
e.g.	O
,	O
risk	O
of	O
additive	O
immunosuppressant	B
effects	I
)	O
[	O
see	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
AMPYRA	O
should	O
be	O
discontinued	O
and	O
not	O
restarted	O
in	O
patients	O
who	O
experience	O
a	O
seizure	O
while	O
on	O
treatment	O
.	O
	
All	O
patients	O
had	O
normal	O
values	O
at	O
the	O
next	O
visit	O
.	O
	
The	O
pooled	O
analyses	O
of	O
placebo-controlled	O
studies	O
in	O
children	O
and	O
adolescents	O
with	O
MDD	O
,	O
obsessive	O
compulsive	O
disorder	O
(	O
OCD	O
)	O
,	O
or	O
other	O
psychiatric	O
disorders	O
included	O
a	O
total	O
of	O
24	O
short-term	O
studies	O
of	O
9	O
antidepressant	O
drugs	O
in	O
over	O
4,400	O
patients	O
.	O
	
Beyond	O
48	O
hours	O
after	O
VORAXAZE	O
,	O
administer	O
leucovorin	O
based	O
on	O
the	O
measured	O
methotrexate	O
concentration	O
.	O
	
5.10	O
Counseling	O
Patients	O
about	O
Sexually	O
Transmitted	O
Diseases	O
The	O
use	O
of	O
STENDRA	O
offers	O
no	O
protection	O
against	O
sexually	O
transmitted	O
diseases	O
.	O
	
The	O
relative	O
risk	O
of	O
probable	O
dementia	B
for	O
CE-alone	O
versus	O
placebo	O
was	O
1.49	O
(	O
95	O
percent	O
CI	O
,	O
0.83-2.66	O
)	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Drug	O
Reactions	O
that	O
Occurred	O
in	O
at	O
Least	O
1	O
%	O
of	O
Patients	O
and	O
Were	O
More	O
Frequent	O
than	O
Placebo	O
Placebo	O
Dronedarone	O
400	O
mg	O
twice	O
daily	O
(	O
N=2875	O
)	O
(	O
N=3282	O
)	O
Gastrointestinal	O
Diarrhea	B
6	O
%	O
9	O
%	O
Nausea	B
3	O
%	O
5	O
%	O
Abdominal	B
pain	I
3	O
%	O
4	O
%	O
Vomiting	B
1	O
%	O
2	O
%	O
Dyspeptic	B
signs	I
and	I
symptoms	I
1	O
%	O
2	O
%	O
General	O
Asthenic	B
conditions	I
5	O
%	O
7	O
%	O
Cardiac	O
Bradycardia	B
1	O
%	O
3	O
%	O
Skin	O
and	O
subcutaneous	O
tissue	O
Including	O
rashes	B
)	O
,	O
pruritus	B
,	O
eczema	B
,	O
dermatitis	B
,	O
dermatitis	B
allergic	I
3	O
%	O
5	O
%	O
Photosensitivity	B
reaction	I
and	O
dysgeusia	B
have	O
also	O
been	O
reported	O
at	O
an	O
incidence	O
less	O
than	O
1	O
%	O
in	O
patients	O
treated	O
with	O
MULTAQ	O
.	O
	
This	O
increase	O
is	O
due	O
to	O
reduction	O
in	O
serum	O
uric	O
acid	O
levels	O
,	O
resulting	O
in	O
mobilization	O
of	O
urate	O
from	O
tissue	O
deposits	O
.	O
	
Table	O
7	O
presents	O
the	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
experienced	O
by	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
compared	O
with	O
placebo	O
)	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
the	O
development	O
of	O
systemic	O
immune-mediated	O
reactions	O
involving	O
skin	O
and	O
other	O
organs	O
while	O
receiving	O
alglucosidase	O
alfa	O
.	O
	
The	O
use	O
of	O
clinical	O
information	O
in	O
the	O
interpretation	O
of	O
Vizamyl	O
images	O
has	O
not	O
been	O
evaluated	O
and	O
may	O
lead	O
to	O
errors	O
.	O
	
Eleven	O
cases	O
of	O
MAS	B
were	O
observed	O
in	O
201	O
SJIA	O
patients	O
treated	O
with	O
canakinumab	O
in	O
clinical	O
trials	O
.	O
	
Everolimus	O
caused	O
embryo-fetal	B
toxicities	I
in	O
animals	O
at	O
maternal	O
exposures	O
that	O
were	O
lower	O
than	O
human	O
exposures	O
.	O
	
Blood	O
and	O
Lymphatic	O
System	O
Disorders	O
:	O
agranulocytosis	B
,	O
pancytopenia	B
,	O
thrombocytopenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
Gastrointestinal	O
Disorders	O
:	O
mouth	B
ulceration	I
,	O
stomatitis	B
Infections	O
and	O
Infestations	O
:	O
pneumonia	B
,	O
sepsis	B
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
angioedema	B
,	O
urticaria	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
;	O
DRESS	B
)	I
syndrome	I
,	O
exfoliative	B
rash	I
,	O
exfoliative	B
dermatitis	I
,	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
skin	I
eruption	I
,	O
toxicoderma	B
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Use	O
of	O
VICTRELIS	O
with	O
Ribavirin	O
and	O
Peginterferon	O
alfa	O
:	O
*	O
Embryofetal	B
Toxicity	I
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
:	O
Ribavirin	O
may	O
cause	O
birth	B
defects	I
and	O
fetal	B
death	I
;	O
avoid	O
pregnancy	O
in	O
female	O
patients	O
and	O
female	O
partners	O
of	O
male	O
patients	O
.	O
	
Consider	O
obtaining	O
periodic	O
hepatic	O
serum	O
enzymes	O
,	O
especially	O
during	O
the	O
first	O
6	O
months	O
of	O
treatment	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
routine	O
periodic	O
monitoring	O
of	O
serum	O
enzymes	O
will	O
prevent	O
the	O
development	O
of	O
severe	O
liver	O
injury	O
.	O
	
If	O
ribavirin	O
is	O
permanently	O
discontinued	O
,	O
then	O
peginterferon	O
alfa	O
and	O
VICTRELIS	O
must	O
also	O
be	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Endometrial	O
hyperplasia	O
may	O
be	O
a	O
precursor	O
to	O
endometrial	O
cancer	O
.	O
	
The	O
other	O
cases	O
represented	O
a	O
variety	O
of	O
different	O
malignancies	B
and	O
included	O
rare	B
malignancies	I
usually	O
associated	O
with	O
immunosuppression	O
and	O
malignancies	B
that	O
are	O
not	O
usually	O
observed	O
in	O
children	O
and	O
adolescents	O
.	O
	
If	O
immune-mediated	O
reactions	O
occur	O
,	O
consider	O
discontinuation	O
of	O
the	O
administration	O
of	O
alglucosidase	O
alfa	O
,	O
and	O
initiate	O
appropriate	O
medical	O
treatment	O
.	O
	
5.16	O
Use	O
in	O
Patients	O
with	O
Concomitant	O
Illness	O
Clinical	O
experience	O
with	O
SAPHRIS	O
in	O
patients	O
with	O
certain	O
concomitant	O
systemic	O
illnesses	O
is	O
limited	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Cutaneous	O
Malignancies	O
:	O
TAFINLAR	O
results	O
in	O
an	O
increased	O
incidence	O
of	O
cutaneous	B
squamous	I
cell	I
carcinoma	I
,	O
keratoacanthoma	B
,	O
and	O
melanoma	B
.	O
	
In	O
order	O
to	O
prevent	O
gout	O
flares	O
when	O
ULORIC	O
is	O
initiated	O
,	O
concurrent	O
prophylactic	O
treatment	O
with	O
an	O
NSAID	O
or	O
colchicine	O
is	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
]	O
.	O
	
The	O
following	O
laboratory	O
data/ECG	O
parameters	O
were	O
reported	O
with	O
MULTAQ	O
400	O
mg	O
twice	O
daily	O
.	O
	
For	O
the	O
first	O
48	O
hours	O
after	O
VORAXAZE	O
,	O
administer	O
the	O
same	O
leucovorin	O
dose	O
as	O
given	O
prior	O
to	O
VORAXAZE	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
These	O
fractures	B
can	I
occur	I
anywhere	I
in	I
the	I
femoral	I
shaft	I
from	O
just	O
below	O
the	O
lesser	O
trochanter	O
to	O
above	O
the	O
supracondylar	O
flare	O
and	O
are	O
transverse	O
or	O
short	O
oblique	O
in	O
orientation	O
without	O
evidence	O
of	O
comminution	O
.	O
	
Endocarditis	B
was	O
also	O
reported	O
more	O
frequently	O
in	O
Prolia-treated	O
patients	O
.	O
	
Reductions	O
in	O
immunosuppression	O
should	O
be	O
considered	O
for	O
patients	O
who	O
develop	O
evidence	O
of	O
PVAN	O
.	O
	
Assess	O
creatinine	O
clearance	O
(	O
CLcr	O
)	O
,	O
urine	O
glucose	O
and	O
urine	O
protein	O
before	O
initiating	O
treatment	O
with	O
STRIBILD	O
.	O
	
Renal	O
and	O
Urinary	O
Disorders	O
:	O
Renal	B
impairment	I
.	O
	
The	O
most	O
frequent	O
infections	B
(	O
>	O
5	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
)	O
were	O
upper	B
respiratory	I
tract	I
infection	I
,	O
urinary	B
tract	I
infection	I
,	O
nasopharyngitis	B
,	O
sinusitis	B
,	O
bronchitis	B
,	O
and	O
influenza	B
.	O
	
Advise	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
heavy	O
machinery	O
until	O
they	O
know	O
how	O
Toviaz	O
affects	O
them	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
sanofi-aventis	O
U.S.	O
LLC	O
at	O
1-800-633-1610	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
During	O
the	O
12-week	O
,	O
controlled	O
study	O
in	O
patients	O
with	O
PHN	O
,	O
somnolence	B
was	O
reported	O
in	O
10	O
%	O
of	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
8	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
The	O
incidence	O
of	O
dry	B
mouth	I
was	O
higher	O
in	O
those	O
taking	O
8	O
mg/day	O
(	O
35	O
%	O
)	O
and	O
in	O
those	O
taking	O
4	O
mg/day	O
(	O
19	O
%	O
)	O
,	O
as	O
compared	O
to	O
placebo	O
(	O
7	O
%	O
)	O
.	O
	
(	O
5.1	O
)	O
*	O
Patients	O
recently	O
exposed	O
to	O
opioids	O
are	O
expected	O
to	O
be	O
more	O
sensitive	O
to	O
the	O
effects	O
of	O
ENTEREG	O
and	O
therefore	O
may	O
experience	O
abdominal	B
pain	I
,	O
nausea	B
and	O
vomiting	B
,	O
and	O
diarrhea	B
.	O
	
*	O
Long-acting	O
beta2-adrenergic	O
agonists	O
(	O
LABA	O
)	O
,	O
such	O
as	O
vilanterol	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
Initiation	O
of	O
STRIBILD	O
in	O
patients	O
with	O
estimated	O
creatinine	O
clearance	O
below	O
70	O
mL	O
per	O
minute	O
is	O
not	O
recommended	O
.	O
	
(	O
5.9	O
)	O
5.1	O
Bradyarrhythmia	O
and	O
Atrioventricular	O
Blocks	O
Because	O
of	O
a	O
risk	O
for	O
bradyarrhythmia	O
and	O
atrioventricular	O
(	O
AV	O
)	O
blocks	O
,	O
patients	O
should	O
be	O
monitored	O
during	O
GILENYA	O
treatment	O
initiation	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
The	O
risk	O
appears	O
lower	O
for	O
patients	O
with	O
chronic	O
,	O
moderate	O
kidney	O
disease	O
(	O
GFR	O
30	O
-	O
59	O
mL/min/1.73	O
m	O
2	O
)	O
and	O
little	O
,	O
if	O
any	O
,	O
for	O
patients	O
with	O
chronic	O
,	O
mild	O
kidney	O
disease	O
(	O
GFR	O
60	O
-	O
89	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
.	O
	
You	O
and	O
your	O
healthcare	O
provider	O
should	O
decide	O
if	O
you	O
will	O
take	O
DUAVEE	O
or	O
breastfeed	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
should	O
be	O
advised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
and	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
receiving	O
INLYTA	O
.	O
	
If	O
such	O
signs	O
or	O
symptoms	O
are	O
present	O
,	O
the	O
patient	O
should	O
be	O
evaluated	O
immediately	O
.	O
	
Laboratory	O
Test	O
Abnormalities	O
:	O
Transaminases	O
:	O
Transient	O
elevations	B
in	I
serum	I
transaminases	I
)	O
in	O
the	O
short-term	O
schizophrenia	O
and	O
bipolar	O
mania	O
adult	O
trials	O
were	O
more	O
common	O
in	O
treated	O
patients	O
.	O
	
Fatal	B
cerebrovascular	B
accident	I
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.2	O
Cerebrovascular	O
Adverse	O
Events	O
,	O
Including	O
Stroke	O
,	O
In	O
Elderly	O
Patients	O
with	O
Dementia-Related	O
Psychosis	O
In	O
placebo-controlled	O
trials	O
with	O
risperidone	O
,	O
aripiprazole	O
,	O
and	O
olanzapine	O
in	O
elderly	O
subjects	O
with	O
dementia	O
,	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
cerebrovascular	B
adverse	I
reactions	I
(	O
cerebrovascular	B
accidents	I
and	O
transient	B
ischemic	I
attacks	I
)	O
including	O
fatalities	B
compared	O
to	O
placebo-treated	O
subjects	O
.	O
	
Specifically	O
,	O
9	O
patients	O
had	O
a	O
Grade	O
3	O
or	O
4	O
pleural	B
effusion	I
,	O
3	O
patients	O
experienced	O
both	O
Grade	O
3	O
or	O
Grade	O
4	O
pericardial	B
effusions	I
,	O
1	O
patient	O
experienced	O
Grade	O
3	O
pulmonary	B
edema	I
,	O
and	O
1	O
patient	O
had	O
a	O
Grade	O
3	O
edema	B
.	O
	
(	O
5.7	O
)	O
*	O
Leukopenia	B
,	O
Neutropenia	B
,	O
and	O
Agranulocytosis	B
have	O
been	O
reported	O
with	O
antipsychotics	O
.	O
	
Grade	O
3	O
or	O
higher	O
bleeding	B
events	I
(	O
subdural	B
hematoma	I
,	O
gastrointestinal	B
bleeding	I
,	O
hematuria	B
and	O
post	B
procedural	I
hemorrhage	I
)	O
have	O
occurred	O
in	O
up	O
to	O
6	O
%	O
of	O
patients	O
.	O
	
Serious	O
drug-related	O
adverse	O
reactions	O
reported	O
in	O
clinical	O
trials	O
included	O
myelosuppression	B
,	O
infection	B
,	O
pneumonia	B
,	O
tumor	B
lysis	I
syndrome	I
and	O
infusion	B
reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
]	O
.	O
	
Decisions	O
about	O
whether	O
or	O
not	O
to	O
restart	O
TECFIDERA	O
should	O
be	O
individualized	O
based	O
on	O
clinical	O
circumstances	O
.	O
	
A	O
total	O
of	O
242	O
(	O
14.9	O
%	O
)	O
patients	O
had	O
a	O
heart	B
rate	I
less	I
than	I
50	I
beats	I
per	I
minute	I
.	O
	
In	O
patients	O
with	O
abnormal	O
liver	O
tests	O
,	O
NESINA	O
should	O
be	O
initiated	O
with	O
caution	O
.	O
	
Of	O
the	O
1,834	O
patients	O
,	O
12	O
%	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
reaction	O
,	O
compared	O
with	O
3	O
%	O
of	O
the	O
1,116	O
placebo-treated	O
patients	O
.	O
	
Agranulocytosis	B
(	O
including	O
fatal	B
cases	O
)	O
has	O
also	O
been	O
reported	O
.	O
	
Study	O
1	O
CNS	B
PTLD	I
1	O
1	O
Non-CNSPTLD	B
1	O
2	O
1	O
Study	O
2	O
CNS	B
PTLD	I
1	O
1	O
1	O
1	O
Non-CNSPTLD	B
1	O
Study	O
3	O
CNS	B
PTLD	I
2	O
Non-CNSPTLD	B
1	O
Total	O
(	O
%	O
)	O
2	O
(	O
0.5	O
)	O
5	O
(	O
11.6	O
)	O
1	O
(	O
3.6	O
)	O
3	O
(	O
0.7	O
)	O
2	O
(	O
4.1	O
)	O
0	O
0	O
1	O
(	O
1.8	O
)	O
0	O
EBV	O
Seropositive	O
Subpopulation	O
Among	O
the	O
806	O
EBV	O
seropositive	O
patients	O
with	O
known	O
CMV	O
serostatus	O
treated	O
with	O
either	O
NULOJIX	O
regimen	O
in	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
two	O
percent	O
(	O
2	O
%	O
;	O
4/210	O
)	O
of	O
CMV	O
seronegative	O
patients	O
developed	O
PTLD	B
compared	O
to	O
0.2	O
%	O
(	O
1/596	O
)	O
of	O
CMV	O
seropositive	O
patients	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
enterocolitis	O
(	O
such	O
as	O
diarrhea	O
,	O
abdominal	O
pain	O
,	O
mucus	O
or	O
blood	O
in	O
stool	O
,	O
with	O
or	O
without	O
fever	O
)	O
and	O
of	O
bowel	O
perforation	O
(	O
such	O
as	O
peritoneal	O
signs	O
and	O
ileus	O
)	O
.	O
	
5.3	O
Pneumonitis	O
Fatal	B
and	O
serious	O
pneumonitis	B
occurred	O
in	O
patients	O
treated	O
with	O
Zydelig	O
.	O
	
Of	O
the	O
63	O
patients	O
with	O
moderate	O
dermatitis	B
,	O
25	O
(	O
40	O
%	O
)	O
were	O
treated	O
with	O
systemic	O
corticosteroids	O
(	O
median	O
of	O
60	O
mg/day	O
of	O
prednisone	O
or	O
equivalent	O
)	O
for	O
a	O
median	O
of	O
2.1	O
weeks	O
,	O
7	O
(	O
11	O
%	O
)	O
were	O
treated	O
with	O
only	O
topical	O
corticosteroids	O
,	O
and	O
31	O
(	O
49	O
%	O
)	O
did	O
not	O
receive	O
systemic	O
or	O
topical	O
corticosteroids	O
.	O
	
Advise	O
patients	O
to	O
promptly	O
report	O
any	O
new	O
or	O
worsening	O
abdominal	O
pain	O
,	O
chills	O
,	O
fever	O
,	O
nausea	O
,	O
or	O
vomiting	O
.	O
	
*	O
QT	B
interval	I
prolongation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Monitor	O
and	O
treat	O
appropriately	O
.	O
	
ALT	B
abnormalities	I
occurred	O
more	O
frequently	O
in	O
hepatitis	O
B	O
and/or	O
hepatitis	O
C	O
virus	O
co-infected	O
subjects	O
for	O
both	O
treatment	O
groups	O
.	O
	
If	O
bleeding	O
persists	O
or	O
occurs	O
after	O
previously	O
regular	O
cycles	O
,	O
check	O
for	O
causes	O
such	O
as	O
pregnancy	O
or	O
malignancy	O
.	O
	
5.3	O
Embryo-Fetal	O
Toxicity	O
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
HALAVEN	O
in	O
pregnant	O
women	O
.	O
	
In	O
the	O
placebo-controlled	O
portions	O
of	O
Studies	O
1	O
and	O
2	O
through	O
Day	O
90	O
,	O
98	O
%	O
and	O
51	O
%	O
of	O
XIAFLEX-treated	O
and	O
placebo-treated	O
patients	O
had	O
an	O
adverse	O
reaction	O
after	O
up	O
to	O
3	O
injections	O
,	O
respectively	O
.	O
	
If	O
Ferriprox	O
is	O
used	O
during	O
pregnancy	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
Ferriprox	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
.	O
	
5.7	O
Pancreatitis	O
Pancreatitis	B
,	O
including	O
one	O
fatality	B
,	O
has	O
been	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
receiving	O
ZYKADIA	O
in	O
clinical	O
trials	O
.	O
	
After	O
excluding	O
patients	O
in	O
whom	O
exposure	O
to	O
study	O
drug	O
was	O
less	O
than	O
one	O
year	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
bladder	B
cancer	I
,	O
there	O
were	O
4	O
cases	O
with	O
FARXIGA	O
and	O
no	O
cases	O
with	O
placebo/comparator	O
.	O
	
Pooled	O
analyses	O
of	O
199	O
placebo-controlled	O
clinical	O
trials	O
(	O
mono-	O
and	O
adjunctive	O
therapy	O
)	O
of	O
11	O
different	O
AEDs	O
showed	O
that	O
patients	O
randomized	O
to	O
one	O
of	O
the	O
AEDs	O
had	O
approximately	O
twice	O
the	O
risk	O
(	O
adjusted	O
relative	O
risk	O
1.8	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.2	O
,	O
2.7	O
)	O
of	O
suicidal	B
thinking	I
compared	O
to	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
,	O
excluding	O
hypoglycemia	B
,	O
associated	O
with	O
the	O
use	O
of	O
TRULICITY	O
in	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
.	O
	
5.5	O
Hypertension	O
COMETRIQ	O
treatment	O
results	O
in	O
an	O
increased	O
incidence	O
of	O
treatment-emergent	O
hypertension	B
with	O
Joint	O
National	O
Committee	O
on	O
Prevention	O
,	O
Detection	O
,	O
Evaluation	O
,	O
and	O
Treatment	O
of	O
High	O
Blood	O
Pressure	O
(	O
modified	O
JNC	O
criteria	O
)	O
stage	O
1	O
or	O
2	O
hypertension	B
identified	O
in	O
61	O
%	O
in	O
COMETRIQ-treated	O
patients	O
compared	O
with	O
30	O
%	O
of	O
placebo-treated	O
patients	O
in	O
the	O
randomized	O
trial	O
.	O
	
The	O
impact	O
of	O
long-term	O
treatment	O
with	O
CIMZIA	O
on	O
the	O
development	O
of	O
autoimmune	O
diseases	O
is	O
unknown	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
]	O
.	O
	
1915	O
05	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
RashRash	O
includes	O
the	O
following	O
terms	O
:	O
erythema	B
,	O
rash	B
,	O
erythematous	B
rash	I
,	O
generalized	B
rash	I
,	O
macular	B
rash	I
,	O
maculo-papular	B
rash	I
,	O
papular	B
rash	I
,	O
and	O
vesicular	B
rash	I
.	O
	
Whenever	O
clinical	O
judgment	O
dictates	O
,	O
the	O
patient	O
should	O
be	O
examined	O
with	O
the	O
aid	O
of	O
magnification	O
,	O
such	O
as	O
slit-lamp	O
biomicroscopy	O
,	O
and	O
,	O
where	O
appropriate	O
,	O
fluorescein	O
staining	O
.	O
	
The	O
incidence	O
of	O
infections	B
(	O
60	O
%	O
vs	O
58	O
%	O
)	O
and	O
serious	O
infections	B
(	O
2	O
%	O
vs	O
2	O
%	O
)	O
was	O
similar	O
in	O
patients	O
treated	O
with	O
TECFIDERA	O
or	O
placebo	O
,	O
respectively	O
.	O
	
Three	O
of	O
these	O
4	O
adverse	O
reactions	O
were	O
described	O
as	O
a	O
hypertensive	B
crisis	I
and	O
were	O
managed	O
with	O
oral	O
medications	O
and	O
resolved	O
.	O
	
5.6	O
QT	O
Interval	O
Effect	O
A	O
study	O
of	O
cardiac	O
conduction	O
showed	O
that	O
POTIGA	O
produced	O
a	O
mean	O
7.7-msec	O
QT	B
prolongation	I
in	O
healthy	O
volunteers	O
titrated	O
to	O
400	O
mg	O
3	O
times	O
daily	O
.	O
	
The	O
imbalance	O
in	O
deaths	B
is	O
unexplained	O
.	O
	
Discontinue	O
SIRTURO	O
if	O
:	O
*	O
aminotransferase	O
elevations	O
are	O
accompanied	O
by	O
total	O
bilirubin	O
elevation	O
greater	O
than	O
two	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
*	O
aminotransferase	O
elevations	O
are	O
greater	O
than	O
eight	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
*	O
aminotransferase	O
elevations	O
are	O
greater	O
than	O
five	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
and	O
persist	O
beyond	O
two	O
weeks	O
5.4	O
Drug	O
Interactions	O
CYP3A4	O
inducers/inhibitors	O
Bedaquiline	O
is	O
metabolized	O
by	O
CYP3A4	O
and	O
its	O
systemic	O
exposure	O
and	O
therapeutic	O
effect	O
may	O
therefore	O
be	O
reduced	O
during	O
co-administration	O
with	O
inducers	O
of	O
CYP3A4	O
.	O
	
New	O
Malignancies	O
New	O
malignancies	B
were	O
reported	O
in	O
no	O
patients	O
in	O
the	O
placebo	O
group	O
and	O
4	O
(	O
3.3	O
%	O
)	O
patients	O
(	O
3	O
prostate	B
cancers	I
,	O
1	O
basal	B
cell	I
carcinoma	I
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
5.4	O
Patients	O
with	O
Prosthetic	O
Heart	O
Valves	O
The	O
safety	O
and	O
efficacy	O
of	O
ELIQUIS	O
have	O
not	O
been	O
studied	O
in	O
patients	O
with	O
prosthetic	O
heart	O
valves	O
.	O
	
Most	O
events	O
(	O
95	O
%	O
)	O
were	O
Grade	O
1	O
or	O
Grade	O
2	O
in	O
severity	O
.	O
	
For	O
patients	O
receiving	O
hemodialysis	O
,	O
physicians	O
may	O
consider	O
the	O
prompt	O
initiation	O
of	O
hemodialysis	O
following	O
the	O
administration	O
of	O
a	O
GBCA	O
in	O
order	O
to	O
enhance	O
the	O
contrast	O
agent	O
's	O
elimination	O
.	O
	
Features	O
of	O
acute	O
kidney	O
injury	O
consist	O
of	O
rapid	O
(	O
over	O
hours	O
to	O
days	O
)	O
and	O
usually	O
reversible	O
decrease	O
in	O
kidney	O
function	O
,	O
commonly	O
in	O
the	O
setting	O
of	O
surgery	O
,	O
severe	O
infection	O
,	O
injury	O
or	O
drug-induced	O
kidney	O
toxicity	O
.	O
	
After	O
resolution	O
,	O
treatment	O
with	O
ERWINAZE	O
may	O
be	O
resumed	O
.	O
	
Ensure	O
that	O
appropriate	O
medical	O
support	O
measures	O
,	O
including	O
cardiopulmonary	O
resuscitation	O
equipment	O
,	O
are	O
readily	O
available	O
.	O
	
5.2	O
Radiation	O
Risk	O
Amyvid	O
,	O
similar	O
to	O
other	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
overall	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
(	O
5.4	O
)	O
*	O
Not	O
recommended	O
in	O
patients	O
with	O
end-stage	O
renal	O
disease	O
.	O
	
Withhold	O
GILOTRIF	O
for	O
severe	O
and	O
prolonged	O
cutaneous	O
reactions	O
.	O
	
For	O
more	O
information	O
,	O
ask	O
your	O
healthcare	O
provider	O
or	O
pharmacist	O
.	O
	
program	O
may	O
use	O
ENTEREG	O
.	O
	
Hepatobiliary	O
Disorders	O
:	O
Hepatitis	B
.	O
	
Hypersensitivity	B
,	O
including	O
serious	O
reactions	O
,	O
has	O
occurred	O
in	O
patients	O
who	O
have	O
previously	O
tolerated	O
infusions	O
of	O
BENLYSTA	O
.	O
	
Psychiatric	O
Disorders	O
Nervousness	B
.	O
	
These	O
women	O
should	O
have	O
their	O
thyroid	O
function	O
monitored	O
in	O
order	O
to	O
maintain	O
their	O
free	O
thyroid	O
hormone	O
levels	O
in	O
an	O
acceptable	O
range	O
.	O
	
Continue	O
hydration	O
and	O
alkalinization	O
of	O
the	O
urine	O
as	O
indicated	O
.	O
	
5.5	O
Renal	O
Failure	O
Cases	O
of	O
renal	B
failure	I
(	O
including	O
acute	B
renal	I
failure	I
)	O
,	O
some	O
with	O
a	O
fatal	B
outcome	O
,	O
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
AFINITOR	O
[	O
see	O
Laboratory	O
Tests	O
and	O
Monitoring	O
(	O
5.8	O
)	O
]	O
.	O
	
Other	O
fatal	B
adverse	O
reactions	O
in	O
JEVTANA-treated	O
patients	O
included	O
ventricular	B
fibrillation	I
,	O
cerebral	B
hemorrhage	I
,	O
and	O
dyspnea	B
.	O
	
UTIs	O
in	O
AMPYRA-treated	O
patients	O
should	O
be	O
evaluated	O
and	O
treated	O
as	O
clinically	O
indicated	O
.	O
	
The	O
following	O
have	O
been	O
observed	O
with	O
BENLYSTA	O
and	O
are	O
discussed	O
in	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
:	O
*	O
Mortality	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Serious	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Malignancy	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Hypersensitivity	B
Reactions	I
,	O
including	O
Anaphylaxis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Infusion	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Depression	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
EXCERPT	O
:	O
Common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
in	O
clinical	O
trials	O
were	O
:	O
nausea	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
nasopharyngitis	B
,	O
bronchitis	B
,	O
insomnia	B
,	O
pain	B
in	I
extremity	I
,	O
depression	B
,	O
migraine	B
,	O
and	O
pharyngitis	B
.	O
	
Consider	O
the	O
benefit-risk	O
profile	O
in	O
such	O
patients	O
before	O
treating	O
with	O
Prolia	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
is	O
discussed	O
in	O
more	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Seizure	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
10	O
%	O
)	O
are	O
asthenia/fatigue	O
,	O
back	B
pain	I
,	O
decreased	B
appetite	I
,	O
constipation	B
,	O
arthralgia	B
,	O
diarrhea	B
,	O
hot	B
flush	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
dyspnea	B
,	O
musculoskeletal	B
pain	I
,	O
weight	B
decreased	I
,	O
headache	B
,	O
hypertension	B
,	O
and	O
dizziness/vertigo	O
.	O
	
The	O
median	O
number	O
of	O
treatment	O
cycles	O
in	O
each	O
study	O
arm	O
was	O
15	O
(	O
range	O
,	O
1-16	O
)	O
and	O
80	O
patients	O
(	O
48	O
%	O
)	O
in	O
the	O
ADCETRIS-treatment	O
arm	O
received	O
16	O
cycles	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Monitor	O
patients	O
for	O
new	O
malignancies	O
prior	O
to	O
initiation	O
of	O
therapy	O
,	O
while	O
on	O
therapy	O
,	O
and	O
following	O
discontinuation	O
of	O
TAFINLAR	O
or	O
the	O
combination	O
therapy	O
.	O
	
Cardiac	O
:	O
New	O
or	O
worsening	O
heart	B
failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
Atrial	B
flutter	I
has	O
been	O
reported	O
very	O
rarely	O
.	O
	
In	O
clinical	O
studies	O
,	O
the	O
majority	O
of	O
patients	O
developed	O
IgG	O
antibodies	O
to	O
alglucosidase	O
alfa	O
,	O
typically	O
within	O
3	O
months	O
of	O
treatment	O
.	O
	
Adverse	O
Reactions	O
(	O
>	O
=10	O
%	O
)	O
from	O
One	O
Open-label	O
Trial	O
in	O
Adults	O
with	O
Severe	O
Aplastic	O
Anemia	O
Adverse	O
Reaction	O
PROMACTA	O
(	O
n	O
=	O
43	O
)	O
(	O
%	O
)	O
Nausea	B
33	O
Fatigue	B
28	O
Cough	B
23	O
Diarrhea	B
21	O
Headache	B
21	O
Pain	B
in	I
extremity	I
19	O
Dyspnea	B
14	O
Pyrexia	B
14	O
Dizziness	B
14	O
Oropharyngeal	B
pain	I
14	O
Febrile	B
neutropenia	I
14	O
Abdominal	B
pain	I
12	O
Ecchymosis	B
12	O
Muscle	B
spasms	I
12	O
Transaminases	B
increased	I
12	O
Arthralgia	B
12	O
Rhinorrhea	B
12	O
In	O
this	O
trial	O
,	O
patients	O
had	O
bone	O
marrow	O
aspirates	O
evaluated	O
for	O
cytogenetic	O
abnormalities	O
.	O
	
Because	O
of	O
the	O
risk	O
of	O
orthostatic	O
hypotension	O
with	O
SAPHRIS	O
,	O
caution	O
should	O
be	O
observed	O
in	O
cardiac	O
patients	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
PROMACTA	O
was	O
administered	O
to	O
277	O
patients	O
for	O
at	O
least	O
6	O
months	O
and	O
202	O
patients	O
for	O
at	O
least	O
1	O
year	O
.	O
	
If	O
anemia	O
develops	O
during	O
or	O
after	O
therapy	O
,	O
a	O
diagnostic	O
workup	O
for	O
drug-induced	O
hemolytic	O
anemia	O
should	O
be	O
performed	O
and	O
consideration	O
given	O
to	O
discontinuation	O
of	O
Teflaro	O
.	O
	
Adverse	O
reactions	O
reported	O
by	O
these	O
patients	O
who	O
received	O
the	O
additional	O
30	O
mg	O
subcutaneous	O
dose	O
of	O
KALBITOR	O
were	O
consistent	O
with	O
those	O
reported	O
in	O
the	O
patients	O
receiving	O
a	O
single	O
dose	O
.	O
	
Serious	O
febrile	B
reactions	I
and	O
fever	B
of	O
any	O
severity	O
complicated	O
by	O
hypotension	B
,	O
rigors	B
or	O
chills	B
occurred	O
in	O
25	O
%	O
(	O
14/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
GILENYA	O
should	O
be	O
discontinued	O
if	O
significant	O
liver	O
injury	O
is	O
confirmed	O
.	O
	
Causality	O
has	O
not	O
been	O
established	O
as	O
these	O
fractures	O
also	O
occur	O
in	O
osteoporotic	O
patients	O
who	O
have	O
not	O
been	O
treated	O
with	O
anti-resorptive	O
agents	O
.	O
	
In	O
clinical	O
trials	O
,	O
ILARIS	O
has	O
not	O
been	O
administered	O
concomitantly	O
with	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
inhibitors	O
.	O
	
The	O
second	O
most	O
commonly	O
reported	O
adverse	O
event	O
was	O
constipation	B
.	O
	
Discontinue	O
INLYTA	O
in	O
patients	O
developing	O
RPLS	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
were	O
required	O
in	O
57	O
%	O
of	O
GILOTRIF-treated	O
patients	O
.	O
	
Avoid	O
administering	O
STRIBILD	O
with	O
concurrent	O
or	O
recent	O
use	O
of	O
nephrotoxic	O
drugs	O
.	O
	
Only	O
hospitals	O
that	O
have	O
enrolled	O
in	O
and	O
met	O
all	O
of	O
the	O
requirements	O
for	O
the	O
E.A.S.E	O
.	O
	
5.5	O
Immune-mediated	O
Endocrinopathies	O
In	O
Study	O
1	O
,	O
severe	O
to	O
life-threatening	O
immune-mediated	B
endocrinopathies	I
(	O
requiring	O
hospitalization	O
,	O
urgent	O
medical	O
intervention	O
,	O
or	O
interfering	O
with	O
activities	O
of	O
daily	O
living	O
;	O
Grade	O
3-4	O
)	O
occurred	O
in	O
9	O
(	O
1.8	O
%	O
)	O
YERVOY-treated	O
patients	O
.	O
	
Hypertensive	B
crisis	I
was	O
reported	O
in	O
2/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
.	O
	
Before	O
you	O
take	O
DUAVEE	O
,	O
tell	O
your	O
healthcare	O
provider	O
if	O
you	O
:	O
*	O
have	O
any	O
unusual	O
vaginal	O
bleeding	O
.	O
	
In	O
the	O
case	O
of	O
persistent	O
hypertension	O
despite	O
use	O
of	O
anti-hypertensive	O
medications	O
,	O
reduce	O
the	O
INLYTA	O
dose	O
.	O
	
5.3	O
Glucose	O
Intolerance	O
Glucose	O
intolerance	O
has	O
been	O
reported	O
in	O
5	O
%	O
of	O
patients	O
receiving	O
ERWINAZE	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5Includes	O
the	O
preferred	O
terms	O
hyperinsulinemia	B
and	O
blood	B
insulin	I
increased	I
.	O
	
Renal	O
replacement	O
therapy	O
was	O
not	O
required	O
for	O
these	O
subjects	O
.	O
	
(	O
5.4	O
)	O
*	O
Increased	O
risk	O
of	O
pneumonia	B
in	O
patients	O
with	O
COPD	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
with	O
XEOMIN	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
DOTAREM	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
prior	O
to	O
re-administration	O
.	O
	
Clinically	O
notable	O
decreases	B
in	I
serum	I
potassium	I
or	O
changes	B
in	I
blood	I
glucose	I
were	O
infrequent	O
during	O
clinical	O
studies	O
with	O
long-term	O
administration	O
of	O
ARCAPTA	O
NEOHALER	O
with	O
the	O
rates	O
similar	O
to	O
those	O
for	O
placebo	O
controls	O
.	O
	
(	O
5.4	O
)	O
*	O
dispatch	O
:	O
unexpected	O
key	O
:	O
list	O
in	O
dispatch	O
table	O
:	O
{	O
'caption	O
'	O
:	O
<	O
function	O
print_caption	O
at	O
0x1c6c8c0	O
>	O
,	O
'text	O
'	O
:	O
<	O
function	O
print_text	O
at	O
0x1c6c500	O
>	O
}	O
Metabolic	B
Changes	I
:	O
Atypical	O
antipsychotic	O
drugs	O
have	O
been	O
associated	O
with	O
metabolic	B
changes	I
that	O
may	O
increase	O
cerebrovascular	B
risk	I
.	O
	
Withhold	O
,	O
dose	O
reduce	O
,	O
or	O
discontinue	O
BOSULIF	O
as	O
necessary	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
For	O
those	O
patients	O
continued	O
on	O
POTIGA	O
,	O
dizziness	B
and	O
somnolence	B
appeared	O
to	O
diminish	O
with	O
continued	O
use	O
.	O
	
Concurrent	O
hypochloremia	B
was	O
also	O
present	O
in	O
patients	O
with	O
hyponatremia	B
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
leading	O
to	O
study	O
withdrawal	O
for	O
patients	O
receiving	O
TREANDA	O
were	O
hypersensitivity	B
(	O
2	O
%	O
)	O
and	O
pyrexia	B
(	O
1	O
%	O
)	O
.	O
	
It	O
is	O
unknown	O
whether	O
patients	O
with	O
a	O
history	O
of	O
pancreatitis	O
are	O
at	O
increased	O
risk	O
for	O
the	O
development	O
of	O
pancreatitis	O
while	O
using	O
NESINA	O
.	O
	
There	O
was	O
no	O
increased	B
incidence	I
of	I
serious	I
infections	I
observed	O
in	O
patients	O
with	O
lymphocyte	O
counts	O
<	O
0.8x10	O
9	O
/L	O
or	O
0.5x10	O
9	O
/L	O
in	O
controlled	O
trials	O
,	O
although	O
one	O
patient	O
in	O
an	O
extension	O
study	O
developed	O
PML	B
in	O
the	O
setting	O
of	O
prolonged	B
lymphopenia	I
(	O
lymphocyte	O
counts	O
predominantly	O
<	O
0.5x10	O
9	O
/L	O
for	O
3.5	O
years	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Three	O
percent	O
(	O
3	O
%	O
)	O
of	O
patients	O
discontinued	O
TECFIDERA	O
for	O
flushing	B
and	O
<	O
1	O
%	O
had	O
serious	O
flushing	B
symptoms	O
that	O
were	O
not	O
life-threatening	O
but	O
led	O
to	O
hospitalization	O
.	O
	
The	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
5	O
%	O
of	O
the	O
NHL	O
patients	O
,	O
regardless	O
of	O
severity	O
,	O
are	O
shown	O
in	O
Table	O
3	O
.	O
	
Remove	O
contact	O
lenses	O
prior	O
to	O
instillation	O
of	O
DUREZOL	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
(	O
e.g.	O
,	O
angioedema	B
,	O
urticaria	B
,	O
hypersensitivity	B
)	O
were	O
reported	O
with	O
FARXIGA	O
treatment	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Two	O
of	O
the	O
5	O
cases	O
presented	O
with	O
CNS	O
involvement	O
.	O
	
A	O
total	O
of	O
35	O
%	O
were	O
Hispanic	O
or	O
Latino	O
.	O
	
Additional	O
testing	O
may	O
include	O
fluorescein	O
angiograms	O
(	O
FA	O
)	O
,	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
,	O
perimetry	O
,	O
and	O
electroretinograms	O
(	O
ERG	O
)	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Perform	O
an	O
evaluation	O
for	O
RPLS	O
in	O
any	O
patient	O
presenting	O
with	O
seizures	O
,	O
headache	O
,	O
visual	O
disturbances	O
,	O
confusion	O
or	O
altered	O
mental	O
function	O
.	O
	
Therefore	O
,	O
XIAFLEX	O
should	O
be	O
injected	O
only	O
into	O
the	O
Peyronie	O
's	O
plaque	O
and	O
care	O
should	O
be	O
taken	O
to	O
avoid	O
injecting	O
into	O
the	O
urethra	O
,	O
nerves	O
,	O
blood	O
vessels	O
,	O
corpora	O
cavernosa	O
or	O
other	O
collagen-containing	O
structures	O
of	O
the	O
penis	O
.	O
	
Both	O
GRANIX	O
and	O
the	O
non-US-approved	O
filgrastim	O
product	O
were	O
administered	O
at	O
5	O
mcg/kg	O
subcutaneously	O
once	O
daily	O
beginning	O
one	O
day	O
after	O
chemotherapy	O
for	O
at	O
least	O
five	O
days	O
and	O
continued	O
to	O
a	O
maximum	O
of	O
14	O
days	O
or	O
until	O
an	O
ANC	O
of	O
>	O
=10,000	O
x	O
10	O
6	O
/L	O
after	O
nadir	O
was	O
reached	O
.	O
	
6.2	O
Clinical	O
Trials	O
Experience	O
:	O
Pediatric	O
Subjects	O
(	O
6	O
years	O
to	O
less	O
than	O
18	O
years	O
of	O
age	O
)	O
The	O
safety	O
assessment	O
in	O
children	O
and	O
adolescents	O
is	O
based	O
on	O
the	O
Week	O
24	O
analysis	O
of	O
the	O
single-arm	O
,	O
Phase	O
2	O
trial	O
TMC125-C213	O
in	O
which	O
101	O
antiretroviral	O
treatment-experienced	O
HIV-1	O
infected	O
subjects	O
6	O
years	O
to	O
less	O
than	O
18	O
years	O
of	O
age	O
and	O
weighing	O
at	O
least	O
16	O
kg	O
received	O
INTELENCE	O
(	O
r	O
)	O
in	O
combination	O
with	O
other	O
antiretroviral	O
agents	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Treatment	O
discontinuation	O
due	O
to	O
liver	B
enzyme	I
increases	I
occurred	O
in	O
1	O
%	O
of	O
patients	O
taking	O
ZYTIGA	O
.	O
	
Withhold	O
YERVOY	O
in	O
patients	O
with	O
Grade	O
2	O
hepatotoxicity	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
have	O
followed	O
AdreView	O
administration	O
.	O
	
Physicians	O
should	O
remain	O
vigilant	O
for	O
the	O
possible	O
development	O
of	O
pneumonia	O
in	O
patients	O
with	O
COPD	O
as	O
the	O
clinical	O
features	O
of	O
such	O
infections	O
overlap	O
with	O
the	O
symptoms	O
of	O
COPD	O
exacerbations	O
.	O
	
*	O
Peripheral	B
neuropathy	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Twenty-two	O
percent	O
(	O
109/503	O
)	O
of	O
patients	O
developed	O
a	O
new	O
or	O
worsening	O
neuropathy	B
that	O
had	O
not	O
recovered	O
within	O
a	O
median	O
follow-up	O
duration	O
of	O
269	O
days	O
(	O
range	O
25-662	O
days	O
)	O
.	O
	
(	O
5.16	O
)	O
5.1	O
Asthma-Related	O
Death	O
LABA	O
,	O
such	O
as	O
vilanterol	O
,	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
BREO	O
ELLIPTA	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
No	O
apparent	O
correlation	O
of	O
antibody	O
development	O
to	O
adverse	O
events	O
or	O
efficacy	O
was	O
observed	O
.	O
	
Healthcare	O
providers	O
should	O
be	O
prepared	O
to	O
address	O
severe	O
allergic	O
reactions	O
following	O
XIAFLEX	O
injections	O
.	O
	
Signs	O
or	O
symptoms	O
that	O
may	O
reflect	O
serious	O
injury	O
to	O
the	O
penis	O
should	O
be	O
promptly	O
evaluated	O
in	O
order	O
to	O
assess	O
for	O
corporal	O
rupture	O
or	O
severe	O
penile	O
hematoma	O
,	O
which	O
may	O
require	O
surgical	O
intervention	O
.	O
	
One	O
of	O
the	O
1,564	O
Crohn	O
's	O
disease	O
patients	O
treated	O
with	O
CIMZIA	O
developed	O
symptoms	O
of	O
a	O
lupus-like	B
syndrome	I
.	O
	
Placement	O
or	O
removal	O
of	O
an	O
epidural	O
catheter	O
or	O
lumbar	O
puncture	O
is	O
best	O
performed	O
when	O
the	O
anticoagulant	O
effect	O
of	O
dabigatran	O
is	O
low	O
;	O
however	O
,	O
the	O
exact	O
timing	O
to	O
reach	O
a	O
sufficiently	O
low	O
anticoagulant	O
effect	O
in	O
each	O
patient	O
is	O
not	O
known	O
.	O
	
There	O
are	O
insufficient	O
data	O
to	O
support	O
meaningful	O
analyses	O
of	O
adverse	O
reactions	O
by	O
age	O
or	O
race	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
blinatumomab	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Progressive	O
Multifocal	O
Leukoencephalopathy	O
Two	O
fatal	B
cases	O
of	O
progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
have	O
been	O
reported	O
among	O
1096	O
patients	O
treated	O
with	O
a	O
NULOJIX-containing	O
regimen	O
:	O
one	O
patient	O
in	O
clinical	O
trials	O
of	O
kidney	O
transplant	O
(	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
described	O
above	O
)	O
and	O
one	O
patient	O
in	O
a	O
trial	O
of	O
liver	O
transplant	O
(	O
trial	O
of	O
250	O
patients	O
)	O
.	O
	
Other	O
common	O
adverse	O
reactions	O
occurring	O
in	O
greater	O
than	O
1	O
%	O
of	O
patients	O
included	O
pyrexia	B
,	O
transaminase	B
increase	I
,	O
dizziness	B
,	O
and	O
rash	B
.	O
	
These	O
reactions	O
include	O
anaphylaxis	B
,	O
angioedema	B
and	O
severe	O
cutaneous	B
adverse	I
reactions	I
,	O
including	O
Stevens-Johnson	B
syndrome	I
.	O
	
Clinically	O
significant	O
cardiovascular	O
effects	O
and	O
fatalities	O
have	O
been	O
reported	O
in	O
association	O
with	O
excessive	O
use	O
of	O
inhaled	O
sympathomimetic	O
drugs	O
.	O
	
Summary	O
of	O
Treatment-Emergent	O
Laboratory	O
Abnormalities	O
with	O
Grade	O
3	O
or	O
4	O
Incidence	O
of	O
>	O
=4	O
%	O
in	O
XALKORI-Treated	O
Patients	O
in	O
Study	O
2	O
Laboratory	O
Abnormality	O
XALKORI	O
Chemotherapy	O
Any	O
Grade	O
(	O
%	O
)	O
Grade	O
3/4	O
(	O
%	O
)	O
Any	O
Grade	O
(	O
%	O
)	O
Grade	O
3/4	O
(	O
%	O
)	O
Hematology	O
Neutropenia	B
49	O
12	O
28	O
12	O
Lymphopenia	B
51	O
9	O
60	O
25	O
Chemistry	O
ALT	B
elevation	I
76	O
17	O
38	O
4	O
AST	B
elevation	I
61	O
9	O
33	O
0	O
Hypokalemia	B
18	O
4	O
10	O
1	O
Hypophosphatemia	B
28	O
5	O
25	O
6	O
Description	O
of	O
Selected	O
Adverse	O
Drug	O
Reactions	O
Vision	O
disorders	O
Vision	B
disorders	I
,	O
most	O
commonly	O
visual	B
impairment	I
,	O
photopsia	B
,	O
blurred	B
vision	I
,	O
or	O
vitreous	B
floaters	I
,	O
occurred	O
in	O
1038	O
(	O
62	O
%	O
)	O
of	O
1669	O
patients	O
.	O
	
5.7	O
Switching	O
Between	O
Biological	O
Disease	O
Modifying	O
Antirheumatic	O
Drugs	O
(	O
DMARDs	O
)	O
Care	O
should	O
be	O
taken	O
when	O
switching	O
from	O
one	O
biologic	O
product	O
to	O
another	O
biologic	O
product	O
since	O
overlapping	O
biological	O
activity	O
may	O
further	O
increase	O
the	O
risk	O
of	O
infection	O
.	O
	
*	O
Nausea	B
*	O
Muscle	B
spasms	I
*	O
Rash	B
*	O
Pruritus	B
*	O
Angioedema	B
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
FETAL	B
TOXICITY	I
WARNING	O
:	O
FETAL	B
TOXICITY	I
*	O
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Edarbi	O
as	O
soon	O
as	O
possible	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
In	O
the	O
safety	O
population	O
in	O
controlled	O
studies	O
,	O
a	O
total	O
of	O
620	O
patients	O
with	O
Crohn	O
's	O
disease	O
received	O
CIMZIA	O
at	O
a	O
dose	O
of	O
400	O
mg	O
,	O
and	O
614	O
subjects	O
received	O
placebo	O
(	O
including	O
subjects	O
randomized	O
to	O
placebo	O
in	O
Study	O
CD2	O
following	O
open	O
label	O
dosing	O
of	O
CIMZIA	O
at	O
Weeks	O
0	O
,	O
2	O
,	O
4	O
)	O
.	O
	
STRIBILD	O
should	O
be	O
avoided	O
with	O
concurrent	O
or	O
recent	O
use	O
of	O
a	O
nephrotoxic	O
agent	O
.	O
	
Adverse	O
reactions	O
of	O
any	O
cause	O
occurred	O
in	O
48	O
%	O
of	O
the	O
DYSPORT	O
(	O
r	O
)	O
-treated	O
patients	O
and	O
33	O
%	O
of	O
the	O
placebo-	O
treated	O
patients	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
in	O
XEOMIN	O
treated	O
subjects	O
were	O
:	O
headache	B
29	O
(	O
5.4	O
%	O
)	O
,	O
facial	B
paresis	I
4	O
(	O
0.7	O
%	O
)	O
,	O
injection	B
site	I
hematoma	I
3	O
(	O
0.6	O
%	O
)	O
and	O
eyelid	B
edema	I
2	O
(	O
0.4	O
%	O
)	O
.	O
	
5.7	O
Tumorigenic	O
Potential	O
In	O
an	O
oral	O
carcinogenicity	O
study	O
,	O
gabapentin	O
enacarbil	O
increased	O
the	O
incidence	O
of	O
pancreatic	B
acinar	I
cell	I
adenoma	I
in	O
male	O
and	O
female	O
rats	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Unless	O
an	O
alternate	O
etiology	O
has	O
been	O
identified	O
,	O
signs	O
or	O
symptoms	O
of	O
dermatitis	O
should	O
be	O
considered	O
immune-mediated	O
.	O
	
The	O
clinical	O
relevance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O
	
5.2	O
Patients	O
Coinfected	O
with	O
HIV-1	O
and	O
HBV	O
It	O
is	O
recommended	O
that	O
all	O
patients	O
with	O
HIV-1	O
be	O
tested	O
for	O
the	O
presence	O
of	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
before	O
initiating	O
antiretroviral	O
therapy	O
.	O
	
The	O
most	O
common	O
Grade	O
3/4	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
lymphopenia	B
,	O
hyperglycemia	B
,	O
anemia	B
,	O
decreased	B
potassium	I
,	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
and	O
thrombocytopenia	B
.	O
	
5.8	O
Wound	O
Healing	O
Complications	O
No	O
formal	O
studies	O
of	O
the	O
effect	O
of	O
INLYTA	O
on	O
wound	O
healing	O
have	O
been	O
conducted	O
.	O
	
In	O
the	O
remaining	O
patients	O
,	O
symptoms	O
resolved	O
within	O
4	O
to	O
5	O
weeks	O
.	O
	
Mild	O
to	O
severe	O
hypertension	B
may	O
be	O
present	O
.	O
	
Initiate	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
of	O
prednisone	O
or	O
equivalent	O
,	O
and	O
initiate	O
appropriate	O
hormone	O
replacement	O
therapy	O
.	O
	
In	O
a	O
multicenter	O
,	O
open-label	O
trial	O
(	O
FLAMINGO	O
)	O
,	O
243	O
subjects	O
received	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
versus	O
242	O
subjects	O
who	O
received	O
darunavir	O
800	O
mg/ritonavir	O
100	O
mg	O
once	O
daily	O
,	O
both	O
in	O
combination	O
with	O
investigator-selected	O
NRTI	O
background	O
regimen	O
(	O
either	O
EPZICOM	O
or	O
TRUVADA	O
)	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
KALBITOR	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
5.10	O
Hypothyroidism	O
Estrogen	O
administration	O
leads	O
to	O
increased	B
thyroid-binding	I
globulin	I
(	I
TBG	I
)	I
levels	I
.	O
	
Discontinue	O
treatment	O
with	O
ILARIS	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
.	O
	
The	O
safety	O
of	O
resuming	O
TNF	O
blocker	O
therapy	O
after	O
HBV	O
reactivation	O
is	O
controlled	O
is	O
not	O
known	O
.	O
	
In	O
ARISTOTLE	O
,	O
the	O
mean	O
duration	O
of	O
exposure	O
was	O
89	O
weeks	O
(	O
>	O
15,000	O
patient-years	O
)	O
.	O
	
Hemoglobin	O
Decreases	O
in	O
hemoglobin	O
may	O
require	O
a	O
decrease	O
in	O
dosage	O
or	O
discontinuation	O
of	O
ribavirin	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
[	O
see	O
prescribing	O
information	O
for	O
ribavirin	O
]	O
.	O
	
Neoplasm	O
Benign	O
and	O
Malignant	O
:	O
Melanoma	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
Immune	O
System	O
Disorders	O
:	O
Serious	O
systemic	B
hypersensitivity	I
reactions	I
(	O
including	O
anaphylactic	B
reaction	I
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.10	O
)	O
]	O
,	O
sarcoidosis	B
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
Interstitial	B
lung	I
disease	I
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Skin	B
exfoliation	I
,	O
bullous	B
skin	I
reactions	I
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
SERIOUS	O
INFECTIONS	B
AND	O
MALIGNANCY	B
WARNING	O
:	O
SERIOUS	O
INFECTIONS	B
AND	O
MALIGNANCY	B
EXCERPT	O
:	O
WARNING	O
:	O
SERIOUS	O
INFECTIONS	B
AND	O
MALIGNANCY	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
5.3	O
Hypersensitivity	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
with	O
ILARIS	O
therapy	O
.	O
	
There	O
are	O
currently	O
no	O
marketed	O
tests	O
for	O
antibodies	O
against	O
alglucosidase	O
alfa	O
;	O
however	O
,	O
a	O
testing	O
service	O
is	O
provided	O
by	O
Genzyme	O
.	O
	
If	O
EOVIST	O
is	O
used	O
in	O
these	O
patients	O
,	O
complete	O
MRI	O
no	O
later	O
than	O
60	O
minutes	O
after	O
EOVIST	O
administration	O
and	O
use	O
a	O
paired	O
non-contrast	O
and	O
contrast	O
MRI	O
set	O
for	O
diagnosis	O
.	O
	
5.3	O
Heart	O
Failure	O
Cases	O
of	O
worsening	B
congestive	I
heart	I
failure	I
)	O
and	O
new	B
onset	I
CHF	I
have	O
been	O
reported	O
with	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
event	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
any	O
other	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.3	O
Radiation	O
Risk	O
Vizamyl	O
,	O
similar	O
to	O
other	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
overall	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Cubist	O
Pharmaceuticals	O
at	O
1-877-CUBIST-6	O
(	O
1-877-282-4786	O
)	O
or	O
FDA	O
at	O
(	O
1-800-FDA-1088	O
)	O
or	O
www.fda.gov/medwatch	O
.	O
	
Infections	O
Serious	O
infections	B
observed	O
in	O
SIMPONI	O
ARIA-treated	O
patients	O
included	O
sepsis	B
,	O
pneumonia	B
,	O
cellulitis	B
,	O
abscess	B
,	O
opportunistic	B
infections	I
,	O
tuberculosis	B
(	O
TB	B
)	O
,	O
and	O
invasive	B
fungal	I
infections	I
.	O
	
(	O
14.3	O
)	O
MULTAQ	O
is	O
contraindicated	O
in	O
patients	O
with	O
symptomatic	O
heart	O
failure	O
with	O
recent	O
decompensation	O
requiring	O
hospitalization	O
or	O
NYHA	O
Class	O
IV	O
heart	O
failure	O
.	O
	
*	O
Administer	O
EOVIST	O
only	O
in	O
situations	O
where	O
trained	O
personnel	O
and	O
therapies	O
are	O
promptly	O
available	O
for	O
the	O
treatment	O
of	O
hypersensitivity	O
reactions	O
,	O
including	O
personnel	O
trained	O
in	O
resuscitation	O
.	O
	
(	O
5.7	O
,	O
2.3	O
)	O
*	O
Serious	O
Skin	B
Toxicity	I
:	O
Monitor	O
for	O
skin	O
toxicities	O
and	O
for	O
secondary	O
infections	O
.	O
	
Adverse	O
reactions	O
collected	O
in	O
clinical	O
trials	O
included	O
signs	O
and	O
symptoms	O
at	O
baseline	O
but	O
only	O
treatment	O
emergent	O
adverse	O
events	O
,	O
defined	O
as	O
events	O
that	O
appeared	O
or	O
worsened	O
after	O
the	O
start	O
of	O
treatment	O
,	O
are	O
presented	O
below	O
.	O
	
DUAVEE	O
contains	O
an	O
estrogen	O
agonist/antagonist	O
.	O
	
When	O
feasible	O
,	O
the	O
decision	O
to	O
administer	O
empiric	O
antifungal	O
therapy	O
in	O
these	O
patients	O
should	O
be	O
made	O
in	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
invasive	O
fungal	O
infections	O
and	O
should	O
take	O
into	O
account	O
both	O
the	O
risk	O
for	O
severe	O
fungal	O
infection	O
and	O
risks	O
of	O
antifungal	O
therapy	O
.	O
	
If	O
such	O
symptoms	O
occur	O
,	O
discontinue	O
PRISTIQ	O
and	O
initiate	O
supportive	O
treatment	O
.	O
	
Prophylaxis	O
for	O
cytomegalovirus	O
is	O
recommended	O
for	O
at	O
least	O
3	O
months	O
after	O
transplantation	O
.	O
	
5.7	O
Dermatologic	O
Adverse	O
Reactions	O
In	O
a	O
large	O
clinical	O
trial	O
of	O
over	O
7800	O
women	O
with	O
postmenopausal	O
osteoporosis	O
,	O
dermal	B
adverse	I
events	I
such	O
as	O
dermatitis	B
,	O
eczema	B
,	O
and	O
rashes	B
occurred	O
at	O
a	O
significantly	O
higher	O
rate	O
in	O
the	O
Prolia	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
.	O
	
Common	O
adverse	O
reactions	O
in	O
placebo-controlled	O
perioperative	O
studies	O
.	O
	
In	O
patients	O
who	O
develop	O
HBV	O
reactivation	O
,	O
discontinue	O
CIMZIA	O
and	O
initiate	O
effective	O
anti-viral	O
therapy	O
with	O
appropriate	O
supportive	O
treatment	O
.	O
	
In	O
2-year	O
placebo-controlled	O
clinical	O
trials	O
,	O
elevation	B
of	I
liver	I
transaminases	I
to	O
3-fold	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
or	O
greater	O
occurred	O
in	O
14	O
%	O
of	O
patients	O
treated	O
with	O
GILENYA	O
0.5	O
mg	O
and	O
3	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
In	O
such	O
cases	O
,	O
topical	O
treatments	O
are	O
recommended	O
,	O
but	O
alcohol-	O
,	O
hydrogen	O
peroxide-	O
,	O
iodine-	O
,	O
or	O
thyme-	O
containing	O
mouthwashes	O
should	O
be	O
avoided	O
as	O
they	O
may	O
exacerbate	O
the	O
condition	O
.	O
	
Women	O
with	O
normal	O
thyroid	O
function	O
can	O
compensate	O
for	O
the	O
increased	B
TBG	I
by	O
making	O
more	O
thyroid	O
hormone	O
,	O
thus	O
maintaining	O
free	O
T4	O
and	O
T3	O
serum	O
concentrations	O
in	O
the	O
normal	O
range	O
.	O
	
RPLS	B
is	O
a	O
neurological	O
disorder	O
which	O
can	O
present	O
with	O
headache	B
,	O
seizure	B
,	O
lethargy	B
,	O
confusion	B
,	O
blindness	B
and	O
other	O
neurologic	B
disturbances	I
.	O
	
These	O
events	O
were	O
not	O
treatment	O
limiting	O
.	O
	
This	O
finding	O
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
all	O
LABA	O
.	O
	
Furthermore	O
,	O
CRIM-negative	O
infants	O
have	O
shown	O
reduced	O
clinical	O
effect	O
in	O
the	O
presence	O
of	O
high	O
sustained	O
IgG	B
antibody	I
titers	I
with	I
inhibitory	I
activity	I
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
Muscle	B
spasms	I
.	O
	
Fatal	B
adverse	O
reactions	O
occurred	O
more	O
frequently	O
in	O
patients	O
who	O
received	O
AFINITOR	O
plus	O
exemestane	O
(	O
2	O
%	O
)	O
compared	O
to	O
patients	O
on	O
the	O
placebo	O
plus	O
exemestane	O
arm	O
(	O
0.4	O
%	O
)	O
.	O
	
5.3	O
Drug	O
Interactions	O
Co-administration	O
of	O
strong	O
cytochrome	O
P450	O
enzyme	O
inducer	O
,	O
rifampin	O
,	O
resulted	O
in	O
a	O
reduction	O
of	O
systemic	O
exposure	O
of	O
apremilast	O
,	O
which	O
may	O
result	O
in	O
a	O
loss	O
of	O
efficacy	O
of	O
OTEZLA	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
LACTIC	B
ACIDOSIS/SEVERE	O
HEPATOMEGALY	B
WITH	O
STEATOSIS	B
and	O
POST	O
TREATMENT	O
ACUTE	B
EXACERBATION	I
OF	I
HEPATITIS	I
B	I
WARNING	O
:	O
LACTIC	B
ACIDOSIS/SEVERE	O
HEPATOMEGALY	B
WITH	O
STEATOSIS	B
and	O
POST	O
TREATMENT	O
ACUTE	B
EXACERBATION	I
OF	I
HEPATITIS	I
B	I
Lactic	B
acidosis	I
and	O
severe	O
hepatomegaly	B
with	O
steatosis	B
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
nucleoside	O
analogs	O
,	O
including	O
tenofovir	O
disoproxil	O
fumarate	O
,	O
a	O
component	O
of	O
STRIBILD	O
,	O
in	O
combination	O
with	O
other	O
antiretrovirals	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
At	O
48	O
weeks	O
,	O
the	O
rates	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
3	O
%	O
in	O
subjects	O
receiving	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
+	O
background	O
regimen	O
and	O
4	O
%	O
in	O
subjects	O
receiving	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
+	O
background	O
regimen	O
.	O
	
Some	O
patients	O
have	O
been	O
rechallenged	O
and	O
have	O
continued	O
to	O
receive	O
alglucosidase	O
alfa	O
under	O
close	O
clinical	O
supervision	O
.	O
	
Tell	O
your	O
healthcare	O
provider	O
about	O
all	O
the	O
medicines	O
you	O
take	O
,	O
including	O
prescription	O
and	O
over-the-counter	O
medicines	O
,	O
vitamins	O
,	O
and	O
herbal	O
supplements	O
.	O
	
d	O
Hypertension	B
includes	O
the	O
preferred	O
terms	O
of	O
hypertension	B
,	O
hypertensive	B
crisis	I
,	O
and	O
hypertensive	B
emergency	I
.	O
	
*	O
Immune-Mediated	B
Reactions	I
:	O
Monitor	O
patients	O
for	O
the	O
development	O
of	O
systemic	O
immune-mediated	O
reactions	O
involving	O
skin	O
and	O
other	O
organs	O
(	O
5.2	O
)	O
.	O
	
In	O
a	O
3-week	O
,	O
placebo-controlled	O
pediatric	O
trial	O
with	O
bipolar	O
I	O
disorder	O
,	O
transient	O
elevations	B
in	I
serum	I
transaminases	I
)	O
were	O
more	O
common	O
in	O
treated	O
patients	O
.	O
	
5.3	O
Impaired	O
Renal	O
Function	O
As	O
a	O
consequence	O
of	O
inhibiting	O
the	O
renin-angiotensin	O
system	O
,	O
changes	B
in	I
renal	I
function	I
may	O
be	O
anticipated	O
in	O
susceptible	O
individuals	O
treated	O
with	O
Edarbi	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
across	O
products	O
in	O
this	O
class	O
may	O
be	O
misleading	O
.	O
	
Controlled	O
Studies	O
with	O
Crohn	O
's	O
Disease	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
CIMZIA	O
at	O
400	O
mg	O
subcutaneous	O
dosing	O
in	O
studies	O
of	O
patients	O
with	O
Crohn	O
's	O
disease	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
e.g.	O
,	O
age	O
>	O
60	O
years	O
,	O
diabetes	O
mellitus	O
or	O
chronic	O
hypertension	O
)	O
,	O
estimate	O
the	O
GFR	O
through	O
laboratory	O
testing	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
INVOKANA	O
.	O
	
The	O
majority	O
of	O
patients	O
on	O
the	O
XALKORI	O
arms	O
in	O
Studies	O
1	O
and	O
2	O
(	O
>	O
50	O
%	O
)	O
reported	O
visual	B
disturbances	I
which	O
occurred	O
at	O
a	O
frequency	O
of	O
4-7	O
days	O
each	O
week	O
,	O
lasted	O
up	O
to	O
1	O
minute	O
,	O
and	O
had	O
mild	O
or	O
no	O
impact	O
(	O
scores	O
0	O
to	O
3	O
out	O
of	O
a	O
maximum	O
score	O
of	O
10	O
)	O
on	O
daily	O
activities	O
as	O
captured	O
in	O
the	O
VSAQ-ALK	O
questionnaire	O
.	O
	
5.8	O
Hypokalemia	O
and	O
Hyperglycemia	O
Beta2-agonist	O
medications	O
may	O
produce	O
significant	O
hypokalemia	B
in	O
some	O
patients	O
,	O
possibly	O
through	O
intracellular	O
shunting	O
,	O
which	O
has	O
the	O
potential	O
to	O
produce	O
adverse	B
cardiovascular	I
effects	I
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Twenty	O
percent	O
of	O
the	O
patients	O
experienced	O
an	O
increase	B
in	I
either	I
ALT	I
.	O
	
Other	O
ocular	O
adverse	O
reactions	O
occurring	O
in	O
1-5	O
%	O
of	O
subjects	O
included	O
reduced	B
visual	I
acuity	I
,	O
punctate	B
keratitis	I
,	O
eye	B
inflammation	I
,	O
and	O
iritis	B
.	O
	
5.8	O
Drug	O
Induced	O
Liver	O
Injury	O
Hepatic	O
effects	O
,	O
ranging	O
from	O
mild	O
to	O
moderate	O
elevations	B
in	I
transaminases	I
(	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
)	O
to	O
rare	O
cases	O
with	O
concomitant	O
elevations	B
of	I
total	I
bilirubin	I
(	O
>	O
2	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
)	O
have	O
been	O
reported	O
with	O
APTIOM	O
use	O
.	O
	
5.4	O
Bradycardia	O
Symptomatic	B
bradycardia	I
can	O
occur	O
in	O
patients	O
receiving	O
XALKORI	O
.	O
	
Patients	O
with	O
type	O
2	O
diabetes	O
may	O
have	O
fatty	O
liver	O
disease	O
,	O
which	O
may	O
cause	O
liver	O
test	O
abnormalities	O
,	O
and	O
they	O
may	O
also	O
have	O
other	O
forms	O
of	O
liver	O
disease	O
,	O
many	O
of	O
which	O
can	O
be	O
treated	O
or	O
managed	O
.	O
	
In	O
clinical	O
trials	O
,	O
40	O
%	O
of	O
TECFIDERA	O
treated	O
patients	O
experienced	O
flushing	B
.	O
	
Cases	O
of	O
progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
*	O
Second	B
Primary	I
Malignancies	I
:	O
Other	O
malignancies	B
have	O
occurred	O
in	O
patients	O
,	O
including	O
skin	B
cancers	I
,	O
and	O
other	O
carcinomas	B
(	O
5.5	O
)	O
.	O
	
Therefore	O
,	O
administration	O
of	O
higher	O
than	O
the	O
recommended	O
doses	O
or	O
more	O
frequent	O
dosing	O
of	O
NULOJIX	O
is	O
not	O
recommended	O
.	O
	
Across	O
the	O
clinical	O
program	O
,	O
serious	O
anaphylactic	B
reactions	I
and	O
severe	O
cutaneous	B
adverse	I
reactions	I
and	O
angioedema	B
were	O
reported	O
in	O
0.2	O
%	O
of	O
comparator-treated	O
patients	O
and	O
0.3	O
%	O
of	O
FARXIGA-treated	O
patients	O
.	O
	
Comparison	O
of	O
Gender	O
,	O
Age	O
,	O
and	O
Race	O
The	O
overall	O
adverse	O
reaction	O
profile	O
of	O
POTIGA	O
was	O
similar	O
for	O
females	O
and	O
males	O
.	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
who	O
develop	O
RPLS	O
.	O
	
YERVOY	O
can	O
result	O
in	O
severe	O
and	O
fatal	B
immune-mediated	B
adverse	I
reactions	I
due	O
to	O
T-cell	O
activation	O
and	O
proliferation	O
.	O
	
(	O
5.2	O
)	O
Nutritional	O
Management	O
:	O
In	O
the	O
initial	O
treatment	O
of	O
NAGS	O
deficiency	O
,	O
protein	O
restriction	O
is	O
recommended	O
.	O
	
(	O
B	O
)	O
SPINAL/EPIDURAL	O
HEMATOMAspinal	O
hematomas	B
may	O
occur	O
in	O
patients	O
treated	O
with	O
PRADAXA	O
who	O
are	O
receiving	O
neuraxial	O
anesthesia	O
or	O
undergoing	O
spinal	O
puncture	O
.	O
	
The	O
adverse	O
reactions	O
reported	O
most	O
frequently	O
as	O
the	O
reason	O
for	O
discontinuation	O
of	O
treatment	O
included	O
anemia	B
,	O
febrile	B
neutropenia	I
,	O
fatigue	B
,	O
and	O
multi-organ	B
failure	I
.	O
	
Women	O
with	O
uncontrolled	O
hypertension	O
or	O
hypertension	O
with	O
vascular	O
disease	O
should	O
not	O
use	O
COCs	O
.	O
	
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Neutropenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
In	O
replicate	O
12-month	O
trials	O
in	O
3,255	O
subjects	O
with	O
COPD	O
who	O
had	O
experienced	O
a	O
COPD	O
exacerbation	O
in	O
the	O
previous	O
year	O
,	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
pneumonia	B
reported	O
in	O
subjects	O
receiving	O
fluticasone	O
furoate/vilanterol	O
50	O
mcg/25	O
mcg	O
:	O
6	O
%	O
(	O
48	O
of	O
820	O
subjects	O
)	O
;	O
BREO	O
ELLIPTA	O
100/25	O
:	O
6	O
%	O
(	O
51	O
of	O
806	O
subjects	O
)	O
;	O
or	O
BREO	O
ELLIPTA	O
200/25	O
:	O
7	O
%	O
(	O
55	O
of	O
811	O
subjects	O
)	O
than	O
in	O
subjects	O
receiving	O
vilanterol	O
25	O
mcg	O
:	O
3	O
%	O
(	O
27	O
of	O
818	O
subjects	O
)	O
.	O
	
of	O
at	O
least	O
Moderate	O
IntensityIntensities	O
are	O
defined	O
as	O
follows	O
:	O
Moderate	O
(	O
discomfort	O
enough	O
to	O
cause	O
interference	O
with	O
usual	O
activity	O
)	O
;	O
Severe	O
(	O
incapacitating	O
with	O
inability	O
to	O
work	O
or	O
do	O
usual	O
activity	O
)	O
.	O
	
Errors	O
may	O
also	O
occur	O
due	O
to	O
motion	O
artifacts	O
that	O
result	O
in	O
image	O
distortion	O
.	O
	
In	O
addition	O
,	O
patients	O
should	O
be	O
observed	O
for	O
signs	O
and	O
symptoms	O
of	O
adrenal	O
insufficiency	O
,	O
such	O
as	O
fatigue	O
,	O
lassitude	O
,	O
weakness	O
,	O
nausea	O
and	O
vomiting	O
,	O
and	O
hypotension	O
.	O
	
c	O
Includes	O
:	O
injection	B
site	I
pain	I
,	O
penile	B
pain	I
,	O
and	O
injection	B
site	I
discomfort	I
.	O
	
5.5	O
Tumor	O
Lysis	O
Syndrome	O
Patients	O
with	O
rapidly	O
proliferating	O
tumor	O
and	O
high	O
tumor	O
burden	O
may	O
be	O
at	O
increased	O
risk	O
of	O
tumor	B
lysis	I
syndrome	I
.	O
	
Discontinue	O
BREO	O
ELLIPTA	O
if	O
such	O
reactions	O
occur	O
.	O
	
The	O
treatment	O
emergent	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
of	O
at	O
least	O
2	O
patients	O
treated	O
with	O
AMPYRA	O
and	O
that	O
led	O
to	O
discontinuation	O
more	O
frequently	O
compared	O
to	O
placebo	O
were	O
headache	B
(	O
AMPYRA	O
0.5	O
%	O
,	O
placebo	O
0	O
%	O
)	O
,	O
balance	B
disorder	I
(	O
AMPYRA	O
0.5	O
%	O
,	O
placebo	O
0	O
%	O
)	O
,	O
dizziness	B
(	O
AMPYRA	O
0.5	O
%	O
,	O
placebo	O
0	O
%	O
)	O
,	O
and	O
confusional	B
state	I
(	O
AMPYRA	O
0.3	O
%	O
,	O
placebo	O
0	O
%	O
)	O
.	O
	
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
in	O
greater	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Clostridium	B
difficile	I
-Associated	I
diarrhea	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Direct	B
Coombs	I
'	I
Test	I
Seroconversion	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
>	O
2	O
%	O
of	O
patients	O
are	O
diarrhea	B
,	O
nausea	B
,	O
and	O
rash	B
.	O
	
Thirty-nine	O
subjects	O
(	O
35	O
%	O
)	O
had	O
dose	O
interruptions	O
and	O
sixteen	O
subjects	O
(	O
15	O
%	O
)	O
had	O
dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
or	O
laboratory	O
abnormalities	O
.	O
	
Across	O
these	O
13	O
studies	O
,	O
2360	O
patients	O
were	O
treated	O
once	O
daily	O
with	O
FARXIGA	O
10	O
mg	O
for	O
a	O
mean	O
duration	O
of	O
exposure	O
of	O
22	O
weeks	O
.	O
	
For	O
these	O
reasons	O
,	O
the	O
incidence	O
of	O
antibodies	O
to	O
dulaglutide	O
can	O
not	O
be	O
directly	O
compared	O
with	O
the	O
incidence	O
of	O
antibodies	O
of	O
other	O
products	O
.	O
	
nasopharyngitis	B
,	O
laryngitis	B
,	O
viral	B
infection	I
)	O
in	O
20	O
%	O
of	O
CIMZIA-treated	O
patients	O
and	O
13	O
%	O
of	O
placebo-treated	O
patients	O
,	O
urinary	B
tract	I
infections	I
(	O
e.g	O
.	O
	
Grade	O
3-4	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
which	O
occurred	O
in	O
>	O
=	O
5	O
%	O
of	O
COMETRIQ-treated	O
patients	O
occurring	O
more	O
frequently	O
in	O
the	O
COMETRIQ	O
arm	O
with	O
a	O
between-arm	O
difference	O
of	O
>	O
=	O
2	O
%	O
included	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
;	O
diarrhea	B
,	O
PPES	B
,	O
lymphopenia	B
,	O
hypocalcemia	B
,	O
fatigue	B
,	O
hypertension	B
,	O
asthenia	B
,	O
increased	B
ALT	I
,	O
decreased	B
weight	I
,	O
stomatitis	B
,	O
and	O
decreased	B
appetite	I
(	O
see	O
Table	O
1	O
,	O
Table	O
2	O
)	O
.	O
	
(	O
5.8	O
)	O
5.1	O
Suicidal	O
Behavior	O
and	O
Ideation	O
Antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
including	O
APTIOM	O
,	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
patients	O
taking	O
these	O
drugs	O
for	O
any	O
indication	O
.	O
	
Therefore	O
,	O
remove	O
Qutenza	O
patches	O
gently	O
and	O
slowly	O
by	O
rolling	O
the	O
adhesive	O
side	O
inward	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Of	O
this	O
total	O
,	O
782	O
received	O
Toviaz	O
4	O
mg/day	O
,	O
and	O
785	O
received	O
Toviaz	O
8	O
mg/day	O
in	O
Phase	O
2	O
or	O
3	O
studies	O
with	O
treatment	O
periods	O
of	O
8	O
or	O
12	O
weeks	O
.	O
	
If	O
skin	O
not	O
intended	O
to	O
be	O
treated	O
comes	O
into	O
contact	O
with	O
Qutenza	O
,	O
apply	O
Cleansing	O
Gel	O
and	O
then	O
wipe	O
off	O
with	O
dry	O
gauze	O
.	O
	
Among	O
patients	O
treated	O
with	O
Qutenza	O
,	O
1	O
%	O
discontinued	O
prematurely	O
due	O
to	O
an	O
adverse	O
event	O
.	O
	
6.2	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rate	O
observed	O
in	O
practice	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
If	O
the	O
following	O
occur	O
,	O
discontinue	O
ERWINAZE	O
:	O
Serious	O
hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
(	O
5.1	O
)	O
Severe	O
or	O
pancreatitis	B
(	O
5.2	O
)	O
*	O
Glucose	B
intolerance	I
can	O
occur	O
and	O
,	O
in	O
some	O
cases	O
,	O
may	O
be	O
irreversible	O
.	O
	
For	O
persistent	O
hypertension	O
despite	O
use	O
of	O
anti-hypertensive	O
medications	O
,	O
reduce	O
the	O
INLYTA	O
dose	O
.	O
	
The	O
diagnosis	O
of	O
probable	O
PML	B
was	O
based	O
on	O
MRI	O
findings	O
and	O
the	O
detection	O
of	O
JCV	B
DNA	I
in	I
the	I
CSF	I
in	O
the	O
absence	O
of	O
clinical	O
signs	O
or	O
symptoms	O
specific	O
to	O
PML	B
.	O
	
(	O
5.3	O
)	O
*	O
Pulmonary	B
Toxicity	I
:	O
including	O
Acute	B
Respiratory	I
Distress	I
Syndrome	I
,	O
acute	B
respiratory	I
failure	I
,	O
and	O
acute	B
diffuse	I
infiltrative	I
pulmonary	I
disease	I
:	O
Withhold	O
Kyprolis	O
and	O
evaluate	O
promptly	O
(	O
5.4	O
)	O
*	O
Pulmonary	B
Hypertension	I
:	O
Withhold	O
Kyprolis	O
and	O
evaluate	O
(	O
5.5	O
)	O
*	O
Dyspnea	B
:	O
For	O
severe	O
or	O
life	O
threatening	O
dyspnea	O
,	O
withhold	O
Kyprolis	O
and	O
evaluate	O
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
related	O
to	O
spread	B
of	I
toxin	I
effects	I
.	O
	
For	O
this	O
same	O
group	O
of	O
AFINITOR-treated	O
females	O
,	O
the	O
following	O
menstrual	B
abnormalities	I
were	O
reported	O
:	O
dysmenorrhea	B
(	O
6	O
%	O
)	O
,	O
menorrhagia	B
(	O
6	O
%	O
)	O
,	O
metrorrhagia	B
(	O
6	O
%	O
)	O
,	O
and	O
unspecified	B
menstrual	I
irregularity	I
(	O
6	O
%	O
)	O
.	O
	
5.4	O
Immune	O
Reconstitution	O
Syndrome	O
Immune	B
reconstitution	I
syndrome	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
,	O
including	O
TIVICAY	O
.	O
	
5.4	O
Pulmonary	O
Toxicity	O
Acute	B
Respiratory	I
Distress	I
Syndrome	I
(	O
ARDS	B
)	O
,	O
acute	B
respiratory	I
failure	I
,	O
and	O
acute	B
diffuse	I
infiltrative	I
pulmonary	I
disease	I
such	O
as	O
pneumonitis	B
and	O
interstitial	B
lung	I
disease	I
have	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
receiving	O
Kyprolis	O
.	O
	
If	O
this	O
product	O
is	O
to	O
be	O
given	O
to	O
a	O
patient	O
with	O
a	O
cephalosporin	O
,	O
penicillin	O
,	O
or	O
other	O
beta-lactam	O
allergy	O
,	O
exercise	O
caution	O
because	O
cross	O
sensitivity	O
has	O
been	O
established	O
.	O
	
5.13	O
Posterior	O
Reversible	O
Encephalopathy	O
Syndrome	O
(	O
PRES	O
)	O
Cases	O
of	O
PRES	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
Kyprolis	O
.	O
	
The	O
safety	O
data	O
described	O
below	O
are	O
based	O
on	O
the	O
confirmatory	O
6-	O
and	O
12-month	O
trials	O
.	O
	
(	O
B	O
)	O
SPINAL/EPIDURAL	O
HEMATOMA	O
spinal	B
hematomas	I
may	O
occur	O
in	O
patients	O
treated	O
with	O
ELIQUIS	O
who	O
are	O
receiving	O
neuraxial	O
anesthesia	O
or	O
undergoing	O
spinal	O
puncture	O
.	O
	
Data	O
in	O
Table	O
1	O
are	O
for	O
all	O
AEs	O
for	O
all	O
CAPS	O
patients	O
receiving	O
canakinumab	O
.	O
	
In	O
Study	O
2	O
only	O
VORAXAZE-related	O
adverse	O
reactions	O
were	O
collected	O
and	O
severity	O
was	O
graded	O
according	O
to	O
NCI	O
CTCAE	O
version	O
3	O
.	O
	
The	O
significance	O
of	O
these	O
findings	O
and	O
the	O
effect	O
of	O
long-term	O
treatment	O
with	O
Prolia	O
are	O
unknown	O
.	O
	
Localized	O
and	O
systemic	O
infections	O
,	O
including	O
pneumonia	B
,	O
mycobacterial	B
infections	I
,	O
other	O
bacterial	B
infections	I
,	O
invasive	B
fungal	I
infections	I
,	O
such	O
as	O
aspergillosis	B
,	O
candidiasis	B
,	O
or	O
pneumocystis	B
jiroveci	I
pneumonia	I
(	O
PJP	B
)	O
and	O
viral	B
infections	I
including	O
reactivation	B
of	I
hepatitis	I
B	I
virus	I
have	O
occurred	O
in	O
patients	O
taking	O
AFINITOR	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
Picato	O
(	O
r	O
)	O
(	O
ingenol	O
mebutate	O
)	O
gel	O
,	O
0.015	O
%	O
and	O
0.05	O
%	O
:	O
hypersensitivity	B
,	O
allergic	B
contact	I
dermatitis	I
,	O
herpes	B
zoster	I
,	O
chemical	B
conjunctivitis	I
,	O
and	O
corneal	B
burn	I
.	O
	
Advise	O
patients	O
to	O
report	O
promptly	O
any	O
new	O
or	O
worsening	O
respiratory	O
symptoms	O
.	O
	
(	O
5.1	O
)	O
*	O
Acute	B
hypersensitivity	I
reactions	I
(	O
angioedema	B
,	O
dyspnea	B
,	O
pruritus	B
,	O
and	O
rash	B
)	O
have	O
been	O
reported	O
.	O
	
The	O
immunogenicity	O
of	O
EYLEA	O
was	O
evaluated	O
in	O
serum	O
samples	O
.	O
	
A	O
causal	O
relationship	O
with	O
ULORIC	O
has	O
not	O
been	O
established	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
the	O
postmarketing	O
use	O
of	O
EOVIST	O
.	O
	
A	O
total	O
of	O
58	O
patient	O
samples	O
that	O
were	O
either	O
transiently	O
or	O
persistently	O
positive	O
for	O
anti-brentuximab	O
vedotin	O
antibodies	O
were	O
tested	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
.	O
	
Should	O
any	O
of	O
these	O
occur	O
or	O
be	O
suspected	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
immediately	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
treatment	O
should	O
be	O
considered	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
:	O
*	O
with	O
chronic	O
or	O
recurrent	O
infection	O
*	O
who	O
have	O
been	O
exposed	O
to	O
tuberculosis	O
*	O
with	O
a	O
history	O
of	O
an	O
opportunistic	O
infection	O
*	O
who	O
have	O
resided	O
or	O
traveled	O
in	O
areas	O
of	O
endemic	O
tuberculosis	O
or	O
endemic	O
mycoses	O
,	O
such	O
as	O
histoplasmosis	O
,	O
coccidioidomycosis	O
,	O
or	O
blastomycosis	O
*	O
with	O
underlying	O
conditions	O
that	O
may	O
predispose	O
them	O
to	O
infection	O
Tuberculosis	O
Cases	O
of	O
reactivation	B
of	I
tuberculosis	I
or	O
new	O
tuberculosis	B
infections	I
have	O
been	O
observed	O
in	O
patients	O
receiving	O
CIMZIA	O
,	O
including	O
patients	O
who	O
have	O
previously	O
received	O
treatment	O
for	O
latent	O
or	O
active	O
tuberculosis	O
.	O
	
CDAD	O
must	O
be	O
considered	O
in	O
all	O
patients	O
who	O
present	O
with	O
diarrhea	O
following	O
antibacterial	O
use	O
.	O
	
5.2	O
Anemia	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
Anemia	B
has	O
been	O
reported	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
therapy	O
.	O
	
In	O
addition	O
to	O
the	O
adverse	O
reactions	O
presented	O
in	O
Table	O
1	O
,	O
dizziness	B
was	O
reported	O
in	O
more	O
than	O
1	O
%	O
of	O
ULORIC-treated	O
subjects	O
although	O
not	O
at	O
a	O
rate	O
more	O
than	O
0.5	O
%	O
greater	O
than	O
placebo	O
.	O
	
The	O
values	O
did	O
not	O
exceed	O
more	O
than	O
3	O
times	O
the	O
baseline	O
values	O
and	O
returned	O
to	O
baseline	O
within	O
1	O
to	O
4	O
days	O
.	O
	
The	O
risk	O
of	O
portal	B
venous	I
thrombosis	I
was	O
increased	O
in	O
thrombocytopenic	O
patients	O
with	O
chronic	O
liver	O
disease	O
treated	O
with	O
75	O
mg	O
of	O
PROMACTA	O
once	O
daily	O
for	O
2	O
weeks	O
in	O
preparation	O
for	O
invasive	O
procedures	O
.	O
	
The	O
incidence	O
of	O
adverse	O
events	O
resulting	O
in	O
permanent	O
discontinuation	O
of	O
study	O
medication	O
in	O
Trial	O
1	O
was	O
3	O
%	O
for	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
3	O
%	O
for	O
patients	O
treated	O
with	O
dacarbazine	O
.	O
	
Serious	O
infections	B
(	O
e.g.	O
,	O
pneumonia	B
,	O
varicella	B
,	O
gastroenteritis	B
,	O
measles	B
,	O
sepsis	B
,	O
otitis	B
media	I
,	O
sinusitis	B
,	O
adenovirus	B
,	O
lymph	B
node	I
abscess	I
,	O
pharyngitis	B
)	O
were	O
observed	O
in	O
approximately	O
4	O
%	O
to	O
5	O
%	O
(	O
0.02	O
to	O
0.17	O
per	O
100	O
patient-days	O
)	O
of	O
patients	O
receiving	O
ILARIS	O
in	O
both	O
studies	O
.	O
	
5.4	O
Use	O
in	O
Children	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
should	O
only	O
be	O
used	O
on	O
children	O
(	O
6	O
months	O
of	O
age	O
and	O
older	O
)	O
under	O
the	O
direct	O
supervision	O
of	O
an	O
adult	O
.	O
	
Common	O
adverse	O
reactions	O
in	O
placebo-controlled	O
MDD	O
studies	O
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
in	O
PRISTIQ	O
treated	O
MDD	O
patients	O
in	O
pre-marketing	O
pooled	O
8-week	O
,	O
placebo-controlled	O
,	O
fixed-dose	O
studies	O
(	O
incidence	O
>	O
=	O
5	O
%	O
and	O
at	O
least	O
twice	O
the	O
rate	O
of	O
placebo	O
in	O
the	O
50	O
or	O
100	O
mg	O
dose	O
groups	O
)	O
were	O
:	O
nausea	B
,	O
dizziness	B
,	O
insomnia	B
,	O
hyperhidrosis	B
,	O
constipation	B
,	O
somnolence	B
,	O
decreased	B
appetite	I
,	O
anxiety	B
,	O
and	O
specific	O
male	B
sexual	I
function	I
disorders	I
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
DIFICID	O
should	O
not	O
be	O
used	O
for	O
systemic	O
infections	O
.	O
	
Opportunistic	O
infections	O
such	O
as	O
pneumocystis	O
jiroveci	O
pneumonia	O
(	O
PJP	O
)	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
.	O
	
5.2	O
Infections	O
AFINITOR	O
has	O
immunosuppressive	O
properties	O
and	O
may	O
predispose	O
patients	O
to	O
protozoal	B
infections	I
,	O
including	O
infections	B
with	I
opportunistic	I
pathogens	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
The	O
physician	O
responsible	O
for	O
the	O
maintenance	O
therapy	O
should	O
have	O
complete	O
information	O
requisite	O
for	O
the	O
follow-up	O
of	O
the	O
patient	O
[	O
see	O
Boxed	O
Warning	O
]	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
paralysis	I
.	O
	
5.2	O
Impairment	O
in	O
Renal	O
Function	O
JARDIANCE	O
increases	B
serum	I
creatinine	I
and	O
decreases	B
eGFR	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Macular	B
edema	I
generally	O
partially	O
or	O
completely	O
resolved	O
with	O
or	O
without	O
treatment	O
after	O
drug	O
discontinuation	O
.	O
	
Consider	O
whether	O
to	O
restart	O
Kyprolis	O
based	O
on	O
a	O
benefit/risk	O
assessment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
Observe	O
patients	O
carefully	O
when	O
the	O
dosage	O
of	O
NORTHERA	O
is	O
changed	O
or	O
when	O
concomitant	O
levodopa	O
is	O
reduced	O
abruptly	O
or	O
discontinued	O
,	O
especially	O
if	O
the	O
patient	O
is	O
receiving	O
neuroleptics	O
.	O
	
Periodic	O
skin	O
examination	O
is	O
recommended	O
for	O
all	O
patients	O
,	O
particularly	O
those	O
with	O
risk	O
factors	O
for	O
skin	O
cancer	O
.	O
	
Other	O
adverse	O
reactions	O
involving	O
the	O
female	O
reproductive	O
system	O
were	O
menorrhagia	B
(	O
10	O
%	O
)	O
,	O
menstrual	B
irregularities	I
(	O
10	O
%	O
)	O
,	O
and	O
vaginal	B
hemorrhage	I
(	O
8	O
%	O
)	O
.	O
	
The	O
management	O
of	O
this	O
syndrome	O
should	O
include	O
:	O
(	O
1	O
)	O
immediate	O
discontinuation	O
of	O
the	O
antipsychotic	O
drugs	O
and	O
other	O
drugs	O
not	O
essential	O
to	O
concurrent	O
therapy	O
,	O
(	O
2	O
)	O
intensive	O
symptomatic	O
treatment	O
and	O
medical	O
monitoring	O
,	O
and	O
(	O
3	O
)	O
treatment	O
of	O
any	O
concomitant	O
serious	O
medical	O
problems	O
for	O
which	O
specific	O
treatments	O
are	O
available	O
.	O
	
(	O
2.1	O
,	O
5.9	O
)	O
*	O
Thrombocytopenia	B
:	O
Monitor	O
platelet	O
counts	O
;	O
interrupt	O
or	O
reduce	O
Kyprolis	O
dosing	O
as	O
clinically	O
indicated	O
.	O
	
5.8	O
Increases	O
in	O
Low-Density	O
Lipoprotein	O
(	O
LDL-C	O
)	O
Dose-related	O
increases	B
in	I
LDL-C	I
occur	O
with	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
stated	O
frequencies	O
of	O
adverse	O
reactions	O
represent	O
the	O
proportion	O
of	O
individuals	O
who	O
experienced	O
a	O
treatment-emergent	O
adverse	O
event	O
of	O
the	O
type	O
listed	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reaction	O
reported	O
in	O
2	O
%	O
of	O
patients	O
treated	O
with	O
Besivance	O
was	O
conjunctival	B
redness	I
.	O
	
All	O
women	O
were	O
instructed	O
to	O
take	O
at	O
least	O
1000	O
mg	O
of	O
calcium	O
and	O
400	O
IU	O
of	O
vitamin	O
D	O
supplementation	O
per	O
day	O
.	O
	
Pediatric	O
Patients	O
:	O
Data	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
trial	O
in	O
pediatric	O
patients	O
with	O
bipolar	O
I	O
disorder	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
Given	O
these	O
confounders	O
,	O
the	O
relationship	O
between	O
atypical	O
antipsychotic	O
use	O
and	O
hyperglycemia-related	O
adverse	O
reactions	O
is	O
not	O
completely	O
understood	O
.	O
	
Therefore	O
,	O
a	O
RANKL	O
inhibitor	O
such	O
as	O
Prolia	O
may	O
increase	O
the	O
risk	O
of	O
infection	B
.	O
	
If	O
irritation	O
of	O
eyes	O
or	O
airways	O
occurs	O
,	O
remove	O
the	O
affected	O
individual	O
from	O
the	O
vicinity	O
of	O
Qutenza	O
.	O
	
The	O
adverse	O
event	O
information	O
from	O
clinical	O
trials	O
does	O
,	O
however	O
,	O
provide	O
a	O
basis	O
for	O
identifying	O
the	O
adverse	O
events	O
that	O
appear	O
to	O
be	O
related	O
to	O
drug	O
use	O
and	O
for	O
approximating	O
rates	O
.	O
	
In	O
two	O
clinical	O
trials	O
,	O
1227	O
subjects	O
were	O
treated	O
with	O
JUBLIA	O
,	O
1161	O
for	O
at	O
least	O
24	O
weeks	O
and	O
780	O
for	O
48	O
weeks	O
.	O
	
Ask	O
patients	O
about	O
symptoms	O
suggestive	O
of	O
infusion	O
reactions	O
after	O
their	O
first	O
cycle	O
of	O
therapy	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatic	B
effects	I
:	O
Postmarketing	O
reports	O
of	O
hepatic	B
failure	I
,	O
sometimes	O
fatal	B
.	O
	
5.1	O
Risk	O
of	O
Thyroid	O
C-cell	O
Tumors	O
In	O
male	O
and	O
female	O
rats	O
,	O
dulaglutide	O
causes	O
a	O
dose-related	O
and	O
treatment-duration-dependent	O
increase	O
in	O
the	O
incidence	O
of	O
thyroid	B
C-cell	I
tumors	I
)	O
after	O
lifetime	O
exposure	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
In	O
double-blind	O
placebo-controlled	O
short-term	O
studies	O
,	O
where	O
the	O
dose	O
was	O
increased	O
slowly	O
,	O
as	O
recommended	O
above	O
,	O
syncope	B
was	O
reported	O
in	O
0.4	O
%	O
(	O
5/1344	O
)	O
of	O
patients	O
treated	O
with	O
FANAPT	O
,	O
compared	O
with	O
0.2	O
%	O
(	O
1/587	O
)	O
on	O
placebo	O
.	O
	
Data	O
from	O
a	O
4-week	O
,	O
fixed-dose	O
study	O
in	O
adult	O
subjects	O
with	O
schizophrenia	O
,	O
in	O
which	O
fasting	O
blood	O
samples	O
were	O
drawn	O
,	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
This	O
pool	O
combined	O
13	O
placebo-controlled	O
studies	O
,	O
including	O
3	O
monotherapy	O
studies	O
,	O
9	O
add-on	O
to	O
background	O
antidiabetic	O
therapy	O
studies	O
,	O
and	O
an	O
initial	O
combination	O
with	O
metformin	O
study	O
.	O
	
Infections	B
not	O
meeting	O
these	O
criteria	O
are	O
considered	O
non-serious	O
.	O
	
Hypersensitivity	O
Systemic	B
hypersensitivity	I
adverse	O
reactions	O
sometimes	O
severe	O
(	O
e.g.	O
,	O
severe	O
urticaria	B
,	O
systemic	B
rash	I
,	O
facial	B
edema	I
,	O
lip	B
swelling	I
)	O
occurred	O
in	O
0.5	O
%	O
of	O
patients	O
on	O
TRULICITY	O
in	O
the	O
four	O
Phase	O
2	O
and	O
five	O
Phase	O
3	O
studies	O
.	O
	
(	O
5.6	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
to	O
Zydelig	O
was	O
5	O
months	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
that	O
led	O
to	O
treatment	O
discontinuations	O
were	O
hepatotoxicity	B
and	O
diarrhea/colitis	O
.	O
	
Clevidipine	O
was	O
evaluated	O
in	O
15	O
studies	O
in	O
hypertensive	O
patients	O
:	O
1099	O
patients	O
with	O
perioperative	O
hypertension	O
,	O
126	O
with	O
severe	O
hypertension	O
and	O
82	O
patients	O
with	O
essential	O
hypertension	O
.	O
	
b	O
Includes	O
:	O
injection	B
site	I
swelling	I
,	O
penile	B
edema	I
,	O
penile	B
swelling	I
,	O
local	B
swelling	I
,	O
scrotal	B
swelling	I
,	O
and	O
injection	B
site	I
edema	I
.	O
	
Transfer	O
of	O
patients	O
from	O
systemic	O
corticosteroid	O
therapy	O
to	O
BREO	O
ELLIPTA	O
may	O
unmask	O
allergic	O
conditions	O
previously	O
suppressed	O
by	O
the	O
systemic	O
corticosteroid	O
therapy	O
(	O
e.g.	O
,	O
rhinitis	O
,	O
conjunctivitis	O
,	O
eczema	O
,	O
arthritis	O
,	O
eosinophilic	O
conditions	O
)	O
.	O
	
The	O
most	O
frequent	O
adverse	O
drug	O
reactions	O
that	O
led	O
to	O
discontinuation	O
in	O
1	O
%	O
or	O
more	O
of	O
patients	O
in	O
Study	O
1	O
were	O
pneumonia	B
,	O
ILD/pneumonitis	O
,	O
and	O
decreased	B
appetite	I
.	O
	
Pool	O
of	O
12	O
Placebo-Controlled	O
Studies	O
for	O
FARXIGA	O
5	O
and	O
10	O
mg	O
The	O
data	O
in	O
Table	O
1	O
is	O
derived	O
from	O
12	O
placebo-controlled	O
studies	O
ranging	O
from	O
12	O
to	O
24	O
weeks	O
.	O
	
At	O
three	O
years	O
after	O
transplantation	O
,	O
systolic	O
blood	O
pressures	O
were	O
6	O
mmHg	O
lower	O
and	O
diastolic	O
blood	O
pressures	O
were	O
3	O
mmHg	O
lower	O
in	O
NULOJIX-treated	O
patients	O
compared	O
to	O
cyclosporine-treated	O
patients	O
.	O
	
The	O
safety	O
of	O
ZYTIGA	O
in	O
patients	O
with	O
LVEF	O
<	O
50	O
%	O
or	O
NYHA	O
Class	O
III	O
or	O
IV	O
heart	O
failure	O
in	O
Study	O
1	O
or	O
LVEF	O
<	O
50	O
%	O
or	O
NYHA	O
Class	O
II	O
to	O
IV	O
heart	O
failure	O
in	O
Study	O
2	O
was	O
not	O
established	O
.	O
	
Lung	O
function	O
(	O
FEV1or	O
peak	O
expiratory	O
flow	O
)	O
,	O
beta-agonist	O
use	O
,	O
and	O
COPD	O
or	O
asthma	O
symptoms	O
should	O
be	O
carefully	O
monitored	O
during	O
withdrawal	O
of	O
oral	O
corticosteroids	O
.	O
	
No	O
fractures	B
occurred	O
in	O
the	O
placebo	O
group	O
,	O
5	O
occurred	O
in	O
the	O
FARXIGA	O
5	O
mg	O
group	O
,	O
and	O
8	O
occurred	O
in	O
the	O
FARXIGA	O
10	O
mg	O
group	O
.	O
	
A	O
total	O
of	O
4814	O
patients	O
were	O
evaluated	O
for	O
safety	O
when	O
treated	O
with	O
Edarbi	O
at	O
doses	O
of	O
20	O
,	O
40	O
,	O
or	O
80	O
mg	O
in	O
clinical	O
trials	O
.	O
	
5.3	O
Delayed	O
Healing	O
The	O
use	O
of	O
steroids	O
after	O
cataract	O
surgery	O
may	O
delay	B
healing	I
and	O
increase	B
the	I
incidence	I
of	I
bleb	I
formation	I
.	O
	
Table	O
2	O
.	O
	
Discontinuations	O
due	O
to	O
elevated	B
hepatic	I
transaminases	I
were	O
<	O
1	O
%	O
and	O
were	O
similar	O
in	O
patients	O
treated	O
with	O
TECFIDERA	O
or	O
placebo	O
.	O
	
Approximately	O
five	O
percent	O
of	O
patients	O
receiving	O
IMBRUVICA	O
in	O
Study	O
1	O
and	O
Study	O
2	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
events	O
.	O
	
5.2	O
Progressive	O
Multifocal	O
Leukoencephalopathy	O
A	O
fatal	B
case	O
of	O
progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
occurred	O
in	O
a	O
patient	O
with	O
MS	O
who	O
received	O
TECFIDERA	O
for	O
4	O
years	O
while	O
enrolled	O
in	O
a	O
clinical	O
trial	O
.	O
	
Patients	O
receiving	O
SAPHRIS	O
should	O
receive	O
regular	O
monitoring	O
of	O
weight	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
The	O
majority	O
of	O
patients	O
(	O
78	O
%	O
)	O
were	O
non-Hispanic	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
dose	O
reduction	O
in	O
these	O
patients	O
were	O
nausea	B
(	O
1.8	O
%	O
)	O
and	O
elevated	B
transaminases	I
(	O
1.8	O
%	O
)	O
.	O
	
Opioids	O
may	O
affect	O
the	O
ability	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
or	O
operating	O
machinery	O
.	O
	
In	O
the	O
open-label	O
Study	O
3	O
,	O
6.9	O
%	O
(	O
16/233	O
)	O
subjects	O
died	B
.	O
	
Among	O
patients	O
with	O
moderate	O
renal	O
impairment	O
,	O
approximately	O
84	O
%	O
were	O
taking	O
medications	O
that	O
interfere	O
with	O
potassium	O
excretion	O
,	O
such	O
as	O
potassium-sparing	O
diuretics	O
,	O
angiotensin-converting-enzyme	O
inhibitors	O
,	O
and	O
angiotensin-receptor	O
blockers	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
and	O
5.3	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Precise	O
risk	O
estimates	O
for	O
hyperglycemia-related	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
are	O
not	O
available	O
.	O
	
(	O
5.6	O
)	O
*	O
Hypertension	B
including	O
hypertensive	B
crisis	I
:	O
Monitor	O
blood	O
pressure	O
regularly	O
.	O
	
(	O
5.2,5.3	O
)	O
*	O
Hemorrhagic	B
events	I
,	O
including	O
fatal	B
events	O
,	O
have	O
been	O
reported	O
.	O
	
Withhold	O
Kyprolis	O
if	O
suspected	O
.	O
	
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
less	O
than	O
10	O
%	O
of	O
AFINITOR-treated	O
patients	O
:	O
nausea	B
(	O
8	O
%	O
)	O
,	O
pain	B
in	I
extremity	I
(	O
8	O
%	O
)	O
,	O
insomnia	B
(	O
6	O
%	O
)	O
,	O
pneumonia	B
(	O
6	O
%	O
)	O
,	O
epistaxis	B
(	O
5	O
%	O
)	O
,	O
hypersensitivity	B
(	O
3	O
%	O
)	O
,	O
increased	B
blood	I
luteinizing	I
hormone	I
(	I
LH	I
)	I
levels	I
(	O
1	O
%	O
)	O
and	O
pneumonitis	B
(	O
1	O
%	O
)	O
.	O
	
These	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
and	O
breathing	B
difficulties	I
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
2	O
%	O
)	O
were	O
stomatitis	B
and	O
amenorrhea	B
.	O
	
Six	O
out	O
of	O
107	O
(	O
6	O
%	O
)	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
events	O
compared	O
with	O
12	O
of	O
the	O
95	O
(	O
13	O
%	O
)	O
patients	O
who	O
received	O
placebo	O
.	O
	
FANAPT	O
should	O
also	O
be	O
avoided	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
and	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiac	O
arrhythmias	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
these	O
three	O
12	O
week	O
studies	O
in	O
<	O
2	O
%	O
of	O
patients	O
treated	O
with	O
600	O
mg	O
of	O
HORIZANT	O
and	O
numerically	O
greater	O
than	O
placebo	O
were	O
balance	B
disorder	I
,	O
blurred	B
vision	I
,	O
disorientation	B
,	O
feeling	B
drunk	I
,	O
lethargy	B
,	O
and	O
vertigo	B
.	O
	
Psoriasis	O
:	O
During	O
the	O
0	O
to	O
16	O
week	O
placebo-controlled	O
period	O
of	O
the	O
3	O
controlled	O
clinical	O
trials	O
,	O
1.3	O
%	O
(	O
12/920	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
reported	O
depression	B
compared	O
to	O
0.4	O
%	O
(	O
2/506	O
)	O
treated	O
with	O
placebo	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GUERBET	O
LLC	O
at	O
1-877-729-6679	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
5.2	O
Anaphylaxis	O
and	O
Infusion	O
Reactions	O
Infusion-related	B
reactions	I
,	O
including	O
anaphylaxis	B
,	O
have	O
occurred	O
with	O
ADCETRIS	O
.	O
	
P-gp	O
inhibition	O
and	O
impaired	O
renal	O
function	O
are	O
the	O
major	O
independent	O
factors	O
that	O
result	O
in	O
increased	O
exposure	O
to	O
dabigatran	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
in	O
at	O
least	O
2	O
%	O
and	O
at	O
a	O
rate	O
greater	O
than	O
placebo	O
of	O
the	O
PRISTIQ	O
treated	O
patients	O
in	O
the	O
short-term	O
studies	O
,	O
up	O
to	O
8	O
weeks	O
,	O
were	O
:	O
nausea	B
(	O
4	O
%	O
)	O
;	O
dizziness	B
,	O
headache	B
and	O
vomiting	B
(	O
2	O
%	O
each	O
)	O
.	O
	
5.7	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
JARDIANCE	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Grade	O
3-4	O
neutropenia	B
has	O
been	O
observed	O
in	O
82	O
%	O
of	O
patients	O
treated	O
with	O
JEVTANA	O
in	O
the	O
randomized	O
trial	O
.	O
	
Complete	O
blood	O
count	O
(	O
with	O
white	O
blood	O
cell	O
differential	O
counts	O
)	O
should	O
be	O
obtained	O
at	O
pretreatment	O
,	O
and	O
at	O
Treatment	O
Weeks	O
2	O
,	O
4	O
,	O
8	O
,	O
and	O
12	O
,	O
and	O
should	O
be	O
monitored	O
closely	O
at	O
other	O
time	O
points	O
,	O
as	O
clinically	O
appropriate	O
.	O
	
For	O
patients	O
who	O
require	O
use	O
of	O
corticosteroids	O
for	O
treatment	O
of	O
non-infectious	O
pneumonitis	O
,	O
prophylaxis	O
for	O
PJP	O
may	O
be	O
considered	O
.	O
	
However	O
,	O
relapsing	O
malaria	O
caused	O
by	O
P.	O
vivax	O
requires	O
additional	O
treatment	O
with	O
other	O
antimalarial	O
agents	O
to	O
achieve	O
radical	O
cure	O
i.e.	O
,	O
eradicate	O
any	O
hypnozoites	O
forms	O
that	O
may	O
remain	O
dormant	O
in	O
the	O
liver	O
.	O
	
In	O
clinical	O
trials	O
,	O
the	O
median	O
time	O
to	O
onset	O
of	O
hemoglobin	B
less	I
than	I
10	I
g	I
per	I
dL	I
from	O
the	O
initiation	O
of	O
therapy	O
was	O
similar	O
among	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
and	O
PegIntron/REBETOL	O
(	O
71	O
days	O
with	O
a	O
range	O
of	O
15-337	O
days	O
)	O
,	O
compared	O
to	O
those	O
who	O
received	O
PegIntron/REBETOL	O
(	O
71	O
days	O
with	O
a	O
range	O
of	O
8-337	O
days	O
)	O
.	O
	
If	O
liver	O
test	O
abnormalities	O
persist	O
,	O
worsen	O
or	O
recur	O
,	O
then	O
permanently	O
discontinue	O
PROMACTA	O
.	O
	
Therefore	O
,	O
treatments	O
for	O
ED	O
,	O
including	O
STENDRA	O
,	O
should	O
not	O
be	O
used	O
in	O
men	O
for	O
whom	O
sexual	O
activity	O
is	O
inadvisable	O
because	O
of	O
their	O
underlying	O
cardiovascular	O
status	O
.	O
	
Complete	O
blood	O
counts	O
(	O
with	O
white	O
blood	O
cell	O
differential	O
counts	O
)	O
should	O
be	O
obtained	O
pretreatment	O
,	O
and	O
at	O
Treatment	O
Weeks	O
2	O
,	O
4	O
,	O
8	O
,	O
and	O
12	O
,	O
and	O
should	O
be	O
monitored	O
closely	O
at	O
other	O
time	O
points	O
,	O
as	O
clinically	O
appropriate	O
.	O
	
No	O
new	O
safety	O
findings	O
were	O
reported	O
compared	O
to	O
the	O
placebo	O
controlled	O
trials	O
.	O
	
Patients	O
with	O
a	O
``	O
crowded	O
''	O
optic	O
disc	O
may	O
also	O
be	O
at	O
an	O
increased	O
risk	O
of	O
NAION	O
(	O
5.4,6.2	O
)	O
*	O
Patients	O
should	O
stop	O
taking	O
STENDRA	O
and	O
seek	O
prompt	O
medical	O
attention	O
in	O
the	O
event	O
of	O
sudden	O
decrease	O
or	O
loss	O
of	O
hearing	O
(	O
5.5	O
)	O
5.1	O
Cardiovascular	O
Risks	O
There	O
is	O
a	O
potential	O
for	O
cardiac	B
risk	I
during	O
sexual	O
activity	O
in	O
patients	O
with	O
pre-existing	O
cardiovascular	O
disease	O
.	O
	
What	O
are	O
the	O
ingredients	O
in	O
DUAVEE	O
?	O
	
Approximately	O
7	O
%	O
of	O
patients	O
in	O
these	O
trials	O
developed	O
persistently	O
positive	O
antibodies	O
(	O
positive	O
test	O
at	O
more	O
than	O
2	O
timepoints	O
)	O
and	O
30	O
%	O
developed	O
transiently	O
positive	O
antibodies	O
(	O
positive	O
in	O
1	O
or	O
2	O
post-baseline	O
timepoints	O
)	O
.	O
	
Patients	O
with	O
tuberculosis	B
disease	O
.	O
	
Agranulocytosis	B
(	O
including	O
fatal	B
cases	O
)	O
has	O
been	O
reported	O
with	O
other	O
agents	O
in	O
the	O
class	O
.	O
	
Adverse	O
reactions	O
were	O
all	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
were	O
predominantly	O
isolated	O
occurrences	O
(	O
<	O
=	O
2	O
patients	O
)	O
of	O
one	O
of	O
the	O
following	O
reactions	O
:	O
dizziness	B
,	O
rash	B
,	O
pruritus	B
,	O
flushing	B
or	O
injection	B
site	I
hemorrhage	I
.	O
	
Patients	O
were	O
treated	O
and	O
followed	O
for	O
3	O
years	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reaction	O
Rate	O
(	O
%	O
)	O
n=6330	O
Headache	B
1.5	O
Nausea	B
1.2	O
Dizziness	B
0.5	O
Dysgeusia	B
0.4	O
Feeling	B
Hot	I
0.4	O
Injection	B
site	I
reactions	I
0.4	O
Vomiting	B
0.4	O
Rash	B
)	O
0.3	O
Pruritus	B
)	O
0.2	O
Erythema	B
0.2	O
Hypersensitivity/Anaphylactoid*	O
0.1	O
Dyspnea	B
0.1	O
Paresthesia	B
0.1	O
*Hypersensitivity/anaphylactoid	O
reaction	B
may	O
occur	O
with	O
one	O
or	O
more	O
of	O
the	O
following	O
adverse	O
reactions	O
:	O
for	O
example	O
,	O
hypotension	B
,	O
urticaria	B
,	O
face	B
edema	I
,	O
eyelid	B
edema	I
,	O
flushing	B
Adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
of	O
<	O
0.1	O
%	O
in	O
subjects	O
who	O
received	O
Gadavist	O
include	O
:	O
loss	B
of	I
consciousness	I
,	O
convulsion	B
,	O
parosmia	B
,	O
tachycardia	B
,	O
palpitation	B
,	O
dry	B
mouth	I
,	O
malaise	B
and	O
feeling	B
cold	I
.	O
	
Table	O
7	O
:	O
Change	O
in	O
Body	O
Weight	O
in	O
Pediatric	O
Subjects	O
from	O
Baseline	O
N*	O
=	O
Number	O
of	O
subjects	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
*	O
c	O
Plasma	B
glucose	I
concentration	I
<	I
=70	I
mg/dL	I
and	O
presence	O
of	O
hypoglycemic	B
symptoms	I
.	O
	
In	O
a	O
longer-term	O
study	O
,	O
up	O
to	O
9	O
months	O
,	O
the	O
most	O
common	O
was	O
vomiting	B
(	O
2	O
%	O
)	O
.	O
	
3	O
Contact	O
Dermatitis	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
may	O
cause	O
irritant	B
dermatitis	I
.	O
	
Monitor	O
patients	O
during	O
infusion	O
.	O
	
In	O
patients	O
of	O
all	O
ages	O
who	O
are	O
started	O
on	O
antidepressant	O
therapy	O
,	O
monitor	O
closely	O
for	O
worsening	O
,	O
and	O
for	O
emergence	O
of	O
suicidal	O
thoughts	O
and	O
behaviors	O
.	O
	
Monitor	O
patients	O
for	O
these	O
consequences	O
.	O
	
Baseline	O
and	O
follow-up	O
ophthalmological	O
examinations	O
are	O
recommended	O
in	O
pediatric	O
patients	O
initiating	O
KALYDECO	O
treatment	O
.	O
	
Clinical	O
Trials	O
in	O
Late-Onset	O
Pompe	O
Disease	O
Assessment	O
of	O
adverse	O
reactions	O
in	O
patients	O
with	O
late-onset	O
Pompe	O
disease	O
is	O
based	O
on	O
the	O
exposure	O
of	O
90	O
patients	O
(	O
45	O
male	O
,	O
45	O
female	O
)	O
,	O
aged	O
10	O
to	O
70	O
years	O
,	O
to	O
20	O
mg/kg	O
alglucosidase	O
alfa	O
or	O
placebo	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O
	
The	O
cobicistat	O
component	O
of	O
STRIBILD	O
has	O
been	O
shown	O
to	O
increase	B
serum	I
creatinine	I
and	O
decrease	B
estimated	I
creatinine	I
clearance	I
due	O
to	O
inhibition	O
of	O
tubular	O
secretion	O
of	O
creatinine	O
without	O
affecting	B
renal	I
glomerular	I
function	I
.	O
	
Certain	O
circumstances	O
may	O
increase	O
the	O
risk	O
of	O
torsade	O
de	O
pointes	O
and/or	O
sudden	O
death	O
in	O
association	O
with	O
the	O
use	O
of	O
drugs	O
that	O
prolong	O
the	O
QTc	O
interval	O
,	O
including	O
(	O
1	O
)	O
bradycardia	O
;	O
(	O
2	O
)	O
hypokalemia	O
or	O
hypomagnesemia	O
;	O
(	O
3	O
)	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
prolong	O
the	O
QTc	O
interval	O
;	O
and	O
(	O
4	O
)	O
presence	O
of	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
;	O
(	O
5	O
)	O
recent	O
acute	O
myocardial	O
infarction	O
;	O
and/or	O
(	O
6	O
)	O
uncompensated	O
heart	O
failure	O
.	O
	
The	O
following	O
adverse	O
reactions	O
were	O
dose-related	O
:	O
somnolence/sedation	O
,	O
dizziness	B
,	O
feeling	B
drunk	I
,	O
libido	B
decreased	I
,	O
depression	B
,	O
headache	B
,	O
peripheral	B
edema	I
,	O
and	O
vertigo	B
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Driving	B
impairment	I
:	O
Warn	O
patients	O
not	O
to	O
drive	O
until	O
they	O
have	O
gained	O
sufficient	O
experience	O
with	O
HORIZANT	O
to	O
assess	O
whether	O
it	O
will	O
impair	O
their	O
ability	O
to	O
drive	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
9.5	O
years	O
(	O
range	O
0.8	O
to	O
26	O
years	O
)	O
,	O
93	O
%	O
were	O
Caucasian	O
,	O
and	O
57	O
%	O
were	O
male	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Autoimmune	B
disorders	I
(	O
such	O
as	O
Graves	B
'	I
disease	I
,	O
polymyositis	B
,	O
and	O
Guillain-Barre	B
syndrome	I
)	O
have	O
also	O
been	O
reported	O
to	O
occur	O
in	O
the	O
setting	O
of	O
immune	O
reconstitution	O
;	O
however	O
,	O
the	O
time	O
to	O
onset	O
is	O
more	O
variable	O
and	O
can	O
occur	O
many	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
A	O
reaction	O
was	O
considered	O
treatment	O
emergent	O
if	O
it	O
occurred	O
for	O
the	O
first	O
time	O
or	O
worsened	O
while	O
receiving	O
therapy	O
following	O
baseline	O
evaluation	O
.	O
	
None	O
of	O
these	O
4	O
patients	O
had	O
neutralizing	O
antibodies.The	O
presence	O
of	O
ADA	O
to	O
ERWINAZE	O
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
hypersensitivity	B
reactions	I
in	O
patients	O
who	O
received	O
ERWINAZE	O
through	O
intravenous	O
infusion	O
compared	O
to	O
intramuscular	O
administration	O
of	O
ERWINAZE.Immunogenicity	O
assay	O
are	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
and	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
such	O
as	O
:	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Overall	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
in	O
255	O
patients	O
with	O
HAE	O
were	O
headache	B
(	O
16	O
%	O
)	O
,	O
nausea	B
(	O
13	O
%	O
)	O
,	O
fatigue	B
(	O
12	O
%	O
)	O
,	O
diarrhea	B
(	O
11	O
%	O
)	O
,	O
upper	B
respiratory	I
tract	I
infection	I
(	O
8	O
%	O
)	O
,	O
injection	B
site	I
reactions	I
(	O
7	O
%	O
)	O
,	O
nasopharyngitis	B
(	O
6	O
%	O
)	O
,	O
vomiting	B
(	O
6	O
%	O
)	O
,	O
pruritus	B
(	O
5	O
%	O
)	O
,	O
upper	B
abdominal	I
pain	I
(	O
5	O
%	O
)	O
,	O
and	O
pyrexia	B
(	O
5	O
%	O
)	O
.	O
	
(	O
5.2	O
)	O
Increased	O
Mortality	O
*	O
An	O
increased	O
risk	O
of	O
death	B
was	O
seen	O
in	O
the	O
SIRTURO	O
treatment	O
group	O
(	O
9/79	O
,	O
11.4	O
%	O
)	O
compared	O
to	O
the	O
placebo	O
treatment	O
group	O
(	O
2/81	O
,	O
2.5	O
%	O
)	O
in	O
one	O
placebo-controlled	O
trial	O
.	O
	
Increased	O
Mortality	O
*	O
An	O
increased	O
risk	O
of	O
death	B
was	O
seen	O
in	O
the	O
SIRTURO	O
treatment	O
group	O
(	O
9/79	O
,	O
11.4	O
%	O
)	O
compared	O
to	O
the	O
placebo	O
treatment	O
group	O
(	O
2/81	O
,	O
2.5	O
%	O
)	O
in	O
one	O
placebo-controlled	O
trial	O
.	O
	
These	O
adverse	O
reactions	O
are	O
presented	O
by	O
system	O
organ	O
class	O
and	O
are	O
ranked	O
by	O
frequency	O
.	O
	
Overall	O
,	O
approximately	O
4	O
%	O
of	O
subjects	O
reported	O
one	O
or	O
more	O
adverse	O
reactions	O
during	O
a	O
follow-up	O
period	O
that	O
ranged	O
from	O
24	O
hours	O
to	O
7	O
days	O
after	O
Gadavist	O
administration	O
.	O
	
Prepare	O
to	O
treat	O
acute	O
pain	O
during	O
and	O
following	O
the	O
application	O
procedure	O
with	O
local	O
cooling	O
(	O
such	O
as	O
an	O
ice	O
pack	O
)	O
and/or	O
appropriate	O
analgesic	O
medication	O
,	O
such	O
as	O
opioids	O
.	O
	
Adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
described	O
below	O
in	O
Tables	O
7	O
and	O
8	O
reflect	O
exposure	O
to	O
IMBRUVICA	O
with	O
a	O
median	O
duration	O
of	O
11.7	O
months	O
in	O
the	O
WM	O
trial	O
.	O
	
Patients	O
with	O
acute	O
respiratory	O
illness	O
may	O
be	O
at	O
risk	O
of	O
serious	O
acute	O
exacerbation	O
of	O
their	O
respiratory	O
compromise	O
due	O
to	O
hypersensitivity	O
reactions	O
,	O
and	O
require	O
additional	O
monitoring	O
(	O
5.1	O
,	O
5.2	O
,	O
6	O
)	O
.	O
	
Incidence	O
and	O
Rate	O
of	O
HypoglycemiaAdverse	O
reactions	O
of	O
hypoglycemia	B
were	O
based	O
on	O
all	O
reports	O
of	O
symptomatic	O
and	O
asymptomatic	O
hypoglycemia	B
;	O
a	O
concurrent	O
glucose	O
measurement	O
was	O
not	O
required	O
;	O
intent-to-treat	O
population	O
.	O
	
In	O
this	O
analysis	O
,	O
6.9	O
%	O
of	O
58	O
evaluable	O
patients	O
,	O
who	O
were	O
treated	O
with	O
0.3	O
mg/kg	O
dose	O
,	O
tested	O
positive	O
for	O
binding	O
antibodies	O
against	O
ipilimumab	O
.	O
	
Monitor	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
gamma-glutamyl	O
transferase	O
(	O
GGT	O
)	O
,	O
and	O
total	O
blood	O
bilirubin	O
prior	O
to	O
the	O
start	O
of	O
and	O
during	O
BLINCYTO	O
treatment	O
.	O
	
Fatal	B
adverse	O
reactions	O
occurred	O
in	O
5	O
%	O
of	O
patients	O
receiving	O
placebo	O
and	O
resulted	O
from	O
septicemia	B
,	O
pneumonia	B
,	O
and	O
general	B
deterioration	I
.	O
	
5.3	O
Elevated	O
Blood	O
Pressure	O
Patients	O
receiving	O
PRISTIQ	O
should	O
have	O
regular	O
monitoring	O
of	O
blood	O
pressure	O
since	O
increases	B
in	I
blood	I
pressure	I
were	O
observed	O
in	O
clinical	O
studies	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
This	O
includes	O
1704	O
patients	O
treated	O
for	O
at	O
least	O
six	O
months	O
;	O
of	O
these	O
,	O
588	O
were	O
treated	O
for	O
at	O
least	O
one	O
year	O
.	O
	
Eight	O
of	O
these	O
13	O
fractures	B
were	O
in	O
patients	O
who	O
had	O
a	O
baseline	O
eGFR	O
of	O
30	O
to	O
45	O
mL/min/1.73	O
m	O
2	O
.	O
	
FANAPT	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
known	O
cardiovascular	O
disease	O
(	O
e.g.	O
,	O
heart	O
failure	O
,	O
history	O
of	O
myocardial	O
infarction	O
,	O
ischemia	O
,	O
or	O
conduction	O
abnormalities	O
)	O
,	O
cerebrovascular	O
disease	O
,	O
or	O
conditions	O
that	O
predispose	O
the	O
patient	O
to	O
hypotension	O
(	O
dehydration	O
,	O
hypovolemia	O
,	O
and	O
treatment	O
with	O
antihypertensive	O
medications	O
)	O
.	O
	
Manage	O
with	O
dose	O
delay	O
and	O
adjustment	O
(	O
2.2	O
,	O
5.2	O
,	O
6	O
)	O
*	O
Embryo-Fetal	B
Toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
(	O
5.3	O
)	O
(	O
8.1	O
)	O
*	O
QT	B
Prolongation	I
:	O
Monitor	O
for	O
prolonged	O
QT	O
intervals	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
drugs	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
,	O
and	O
electrolyte	O
abnormalities	O
.	O
	
(	O
5.8	O
)	O
*	O
CYP3A4	O
induction	O
:	O
Women	O
taking	O
strong	O
CYP3A4	O
inducers	O
(	O
for	O
example	O
,	O
carbamazepine	O
,	O
phenytoin	O
,	O
rifampicin	O
,	O
and	O
St.	O
John	O
's	O
wort	O
)	O
should	O
not	O
choose	O
Natazia	O
as	O
their	O
oral	O
contraceptive	O
due	O
to	O
the	O
possibility	O
of	O
decreased	O
contraceptive	O
efficacy	O
.	O
	
Febrile	B
neutropenia	I
occurred	O
in	O
5	O
%	O
(	O
23/503	O
)	O
of	O
patients	O
;	O
two	O
patients	O
(	O
0.4	O
%	O
)	O
died	B
from	O
complications	O
of	O
febrile	B
neutropenia	I
.	O
	
5.2	O
Pancreatitis	O
In	O
Phase	O
2	O
and	O
Phase	O
3	O
clinical	O
studies	O
,	O
12	O
(	O
3.4	O
cases	O
per	O
1000	O
patient	O
years	O
)	O
pancreatitis	B
related	O
adverse	O
reactions	O
were	O
reported	O
in	O
patients	O
exposed	O
to	O
TRULICITY	O
versus	O
3	O
in	O
non-incretin	O
comparators	O
(	O
2.7	O
cases	O
per	O
1000	O
patient	O
years	O
)	O
.	O
	
Monitor	O
patients	O
for	O
fever	O
.	O
	
Hypertension	B
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
32	O
%	O
of	O
NULOJIX-treated	O
patients	O
and	O
37	O
%	O
of	O
cyclosporine-treated	O
patients	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
For	O
this	O
reason	O
,	O
COCs	O
should	O
not	O
be	O
used	O
by	O
women	O
who	O
are	O
over	O
35	O
years	O
of	O
age	O
and	O
smoke	O
.	O
	
G-CSF	O
(	O
granulocyte	O
colony-stimulating	O
factor	O
)	O
or	O
GM-CSF	O
(	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
)	O
was	O
used	O
in	O
19	O
%	O
of	O
patients	O
who	O
received	O
HALAVEN	O
.	O
	
1	O
)	O
]	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
compared	O
directly	O
to	O
rates	O
from	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
rates	O
observed	O
in	O
practice	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
Natazia	O
.	O
	
The	O
clinical	O
significance	O
of	O
these	O
imaging	O
changes	O
is	O
unknown	O
.	O
	
b	O
Including	O
intestinal	B
perforation	I
.	O
	
Patients	O
should	O
be	O
cautioned	O
about	O
the	O
risk	O
of	O
bleeding	O
associated	O
with	O
the	O
concomitant	O
use	O
of	O
PRISTIQ	O
and	O
NSAIDs	O
,	O
aspirin	O
,	O
or	O
other	O
drugs	O
that	O
affect	O
coagulation	O
or	O
bleeding	O
.	O
	
The	O
overall	O
number	O
of	O
infections	B
,	O
serious	O
infections	B
,	O
and	O
select	O
infections	B
with	O
identified	O
etiology	O
reported	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
or	O
the	O
cyclosporine	O
control	O
in	O
Studies	O
1	O
and	O
2	O
are	O
shown	O
in	O
Table	O
3	O
.	O
	
Such	O
patients	O
should	O
undergo	O
a	O
prompt	O
medical	O
evaluation	O
,	O
and	O
discontinuation	O
of	O
PRISTIQ	O
should	O
be	O
considered	O
.	O
	
Closer	O
monitoring	O
is	O
recommended	O
for	O
patients	O
who	O
have	O
other	O
risk	O
factors	O
for	O
urinary	O
retention	O
(	O
e.g.	O
,	O
benign	O
prostatic	O
hyperplasia	O
[	O
BPH	O
]	O
)	O
,	O
patients	O
who	O
are	O
unable	O
to	O
communicate	O
clinical	O
symptoms	O
(	O
e.g.	O
,	O
cognitively	O
impaired	O
patients	O
)	O
,	O
or	O
patients	O
who	O
use	O
concomitant	O
medications	O
that	O
may	O
affect	O
voiding	O
(	O
e.g.	O
,	O
anticholinergics	O
)	O
.	O
	
In	O
other	O
XIAFLEX-treated	O
patients	O
(	O
9	O
of	O
1044	O
;	O
0.9	O
%	O
)	O
,	O
a	O
combination	O
of	O
penile	B
ecchymoses	I
,	O
sudden	O
penile	B
detumescence	I
,	O
and/or	O
a	O
penile	B
``	O
popping	B
''	O
sound	B
was	O
reported	O
,	O
and	O
in	O
these	O
cases	O
,	O
a	O
diagnosis	O
of	O
corporal	B
rupture	I
can	O
not	O
be	O
excluded	O
.	O
	
Because	O
these	O
studies	O
did	O
not	O
include	O
a	O
placebo	O
control	O
group	O
,	O
causality	O
could	O
not	O
be	O
established	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling	O
:	O
Application-Associated	B
Pain	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
Increase	B
in	I
Blood	I
Pressure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
5	O
%	O
and	O
greater	O
than	O
control	O
)	O
are	O
application	B
site	I
erythema	I
,	O
application	B
site	I
pain	I
,	O
application	B
site	I
pruritus	I
and	O
application	B
site	I
papules	I
.	O
	
Increases	B
in	I
blood	I
pressure	I
were	O
unrelated	O
to	O
the	O
pretreatment	O
blood	O
pressure	O
but	O
were	O
related	O
to	O
treatment-related	O
increases	B
in	I
pain	I
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pfizer	O
Inc	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Females	O
of	O
reproductive	O
potential	O
should	O
avoid	O
becoming	O
pregnant	O
while	O
being	O
treated	O
with	O
BOSULIF	O
.	O
	
The	O
mean	O
baseline	O
LDL-C	O
levels	O
were	O
104	O
to	O
110	O
mg/dL	O
across	O
treatment	O
groups	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
.	O
	
EXCERPT	O
:	O
*	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
0.5	O
%	O
)	O
are	O
headache	B
,	O
nausea	B
,	O
and	O
dizziness	B
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bayer	O
HealthCare	O
Pharmaceuticals	O
Inc.	O
at	O
1-888-842-2937	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
(	O
2.3	O
,	O
5.1	O
)	O
*	O
Myelosuppression	B
:	O
Monitor	O
blood	O
counts	O
and	O
manage	O
as	O
necessary	O
.	O
	
A	O
total	O
of	O
1314	O
SAPHRIS-treated	O
patients	O
were	O
treated	O
for	O
at	O
least	O
24	O
weeks	O
and	O
785	O
SAPHRIS-treated	O
patients	O
had	O
at	O
least	O
52	O
weeks	O
of	O
exposure	O
at	O
therapeutic	O
doses	O
.	O
	
Cervical	O
Dystonia	O
(	O
5.4	O
)	O
:	O
*	O
Patients	O
with	O
smaller	O
neck	O
muscle	O
mass	O
and	O
patients	O
who	O
require	O
bilateral	O
injections	O
into	O
the	O
sternocleidomastoid	O
muscles	O
are	O
at	O
greater	O
risk	O
of	O
dysphagia	B
.	O
	
In	O
controlled	O
clinical	O
trials	O
,	O
first-degree	B
AV	I
block	I
after	O
the	O
first	O
dose	O
occurred	O
in	O
4.7	O
%	O
of	O
patients	O
receiving	O
GILENYA	O
and	O
1.6	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
Under	O
conditions	O
of	O
metabolic	O
inhibition	O
for	O
both	O
2D6	O
and	O
3A4	O
,	O
FANAPT	O
12	O
mg	O
twice	O
daily	O
was	O
associated	O
with	O
a	O
mean	O
QTcF	B
increase	I
from	O
baseline	O
of	O
about	O
19	O
msec	O
.	O
	
Depression	B
was	O
reported	O
as	O
serious	O
in	O
0.2	O
%	O
(	O
3/1441	O
)	O
of	O
subjects	O
exposed	O
to	O
OTEZLA	O
,	O
compared	O
to	O
none	O
in	O
placebo-treated	O
subjects	O
(	O
0/495	O
)	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
56	O
years	O
and	O
2	O
%	O
were	O
older	O
than	O
75	O
years	O
of	O
age	O
.	O
	
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
potential	O
for	O
immunogenicity	O
.	O
	
All	O
patients	O
were	O
naive	O
to	O
enzyme	O
replacement	O
therapy	O
.	O
	
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
.	O
	
Imaging	O
appears	O
to	O
overestimate	O
the	O
incidence	O
of	O
clinical	O
pneumonitis	O
.	O
	
Therapeutic	O
use	O
of	O
G-CSF	O
and	O
secondary	O
prophylaxis	O
should	O
be	O
considered	O
in	O
all	O
patients	O
considered	O
to	O
be	O
at	O
increased	O
risk	O
for	O
neutropenia	O
complications	O
.	O
	
Please	O
refer	O
to	O
Table	O
5	O
for	O
established	O
and	O
other	O
potentially	O
significant	O
drug	O
interactions	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.3	O
)	O
]	O
.	O
	
Injection	O
Site	O
Reactions	O
In	O
CAPS	O
Study	O
1	O
,	O
subcutaneous	B
injection	I
site	I
reactions	I
were	O
observed	O
in	O
9	O
%	O
of	O
patients	O
in	O
Part	O
1	O
with	O
mild	O
tolerability	O
reactions	O
;	O
in	O
Part	O
2	O
,	O
one	O
patient	O
each	O
(	O
7	O
%	O
)	O
had	O
a	O
mild	O
or	O
a	O
moderate	O
tolerability	O
reaction	O
and	O
,	O
in	O
Part	O
3	O
,	O
one	O
patient	O
had	O
a	O
mild	O
local	B
tolerability	I
reaction	I
.	O
	
Adverse	O
reactions	O
were	O
similar	O
in	O
patients	O
who	O
received	O
doses	O
greater	O
than	O
250	O
mg	O
daily	O
.	O
	
To	O
reduce	O
this	O
risk	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
if	O
ELIQUIS	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
.	O
	
Since	O
CMV	O
seronegative	O
patients	O
are	O
at	O
increased	O
risk	O
for	O
CMV	O
disease	O
(	O
a	O
known	O
risk	O
factor	O
for	O
PTLD	O
)	O
,	O
the	O
clinical	O
significance	O
of	O
CMV	O
serology	O
for	O
PTLD	O
remains	O
to	O
be	O
determined	O
;	O
however	O
,	O
these	O
findings	O
should	O
be	O
considered	O
when	O
prescribing	O
NULOJIX	O
.	O
	
5.4	O
Thromboembolic	O
and	O
Bleeding	O
Events	O
in	O
Patients	O
with	O
thromboembolic	B
events	I
,	O
transient	B
ischemic	I
attack	I
,	O
and	O
myocardial	B
infarction	I
)	O
and	O
an	O
excess	O
of	O
major	O
bleeding	B
(	O
predominantly	O
post-operative	O
pericardial	B
effusions	I
requiring	O
intervention	O
for	O
hemodynamic	O
compromise	O
)	O
in	O
the	O
PRADAXA	O
treatment	O
arm	O
as	O
compared	O
to	O
the	O
warfarin	O
treatment	O
arm	O
.	O
	
Epstein-Barr	O
virus	O
serology	O
should	O
be	O
ascertained	O
before	O
starting	O
administration	O
of	O
NULOJIX	O
,	O
and	O
only	O
patients	O
who	O
are	O
EBV	O
seropositive	O
should	O
receive	O
NULOJIX	O
.	O
	
The	O
safety	O
of	O
XALKORI	O
is	O
based	O
primarily	O
on	O
343	O
patients	O
with	O
ALK-positive	O
metastatic	O
NSCLC	O
who	O
received	O
XALKORI	O
250	O
mg	O
twice	O
daily	O
in	O
two	O
open-label	O
,	O
randomized	O
,	O
active-controlled	O
trials	O
(	O
Studies	O
1	O
and	O
2	O
)	O
.	O
	
(	O
5.1	O
)	O
*	O
Pancreatitis	B
:	O
Discontinue	O
promptly	O
if	O
suspected	O
.	O
	
To	O
minimize	O
the	O
risk	O
for	O
thrombotic/thromboembolic	O
complications	O
,	O
do	O
not	O
use	O
PROMACTA	O
in	O
an	O
attempt	O
to	O
normalize	O
platelet	O
counts	O
.	O
	
Therefore	O
,	O
patients	O
may	O
require	O
a	O
lower	O
dose	O
of	O
sulfonylurea	O
or	O
insulin	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	B
in	O
this	O
setting	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
*	O
Hypersensitivity	B
reactions	I
(	O
anaphylacticshock	B
,	O
hypotension	B
,	O
pharyngolaryngeal	B
edema	I
,	O
urticaria	B
,	O
face	B
edema	I
,	O
rhinitis	B
,	O
conjunctivitis	B
,	O
abdominal	B
pain	I
,	O
hypoesthesia	B
,	O
sneezing	B
,	O
cough	B
and	O
pallor	B
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Tachycardia	B
*	O
Restlessness	B
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
This	O
Patient	O
Information	O
has	O
been	O
approved	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
.	O
	
MALIGNANCY	O
Lymphoma	B
and	O
other	O
malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
children	O
and	O
adolescent	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Two	O
of	O
these	O
trials	O
were	O
extensions	O
of	O
the	O
3-month	O
trials	O
,	O
and	O
one	O
was	O
a	O
dedicated	O
long	O
term	O
safety	O
trial	O
.	O
	
The	O
median	O
duration	O
on	O
treatment	O
was	O
4.9	O
months	O
for	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
2.8	O
months	O
for	O
dacarbazine-treated	O
patients	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Amgen	O
Medical	O
Information	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Two	O
randomized	O
placebo-controlled	O
,	O
multicenter	O
clinical	O
trials	O
enrolled	O
patients	O
who	O
had	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
who	O
were	O
using	O
a	O
gonadotropin-releasing	O
hormone	O
(	O
GnRH	O
)	O
agonist	O
or	O
were	O
previously	O
treated	O
with	O
orchiectomy	O
.	O
	
In	O
both	O
Study	O
1	O
and	O
Study	O
2	O
ZYTIGA	O
was	O
administered	O
at	O
a	O
dose	O
of	O
1,000	O
mg	O
daily	O
in	O
combination	O
with	O
prednisone	O
5	O
mg	O
twice	O
daily	O
in	O
the	O
active	O
treatment	O
arms	O
.	O
	
*	O
Hypersensitivity	B
reactions	I
:	O
Serious	O
systemic	B
hypersensitivity	I
reactions	I
including	O
anaphylaxis	B
may	O
occur	O
(	O
5.10	O
)	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Serious	O
skin	B
reactions	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
DALVANCE	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
STENDRA	O
200	O
mg	O
resulted	O
in	O
transient	B
decreases	I
in	I
sitting	I
blood	I
pressure	I
in	O
healthy	O
volunteers	O
of	O
8.0	O
mmHg	O
systolic	O
and	O
3.3	O
mmHg	O
diastolic	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
,	O
with	O
the	O
maximum	O
decrease	O
observed	O
at	O
1	O
hour	O
after	O
dosing	O
.	O
	
5.2	O
Cardiovascular	O
Disorders	O
Estrogen	O
agonist/antagonists	O
(	O
including	O
bazedoxifene	O
,	O
a	O
component	O
of	O
DUAVEE	O
)	O
and	O
estrogens	O
individually	O
are	O
known	O
to	O
increase	O
the	O
risk	O
of	O
VTE	B
.	O
	
The	O
use	O
of	O
erythropoiesis	O
stimulating	O
agents	O
(	O
ESAs	O
)	O
was	O
permitted	O
for	O
management	O
of	O
anemia	O
,	O
at	O
the	O
investigator	O
's	O
discretion	O
,	O
with	O
or	O
without	O
ribavirin	O
dose	O
reduction	O
in	O
the	O
Phase	O
2	O
and	O
3	O
clinical	O
trials	O
.	O
	
Resume	O
TAFINLAR	O
at	O
the	O
same	O
dose	O
level	O
upon	O
recovery	O
of	O
cardiac	O
function	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
These	O
bleeding	B
and	O
thromboembolic	B
events	I
were	O
seen	O
both	O
in	O
patients	O
who	O
were	O
initiated	O
on	O
PRADAXA	O
post-operatively	O
within	O
three	O
days	O
of	O
mechanical	O
bileaflet	O
valve	O
implantation	O
,	O
as	O
well	O
as	O
in	O
patients	O
whose	O
valves	O
had	O
been	O
implanted	O
more	O
than	O
three	O
months	O
prior	O
to	O
enrollment	O
.	O
	
*	O
Angioedema	B
with	O
concomitant	O
use	O
of	O
ACE	O
inhibitors	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Results	O
from	O
these	O
studies	O
did	O
not	O
change	O
the	O
safety	O
profile	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
.	O
	
No	O
severe	O
injection-site	B
reactions	I
were	O
reported	O
and	O
none	O
led	O
to	O
discontinuation	O
of	O
treatment	O
.	O
	
Antibodies	O
against	O
ILARIS	O
were	O
observed	O
in	O
approximately	O
1.5	O
%	O
and	O
3.1	O
%	O
of	O
the	O
patients	O
treated	O
with	O
ILARIS	O
for	O
CAPS	O
and	O
SJIA	O
,	O
respectively	O
.	O
	
Monitor	O
platelet	O
counts	O
frequently	O
during	O
treatment	O
with	O
Kyprolis	O
.	O
	
In	O
the	O
event	O
of	O
drug-induced	O
pulmonary	O
toxicity	O
,	O
discontinue	O
Kyprolis	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
(	O
5.14	O
)	O
*	O
See	O
Full	O
Prescribing	O
Information	O
for	O
additional	O
WARNINGS	O
and	O
PRECAUTIONS	O
.	O
	
Hepatitis	O
B	O
and/or	O
Hepatitis	O
C	O
Virus	O
Co-infection	O
:	O
In	O
Phase	O
3	O
trials	O
,	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
C	O
virus	O
co-infection	O
were	O
permitted	O
to	O
enroll	O
provided	O
that	O
baseline	O
liver	O
chemistry	O
tests	O
did	O
not	O
exceed	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
	
Skin	O
,	O
scalp	O
,	O
and	O
ocular	O
irritation	O
were	O
monitored	O
in	O
the	O
clinical	O
trials	O
.	O
	
(	O
5.1	O
)	O
*	O
Weight	B
Decrease	I
:	O
Monitor	O
weight	O
regularly	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
anemia	B
,	O
hypercholesterolemia	B
,	O
hypertriglyceridemia	O
,	O
hyperglycemia	B
,	O
lymphopenia	B
,	O
and	O
increased	B
creatinine	I
.	O
	
Adverse	O
Reactions	O
from	O
Clinical	O
Trials	O
of	O
the	O
Components	O
of	O
STRIBILD	O
Emtricitabine	O
and	O
Tenofovir	O
Disoproxil	O
Fumarate	O
:	O
In	O
addition	O
to	O
the	O
adverse	O
reactions	O
observed	O
with	O
STRIBILD	O
,	O
the	O
following	O
adverse	O
reactions	O
occurred	O
in	O
at	O
least	O
5	O
%	O
of	O
treatment-experienced	O
or	O
treatment-naive	O
subjects	O
receiving	O
emtricitabine	O
or	O
tenofovir	O
DF	O
with	O
other	O
antiretroviral	O
agents	O
in	O
other	O
clinical	O
trials	O
:	O
depression	B
,	O
abdominal	B
pain	I
,	O
dyspepsia	B
,	O
vomiting	B
,	O
fever	B
,	O
pain	B
,	O
nasopharyngitis	B
,	O
pneumonia	B
,	O
sinusitis	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
arthralgia	B
,	O
back	B
pain	I
,	O
myalgia	B
,	O
paresthesia	B
,	O
peripheral	B
neuropathy	I
(	O
including	O
peripheral	B
neuritis	I
)	O
,	O
anxiety	B
,	O
increased	B
cough	I
,	O
and	O
rhinitis	B
.	O
	
While	O
subjects	O
aged	O
12	O
to	O
17	O
years	O
were	O
included	O
in	O
these	O
trials	O
,	O
BREO	O
ELLIPTA	O
is	O
not	O
approved	O
for	O
use	O
in	O
this	O
age-group	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
.	O
	
These	O
reactions	O
can	O
occur	O
within	O
hours	O
to	O
weeks	O
after	O
injection	O
with	O
botulinum	O
toxin	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Permanently	O
discontinue	O
INLYTA	O
if	O
signs	O
or	O
symptoms	O
of	O
RPLS	O
occur	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
2	O
%	O
)	O
were	O
stomatitis	B
,	O
pyrexia	B
,	O
pneumonia	B
,	O
gastroenteritis	B
,	O
aggression	B
,	O
agitation	B
,	O
and	O
amenorrhea	B
.	O
	
Patients	O
with	O
active	O
acute	O
or	O
chronic	O
infections	O
should	O
not	O
start	O
treatment	O
until	O
the	O
infection	O
(	O
s	O
)	O
is	O
resolved	O
.	O
	
In	O
a	O
study	O
of	O
697	O
patients	O
with	O
available	O
24-hour	O
Holter	O
monitoring	O
data	O
after	O
their	O
first	O
dose	O
(	O
N=351	O
receiving	O
GILENYA	O
and	O
N=346	O
on	O
placebo	O
)	O
,	O
second-degree	B
AV	I
blocks	I
]	O
or	O
2:1	B
AV	I
blocks	I
)	O
occurred	O
in	O
4	O
%	O
(	O
N=14	O
)	O
of	O
patients	O
receiving	O
GILENYA	O
and	O
2	O
%	O
(	O
N=7	O
)	O
of	O
patients	O
on	O
placebo	O
.	O
	
(	O
2.3	O
,	O
5.4	O
)	O
*	O
Renal	B
Toxicity	I
Monitor	O
patients	O
for	O
renal	O
function	O
at	O
baseline	O
and	O
during	O
therapy	O
with	O
BOSULIF	O
(	O
5.5	O
)	O
*	O
Embryofetal	B
Toxicity	I
:	O
May	O
cause	O
fetal	B
harm	I
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
safety	O
of	O
Toviaz	O
was	O
evaluated	O
in	O
Phase	O
2	O
and	O
3	O
controlled	O
trials	O
in	O
a	O
total	O
of	O
2859	O
patients	O
with	O
overactive	O
bladder	O
,	O
of	O
which	O
2288	O
were	O
treated	O
with	O
fesoterodine	O
.	O
	
SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
with	O
flexible	O
dosing	O
.	O
	
Treatment	O
of	O
Postmenopausal	O
Women	O
with	O
Osteoporosis	O
The	O
safety	O
of	O
Prolia	O
in	O
the	O
treatment	O
of	O
postmenopausal	O
osteoporosis	O
was	O
assessed	O
in	O
a	O
3-year	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multinational	O
study	O
of	O
7808	O
postmenopausal	O
women	O
aged	O
60	O
to	O
91	O
years	O
.	O
	
Severe	O
elevations	O
(	O
greater	O
than	O
or	O
equal	O
to	O
6.5	O
mEq/L	O
)	O
occurred	O
in	O
0.4	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
no	O
patients	O
treated	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
1.3	O
%	O
of	O
patients	O
treated	O
with	O
INVOKANA	O
300	O
mg	O
.	O
	
Discontinue	O
SIRTURO	O
if	O
significant	O
ventricular	O
arrhythmia	O
or	O
if	O
QTcF	O
interval	O
prolongation	O
of	O
greater	O
than	O
500	O
ms	O
develops	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
most	O
frequently	O
reported	O
ocular	B
adverse	I
reaction	I
was	O
conjunctival	B
redness	I
,	O
reported	O
in	O
approximately	O
2	O
%	O
of	O
patients	O
.	O
	
Fatal	B
adverse	O
events	O
in	O
XALKORI-treated	O
patients	O
occurred	O
in	O
2.3	O
%	O
patients	O
,	O
consisting	O
of	O
septic	B
shock	I
,	O
acute	B
respiratory	I
failure	I
,	O
and	O
diabetic	B
ketoacidosis	I
.	O
	
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
:	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
serious	O
hypersensitivity	B
reactions	I
in	O
patients	O
treated	O
with	O
NESINA	O
such	O
as	O
anaphylaxis	B
,	O
angioedema	B
and	O
severe	O
cutaneous	B
adverse	I
reactions	I
.	O
	
Adverse	O
events	O
leading	O
to	O
dose	O
reduction	O
occurred	O
in	O
approximately	O
6	O
%	O
of	O
patients	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
at	O
Least	O
1	O
%	O
of	O
Subjects	O
Treated	O
for	O
up	O
to	O
48	O
Weeks	O
Adverse	O
Event	O
,	O
n	O
(	O
%	O
)	O
JUBLIAN	O
=	O
1227	O
VehicleN	O
=	O
413	O
Ingrown	B
toenail	I
28	O
(	O
2.3	O
%	O
)	O
3	O
(	O
0.7	O
%	O
)	O
Application	B
site	I
dermatitis	I
27	O
(	O
2.2	O
%	O
)	O
1	O
(	O
0.2	O
%	O
)	O
Application	B
site	I
vesicles	I
20	O
(	O
1.6	O
%	O
)	O
0	O
(	O
0.0	O
%	O
)	O
Application	B
site	I
pain	I
13	O
(	O
1.1	O
%	O
)	O
1	O
(	O
0.2	O
%	O
)	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
(	O
>	O
=20	O
%	O
)	O
adverse	O
reactions	O
are	O
diarrhea	B
,	O
hypertension	B
,	O
fatigue	B
,	O
decreased	B
appetite	I
,	O
nausea	B
,	O
dysphonia	B
,	O
hand-foot	B
)	I
syndrome	I
,	O
weight	B
decreased	I
,	O
vomiting	B
,	O
asthenia	B
,	O
and	O
constipation	B
.	O
	
The	O
possibility	O
of	O
these	O
adverse	O
events	O
should	O
be	O
considered	O
in	O
patients	O
treated	O
with	O
PRISTIQ	O
who	O
present	O
with	O
progressive	O
dyspnea	O
,	O
cough	O
,	O
or	O
chest	O
discomfort	O
.	O
	
Discontinue	O
promptly	O
if	O
pancreatitis	O
is	O
suspected	O
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
Systemic	B
hypersensitivity	I
reactions	O
were	O
observed	O
in	O
patients	O
receiving	O
TRULICITY	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
If	O
such	O
effects	O
occur	O
,	O
BREO	O
ELLIPTA	O
should	O
be	O
reduced	O
slowly	O
,	O
consistent	O
with	O
accepted	O
procedures	O
for	O
reducing	O
systemic	O
corticosteroids	O
,	O
and	O
other	O
treatments	O
for	O
management	O
of	O
COPD	O
or	O
asthma	O
symptoms	O
should	O
be	O
considered	O
.	O
	
Immunogenicity	O
assay	O
results	O
are	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
used	O
in	O
detection	O
and	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
,	O
including	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
*	O
Blood	O
and	O
Lymphatic	O
System	O
Disorders	O
:	O
lymphopenia	B
*	O
Gastrointestinal	O
Disorders	O
:	O
pancreatitis	B
*	O
Hepatobiliary	O
Disorders	O
:	O
hepatotoxicity	B
*	O
Immune	O
System	O
Disorders	O
:	O
drug	O
hypersensitivity	B
*	O
Infections	O
and	O
Infestations	O
:	O
pneumonia	B
,	O
sepsis/neutropenic	O
sepsis	B
*	O
Metabolism	O
and	O
Nutrition	O
Disorders	O
:	O
hypomagnesemia	B
,	O
dehydration	B
*	O
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
interstitial	B
lung	I
disease	I
*	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
pruritus	B
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Neutropenia	B
:	O
Monitor	O
peripheral	O
blood	O
cell	O
counts	O
and	O
adjust	O
dose	O
as	O
appropriate	O
(	O
2.2	O
,	O
5.1	O
,	O
6	O
)	O
*	O
Peripheral	B
Neuropathy	I
:	O
Monitor	O
for	O
signs	O
of	O
neuropathy	O
.	O
	
Patients	O
treated	O
with	O
Teflaro	O
were	O
predominantly	O
male	O
(	O
63	O
%	O
)	O
and	O
Caucasian	O
(	O
82	O
%	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Commonly	O
observed	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=5	O
%	O
and	O
2-fold	O
greater	O
than	O
placebo	O
)	O
were	O
:	O
dizziness	B
,	O
dry	B
mouth	I
,	O
fatigue	B
,	O
nasal	B
congestion	I
,	O
orthostatic	B
hypotension	I
,	O
somnolence	B
,	O
tachycardia	B
,	O
and	O
weight	B
increased	I
.	O
	
However	O
,	O
exceeding	O
the	O
recommended	O
dosage	O
or	O
coadministration	O
with	O
a	O
strong	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhibitor	O
may	O
result	O
in	O
HPA	B
dysfunction	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
The	O
finding	O
of	O
increased	O
risk	O
with	O
AEDs	O
of	O
varying	O
mechanisms	O
of	O
action	O
and	O
across	O
a	O
range	O
of	O
indications	O
suggests	O
that	O
the	O
risk	O
applies	O
to	O
all	O
AEDs	O
used	O
for	O
any	O
indication	O
.	O
	
Due	O
to	O
higher	O
MMAE	O
exposure	O
,	O
>	O
=Grade	O
3	O
adverse	O
reactions	O
may	O
be	O
more	O
frequent	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
compared	O
to	O
patients	O
with	O
normal	O
renal	O
function	O
.	O
	
5.5	O
Angle	O
Closure	O
Glaucoma	O
Angle-Closure	B
Glaucoma	I
:	O
The	O
pupillary	O
dilation	O
that	O
occurs	O
following	O
use	O
of	O
many	O
antidepressant	O
drugs	O
including	O
Pristiq	O
may	O
trigger	O
an	O
angle	B
closure	I
attack	I
in	O
a	O
patient	O
with	O
anatomically	O
narrow	O
angles	O
who	O
does	O
not	O
have	O
a	O
patent	O
iridectomy	O
.	O
	
In	O
controlled	O
and	O
uncontrolled	O
studies	O
,	O
1,564	O
patients	O
received	O
CIMZIA	O
at	O
some	O
dose	O
level	O
,	O
of	O
whom	O
1,350	O
patients	O
received	O
400	O
mg	O
CIMZIA	O
.	O
	
At	O
baseline	O
,	O
17	O
%	O
of	O
the	O
population	O
in	O
these	O
studies	O
reported	O
peripheral	O
neuropathy	O
and	O
4	O
%	O
reported	O
retinopathy	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thyroid	B
C-cell	I
Tumors	I
:	O
See	O
Boxed	O
Warning	O
(	O
5.1	O
)	O
.	O
	
The	O
dose	O
was	O
reduced	O
in	O
79	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
compared	O
to	O
9	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Fungus	O
invasion	O
must	O
be	O
considered	O
in	O
any	O
persistent	O
corneal	O
ulceration	O
where	O
a	O
steroid	O
has	O
been	O
used	O
or	O
is	O
in	O
use	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
signs	O
or	O
symptoms	O
of	O
these	O
events	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
9	O
years	O
,	O
had	O
a	O
mean	O
HbA1c	O
of	O
8.2	O
%	O
,	O
and	O
30	O
%	O
had	O
established	O
microvascular	O
disease	O
.	O
	
In	O
patients	O
with	O
normal	O
or	O
mildly	O
impaired	O
renal	O
function	O
at	O
baseline	O
,	O
serum	O
creatinine	O
and	O
eGFR	O
returned	O
to	O
baseline	O
values	O
at	O
Week	O
24	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hemorrhage	B
:	O
Monitor	O
for	O
bleeding	O
(	O
5.1	O
)	O
.	O
	
The	O
most	O
common	O
Grade	O
3	O
or	O
4	O
non-hematological	O
adverse	O
reactions	O
(	O
>	O
=	O
5	O
%	O
)	O
were	O
pneumonia	B
,	O
abdominal	B
pain	I
,	O
atrial	B
fibrillation	I
,	O
diarrhea	B
,	O
fatigue	B
,	O
and	O
skin	B
infections	I
.	O
	
These	O
adverse	O
reactions	O
are	O
included	O
based	O
on	O
clinical	O
relevance	O
and	O
ranked	O
in	O
order	O
of	O
decreasing	O
seriousness	O
within	O
each	O
category	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
worldwide	O
post-approval	O
use	O
of	O
indacaterol	O
,	O
the	O
active	O
ingredient	O
in	O
ARCAPTA	O
NEOHALER	O
.	O
	
The	O
mean	O
baseline	O
non-HDL-C	O
levels	O
were	O
140	O
to	O
147	O
mg/dL	O
across	O
treatment	O
groups	O
.	O
	
Dose	O
adjustments	O
(	O
interruptions	O
or	O
reductions	O
)	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
55	O
%	O
of	O
AFINITOR-treated	O
patients	O
.	O
	
Patients	O
with	O
symptoms	O
and	O
signs	O
consistent	O
with	O
cryptococcal	O
meningitis	O
should	O
undergo	O
prompt	O
diagnostic	O
evaluation	O
and	O
treatment	O
.	O
	
5.6	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
(	O
e.g.	O
,	O
generalized	B
urticaria	I
)	O
,	O
some	O
serious	O
,	O
were	O
reported	O
with	O
INVOKANA	O
treatment	O
;	O
these	O
reactions	O
generally	O
occurred	O
within	O
hours	O
to	O
days	O
after	O
initiating	O
INVOKANA	O
.	O
	
A	O
decision	O
on	O
whether	O
or	O
not	O
to	O
discontinue	O
GILENYA	O
therapy	O
should	O
include	O
an	O
assessment	O
of	O
the	O
potential	O
benefits	O
and	O
risks	O
for	O
the	O
individual	O
patient	O
.	O
	
No	O
cases	O
of	O
torsade	B
de	I
pointes	I
or	O
other	O
severe	O
cardiac	B
arrhythmias	I
were	O
observed	O
during	O
the	O
pre-marketing	O
clinical	O
program	O
.	O
	
Patients	O
receiving	O
more	O
than	O
3	O
doses	O
of	O
an	O
opioid	O
within	O
the	O
week	O
prior	O
to	O
surgery	O
were	O
not	O
studied	O
in	O
the	O
postoperative	O
ileus	O
clinical	O
trials	O
.	O
	
(	O
5.6	O
)	O
*	O
Immunization	O
:	O
Live	O
vaccines	O
should	O
not	O
be	O
given	O
concurrently	O
with	O
BENLYSTA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Depression	B
:	O
Advise	O
patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
depression	O
,	O
suicidal	O
thoughts	O
or	O
other	O
mood	O
changes	O
and	O
if	O
such	O
changes	O
occur	O
to	O
contact	O
their	O
healthcare	O
provider	O
.	O
	
Deaths	B
due	O
to	O
acute	B
respiratory	I
failure	I
(	O
0.7	O
%	O
)	O
,	O
infection	B
(	O
0.7	O
%	O
)	O
,	O
and	O
acute	B
renal	I
failure	I
(	O
0.4	O
%	O
)	O
were	O
observed	O
on	O
the	O
AFINITOR	O
arm	O
but	O
none	O
on	O
the	O
placebo	O
arm	O
.	O
	
Monitor	O
blood	O
pressure	O
,	O
both	O
in	O
the	O
supine	O
position	O
and	O
in	O
the	O
recommended	O
head-elevated	O
sleeping	O
position	O
.	O
	
6.2	O
Clinical	O
Trials	O
Experience	O
in	O
Asthma	O
In	O
a	O
6-month	O
randomized	O
,	O
active	O
controlled	O
asthma	O
safety	O
trial	O
,	O
805	O
adult	O
patients	O
with	O
moderate	O
to	O
severe	O
persistent	O
asthma	O
were	O
treated	O
with	O
ARCAPTA	O
NEOHALER	O
300	O
mcg	O
(	O
n=268	O
)	O
,	O
ARCAPTA	O
NEOHALER	O
600	O
mcg	O
(	O
n=268	O
)	O
,	O
and	O
salmeterol	O
(	O
n=269	O
)	O
,	O
all	O
concomitant	O
with	O
inhaled	O
corticosteroids	O
,	O
which	O
were	O
not	O
co-randomized	O
.	O
	
The	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
alglucosidase	O
alfa	O
using	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
confirmed	O
by	O
a	O
radioimmunoprecipitation	O
(	O
RIP	O
)	O
assay	O
for	O
alglucosidase	O
alfa-specific	O
IgG	O
antibodies	O
.	O
	
The	O
safety	O
of	O
HORIZANT	O
in	O
doses	O
ranging	O
from	O
1,200	O
to	O
3,600	O
mg	O
has	O
been	O
evaluated	O
in	O
417	O
patients	O
with	O
PHN	O
in	O
3	O
clinical	O
studies	O
.	O
	
Manage	O
fluid	O
and	O
electrolyte	O
levels	O
as	O
appropriate	O
,	O
supplement	O
protein	O
intake	O
,	O
monitor	O
antibacterial	O
treatment	O
of	O
C.	O
difficile	O
,	O
and	O
institute	O
surgical	O
evaluation	O
as	O
clinically	O
indicated	O
.	O
	
(	O
5.6	O
)	O
*	O
Graft	B
Loss	I
with	O
Corticosteroid	O
Minimization	O
:	O
corticosteroid	O
utilization	O
should	O
be	O
consistent	O
with	O
the	O
NULOJIX	O
clinical	O
trial	O
experience	O
.	O
	
If	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
comes	O
in	O
contact	O
with	O
the	O
eyes	O
,	O
flush	O
them	O
immediately	O
with	O
water	O
.	O
	
Consistent	O
with	O
the	O
high	O
homology	O
of	O
albiglutide	O
with	O
human	O
GLP-1	O
,	O
the	O
majority	O
of	O
patients	O
(	O
approximately	O
79	O
%	O
)	O
with	O
anti-albiglutide	O
antibodies	O
also	O
tested	O
positive	O
for	O
anti-GLP-1	O
antibodies	O
;	O
none	O
were	O
neutralizing	O
.	O
	
Previously	O
Untreated	O
ALK-Positive	O
Metastatic	O
NSCLC	O
-	O
Study	O
1	O
The	O
data	O
in	O
Table	O
3	O
are	O
derived	O
from	O
340	O
patients	O
with	O
ALK-positive	O
metastatic	O
NSCLC	O
who	O
had	O
not	O
received	O
previous	O
systemic	O
treatment	O
for	O
advanced	O
disease	O
who	O
received	O
treatment	O
in	O
a	O
randomized	O
,	O
multicenter	O
,	O
open-label	O
,	O
active-controlled	O
trial	O
(	O
Study	O
1	O
)	O
.	O
	
Consider	O
the	O
benefits	O
and	O
risks	O
before	O
neuraxial	O
intervention	O
in	O
patients	O
anticoagulated	O
or	O
to	O
be	O
anticoagulated	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
The	O
time	O
to	O
onset	O
of	O
symptoms	O
varied	O
from	O
one	O
day	O
to	O
several	O
months	O
after	O
starting	O
Prolia	O
.	O
	
Seven	O
thrombotic	B
complications	I
(	O
six	O
patients	O
)	O
were	O
reported	O
in	O
the	O
group	O
that	O
received	O
PROMACTA	O
and	O
three	O
thrombotic	B
complications	I
were	O
reported	O
in	O
the	O
placebo	O
group	O
(	O
two	O
patients	O
)	O
.	O
	
Active	O
Ingredients	O
:	O
conjugated	O
estrogens	O
and	O
bazedoxifene	O
.	O
	
The	O
following	O
groups	O
of	O
patients	O
were	O
not	O
included	O
in	O
clinical	O
safety	O
and	O
efficacy	O
trials	O
for	O
STENDRA	O
,	O
and	O
therefore	O
until	O
further	O
information	O
is	O
available	O
,	O
STENDRA	O
is	O
not	O
recommended	O
for	O
the	O
following	O
groups	O
:	O
*	O
Patients	O
who	O
have	O
suffered	O
a	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
life-threatening	O
arrhythmia	O
,	O
or	O
coronary	O
revascularization	O
within	O
the	O
last	O
6	O
months	O
;	O
*	O
Patients	O
with	O
resting	O
hypotension	O
(	O
blood	O
pressure	O
less	O
than	O
90/50	O
mmHg	O
)	O
or	O
hypertension	O
(	O
blood	O
pressure	O
greater	O
than	O
170/100	O
mmHg	O
)	O
;	O
*	O
Patients	O
with	O
unstable	O
angina	O
,	O
angina	O
with	O
sexual	O
intercourse	O
,	O
or	O
New	O
York	O
Heart	O
Association	O
Class	O
2	O
or	O
greater	O
congestive	O
heart	O
failure	O
.	O
	
The	O
next	O
dose	O
of	O
ELIQUIS	O
should	O
not	O
be	O
administered	O
earlier	O
than	O
5	O
hours	O
after	O
the	O
removal	O
of	O
the	O
catheter	O
.	O
	
A	O
patient	O
who	O
develops	O
a	O
new	O
infection	O
during	O
treatment	O
with	O
CIMZIA	O
should	O
be	O
closely	O
monitored	O
,	O
undergo	O
a	O
prompt	O
and	O
complete	O
diagnostic	O
workup	O
appropriate	O
for	O
an	O
immunocompromised	O
patient	O
,	O
and	O
appropriate	O
antimicrobial	O
therapy	O
should	O
be	O
initiated	O
.	O
	
5.4	O
Clostridium	O
difficile-Associated	O
Diarrhea	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
in	O
users	O
of	O
nearly	O
all	O
systemic	O
antibacterial	O
drugs	O
,	O
including	O
DALVANCE	O
,	O
with	O
severity	O
ranging	O
from	O
mild	O
diarrhea	B
to	O
fatal	B
colitis	B
.	O
	
During	O
adult	O
pre-marketing	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
syncope	B
was	O
reported	O
in	O
0.6	O
%	O
(	O
11/1953	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
*	O
The	O
risk	O
for	O
NSF	B
appears	O
highest	O
among	O
patients	O
with	O
:	O
Chronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73m2	O
)	O
,	O
orAcute	O
kidney	O
injury	O
.	O
	
Trial	O
1	O
,	O
a	O
multicenter	O
,	O
international	O
,	O
open-label	O
,	O
randomized	O
(	O
3:1	O
)	O
,	O
controlled	O
trial	O
allocated	O
250	O
patients	O
with	O
unresectable	O
or	O
metastatic	O
BRAF	O
V600E	O
mutation-positive	O
melanoma	O
to	O
receive	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
(	O
n	O
=	O
187	O
)	O
or	O
dacarbazine	O
1,000	O
mg/m	O
2	O
intravenously	O
every	O
3	O
weeks	O
(	O
n	O
=	O
63	O
)	O
.	O
	
5.8	O
QT	O
Interval	O
Prolongation	O
Dronedarone	O
induces	O
a	O
moderate	O
(	O
average	O
of	O
about	O
10	O
ms	O
but	O
much	O
greater	O
effects	O
have	O
been	O
observed	O
)	O
QTc	B
(	I
Bazett	I
)	I
prolongation	I
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Patients	O
with	O
left	O
ventricular	O
outflow	O
obstruction	O
(	O
e.g.	O
,	O
aortic	O
stenosis	O
,	O
idiopathic	O
hypertrophic	O
subaortic	O
stenosis	O
)	O
and	O
those	O
with	O
severely	O
impaired	O
autonomic	O
control	O
of	O
blood	O
pressure	O
can	O
be	O
particularly	O
sensitive	O
to	O
the	O
actions	O
of	O
vasodilators	O
,	O
including	O
STENDRA	O
.	O
	
All	O
of	O
the	O
thrombotic	B
complications	I
reported	O
in	O
the	O
group	O
that	O
received	O
PROMACTA	O
were	O
portal	B
vein	I
thrombosis	I
(	O
PVT	B
)	O
.	O
	
Metabolism	O
and	O
nutrition	O
disorders	O
:	O
hyperglycemia	B
.	O
	
In	O
Trial	O
2	O
,	O
ophthalmologic	O
examinations	O
including	O
retinal	O
evaluation	O
were	O
performed	O
pretreatment	O
and	O
at	O
regular	O
intervals	O
during	O
treatment	O
.	O
	
If	O
neurological	O
compromise	O
is	O
noted	O
,	O
urgent	O
treatment	O
is	O
necessary	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Instruct	O
patients	O
to	O
immediately	O
report	O
if	O
they	O
experience	O
any	O
of	O
the	O
above	O
signs	O
or	O
symptoms	O
.	O
	
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
-	O
Musculoskeletal	B
stiffness	I
.	O
	
(	O
2.2	O
)	O
Deaths	B
have	O
occurred	O
due	O
to	O
gastrointestinal	B
hemorrhage	I
and	O
neutropenic	B
enterocolitis	I
.	O
	
In	O
CAPS	O
trials	O
one	O
patient	O
discontinued	O
and	O
in	O
SJIA	O
trials	O
no	O
patients	O
discontinued	O
due	O
to	O
hypersensitivity	B
reactions	I
.	O
	
Adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
subjects	O
treated	O
with	O
Picato	O
(	O
r	O
)	O
gel	O
and	O
at	O
a	O
higher	O
frequency	O
than	O
the	O
vehicle	O
are	O
presented	O
in	O
Table	O
3	O
and	O
Table	O
4	O
.	O
	
(	O
5.1	O
,	O
5.4	O
,	O
5.5	O
)	O
*	O
Liver	O
transplant	O
:	O
use	O
is	O
not	O
recommended	O
.	O
	
5.5	O
Pulmonary	O
Hypertension	O
Pulmonary	B
arterial	I
hypertension	I
(	O
PAH	B
)	O
was	O
reported	O
in	O
approximately	O
1	O
%	O
of	O
patients	O
treated	O
with	O
Kyprolis	O
and	O
was	O
Grade	O
3	O
or	O
greater	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
1667	O
patients	O
to	O
INVOKANA	O
and	O
a	O
mean	O
duration	O
of	O
exposure	O
to	O
INVOKANA	O
of	O
24	O
weeks	O
.	O
	
With	O
Kyprolis	O
monotherapy	O
,	O
the	O
incidence	O
of	O
venous	B
thromboembolic	I
events	I
was	O
2	O
%	O
.	O
	
Treatment-experienced	O
,	O
Integrase	O
Strand	O
Transfer	O
Inhibitor-naive	O
Subjects	O
:	O
Laboratory	O
abnormalities	O
observed	O
in	O
SAILING	O
were	O
generally	O
similar	O
compared	O
with	O
observations	O
seen	O
in	O
the	O
treatment-naive	O
(	O
SPRING-2	O
and	O
SINGLE	O
)	O
trials	O
.	O
	
The	O
use	O
of	O
FANAPT	O
should	O
be	O
avoided	O
in	O
combination	O
with	O
other	O
drugs	O
that	O
are	O
known	O
to	O
prolong	O
QTc	O
including	O
Class	O
1A	O
(	O
e.g.	O
,	O
quinidine	O
,	O
procainamide	O
)	O
or	O
Class	O
III	O
(	O
e.g.	O
,	O
amiodarone	O
,	O
sotalol	O
)	O
antiarrhythmic	O
medications	O
,	O
antipsychotic	O
medications	O
(	O
e.g.	O
,	O
chlorpromazine	O
,	O
thioridazine	O
)	O
,	O
antibiotics	O
(	O
e.g.	O
,	O
gatifloxacin	O
,	O
moxifloxacin	O
)	O
,	O
or	O
any	O
other	O
class	O
of	O
medications	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
(	O
e.g.	O
,	O
pentamidine	O
,	O
levomethadyl	O
acetate	O
,	O
methadone	O
)	O
.	O
	
The	O
risk	O
of	O
recurrence	O
after	O
rechallenge	O
has	O
not	O
been	O
evaluated	O
.	O
	
5.3	O
Cataracts	O
Cases	O
of	O
non-congenital	B
lens	I
opacities	I
have	O
been	O
reported	O
in	O
pediatric	O
patients	O
treated	O
with	O
KALYDECO	O
.	O
	
NSF	B
has	O
not	O
been	O
reported	O
in	O
patients	O
with	O
a	O
clear	O
history	O
of	O
exposure	O
to	O
DOTAREM	O
alone	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
DOTAREM	O
.	O
	
Cryptococcal	O
infections	O
Cryptococcal	B
infections	I
,	O
including	O
cases	O
of	O
cryptococcal	B
meningitis	I
,	O
have	O
been	O
reported	O
with	O
GILENYA	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
If	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
use	O
of	O
INVOKANA	O
;	O
treat	O
and	O
monitor	O
until	O
signs	O
and	O
symptoms	O
resolve	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
With	O
continued	O
dosing	O
,	O
the	O
heart	O
rate	O
returns	O
to	O
baseline	O
within	O
1	O
month	O
of	O
chronic	O
treatment	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
Blood	O
pressure	O
should	O
be	O
well-controlled	O
prior	O
to	O
initiating	O
INLYTA	O
.	O
	
Therefore	O
,	O
Units	O
of	O
biological	O
activity	O
of	O
XEOMIN	O
can	O
not	O
be	O
compared	O
to	O
or	O
converted	O
into	O
Units	O
of	O
any	O
other	O
botulinum	O
toxin	O
products	O
(	O
5.2	O
)	O
.	O
	
S	O
Also	O
includes	O
the	O
Flexible-dose	O
trial	O
(	O
N=90	O
)	O
.	O
	
Summary	O
of	O
Treatment-Emergent	O
Laboratory	O
Abnormalities	O
with	O
Grade	O
3	O
or	O
4	O
Incidence	O
of	O
>	O
=4	O
%	O
in	O
XALKORI-Treated	O
Patients	O
in	O
Study	O
1	O
Laboratory	O
Abnormality	O
XALKORI	O
Chemotherapy	O
Any	O
Grade	O
(	O
%	O
)	O
Grade	O
3/4	O
(	O
%	O
)	O
Any	O
Grade	O
(	O
%	O
)	O
Grade	O
3/4	O
(	O
%	O
)	O
Hematology	O
Neutropenia	B
52	O
11	O
59	O
16	O
Lymphopenia	B
48	O
7	O
53	O
13	O
Chemistry	O
ALT	B
elevation	I
79	O
15	O
33	O
2	O
AST	B
elevation	I
66	O
8	O
28	O
1	O
Hypophosphatemia	B
32	O
10	O
21	O
6	O
Previously	O
Treated	O
ALK-Positive	O
Metastatic	O
NSCLC	O
-	O
Study	O
2	O
The	O
data	O
in	O
Table	O
5	O
are	O
derived	O
from	O
343	O
patients	O
with	O
ALK-positive	O
metastatic	O
NSCLC	O
enrolled	O
in	O
a	O
randomized	O
,	O
multicenter	O
,	O
active-controlled	O
,	O
open-label	O
trial	O
(	O
Study	O
2	O
)	O
.	O
	
5.5	O
Increase	O
in	O
Blood	O
Pressure	O
In	O
clinical	O
trials	O
,	O
increases	B
in	I
blood	I
pressure	I
occurred	O
during	O
or	O
shortly	O
after	O
exposure	O
to	O
Qutenza	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reaction	O
(	O
incidence	O
>	O
=1.5	O
%	O
)	O
occurring	O
with	O
a	O
higher	O
frequency	O
than	O
placebo	O
among	O
ENTEREG-treated	O
patients	O
undergoing	O
surgeries	O
that	O
included	O
a	O
bowel	O
resection	O
was	O
dyspepsia	B
.	O
	
In	O
the	O
pool	O
of	O
four	O
placebo	O
controlled	O
trials	O
,	O
the	O
mean	O
percent	O
change	B
in	I
serum	I
phosphate	I
levels	I
were	O
3.6	O
%	O
and	O
5.1	O
%	O
with	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
,	O
compared	O
to	O
1.5	O
%	O
with	O
placebo	O
.	O
	
While	O
all	O
of	O
the	O
drugs	O
in	O
the	O
class	O
have	O
been	O
shown	O
to	O
produce	O
some	O
metabolic	B
changes	I
,	O
each	O
drug	O
has	O
its	O
own	O
specific	O
risk	O
profile	O
.	O
	
In	O
the	O
monotherapy	O
study	O
,	O
the	O
incidence	O
of	O
hypoglycemia	B
was	O
1.5	O
%	O
in	O
patients	O
treated	O
with	O
NESINA	O
compared	O
to	O
1.6	O
%	O
with	O
placebo	O
.	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
with	O
perforation	O
or	O
fistula	O
.	O
	
Management	O
of	O
these	O
events	O
may	O
require	O
either	O
temporary	O
interruption	O
or	O
discontinuation	O
of	O
BLINCYTO	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Table	O
4	O
:	O
Change	O
in	O
Cholesterol	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
3-6	O
months	O
6-12	O
months	O
>	O
12	O
months	O
FANAPT	O
10-16	O
mg/day	O
-3.9	O
(	O
N=783	O
)	O
-3.9	O
(	O
N=726	O
)	O
-7.7	O
(	O
N=428	O
)	O
FANAPT	O
20-24	O
mg/day	O
-19.4	O
(	O
N=34	O
)	O
-23.2	O
(	O
N=31	O
)	O
-19.4	O
(	O
N=20	O
)	O
Table	O
5	O
:	O
Change	O
in	O
Triglycerides	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
3-6	O
months	O
6-12	O
months	O
>	O
12	O
months	O
FANAPT	O
10-16	O
mg/day	O
-8.9	O
(	O
N=783	O
)	O
-8.9	O
(	O
N=726	O
)	O
-17.7	O
(	O
N=428	O
)	O
FANAPT	O
20-24	O
mg/day	O
-26.6	O
(	O
N=34	O
)	O
-35.4	O
(	O
N=31	O
)	O
-17.7	O
(	O
N=20	O
)	O
Weight	O
Gain	O
Weight	B
gain	I
has	O
been	O
observed	O
with	O
atypical	O
antipsychotic	O
use	O
.	O
	
In	O
the	O
placebo-controlled	O
epilepsy	O
trials	O
,	O
``	O
urinary	B
retention	I
,	O
''	O
``	O
urinary	B
hesitation	B
,	O
''	O
and	O
``	O
dysuria	B
''	O
were	O
reported	O
in	O
0.9	O
%	O
,	O
2.2	O
%	O
,	O
and	O
2.3	O
%	O
of	O
patients	O
on	O
POTIGA	O
,	O
respectively	O
,	O
and	O
in	O
0.5	O
%	O
,	O
0.9	O
%	O
,	O
and	O
0.7	O
%	O
of	O
patients	O
on	O
placebo	O
,	O
respectively	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
type	O
2	O
diabetes	O
for	O
an	O
average	O
of	O
7	O
years	O
and	O
had	O
a	O
mean	O
HbA1c	O
of	O
8.1	O
%	O
.	O
	
*	O
Hypoglycemia	B
:	O
When	O
TRULICITY	O
is	O
used	O
with	O
an	O
insulin	O
secretagogue	O
(	O
e.g.	O
,	O
a	O
sulfonylurea	O
)	O
or	O
insulin	O
,	O
consider	O
lowering	O
the	O
dose	O
of	O
the	O
sulfonylurea	O
or	O
insulin	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	O
(	O
5.3	O
)	O
.	O
	
Approximately	O
55	O
%	O
of	O
subjects	O
were	O
female	O
,	O
45	O
%	O
were	O
male	O
,	O
and	O
94	O
%	O
were	O
Caucasian	O
.	O
	
In	O
some	O
cases	O
,	O
hyperglycemia	O
has	O
resolved	O
when	O
the	O
atypical	O
antipsychotic	O
was	O
discontinued	O
;	O
however	O
,	O
some	O
patients	O
required	O
continuation	O
of	O
antidiabetic	O
treatment	O
despite	O
discontinuation	O
of	O
the	O
suspect	O
drug	O
.	O
	
At	O
one	O
year	O
after	O
transplantation	O
,	O
systolic	O
blood	O
pressures	O
were	O
8	O
mmHg	O
lower	O
and	O
diastolic	O
blood	O
pressures	O
were	O
3	O
mmHg	O
lower	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
compared	O
to	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
Avoid	O
the	O
use	O
of	O
ADCETRIS	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
[	O
creatinine	O
clearance	O
(	O
CLcr	O
)	O
<	O
30	O
mL/min	O
]	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Vascular	O
disorders	O
:	O
arterial	B
thromboembolic	I
events	I
(	O
including	O
pulmonary	B
emboli	I
,	O
deep	B
vein	I
thrombosis	I
,	O
cerebral	B
thrombosis	I
,	O
myocardial	B
infarction	I
and	O
stroke	B
)	O
,	O
hypertension	B
Hepatobiliary	O
disorders	O
:	O
Gallbladder	B
disease	I
,	O
hepatitis	B
Immune	O
system	O
disorders	O
:	O
Hypersensitivity	B
Metabolism	O
and	O
nutrition	O
disorders	O
:	O
Fluid	B
retention	I
,	O
hypertriglyceridemia	B
Nervous	O
system	O
disorders	O
:	O
Dizziness	B
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Chloasma	B
,	O
angioedema	B
,	O
erythema	B
nodosum	I
,	O
erythema	B
multiforme	I
Gastrointestinal	O
disorders	O
:	O
Gastrointestinal	B
symptoms	I
(	O
for	O
example	O
,	O
abdominal	B
pain	I
)	O
Infections	O
and	O
infestations	O
:	O
Vulvovaginal	B
candidiasis	I
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
CIGARETTE	O
SMOKING	O
AND	O
SERIOUS	O
CARDIOVASCULAR	B
EVENTS	I
WARNING	O
:	O
CIGARETTE	O
SMOKING	O
AND	O
SERIOUS	O
CARDIOVASCULAR	B
EVENTS	I
Cigarette	O
smoking	O
increases	O
the	O
risk	O
of	O
serious	O
cardiovascular	B
events	I
from	O
combination	O
oral	O
contraceptives	O
(	O
COC	O
)	O
use	O
.	O
	
Neutralizing	O
antibodies	O
were	O
assayed	O
for	O
all	O
patients	O
(	O
204	O
)	O
in	O
Study	O
1	O
.	O
	
Eye	O
disorders	O
:	O
diplopia	B
,	O
papilledema	B
,	O
retinal	B
toxicity	I
.	O
	
Rash	B
occurred	O
most	O
commonly	O
during	O
the	O
first	O
6	O
weeks	O
of	O
therapy	O
.	O
	
(	O
2.2	O
,	O
5.5	O
)	O
*	O
Bradycardia	B
:	O
ZYKADIA	O
can	O
cause	O
bradycardia	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
risk	O
is	O
discussed	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Hypotension	B
and	O
Reflex	B
Tachycardia	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
2	O
%	O
)	O
are	O
headache	B
,	O
nausea	B
,	O
and	O
vomiting	B
.	O
